[
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01048",
      "source": "DB00001",
      "target": "DB01048",
      "description": "The serum concentration of Abacavir can be decreased when it is combined with Lepirudin.",
      "name": "Abacavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00054",
      "source": "DB00001",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Lepirudin.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06736",
      "source": "DB00001",
      "target": "DB06736",
      "description": "Aceclofenac may increase the anticoagulant activities of Lepirudin.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01418",
      "source": "DB00001",
      "target": "DB01418",
      "description": "Lepirudin may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00945",
      "source": "DB00001",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00210",
      "source": "DB00001",
      "target": "DB00210",
      "description": "Adapalene may increase the anticoagulant activities of Lepirudin.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00346",
      "source": "DB00001",
      "target": "DB00346",
      "description": "The serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01431",
      "source": "DB00001",
      "target": "DB01431",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Allylestrenol.",
      "name": "Allylestrenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00404",
      "source": "DB00001",
      "target": "DB00404",
      "description": "The serum concentration of Alprazolam can be increased when it is combined with Lepirudin.",
      "name": "Alprazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00770",
      "source": "DB00001",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Lepirudin.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00009",
      "source": "DB00001",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11372",
      "source": "DB00001",
      "target": "DB11372",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Altrenogest.",
      "name": "Altrenogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06081",
      "source": "DB00001",
      "target": "DB06081",
      "description": "ALX-0081 may increase the anticoagulant activities of Lepirudin.",
      "name": "ALX-0081"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04836",
      "source": "DB00001",
      "target": "DB04836",
      "description": "The serum concentration of Amineptine can be increased when it is combined with Lepirudin.",
      "name": "Amineptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01223",
      "source": "DB00001",
      "target": "DB01223",
      "description": "The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00233",
      "source": "DB00001",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00321",
      "source": "DB00001",
      "target": "DB00321",
      "description": "The serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00261",
      "source": "DB00001",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Lepirudin.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05099",
      "source": "DB00001",
      "target": "DB05099",
      "description": "Lepirudin may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00029",
      "source": "DB00001",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01435",
      "source": "DB00001",
      "target": "DB01435",
      "description": "Antipyrine may increase the anticoagulant activities of Lepirudin.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11598",
      "source": "DB00001",
      "target": "DB11598",
      "description": "Lepirudin may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06605",
      "source": "DB00001",
      "target": "DB06605",
      "description": "Apixaban may increase the anticoagulant activities of Lepirudin.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05676",
      "source": "DB00001",
      "target": "DB05676",
      "description": "Apremilast may increase the anticoagulant activities of Lepirudin.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06692",
      "source": "DB00001",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00407",
      "source": "DB00001",
      "target": "DB00407",
      "description": "Lepirudin may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00278",
      "source": "DB00001",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Lepirudin.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06543",
      "source": "DB00001",
      "target": "DB06543",
      "description": "Astaxanthin may increase the anticoagulant activities of Lepirudin.",
      "name": "Astaxanthin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01076",
      "source": "DB00001",
      "target": "DB01076",
      "description": "The serum concentration of Atorvastatin can be increased when it is combined with Lepirudin.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB07402",
      "source": "DB00001",
      "target": "DB07402",
      "description": "Azapropazone may increase the anticoagulant activities of Lepirudin.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00972",
      "source": "DB00001",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Lepirudin.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01014",
      "source": "DB00001",
      "target": "DB01014",
      "description": "Balsalazide may increase the anticoagulant activities of Lepirudin.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09005",
      "source": "DB00001",
      "target": "DB09005",
      "description": "Batroxobin may increase the anticoagulant activities of Lepirudin.",
      "name": "Batroxobin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06401",
      "source": "DB00001",
      "target": "DB06401",
      "description": "Bazedoxifene may decrease the anticoagulant activities of Lepirudin.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00102",
      "source": "DB00001",
      "target": "DB00102",
      "description": "Lepirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09258",
      "source": "DB00001",
      "target": "DB09258",
      "description": "Bemiparin may increase the anticoagulant activities of Lepirudin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04812",
      "source": "DB00001",
      "target": "DB04812",
      "description": "Benoxaprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05229",
      "source": "DB00001",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Lepirudin.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00006",
      "source": "DB00001",
      "target": "DB00006",
      "description": "Lepirudin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08873",
      "source": "DB00001",
      "target": "DB08873",
      "description": "The serum concentration of Lepirudin can be decreased when it is combined with Boceprevir.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00963",
      "source": "DB00001",
      "target": "DB00963",
      "description": "Bromfenac may increase the anticoagulant activities of Lepirudin.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01200",
      "source": "DB00001",
      "target": "DB01200",
      "description": "The serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00248",
      "source": "DB00001",
      "target": "DB00248",
      "description": "The serum concentration of Cabergoline can be increased when it is combined with Lepirudin.",
      "name": "Cabergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06441",
      "source": "DB00001",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Lepirudin.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00564",
      "source": "DB00001",
      "target": "DB00564",
      "description": "The metabolism of Lepirudin can be increased when combined with Carbamazepine.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00821",
      "source": "DB00001",
      "target": "DB00821",
      "description": "Carprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01816",
      "source": "DB00001",
      "target": "DB01816",
      "description": "Castanospermine may increase the anticoagulant activities of Lepirudin.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00482",
      "source": "DB00001",
      "target": "DB00482",
      "description": "Celecoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09261",
      "source": "DB00001",
      "target": "DB09261",
      "description": "Lepirudin may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00608",
      "source": "DB00001",
      "target": "DB00608",
      "description": "Chloroquine may increase the anticoagulant activities of Lepirudin.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00269",
      "source": "DB00001",
      "target": "DB00269",
      "description": "Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01166",
      "source": "DB00001",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Lepirudin.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00604",
      "source": "DB00001",
      "target": "DB00604",
      "description": "The serum concentration of Cisapride can be increased when it is combined with Lepirudin.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04272",
      "source": "DB00001",
      "target": "DB04272",
      "description": "Lepirudin may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01211",
      "source": "DB00001",
      "target": "DB01211",
      "description": "The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01242",
      "source": "DB00001",
      "target": "DB01242",
      "description": "The serum concentration of Clomipramine can be increased when it is combined with Lepirudin.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09218",
      "source": "DB00001",
      "target": "DB09218",
      "description": "Clonixin may increase the anticoagulant activities of Lepirudin.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00758",
      "source": "DB00001",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Lepirudin.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11249",
      "source": "DB00001",
      "target": "DB11249",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase.",
      "name": "Collagenase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00286",
      "source": "DB00001",
      "target": "DB00286",
      "description": "Conjugated Equine Estrogens may decrease the anticoagulant activities of Lepirudin.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00924",
      "source": "DB00001",
      "target": "DB00924",
      "description": "The serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00531",
      "source": "DB00001",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00091",
      "source": "DB00001",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08921",
      "source": "DB00001",
      "target": "DB08921",
      "description": "D-Limonene may increase the anticoagulant activities of Lepirudin.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06695",
      "source": "DB00001",
      "target": "DB06695",
      "description": "Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06779",
      "source": "DB00001",
      "target": "DB06779",
      "description": "Lepirudin may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06754",
      "source": "DB00001",
      "target": "DB06754",
      "description": "Lepirudin may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01254",
      "source": "DB00001",
      "target": "DB01254",
      "description": "Dasatinib may increase the anticoagulant activities of Lepirudin.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01609",
      "source": "DB00001",
      "target": "DB01609",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04932",
      "source": "DB00001",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Lepirudin.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00705",
      "source": "DB00001",
      "target": "DB00705",
      "description": "The serum concentration of Delavirdine can be decreased when it is combined with Lepirudin.",
      "name": "Delavirdine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB03619",
      "source": "DB00001",
      "target": "DB03619",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Deoxycholic Acid.",
      "name": "Deoxycholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01151",
      "source": "DB00001",
      "target": "DB01151",
      "description": "The serum concentration of Desipramine can be increased when it is combined with Lepirudin.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11095",
      "source": "DB00001",
      "target": "DB11095",
      "description": "Lepirudin may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04925",
      "source": "DB00001",
      "target": "DB04925",
      "description": "Desmoteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Desmoteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00304",
      "source": "DB00001",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09255",
      "source": "DB00001",
      "target": "DB09255",
      "description": "Lepirudin may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11122",
      "source": "DB00001",
      "target": "DB11122",
      "description": "Lepirudin may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11076",
      "source": "DB00001",
      "target": "DB11076",
      "description": "Lepirudin may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11241",
      "source": "DB00001",
      "target": "DB11241",
      "description": "Lepirudin may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00586",
      "source": "DB00001",
      "target": "DB00586",
      "description": "Diclofenac may increase the anticoagulant activities of Lepirudin.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00266",
      "source": "DB00001",
      "target": "DB00266",
      "description": "Lepirudin may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00890",
      "source": "DB00001",
      "target": "DB00890",
      "description": "Dienestrol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09123",
      "source": "DB00001",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00255",
      "source": "DB00001",
      "target": "DB00255",
      "description": "Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00861",
      "source": "DB00001",
      "target": "DB00861",
      "description": "Diflunisal may increase the anticoagulant activities of Lepirudin.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00390",
      "source": "DB00001",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Lepirudin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00320",
      "source": "DB00001",
      "target": "DB00320",
      "description": "The serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.",
      "name": "Dihydroergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00975",
      "source": "DB00001",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Lepirudin.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08994",
      "source": "DB00001",
      "target": "DB08994",
      "description": "Ditazole may increase the anticoagulant activities of Lepirudin.",
      "name": "Ditazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09167",
      "source": "DB00001",
      "target": "DB09167",
      "description": "The serum concentration of Dosulepin can be increased when it is combined with Lepirudin.",
      "name": "Dosulepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01142",
      "source": "DB00001",
      "target": "DB01142",
      "description": "The serum concentration of Doxepin can be increased when it is combined with Lepirudin.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01395",
      "source": "DB00001",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00055",
      "source": "DB00001",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09215",
      "source": "DB00001",
      "target": "DB09215",
      "description": "Droxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00378",
      "source": "DB00001",
      "target": "DB00378",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dydrogesterone.",
      "name": "Dydrogesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00651",
      "source": "DB00001",
      "target": "DB00651",
      "description": "The serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00974",
      "source": "DB00001",
      "target": "DB00974",
      "description": "Lepirudin may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09075",
      "source": "DB00001",
      "target": "DB09075",
      "description": "Edoxaban may increase the anticoagulant activities of Lepirudin.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00109",
      "source": "DB00001",
      "target": "DB00109",
      "description": "The serum concentration of Enfuvirtide can be increased when it is combined with Lepirudin.",
      "name": "Enfuvirtide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01225",
      "source": "DB00001",
      "target": "DB01225",
      "description": "Lepirudin may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00751",
      "source": "DB00001",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Lepirudin.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08991",
      "source": "DB00001",
      "target": "DB08991",
      "description": "Epirizole may increase the anticoagulant activities of Lepirudin.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06392",
      "source": "DB00001",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Lepirudin.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01240",
      "source": "DB00001",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Lepirudin.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00063",
      "source": "DB00001",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Lepirudin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01049",
      "source": "DB00001",
      "target": "DB01049",
      "description": "The serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.",
      "name": "Ergoloid mesylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01253",
      "source": "DB00001",
      "target": "DB01253",
      "description": "The serum concentration of Ergonovine can be increased when it is combined with Lepirudin.",
      "name": "Ergonovine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00696",
      "source": "DB00001",
      "target": "DB00696",
      "description": "The serum concentration of Ergotamine can be increased when it is combined with Lepirudin.",
      "name": "Ergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06678",
      "source": "DB00001",
      "target": "DB06678",
      "description": "The serum concentration of Esmirtazapine can be increased when it is combined with Lepirudin.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00783",
      "source": "DB00001",
      "target": "DB00783",
      "description": "Estradiol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04573",
      "source": "DB00001",
      "target": "DB04573",
      "description": "Estriol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00655",
      "source": "DB00001",
      "target": "DB00655",
      "description": "Estrone may decrease the anticoagulant activities of Lepirudin.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00005",
      "source": "DB00001",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Lepirudin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00977",
      "source": "DB00001",
      "target": "DB00977",
      "description": "Ethinyl Estradiol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08794",
      "source": "DB00001",
      "target": "DB08794",
      "description": "Lepirudin may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00823",
      "source": "DB00001",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00749",
      "source": "DB00001",
      "target": "DB00749",
      "description": "Etodolac may increase the anticoagulant activities of Lepirudin.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08984",
      "source": "DB00001",
      "target": "DB08984",
      "description": "Etofenamate may increase the anticoagulant activities of Lepirudin.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00294",
      "source": "DB00001",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01628",
      "source": "DB00001",
      "target": "DB01628",
      "description": "Etoricoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06414",
      "source": "DB00001",
      "target": "DB06414",
      "description": "The serum concentration of Etravirine can be decreased when it is combined with Lepirudin.",
      "name": "Etravirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11358",
      "source": "DB00001",
      "target": "DB11358",
      "description": "Evening primrose oil may increase the anticoagulant activities of Lepirudin.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06246",
      "source": "DB00001",
      "target": "DB06246",
      "description": "exisulind may increase the anticoagulant activities of Lepirudin.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08981",
      "source": "DB00001",
      "target": "DB08981",
      "description": "Fenbufen may increase the anticoagulant activities of Lepirudin.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00573",
      "source": "DB00001",
      "target": "DB00573",
      "description": "Fenoprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08977",
      "source": "DB00001",
      "target": "DB08977",
      "description": "Fibrinolysin may increase the anticoagulant activities of Lepirudin.",
      "name": "Fibrinolysin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08976",
      "source": "DB00001",
      "target": "DB08976",
      "description": "Floctafenine may increase the anticoagulant activities of Lepirudin.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11518",
      "source": "DB00001",
      "target": "DB11518",
      "description": "Flunixin may increase the anticoagulant activities of Lepirudin.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00712",
      "source": "DB00001",
      "target": "DB00712",
      "description": "Flurbiprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00569",
      "source": "DB00001",
      "target": "DB00569",
      "description": "Lepirudin may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB10532",
      "source": "DB00001",
      "target": "DB10532",
      "description": "The serum concentration of Lepirudin can be decreased when it is combined with Garlic.",
      "name": "Garlic"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01645",
      "source": "DB00001",
      "target": "DB01645",
      "description": "Genistein may decrease the anticoagulant activities of Lepirudin.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06730",
      "source": "DB00001",
      "target": "DB06730",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestodene.",
      "name": "Gestodene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11619",
      "source": "DB00001",
      "target": "DB11619",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestrinone.",
      "name": "Gestrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB03404",
      "source": "DB00001",
      "target": "DB03404",
      "description": "Hemin may increase the anticoagulant activities of Lepirudin.",
      "name": "Hemin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01109",
      "source": "DB00001",
      "target": "DB01109",
      "description": "Lepirudin may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB07931",
      "source": "DB00001",
      "target": "DB07931",
      "description": "Hexestrol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB02351",
      "source": "DB00001",
      "target": "DB02351",
      "description": "Lepirudin may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05767",
      "source": "DB00001",
      "target": "DB05767",
      "description": "HMPL-004 may increase the anticoagulant activities of Lepirudin.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06789",
      "source": "DB00001",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00078",
      "source": "DB00001",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09053",
      "source": "DB00001",
      "target": "DB09053",
      "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05266",
      "source": "DB00001",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Lepirudin.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01050",
      "source": "DB00001",
      "target": "DB01050",
      "description": "Ibuprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08955",
      "source": "DB00001",
      "target": "DB08955",
      "description": "Ibuproxam may increase the anticoagulant activities of Lepirudin.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06196",
      "source": "DB00001",
      "target": "DB06196",
      "description": "Icatibant may increase the anticoagulant activities of Lepirudin.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08887",
      "source": "DB00001",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Lepirudin.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06406",
      "source": "DB00001",
      "target": "DB06406",
      "description": "Lepirudin may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08954",
      "source": "DB00001",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Lepirudin.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01088",
      "source": "DB00001",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Lepirudin.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00458",
      "source": "DB00001",
      "target": "DB00458",
      "description": "The serum concentration of Imipramine can be increased when it is combined with Lepirudin.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00328",
      "source": "DB00001",
      "target": "DB00328",
      "description": "Indomethacin may increase the anticoagulant activities of Lepirudin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08951",
      "source": "DB00001",
      "target": "DB08951",
      "description": "Indoprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08942",
      "source": "DB00001",
      "target": "DB08942",
      "description": "Isoxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08940",
      "source": "DB00001",
      "target": "DB08940",
      "description": "Kebuzone may increase the anticoagulant activities of Lepirudin.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01009",
      "source": "DB00001",
      "target": "DB01009",
      "description": "Ketoprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00465",
      "source": "DB00001",
      "target": "DB00465",
      "description": "Ketorolac may increase the anticoagulant activities of Lepirudin.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01097",
      "source": "DB00001",
      "target": "DB01097",
      "description": "Leflunomide may increase the anticoagulant activities of Lepirudin.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00367",
      "source": "DB00001",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09211",
      "source": "DB00001",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06725",
      "source": "DB00001",
      "target": "DB06725",
      "description": "Lornoxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00227",
      "source": "DB00001",
      "target": "DB00227",
      "description": "The serum concentration of Lovastatin can be increased when it is combined with Lepirudin.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09212",
      "source": "DB00001",
      "target": "DB09212",
      "description": "Loxoprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01283",
      "source": "DB00001",
      "target": "DB01283",
      "description": "Lumiracoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01397",
      "source": "DB00001",
      "target": "DB01397",
      "description": "Magnesium salicylate may increase the anticoagulant activities of Lepirudin.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00179",
      "source": "DB00001",
      "target": "DB00179",
      "description": "Masoprocol may increase the anticoagulant activities of Lepirudin.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00939",
      "source": "DB00001",
      "target": "DB00939",
      "description": "Meclofenamic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09124",
      "source": "DB00001",
      "target": "DB09124",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.",
      "name": "Medrogestone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00603",
      "source": "DB00001",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00784",
      "source": "DB00001",
      "target": "DB00784",
      "description": "Mefenamic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00351",
      "source": "DB00001",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00814",
      "source": "DB00001",
      "target": "DB00814",
      "description": "Meloxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00244",
      "source": "DB00001",
      "target": "DB00244",
      "description": "Mesalazine may increase the anticoagulant activities of Lepirudin.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01357",
      "source": "DB00001",
      "target": "DB01357",
      "description": "Mestranol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04817",
      "source": "DB00001",
      "target": "DB04817",
      "description": "Metamizole may increase the anticoagulant activities of Lepirudin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00683",
      "source": "DB00001",
      "target": "DB00683",
      "description": "The serum concentration of Midazolam can be increased when it is combined with Lepirudin.",
      "name": "Midazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00235",
      "source": "DB00001",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Lepirudin.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00370",
      "source": "DB00001",
      "target": "DB00370",
      "description": "The serum concentration of Mirtazapine can be increased when it is combined with Lepirudin.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00688",
      "source": "DB00001",
      "target": "DB00688",
      "description": "Mycophenolate mofetil may increase the anticoagulant activities of Lepirudin.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01024",
      "source": "DB00001",
      "target": "DB01024",
      "description": "Mycophenolic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00461",
      "source": "DB00001",
      "target": "DB00461",
      "description": "Nabumetone may increase the anticoagulant activities of Lepirudin.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08813",
      "source": "DB00001",
      "target": "DB08813",
      "description": "Lepirudin may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00735",
      "source": "DB00001",
      "target": "DB00735",
      "description": "Naftifine may increase the anticoagulant activities of Lepirudin.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00788",
      "source": "DB00001",
      "target": "DB00788",
      "description": "Naproxen may increase the anticoagulant activities of Lepirudin.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05822",
      "source": "DB00001",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Lepirudin.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01149",
      "source": "DB00001",
      "target": "DB01149",
      "description": "The serum concentration of Nefazodone can be increased when it is combined with Lepirudin.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06802",
      "source": "DB00001",
      "target": "DB06802",
      "description": "Nepafenac may increase the anticoagulant activities of Lepirudin.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04552",
      "source": "DB00001",
      "target": "DB04552",
      "description": "Niflumic Acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04743",
      "source": "DB00001",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Lepirudin.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09079",
      "source": "DB00001",
      "target": "DB09079",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Nintedanib.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00717",
      "source": "DB00001",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00540",
      "source": "DB00001",
      "target": "DB00540",
      "description": "The serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08935",
      "source": "DB00001",
      "target": "DB08935",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00768",
      "source": "DB00001",
      "target": "DB00768",
      "description": "Olopatadine may increase the anticoagulant activities of Lepirudin.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01250",
      "source": "DB00001",
      "target": "DB01250",
      "description": "Olsalazine may increase the anticoagulant activities of Lepirudin.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04865",
      "source": "DB00001",
      "target": "DB04865",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11133",
      "source": "DB00001",
      "target": "DB11133",
      "description": "Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.",
      "name": "Omega-3 fatty acids"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11444",
      "source": "DB00001",
      "target": "DB11444",
      "description": "Orgotein may increase the anticoagulant activities of Lepirudin.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06635",
      "source": "DB00001",
      "target": "DB06635",
      "description": "Lepirudin may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00991",
      "source": "DB00001",
      "target": "DB00991",
      "description": "Oxaprozin may increase the anticoagulant activities of Lepirudin.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB03585",
      "source": "DB00001",
      "target": "DB03585",
      "description": "Oxyphenbutazone may increase the anticoagulant activities of Lepirudin.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08439",
      "source": "DB00001",
      "target": "DB08439",
      "description": "Parecoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09260",
      "source": "DB00001",
      "target": "DB09260",
      "description": "Parnaparin may increase the anticoagulant activities of Lepirudin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00686",
      "source": "DB00001",
      "target": "DB00686",
      "description": "Pentosan Polysulfate may increase the anticoagulant activities of Lepirudin.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00806",
      "source": "DB00001",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Lepirudin.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00454",
      "source": "DB00001",
      "target": "DB00454",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00498",
      "source": "DB00001",
      "target": "DB00498",
      "description": "Lepirudin may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00946",
      "source": "DB00001",
      "target": "DB00946",
      "description": "Lepirudin may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00812",
      "source": "DB00001",
      "target": "DB00812",
      "description": "Phenylbutazone may increase the anticoagulant activities of Lepirudin.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00337",
      "source": "DB00001",
      "target": "DB00337",
      "description": "Pimecrolimus may increase the anticoagulant activities of Lepirudin.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01100",
      "source": "DB00001",
      "target": "DB01100",
      "description": "The serum concentration of Pimozide can be increased when it is combined with Lepirudin.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04951",
      "source": "DB00001",
      "target": "DB04951",
      "description": "Pirfenidone may increase the anticoagulant activities of Lepirudin.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00554",
      "source": "DB00001",
      "target": "DB00554",
      "description": "Piroxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05254",
      "source": "DB00001",
      "target": "DB05254",
      "description": "Plasmin may increase the anticoagulant activities of Lepirudin.",
      "name": "Plasmin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09369",
      "source": "DB00001",
      "target": "DB09369",
      "description": "Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06209",
      "source": "DB00001",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Lepirudin.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00396",
      "source": "DB00001",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09288",
      "source": "DB00001",
      "target": "DB09288",
      "description": "Propacetamol may increase the anticoagulant activities of Lepirudin.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11312",
      "source": "DB00001",
      "target": "DB11312",
      "description": "Lepirudin may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11268",
      "source": "DB00001",
      "target": "DB11268",
      "description": "Lepirudin may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00344",
      "source": "DB00001",
      "target": "DB00344",
      "description": "The serum concentration of Protriptyline can be increased when it is combined with Lepirudin.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05173",
      "source": "DB00001",
      "target": "DB05173",
      "description": "PTC299 may increase the anticoagulant activities of Lepirudin.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04575",
      "source": "DB00001",
      "target": "DB04575",
      "description": "Quinestrol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB02709",
      "source": "DB00001",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Lepirudin.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00015",
      "source": "DB00001",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09259",
      "source": "DB00001",
      "target": "DB09259",
      "description": "Lepirudin may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01207",
      "source": "DB00001",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Lepirudin.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08931",
      "source": "DB00001",
      "target": "DB08931",
      "description": "The serum concentration of Riociguat can be increased when it is combined with Lepirudin.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06228",
      "source": "DB00001",
      "target": "DB06228",
      "description": "Lepirudin may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00533",
      "source": "DB00001",
      "target": "DB00533",
      "description": "Rofecoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00412",
      "source": "DB00001",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the anticoagulant activities of Lepirudin.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01098",
      "source": "DB00001",
      "target": "DB01098",
      "description": "The serum concentration of Rosuvastatin can be increased when it is combined with Lepirudin.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08797",
      "source": "DB00001",
      "target": "DB08797",
      "description": "Salicylamide may increase the anticoagulant activities of Lepirudin.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00936",
      "source": "DB00001",
      "target": "DB00936",
      "description": "Salicylic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01399",
      "source": "DB00001",
      "target": "DB01399",
      "description": "Salsalate may increase the anticoagulant activities of Lepirudin.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05692",
      "source": "DB00001",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Lepirudin.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11362",
      "source": "DB00001",
      "target": "DB11362",
      "description": "Selexipag may increase the anticoagulant activities of Lepirudin.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06739",
      "source": "DB00001",
      "target": "DB06739",
      "description": "Seratrodast may increase the anticoagulant activities of Lepirudin.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01236",
      "source": "DB00001",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Lepirudin.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00203",
      "source": "DB00001",
      "target": "DB00203",
      "description": "The serum concentration of Sildenafil can be increased when it is combined with Lepirudin.",
      "name": "Sildenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06290",
      "source": "DB00001",
      "target": "DB06290",
      "description": "The serum concentration of Simeprevir can be increased when it is combined with Lepirudin.",
      "name": "Simeprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00641",
      "source": "DB00001",
      "target": "DB00641",
      "description": "The serum concentration of Simvastatin can be increased when it is combined with Lepirudin.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB05073",
      "source": "DB00001",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Lepirudin.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01323",
      "source": "DB00001",
      "target": "DB01323",
      "description": "The metabolism of Lepirudin can be increased when combined with St. John&#39;s Wort.",
      "name": "St. John's Wort"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00086",
      "source": "DB00001",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06206",
      "source": "DB00001",
      "target": "DB06206",
      "description": "Sugammadex may increase the anticoagulant activities of Lepirudin.",
      "name": "Sugammadex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00795",
      "source": "DB00001",
      "target": "DB00795",
      "description": "Sulfasalazine may increase the anticoagulant activities of Lepirudin.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00605",
      "source": "DB00001",
      "target": "DB00605",
      "description": "Sulindac may increase the anticoagulant activities of Lepirudin.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06271",
      "source": "DB00001",
      "target": "DB06271",
      "description": "Lepirudin may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00870",
      "source": "DB00001",
      "target": "DB00870",
      "description": "Suprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09317",
      "source": "DB00001",
      "target": "DB09317",
      "description": "Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09318",
      "source": "DB00001",
      "target": "DB09318",
      "description": "Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00864",
      "source": "DB00001",
      "target": "DB00864",
      "description": "The metabolism of Tacrolimus can be decreased when combined with Lepirudin.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06287",
      "source": "DB00001",
      "target": "DB06287",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00031",
      "source": "DB00001",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00469",
      "source": "DB00001",
      "target": "DB00469",
      "description": "Tenoxicam may increase the anticoagulant activities of Lepirudin.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11466",
      "source": "DB00001",
      "target": "DB11466",
      "description": "Tepoxalin may increase the anticoagulant activities of Lepirudin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08880",
      "source": "DB00001",
      "target": "DB08880",
      "description": "Teriflunomide may increase the anticoagulant activities of Lepirudin.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04905",
      "source": "DB00001",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Lepirudin.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00277",
      "source": "DB00001",
      "target": "DB00277",
      "description": "The serum concentration of Theophylline can be decreased when it is combined with Lepirudin.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09289",
      "source": "DB00001",
      "target": "DB09289",
      "description": "The serum concentration of Tianeptine can be increased when it is combined with Lepirudin.",
      "name": "Tianeptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01600",
      "source": "DB00001",
      "target": "DB01600",
      "description": "Tiaprofenic acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09070",
      "source": "DB00001",
      "target": "DB09070",
      "description": "Tibolone may increase the anticoagulant activities of Lepirudin.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08816",
      "source": "DB00001",
      "target": "DB08816",
      "description": "Ticagrelor may increase the anticoagulant activities of Lepirudin.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00208",
      "source": "DB00001",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Lepirudin.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06822",
      "source": "DB00001",
      "target": "DB06822",
      "description": "Tinzaparin may increase the anticoagulant activities of Lepirudin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00932",
      "source": "DB00001",
      "target": "DB00932",
      "description": "The serum concentration of Lepirudin can be decreased when it is combined with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00775",
      "source": "DB00001",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Lepirudin.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09216",
      "source": "DB00001",
      "target": "DB09216",
      "description": "Tolfenamic Acid may increase the anticoagulant activities of Lepirudin.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00500",
      "source": "DB00001",
      "target": "DB00500",
      "description": "Tolmetin may increase the anticoagulant activities of Lepirudin.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00081",
      "source": "DB00001",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB07615",
      "source": "DB00001",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Lepirudin.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09283",
      "source": "DB00001",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Lepirudin.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00374",
      "source": "DB00001",
      "target": "DB00374",
      "description": "Treprostinil may increase the anticoagulant activities of Lepirudin.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00897",
      "source": "DB00001",
      "target": "DB00897",
      "description": "The serum concentration of Triazolam can be increased when it is combined with Lepirudin.",
      "name": "Triazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB08814",
      "source": "DB00001",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Lepirudin.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00726",
      "source": "DB00001",
      "target": "DB00726",
      "description": "The serum concentration of Trimipramine can be increased when it is combined with Lepirudin.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB01401",
      "source": "DB00001",
      "target": "DB01401",
      "description": "Trisalicylate-choline may increase the anticoagulant activities of Lepirudin.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00013",
      "source": "DB00001",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00580",
      "source": "DB00001",
      "target": "DB00580",
      "description": "Valdecoxib may increase the anticoagulant activities of Lepirudin.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00313",
      "source": "DB00001",
      "target": "DB00313",
      "description": "The serum concentration of Valproic Acid can be decreased when it is combined with Lepirudin.",
      "name": "Valproic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00163",
      "source": "DB00001",
      "target": "DB00163",
      "description": "Vitamin E may increase the anticoagulant activities of Lepirudin.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB09030",
      "source": "DB00001",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Lepirudin.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00682",
      "source": "DB00001",
      "target": "DB00682",
      "description": "Lepirudin may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04898",
      "source": "DB00001",
      "target": "DB04898",
      "description": "Lepirudin may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB06737",
      "source": "DB00001",
      "target": "DB06737",
      "description": "Zaltoprofen may increase the anticoagulant activities of Lepirudin.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB11478",
      "source": "DB00001",
      "target": "DB11478",
      "description": "Zeranol may decrease the anticoagulant activities of Lepirudin.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00495",
      "source": "DB00001",
      "target": "DB00495",
      "description": "The serum concentration of Zidovudine can be decreased when it is combined with Lepirudin.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00744",
      "source": "DB00001",
      "target": "DB00744",
      "description": "Zileuton may increase the anticoagulant activities of Lepirudin.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB04828",
      "source": "DB00001",
      "target": "DB04828",
      "description": "Zomepirac may increase the anticoagulant activities of Lepirudin.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00511",
      "source": "DB00002",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB08879",
      "source": "DB00002",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00112",
      "source": "DB00002",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Cetuximab.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB06772",
      "source": "DB00002",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00531",
      "source": "DB00002",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Cetuximab.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB01078",
      "source": "DB00002",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Cetuximab.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB01396",
      "source": "DB00002",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Cetuximab.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00390",
      "source": "DB00002",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Cetuximab.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB01248",
      "source": "DB00002",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB01092",
      "source": "DB00002",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Cetuximab.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB01229",
      "source": "DB00002",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB10283",
      "source": "DB00002",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cetuximab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00072",
      "source": "DB00002",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cetuximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00284",
      "source": "DB00007",
      "target": "DB00284",
      "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00414",
      "source": "DB00007",
      "target": "DB00414",
      "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00511",
      "source": "DB00007",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01700",
      "source": "DB00007",
      "target": "DB01700",
      "description": "The therapeutic efficacy of Aicar can be decreased when used in combination with Leuprolide.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00346",
      "source": "DB00007",
      "target": "DB00346",
      "description": "Alfuzosin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06203",
      "source": "DB00007",
      "target": "DB06203",
      "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00915",
      "source": "DB00007",
      "target": "DB00915",
      "description": "Amantadine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Amantadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01118",
      "source": "DB00007",
      "target": "DB01118",
      "description": "Leuprolide may increase the QTc-prolonging activities of Amiodarone.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00321",
      "source": "DB00007",
      "target": "DB00321",
      "description": "Amitriptyline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00543",
      "source": "DB00007",
      "target": "DB00543",
      "description": "Amoxapine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Amoxapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00261",
      "source": "DB00007",
      "target": "DB00261",
      "description": "Leuprolide may increase the QTc-prolonging activities of Anagrelide.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00714",
      "source": "DB00007",
      "target": "DB00714",
      "description": "Apomorphine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Apomorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01274",
      "source": "DB00007",
      "target": "DB01274",
      "description": "Arformoterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Arformoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01238",
      "source": "DB00007",
      "target": "DB01238",
      "description": "Aripiprazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01169",
      "source": "DB00007",
      "target": "DB01169",
      "description": "Leuprolide may increase the QTc-prolonging activities of Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06697",
      "source": "DB00007",
      "target": "DB06697",
      "description": "Leuprolide may increase the QTc-prolonging activities of Artemether.",
      "name": "Artemether"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06216",
      "source": "DB00007",
      "target": "DB06216",
      "description": "Leuprolide may increase the QTc-prolonging activities of Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01072",
      "source": "DB00007",
      "target": "DB01072",
      "description": "Atazanavir may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00289",
      "source": "DB00007",
      "target": "DB00289",
      "description": "Atomoxetine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Atomoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00207",
      "source": "DB00007",
      "target": "DB00207",
      "description": "Leuprolide may increase the QTc-prolonging activities of Azithromycin.",
      "name": "Azithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08903",
      "source": "DB00007",
      "target": "DB08903",
      "description": "Leuprolide may increase the QTc-prolonging activities of Bedaquiline.",
      "name": "Bedaquiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00112",
      "source": "DB00007",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Leuprolide.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00188",
      "source": "DB00007",
      "target": "DB00188",
      "description": "Bortezomib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Bortezomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04830",
      "source": "DB00007",
      "target": "DB04830",
      "description": "The therapeutic efficacy of Buformin can be decreased when used in combination with Leuprolide.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06719",
      "source": "DB00007",
      "target": "DB06719",
      "description": "Buserelin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Buserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06772",
      "source": "DB00007",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08907",
      "source": "DB00007",
      "target": "DB08907",
      "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01816",
      "source": "DB00007",
      "target": "DB01816",
      "description": "The therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09063",
      "source": "DB00007",
      "target": "DB09063",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00608",
      "source": "DB00007",
      "target": "DB00608",
      "description": "Leuprolide may increase the QTc-prolonging activities of Chloroquine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00477",
      "source": "DB00007",
      "target": "DB00477",
      "description": "Leuprolide may increase the QTc-prolonging activities of Chlorpromazine.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00672",
      "source": "DB00007",
      "target": "DB00672",
      "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09201",
      "source": "DB00007",
      "target": "DB09201",
      "description": "The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00537",
      "source": "DB00007",
      "target": "DB00537",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00604",
      "source": "DB00007",
      "target": "DB00604",
      "description": "Leuprolide may increase the QTc-prolonging activities of Cisapride.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00215",
      "source": "DB00007",
      "target": "DB00215",
      "description": "Leuprolide may increase the QTc-prolonging activities of Citalopram.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01211",
      "source": "DB00007",
      "target": "DB01211",
      "description": "Leuprolide may increase the QTc-prolonging activities of Clarithromycin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01242",
      "source": "DB00007",
      "target": "DB01242",
      "description": "Clomipramine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00363",
      "source": "DB00007",
      "target": "DB00363",
      "description": "Leuprolide may increase the QTc-prolonging activities of Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08865",
      "source": "DB00007",
      "target": "DB08865",
      "description": "Leuprolide may increase the QTc-prolonging activities of Crizotinib.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00531",
      "source": "DB00007",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Leuprolide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08912",
      "source": "DB00007",
      "target": "DB08912",
      "description": "Dabrafenib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01254",
      "source": "DB00007",
      "target": "DB01254",
      "description": "Dasatinib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06699",
      "source": "DB00007",
      "target": "DB06699",
      "description": "Degarelix may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Degarelix"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01189",
      "source": "DB00007",
      "target": "DB01189",
      "description": "Desflurane may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Desflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01151",
      "source": "DB00007",
      "target": "DB01151",
      "description": "Desipramine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01078",
      "source": "DB00007",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Leuprolide.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01396",
      "source": "DB00007",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Leuprolide.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00390",
      "source": "DB00007",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Leuprolide.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01075",
      "source": "DB00007",
      "target": "DB01075",
      "description": "Diphenhydramine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Diphenhydramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00280",
      "source": "DB00007",
      "target": "DB00280",
      "description": "Leuprolide may increase the QTc-prolonging activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01248",
      "source": "DB00007",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00204",
      "source": "DB00007",
      "target": "DB00204",
      "description": "Leuprolide may increase the QTc-prolonging activities of Dofetilide.",
      "name": "Dofetilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00757",
      "source": "DB00007",
      "target": "DB00757",
      "description": "Leuprolide may increase the QTc-prolonging activities of Dolasetron.",
      "name": "Dolasetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01184",
      "source": "DB00007",
      "target": "DB01184",
      "description": "Leuprolide may increase the QTc-prolonging activities of Domperidone.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01142",
      "source": "DB00007",
      "target": "DB01142",
      "description": "Doxepin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04855",
      "source": "DB00007",
      "target": "DB04855",
      "description": "Leuprolide may increase the QTc-prolonging activities of Dronedarone.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00450",
      "source": "DB00007",
      "target": "DB00450",
      "description": "Leuprolide may increase the QTc-prolonging activities of Droperidol.",
      "name": "Droperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09045",
      "source": "DB00007",
      "target": "DB09045",
      "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09039",
      "source": "DB00007",
      "target": "DB09039",
      "description": "Leuprolide may increase the QTc-prolonging activities of Eliglustat.",
      "name": "Eliglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09038",
      "source": "DB00007",
      "target": "DB09038",
      "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08871",
      "source": "DB00007",
      "target": "DB08871",
      "description": "Eribulin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Eribulin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00199",
      "source": "DB00007",
      "target": "DB00199",
      "description": "Leuprolide may increase the QTc-prolonging activities of Erythromycin.",
      "name": "Erythromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01175",
      "source": "DB00007",
      "target": "DB01175",
      "description": "Leuprolide may increase the QTc-prolonging activities of Escitalopram.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01276",
      "source": "DB00007",
      "target": "DB01276",
      "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04953",
      "source": "DB00007",
      "target": "DB04953",
      "description": "Ezogabine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ezogabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00927",
      "source": "DB00007",
      "target": "DB00927",
      "description": "Famotidine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Famotidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00949",
      "source": "DB00007",
      "target": "DB00949",
      "description": "Felbamate may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Felbamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08868",
      "source": "DB00007",
      "target": "DB08868",
      "description": "Fingolimod may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01195",
      "source": "DB00007",
      "target": "DB01195",
      "description": "Leuprolide may increase the QTc-prolonging activities of Flecainide.",
      "name": "Flecainide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00196",
      "source": "DB00007",
      "target": "DB00196",
      "description": "Fluconazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Fluconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00472",
      "source": "DB00007",
      "target": "DB00472",
      "description": "Leuprolide may increase the QTc-prolonging activities of Fluoxetine.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00875",
      "source": "DB00007",
      "target": "DB00875",
      "description": "Leuprolide may increase the QTc-prolonging activities of Flupentixol.",
      "name": "Flupentixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00983",
      "source": "DB00007",
      "target": "DB00983",
      "description": "Formoterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Formoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00529",
      "source": "DB00007",
      "target": "DB00529",
      "description": "Foscarnet may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Foscarnet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00743",
      "source": "DB00007",
      "target": "DB00743",
      "description": "Leuprolide may increase the QTc-prolonging activities of Gadobenic acid.",
      "name": "Gadobenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00674",
      "source": "DB00007",
      "target": "DB00674",
      "description": "Galantamine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Galantamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01155",
      "source": "DB00007",
      "target": "DB01155",
      "description": "Leuprolide may increase the QTc-prolonging activities of Gemifloxacin.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08962",
      "source": "DB00007",
      "target": "DB08962",
      "description": "The therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01120",
      "source": "DB00007",
      "target": "DB01120",
      "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00222",
      "source": "DB00007",
      "target": "DB00222",
      "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01067",
      "source": "DB00007",
      "target": "DB01067",
      "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01251",
      "source": "DB00007",
      "target": "DB01251",
      "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01016",
      "source": "DB00007",
      "target": "DB01016",
      "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00014",
      "source": "DB00007",
      "target": "DB00014",
      "description": "Leuprolide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00889",
      "source": "DB00007",
      "target": "DB00889",
      "description": "Leuprolide may increase the QTc-prolonging activities of Granisetron.",
      "name": "Granisetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00502",
      "source": "DB00007",
      "target": "DB00502",
      "description": "Leuprolide may increase the QTc-prolonging activities of Haloperidol.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06788",
      "source": "DB00007",
      "target": "DB06788",
      "description": "Histrelin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Histrelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00557",
      "source": "DB00007",
      "target": "DB00557",
      "description": "Hydroxyzine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Hydroxyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00710",
      "source": "DB00007",
      "target": "DB00710",
      "description": "Ibandronate may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ibandronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00308",
      "source": "DB00007",
      "target": "DB00308",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ibutilide.",
      "name": "Ibutilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04946",
      "source": "DB00007",
      "target": "DB04946",
      "description": "Leuprolide may increase the QTc-prolonging activities of Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00458",
      "source": "DB00007",
      "target": "DB00458",
      "description": "Imipramine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB05039",
      "source": "DB00007",
      "target": "DB05039",
      "description": "Indacaterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Indacaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00808",
      "source": "DB00007",
      "target": "DB00808",
      "description": "Indapamide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01306",
      "source": "DB00007",
      "target": "DB01306",
      "description": "The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01307",
      "source": "DB00007",
      "target": "DB01307",
      "description": "The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00047",
      "source": "DB00007",
      "target": "DB00047",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01309",
      "source": "DB00007",
      "target": "DB01309",
      "description": "The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00046",
      "source": "DB00007",
      "target": "DB00046",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00071",
      "source": "DB00007",
      "target": "DB00071",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00753",
      "source": "DB00007",
      "target": "DB00753",
      "description": "Isoflurane may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Isoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00270",
      "source": "DB00007",
      "target": "DB00270",
      "description": "Isradipine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Isradipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01167",
      "source": "DB00007",
      "target": "DB01167",
      "description": "Itraconazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Itraconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09083",
      "source": "DB00007",
      "target": "DB09083",
      "description": "Ivabradine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ivabradine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01026",
      "source": "DB00007",
      "target": "DB01026",
      "description": "Ketoconazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ketoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01259",
      "source": "DB00007",
      "target": "DB01259",
      "description": "Lapatinib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Lapatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09078",
      "source": "DB00007",
      "target": "DB09078",
      "description": "Leuprolide may increase the QTc-prolonging activities of Lenvatinib.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01137",
      "source": "DB00007",
      "target": "DB01137",
      "description": "Leuprolide may increase the QTc-prolonging activities of Levofloxacin.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08882",
      "source": "DB00007",
      "target": "DB08882",
      "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06655",
      "source": "DB00007",
      "target": "DB06655",
      "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01356",
      "source": "DB00007",
      "target": "DB01356",
      "description": "Lithium may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Lithium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01601",
      "source": "DB00007",
      "target": "DB01601",
      "description": "Leuprolide may increase the QTc-prolonging activities of Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06708",
      "source": "DB00007",
      "target": "DB06708",
      "description": "Leuprolide may increase the QTc-prolonging activities of Lumefantrine.",
      "name": "Lumefantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00934",
      "source": "DB00007",
      "target": "DB00934",
      "description": "Maprotiline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Maprotiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00358",
      "source": "DB00007",
      "target": "DB00358",
      "description": "Mefloquine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Mefloquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00331",
      "source": "DB00007",
      "target": "DB00331",
      "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00333",
      "source": "DB00007",
      "target": "DB00333",
      "description": "Leuprolide may increase the QTc-prolonging activities of Methadone.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01403",
      "source": "DB00007",
      "target": "DB01403",
      "description": "Methotrimeprazine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01233",
      "source": "DB00007",
      "target": "DB01233",
      "description": "Metoclopramide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Metoclopramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00916",
      "source": "DB00007",
      "target": "DB00916",
      "description": "Metronidazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Metronidazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00834",
      "source": "DB00007",
      "target": "DB00834",
      "description": "Mifepristone may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00491",
      "source": "DB00007",
      "target": "DB00491",
      "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00419",
      "source": "DB00007",
      "target": "DB00419",
      "description": "The therapeutic efficacy of Miglustat can be decreased when used in combination with Leuprolide.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08893",
      "source": "DB00007",
      "target": "DB08893",
      "description": "Mirabegron may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Mirabegron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00370",
      "source": "DB00007",
      "target": "DB00370",
      "description": "Mirtazapine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01252",
      "source": "DB00007",
      "target": "DB01252",
      "description": "The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Leuprolide.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00691",
      "source": "DB00007",
      "target": "DB00691",
      "description": "Moexipril may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00218",
      "source": "DB00007",
      "target": "DB00218",
      "description": "Leuprolide may increase the QTc-prolonging activities of Moxifloxacin.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00731",
      "source": "DB00007",
      "target": "DB00731",
      "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00220",
      "source": "DB00007",
      "target": "DB00220",
      "description": "Nelfinavir may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00622",
      "source": "DB00007",
      "target": "DB00622",
      "description": "Nicardipine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04868",
      "source": "DB00007",
      "target": "DB04868",
      "description": "Leuprolide may increase the QTc-prolonging activities of Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01059",
      "source": "DB00007",
      "target": "DB01059",
      "description": "Norfloxacin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00540",
      "source": "DB00007",
      "target": "DB00540",
      "description": "Nortriptyline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00104",
      "source": "DB00007",
      "target": "DB00104",
      "description": "Octreotide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01165",
      "source": "DB00007",
      "target": "DB01165",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ofloxacin.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00334",
      "source": "DB00007",
      "target": "DB00334",
      "description": "Olanzapine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09080",
      "source": "DB00007",
      "target": "DB09080",
      "description": "Olodaterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Olodaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00904",
      "source": "DB00007",
      "target": "DB00904",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ondansetron.",
      "name": "Ondansetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01092",
      "source": "DB00007",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Leuprolide.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00107",
      "source": "DB00007",
      "target": "DB00107",
      "description": "Oxytocin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Oxytocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01229",
      "source": "DB00007",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01267",
      "source": "DB00007",
      "target": "DB01267",
      "description": "Leuprolide may increase the QTc-prolonging activities of Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06603",
      "source": "DB00007",
      "target": "DB06603",
      "description": "Leuprolide may increase the QTc-prolonging activities of Panobinostat.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00715",
      "source": "DB00007",
      "target": "DB00715",
      "description": "Paroxetine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06663",
      "source": "DB00007",
      "target": "DB06663",
      "description": "Pasireotide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06589",
      "source": "DB00007",
      "target": "DB06589",
      "description": "Leuprolide may increase the QTc-prolonging activities of Pazopanib.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00738",
      "source": "DB00007",
      "target": "DB00738",
      "description": "Leuprolide may increase the QTc-prolonging activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00556",
      "source": "DB00007",
      "target": "DB00556",
      "description": "Leuprolide may increase the QTc-prolonging activities of Perflutren.",
      "name": "Perflutren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00914",
      "source": "DB00007",
      "target": "DB00914",
      "description": "The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01100",
      "source": "DB00007",
      "target": "DB01100",
      "description": "Leuprolide may increase the QTc-prolonging activities of Pimozide.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01132",
      "source": "DB00007",
      "target": "DB01132",
      "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01263",
      "source": "DB00007",
      "target": "DB01263",
      "description": "Posaconazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Posaconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01278",
      "source": "DB00007",
      "target": "DB01278",
      "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01087",
      "source": "DB00007",
      "target": "DB01087",
      "description": "Leuprolide may increase the QTc-prolonging activities of Primaquine.",
      "name": "Primaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01035",
      "source": "DB00007",
      "target": "DB01035",
      "description": "Leuprolide may increase the QTc-prolonging activities of Procainamide.",
      "name": "Procainamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00420",
      "source": "DB00007",
      "target": "DB00420",
      "description": "Leuprolide may increase the QTc-prolonging activities of Promazine.",
      "name": "Promazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01069",
      "source": "DB00007",
      "target": "DB01069",
      "description": "Promethazine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Promethazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01182",
      "source": "DB00007",
      "target": "DB01182",
      "description": "Leuprolide may increase the QTc-prolonging activities of Propafenone.",
      "name": "Propafenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00818",
      "source": "DB00007",
      "target": "DB00818",
      "description": "Propofol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Propofol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00344",
      "source": "DB00007",
      "target": "DB00344",
      "description": "Protriptyline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01224",
      "source": "DB00007",
      "target": "DB01224",
      "description": "Leuprolide may increase the QTc-prolonging activities of Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00908",
      "source": "DB00007",
      "target": "DB00908",
      "description": "Leuprolide may increase the QTc-prolonging activities of Quinidine.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00468",
      "source": "DB00007",
      "target": "DB00468",
      "description": "Leuprolide may increase the QTc-prolonging activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00243",
      "source": "DB00007",
      "target": "DB00243",
      "description": "Ranolazine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ranolazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00912",
      "source": "DB00007",
      "target": "DB00912",
      "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08864",
      "source": "DB00007",
      "target": "DB08864",
      "description": "Rilpivirine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Rilpivirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00734",
      "source": "DB00007",
      "target": "DB00734",
      "description": "Risperidone may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00503",
      "source": "DB00007",
      "target": "DB00503",
      "description": "Ritonavir may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00412",
      "source": "DB00007",
      "target": "DB00412",
      "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01001",
      "source": "DB00007",
      "target": "DB01001",
      "description": "Salbutamol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Salbutamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00938",
      "source": "DB00007",
      "target": "DB00938",
      "description": "Salmeterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Salmeterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01232",
      "source": "DB00007",
      "target": "DB01232",
      "description": "Leuprolide may increase the QTc-prolonging activities of Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06335",
      "source": "DB00007",
      "target": "DB06335",
      "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01104",
      "source": "DB00007",
      "target": "DB01104",
      "description": "Sertraline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01236",
      "source": "DB00007",
      "target": "DB01236",
      "description": "Sevoflurane may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01261",
      "source": "DB00007",
      "target": "DB01261",
      "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01591",
      "source": "DB00007",
      "target": "DB01591",
      "description": "Solifenacin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00398",
      "source": "DB00007",
      "target": "DB00398",
      "description": "Sorafenib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Sorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00489",
      "source": "DB00007",
      "target": "DB00489",
      "description": "Leuprolide may increase the QTc-prolonging activities of Sotalol.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01015",
      "source": "DB00007",
      "target": "DB01015",
      "description": "Sulfamethoxazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00263",
      "source": "DB00007",
      "target": "DB00263",
      "description": "Leuprolide may increase the QTc-prolonging activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06271",
      "source": "DB00007",
      "target": "DB06271",
      "description": "The therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01268",
      "source": "DB00007",
      "target": "DB01268",
      "description": "Sunitinib may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00675",
      "source": "DB00007",
      "target": "DB00675",
      "description": "Tamoxifen may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06402",
      "source": "DB00007",
      "target": "DB06402",
      "description": "Leuprolide may increase the QTc-prolonging activities of Telavancin.",
      "name": "Telavancin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00976",
      "source": "DB00007",
      "target": "DB00976",
      "description": "Leuprolide may increase the QTc-prolonging activities of Telithromycin.",
      "name": "Telithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00871",
      "source": "DB00007",
      "target": "DB00871",
      "description": "Terbutaline may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Terbutaline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04844",
      "source": "DB00007",
      "target": "DB04844",
      "description": "Leuprolide may increase the QTc-prolonging activities of Tetrabenazine.",
      "name": "Tetrabenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00679",
      "source": "DB00007",
      "target": "DB00679",
      "description": "Leuprolide may increase the QTc-prolonging activities of Thioridazine.",
      "name": "Thioridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01623",
      "source": "DB00007",
      "target": "DB01623",
      "description": "Thiothixene may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Thiothixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00697",
      "source": "DB00007",
      "target": "DB00697",
      "description": "Tizanidine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Tizanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00839",
      "source": "DB00007",
      "target": "DB00839",
      "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01124",
      "source": "DB00007",
      "target": "DB01124",
      "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01036",
      "source": "DB00007",
      "target": "DB01036",
      "description": "Tolterodine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00539",
      "source": "DB00007",
      "target": "DB00539",
      "description": "Leuprolide may increase the QTc-prolonging activities of Toremifene.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00072",
      "source": "DB00007",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Leuprolide.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00656",
      "source": "DB00007",
      "target": "DB00656",
      "description": "Trazodone may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Trazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00374",
      "source": "DB00007",
      "target": "DB00374",
      "description": "Treprostinil may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00440",
      "source": "DB00007",
      "target": "DB00440",
      "description": "Trimethoprim may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Trimethoprim"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00726",
      "source": "DB00007",
      "target": "DB00726",
      "description": "Trimipramine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB06825",
      "source": "DB00007",
      "target": "DB06825",
      "description": "Triptorelin may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00197",
      "source": "DB00007",
      "target": "DB00197",
      "description": "The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB05294",
      "source": "DB00007",
      "target": "DB05294",
      "description": "Leuprolide may increase the QTc-prolonging activities of Vandetanib.",
      "name": "Vandetanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00862",
      "source": "DB00007",
      "target": "DB00862",
      "description": "Vardenafil may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Vardenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB08881",
      "source": "DB00007",
      "target": "DB08881",
      "description": "Leuprolide may increase the QTc-prolonging activities of Vemurafenib.",
      "name": "Vemurafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00285",
      "source": "DB00007",
      "target": "DB00285",
      "description": "Venlafaxine may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB09082",
      "source": "DB00007",
      "target": "DB09082",
      "description": "Vilanterol may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Vilanterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04876",
      "source": "DB00007",
      "target": "DB04876",
      "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB04878",
      "source": "DB00007",
      "target": "DB04878",
      "description": "The therapeutic efficacy of Voglibose can be decreased when used in combination with Leuprolide.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00582",
      "source": "DB00007",
      "target": "DB00582",
      "description": "Voriconazole may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Voriconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB02546",
      "source": "DB00007",
      "target": "DB02546",
      "description": "Vorinostat may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00246",
      "source": "DB00007",
      "target": "DB00246",
      "description": "Leuprolide may increase the QTc-prolonging activities of Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB01624",
      "source": "DB00007",
      "target": "DB01624",
      "description": "Leuprolide may increase the QTc-prolonging activities of Zuclopenthixol.",
      "name": "Zuclopenthixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00511",
      "source": "DB00004",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00112",
      "source": "DB00004",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB06772",
      "source": "DB00004",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00531",
      "source": "DB00004",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB01078",
      "source": "DB00004",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Denileukin diftitox.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB01396",
      "source": "DB00004",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Denileukin diftitox.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00390",
      "source": "DB00004",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Denileukin diftitox.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB01248",
      "source": "DB00004",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB01092",
      "source": "DB00004",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Denileukin diftitox.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB01229",
      "source": "DB00004",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00072",
      "source": "DB00004",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01536",
      "source": "DB00005",
      "target": "DB01536",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with 4-Androstenedione.",
      "name": "4-Androstenedione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01281",
      "source": "DB00005",
      "target": "DB01281",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00054",
      "source": "DB00005",
      "target": "DB00054",
      "description": "Etanercept may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01193",
      "source": "DB00005",
      "target": "DB01193",
      "description": "Etanercept may decrease the antihypertensive activities of Acebutolol.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06736",
      "source": "DB00005",
      "target": "DB06736",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Aceclofenac.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01418",
      "source": "DB00005",
      "target": "DB01418",
      "description": "Etanercept may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00945",
      "source": "DB00005",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Acetylsalicylic acid.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11617",
      "source": "DB00005",
      "target": "DB11617",
      "description": "Etanercept may decrease the excretion rate of Aclarubicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Aclarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00210",
      "source": "DB00005",
      "target": "DB00210",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Adapalene.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00240",
      "source": "DB00005",
      "target": "DB00240",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Alclometasone.",
      "name": "Alclometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04630",
      "source": "DB00005",
      "target": "DB04630",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.",
      "name": "Aldosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00630",
      "source": "DB00005",
      "target": "DB00630",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Alendronic acid.",
      "name": "Alendronic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09026",
      "source": "DB00005",
      "target": "DB09026",
      "description": "Etanercept may decrease the antihypertensive activities of Aliskiren.",
      "name": "Aliskiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00866",
      "source": "DB00005",
      "target": "DB00866",
      "description": "Etanercept may decrease the antihypertensive activities of Alprenolol.",
      "name": "Alprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00770",
      "source": "DB00005",
      "target": "DB00770",
      "description": "The therapeutic efficacy of Alprostadil can be decreased when used in combination with Etanercept.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00288",
      "source": "DB00005",
      "target": "DB00288",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Amcinonide.",
      "name": "Amcinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00479",
      "source": "DB00005",
      "target": "DB00479",
      "description": "Etanercept may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Amikacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00594",
      "source": "DB00005",
      "target": "DB00594",
      "description": "Etanercept may decrease the antihypertensive activities of Amiloride.",
      "name": "Amiloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00026",
      "source": "DB00005",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05099",
      "source": "DB00005",
      "target": "DB05099",
      "description": "Etanercept may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01435",
      "source": "DB00005",
      "target": "DB01435",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11598",
      "source": "DB00005",
      "target": "DB11598",
      "description": "Etanercept may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06605",
      "source": "DB00005",
      "target": "DB06605",
      "description": "Etanercept may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05676",
      "source": "DB00005",
      "target": "DB05676",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Apremilast.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00407",
      "source": "DB00005",
      "target": "DB00407",
      "description": "Etanercept may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00278",
      "source": "DB00005",
      "target": "DB00278",
      "description": "Etanercept may increase the anticoagulant activities of Argatroban.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09204",
      "source": "DB00005",
      "target": "DB09204",
      "description": "Etanercept may decrease the antihypertensive activities of Arotinolol.",
      "name": "Arotinolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00335",
      "source": "DB00005",
      "target": "DB00335",
      "description": "Etanercept may decrease the antihypertensive activities of Atenolol.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB07402",
      "source": "DB00005",
      "target": "DB07402",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00972",
      "source": "DB00005",
      "target": "DB00972",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08822",
      "source": "DB00005",
      "target": "DB08822",
      "description": "The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etanercept.",
      "name": "Azilsartan medoxomil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01014",
      "source": "DB00005",
      "target": "DB01014",
      "description": "Etanercept may increase the nephrotoxic activities of Balsalazide.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB12768",
      "source": "DB00005",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Etanercept.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00102",
      "source": "DB00005",
      "target": "DB00102",
      "description": "Etanercept may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00394",
      "source": "DB00005",
      "target": "DB00394",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.",
      "name": "Beclomethasone dipropionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09013",
      "source": "DB00005",
      "target": "DB09013",
      "description": "Etanercept may decrease the antihypertensive activities of Befunolol.",
      "name": "Befunolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08879",
      "source": "DB00005",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00542",
      "source": "DB00005",
      "target": "DB00542",
      "description": "The risk or severity of adverse effects can be increased when Benazepril is combined with Etanercept.",
      "name": "Benazepril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00436",
      "source": "DB00005",
      "target": "DB00436",
      "description": "The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etanercept.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04812",
      "source": "DB00005",
      "target": "DB04812",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Benoxaprofen.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00443",
      "source": "DB00005",
      "target": "DB00443",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00195",
      "source": "DB00005",
      "target": "DB00195",
      "description": "Etanercept may decrease the antihypertensive activities of Betaxolol.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01295",
      "source": "DB00005",
      "target": "DB01295",
      "description": "Etanercept may decrease the antihypertensive activities of Bevantolol.",
      "name": "Bevantolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00905",
      "source": "DB00005",
      "target": "DB00905",
      "description": "The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etanercept.",
      "name": "Bimatoprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00612",
      "source": "DB00005",
      "target": "DB00612",
      "description": "Etanercept may decrease the antihypertensive activities of Bisoprolol.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00006",
      "source": "DB00005",
      "target": "DB00006",
      "description": "Etanercept may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08807",
      "source": "DB00005",
      "target": "DB08807",
      "description": "Etanercept may decrease the antihypertensive activities of Bopindolol.",
      "name": "Bopindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00963",
      "source": "DB00005",
      "target": "DB00963",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Bromfenac.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01222",
      "source": "DB00005",
      "target": "DB01222",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06726",
      "source": "DB00005",
      "target": "DB06726",
      "description": "Etanercept may decrease the antihypertensive activities of Bufuralol.",
      "name": "Bufuralol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00887",
      "source": "DB00005",
      "target": "DB00887",
      "description": "Etanercept may decrease the diuretic activities of Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08808",
      "source": "DB00005",
      "target": "DB08808",
      "description": "Etanercept may decrease the antihypertensive activities of Bupranolol.",
      "name": "Bupranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06168",
      "source": "DB00005",
      "target": "DB06168",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Canakinumab.",
      "name": "Canakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00796",
      "source": "DB00005",
      "target": "DB00796",
      "description": "The risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.",
      "name": "Candesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00616",
      "source": "DB00005",
      "target": "DB00616",
      "description": "The risk or severity of adverse effects can be increased when Candoxatril is combined with Etanercept.",
      "name": "Candoxatril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01197",
      "source": "DB00005",
      "target": "DB01197",
      "description": "The risk or severity of adverse effects can be increased when Captopril is combined with Etanercept.",
      "name": "Captopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00429",
      "source": "DB00005",
      "target": "DB00429",
      "description": "The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etanercept.",
      "name": "Carboprost Tromethamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00821",
      "source": "DB00005",
      "target": "DB00821",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Carprofen.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00521",
      "source": "DB00005",
      "target": "DB00521",
      "description": "Etanercept may decrease the antihypertensive activities of Carteolol.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01136",
      "source": "DB00005",
      "target": "DB01136",
      "description": "Etanercept may decrease the antihypertensive activities of Carvedilol.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01816",
      "source": "DB00005",
      "target": "DB01816",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00482",
      "source": "DB00005",
      "target": "DB00482",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04846",
      "source": "DB00005",
      "target": "DB04846",
      "description": "Etanercept may decrease the antihypertensive activities of Celiprolol.",
      "name": "Celiprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08904",
      "source": "DB00005",
      "target": "DB08904",
      "description": "Etanercept may increase the immunosuppressive activities of Certolizumab pegol.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09261",
      "source": "DB00005",
      "target": "DB09261",
      "description": "Etanercept may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00608",
      "source": "DB00005",
      "target": "DB00608",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Chloroquine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00880",
      "source": "DB00005",
      "target": "DB00880",
      "description": "The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00310",
      "source": "DB00005",
      "target": "DB00310",
      "description": "The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etanercept.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01432",
      "source": "DB00005",
      "target": "DB01432",
      "description": "Cholestyramine can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.",
      "name": "Cholestyramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01410",
      "source": "DB00005",
      "target": "DB01410",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Ciclesonide.",
      "name": "Ciclesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01340",
      "source": "DB00005",
      "target": "DB01340",
      "description": "The risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.",
      "name": "Cilazapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00827",
      "source": "DB00005",
      "target": "DB00827",
      "description": "Etanercept may increase the neuroexcitatory activities of Cinoxacin.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00537",
      "source": "DB00005",
      "target": "DB00537",
      "description": "Etanercept may increase the neuroexcitatory activities of Ciprofloxacin.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04272",
      "source": "DB00005",
      "target": "DB04272",
      "description": "Etanercept may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01013",
      "source": "DB00005",
      "target": "DB01013",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.",
      "name": "Clobetasol propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00838",
      "source": "DB00005",
      "target": "DB00838",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone.",
      "name": "Clocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00720",
      "source": "DB00005",
      "target": "DB00720",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Clodronate.",
      "name": "Clodronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09218",
      "source": "DB00005",
      "target": "DB09218",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Clonixin.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11507",
      "source": "DB00005",
      "target": "DB11507",
      "description": "The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etanercept.",
      "name": "Cloprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00930",
      "source": "DB00005",
      "target": "DB00930",
      "description": "Colesevelam can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.",
      "name": "Colesevelam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00375",
      "source": "DB00005",
      "target": "DB00375",
      "description": "Colestipol can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.",
      "name": "Colestipol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01380",
      "source": "DB00005",
      "target": "DB01380",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00531",
      "source": "DB00005",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00091",
      "source": "DB00005",
      "target": "DB00091",
      "description": "Etanercept may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08921",
      "source": "DB00005",
      "target": "DB08921",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with D-Limonene.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06695",
      "source": "DB00005",
      "target": "DB06695",
      "description": "Etanercept may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06779",
      "source": "DB00005",
      "target": "DB06779",
      "description": "Etanercept may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06754",
      "source": "DB00005",
      "target": "DB06754",
      "description": "Etanercept may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00694",
      "source": "DB00005",
      "target": "DB00694",
      "description": "Etanercept may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01609",
      "source": "DB00005",
      "target": "DB01609",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01708",
      "source": "DB00005",
      "target": "DB01708",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Dehydroepiandrosterone.",
      "name": "Dehydroepiandrosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05804",
      "source": "DB00005",
      "target": "DB05804",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with dehydroepiandrosterone sulfate.",
      "name": "dehydroepiandrosterone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06643",
      "source": "DB00005",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11095",
      "source": "DB00005",
      "target": "DB11095",
      "description": "Etanercept may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00035",
      "source": "DB00005",
      "target": "DB00035",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.",
      "name": "Desmopressin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00547",
      "source": "DB00005",
      "target": "DB00547",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.",
      "name": "Desoximetasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06780",
      "source": "DB00005",
      "target": "DB06780",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone acetate.",
      "name": "Desoxycorticosterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01234",
      "source": "DB00005",
      "target": "DB01234",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11487",
      "source": "DB00005",
      "target": "DB11487",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone isonicotinate.",
      "name": "Dexamethasone isonicotinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09214",
      "source": "DB00005",
      "target": "DB09214",
      "description": "The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etanercept.",
      "name": "Dexketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09255",
      "source": "DB00005",
      "target": "DB09255",
      "description": "Etanercept may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11122",
      "source": "DB00005",
      "target": "DB11122",
      "description": "Etanercept may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11076",
      "source": "DB00005",
      "target": "DB11076",
      "description": "Etanercept may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11241",
      "source": "DB00005",
      "target": "DB11241",
      "description": "Etanercept may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00586",
      "source": "DB00005",
      "target": "DB00586",
      "description": "The risk or severity of adverse effects can be increased when Diclofenac is combined with Etanercept.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00266",
      "source": "DB00005",
      "target": "DB00266",
      "description": "Etanercept may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00223",
      "source": "DB00005",
      "target": "DB00223",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Diflorasone.",
      "name": "Diflorasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00861",
      "source": "DB00005",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09095",
      "source": "DB00005",
      "target": "DB09095",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.",
      "name": "Difluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06781",
      "source": "DB00005",
      "target": "DB06781",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Difluprednate.",
      "name": "Difluprednate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00390",
      "source": "DB00005",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Etanercept.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11512",
      "source": "DB00005",
      "target": "DB11512",
      "description": "Etanercept may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Dihydrostreptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00917",
      "source": "DB00005",
      "target": "DB00917",
      "description": "The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etanercept.",
      "name": "Dinoprostone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00997",
      "source": "DB00005",
      "target": "DB00997",
      "description": "Etanercept may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01395",
      "source": "DB00005",
      "target": "DB01395",
      "description": "Etanercept may increase the hyperkalemic activities of Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09215",
      "source": "DB00005",
      "target": "DB09215",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Droxicam.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00974",
      "source": "DB00005",
      "target": "DB00974",
      "description": "Etanercept may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09075",
      "source": "DB00005",
      "target": "DB09075",
      "description": "Etanercept may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00584",
      "source": "DB00005",
      "target": "DB00584",
      "description": "The risk or severity of adverse effects can be increased when Enalapril is combined with Etanercept.",
      "name": "Enalapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09477",
      "source": "DB00005",
      "target": "DB09477",
      "description": "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etanercept.",
      "name": "Enalaprilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00467",
      "source": "DB00005",
      "target": "DB00467",
      "description": "Etanercept may increase the neuroexcitatory activities of Enoxacin.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01225",
      "source": "DB00005",
      "target": "DB01225",
      "description": "Etanercept may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08991",
      "source": "DB00005",
      "target": "DB08991",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Epirizole.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00445",
      "source": "DB00005",
      "target": "DB00445",
      "description": "Etanercept may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Epirubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00700",
      "source": "DB00005",
      "target": "DB00700",
      "description": "Etanercept may decrease the antihypertensive activities of Eplerenone.",
      "name": "Eplerenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01240",
      "source": "DB00005",
      "target": "DB01240",
      "description": "The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00876",
      "source": "DB00005",
      "target": "DB00876",
      "description": "The risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.",
      "name": "Eprosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB03515",
      "source": "DB00005",
      "target": "DB03515",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Equilenin.",
      "name": "Equilenin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB02187",
      "source": "DB00005",
      "target": "DB02187",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Equilin.",
      "name": "Equilin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00187",
      "source": "DB00005",
      "target": "DB00187",
      "description": "Etanercept may decrease the antihypertensive activities of Esmolol.",
      "name": "Esmolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00655",
      "source": "DB00005",
      "target": "DB00655",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Estrone.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00903",
      "source": "DB00005",
      "target": "DB00903",
      "description": "Etanercept may decrease the diuretic activities of Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08794",
      "source": "DB00005",
      "target": "DB08794",
      "description": "Etanercept may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01077",
      "source": "DB00005",
      "target": "DB01077",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Etidronic acid.",
      "name": "Etidronic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00749",
      "source": "DB00005",
      "target": "DB00749",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Etodolac.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08984",
      "source": "DB00005",
      "target": "DB08984",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Etofenamate.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01628",
      "source": "DB00005",
      "target": "DB01628",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11358",
      "source": "DB00005",
      "target": "DB11358",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Evening primrose oil.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06246",
      "source": "DB00005",
      "target": "DB06246",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with exisulind.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08981",
      "source": "DB00005",
      "target": "DB08981",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fenbufen.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00573",
      "source": "DB00005",
      "target": "DB00573",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fenoprofen.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08868",
      "source": "DB00005",
      "target": "DB08868",
      "description": "Etanercept may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04576",
      "source": "DB00005",
      "target": "DB04576",
      "description": "Etanercept may increase the neuroexcitatory activities of Fleroxacin.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08976",
      "source": "DB00005",
      "target": "DB08976",
      "description": "The risk or severity of adverse effects can be increased when Floctafenine is combined with Etanercept.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00687",
      "source": "DB00005",
      "target": "DB00687",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08972",
      "source": "DB00005",
      "target": "DB08972",
      "description": "Etanercept may increase the neuroexcitatory activities of Flumequine.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00663",
      "source": "DB00005",
      "target": "DB00663",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Flumethasone.",
      "name": "Flumethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00180",
      "source": "DB00005",
      "target": "DB00180",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.",
      "name": "Flunisolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11518",
      "source": "DB00005",
      "target": "DB11518",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Flunixin.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00591",
      "source": "DB00005",
      "target": "DB00591",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone Acetonide.",
      "name": "Fluocinolone Acetonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01047",
      "source": "DB00005",
      "target": "DB01047",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide.",
      "name": "Fluocinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08971",
      "source": "DB00005",
      "target": "DB08971",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.",
      "name": "Fluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00324",
      "source": "DB00005",
      "target": "DB00324",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.",
      "name": "Fluorometholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08970",
      "source": "DB00005",
      "target": "DB08970",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.",
      "name": "Fluprednidene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09378",
      "source": "DB00005",
      "target": "DB09378",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednisolone.",
      "name": "Fluprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00846",
      "source": "DB00005",
      "target": "DB00846",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Flurandrenolide.",
      "name": "Flurandrenolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00712",
      "source": "DB00005",
      "target": "DB00712",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Flurbiprofen.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08906",
      "source": "DB00005",
      "target": "DB08906",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone furoate.",
      "name": "Fluticasone furoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00588",
      "source": "DB00005",
      "target": "DB00588",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone Propionate.",
      "name": "Fluticasone Propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00158",
      "source": "DB00005",
      "target": "DB00158",
      "description": "The therapeutic efficacy of Folic Acid can be decreased when used in combination with Etanercept.",
      "name": "Folic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00569",
      "source": "DB00005",
      "target": "DB00569",
      "description": "Etanercept may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01342",
      "source": "DB00005",
      "target": "DB01342",
      "description": "The risk or severity of adverse effects can be increased when Forasartan is combined with Etanercept.",
      "name": "Forasartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00492",
      "source": "DB00005",
      "target": "DB00492",
      "description": "The risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.",
      "name": "Fosinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00452",
      "source": "DB00005",
      "target": "DB00452",
      "description": "Etanercept may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Framycetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00695",
      "source": "DB00005",
      "target": "DB00695",
      "description": "Etanercept may decrease the diuretic activities of Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06160",
      "source": "DB00005",
      "target": "DB06160",
      "description": "Etanercept may increase the neuroexcitatory activities of Garenoxacin.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01044",
      "source": "DB00005",
      "target": "DB01044",
      "description": "Etanercept may increase the neuroexcitatory activities of Gatifloxacin.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08964",
      "source": "DB00005",
      "target": "DB08964",
      "description": "The therapeutic efficacy of Gemeprost can be decreased when used in combination with Etanercept.",
      "name": "Gemeprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01155",
      "source": "DB00005",
      "target": "DB01155",
      "description": "Etanercept may increase the neuroexcitatory activities of Gemifloxacin.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00798",
      "source": "DB00005",
      "target": "DB00798",
      "description": "Etanercept may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Gentamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00365",
      "source": "DB00005",
      "target": "DB00365",
      "description": "Etanercept may increase the neuroexcitatory activities of Grepafloxacin.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00502",
      "source": "DB00005",
      "target": "DB00502",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01109",
      "source": "DB00005",
      "target": "DB01109",
      "description": "Etanercept may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB02351",
      "source": "DB00005",
      "target": "DB02351",
      "description": "Etanercept may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05767",
      "source": "DB00005",
      "target": "DB05767",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with HMPL-004.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01275",
      "source": "DB00005",
      "target": "DB01275",
      "description": "Etanercept may decrease the antihypertensive activities of Hydralazine.",
      "name": "Hydralazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00999",
      "source": "DB00005",
      "target": "DB00999",
      "description": "The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etanercept.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00741",
      "source": "DB00005",
      "target": "DB00741",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00774",
      "source": "DB00005",
      "target": "DB00774",
      "description": "The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etanercept.",
      "name": "Hydroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11520",
      "source": "DB00005",
      "target": "DB11520",
      "description": "Etanercept may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Hygromycin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00710",
      "source": "DB00005",
      "target": "DB00710",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.",
      "name": "Ibandronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01050",
      "source": "DB00005",
      "target": "DB01050",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuprofen.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08955",
      "source": "DB00005",
      "target": "DB08955",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuproxam.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06196",
      "source": "DB00005",
      "target": "DB06196",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Icatibant.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01177",
      "source": "DB00005",
      "target": "DB01177",
      "description": "Etanercept may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06406",
      "source": "DB00005",
      "target": "DB06406",
      "description": "Etanercept may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01088",
      "source": "DB00005",
      "target": "DB01088",
      "description": "The therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00808",
      "source": "DB00005",
      "target": "DB00808",
      "description": "The therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08952",
      "source": "DB00005",
      "target": "DB08952",
      "description": "Etanercept may decrease the antihypertensive activities of Indenolol.",
      "name": "Indenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00328",
      "source": "DB00005",
      "target": "DB00328",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08951",
      "source": "DB00005",
      "target": "DB08951",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Indoprofen.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00065",
      "source": "DB00005",
      "target": "DB00065",
      "description": "Etanercept may increase the immunosuppressive activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01029",
      "source": "DB00005",
      "target": "DB01029",
      "description": "The risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.",
      "name": "Irbesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08942",
      "source": "DB00005",
      "target": "DB08942",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Isoxicam.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01172",
      "source": "DB00005",
      "target": "DB01172",
      "description": "Etanercept may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Kanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08940",
      "source": "DB00005",
      "target": "DB08940",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Kebuzone.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01009",
      "source": "DB00005",
      "target": "DB01009",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00465",
      "source": "DB00005",
      "target": "DB00465",
      "description": "The risk or severity of adverse effects can be increased when Ketorolac is combined with Etanercept.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00598",
      "source": "DB00005",
      "target": "DB00598",
      "description": "Etanercept may decrease the antihypertensive activities of Labetalol.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01097",
      "source": "DB00005",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00001",
      "source": "DB00005",
      "target": "DB00001",
      "description": "Etanercept may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01210",
      "source": "DB00005",
      "target": "DB01210",
      "description": "Etanercept may decrease the antihypertensive activities of Levobunolol.",
      "name": "Levobunolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01137",
      "source": "DB00005",
      "target": "DB01137",
      "description": "Etanercept may increase the neuroexcitatory activities of Levofloxacin.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00722",
      "source": "DB00005",
      "target": "DB00722",
      "description": "The risk or severity of adverse effects can be increased when Lisinopril is combined with Etanercept.",
      "name": "Lisinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01356",
      "source": "DB00005",
      "target": "DB01356",
      "description": "The serum concentration of Lithium can be increased when it is combined with Etanercept.",
      "name": "Lithium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00978",
      "source": "DB00005",
      "target": "DB00978",
      "description": "Etanercept may increase the neuroexcitatory activities of Lomefloxacin.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06725",
      "source": "DB00005",
      "target": "DB06725",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00678",
      "source": "DB00005",
      "target": "DB00678",
      "description": "The risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09212",
      "source": "DB00005",
      "target": "DB09212",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Loxoprofen.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01046",
      "source": "DB00005",
      "target": "DB01046",
      "description": "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etanercept.",
      "name": "Lubiprostone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01283",
      "source": "DB00005",
      "target": "DB01283",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Lumiracoxib.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01397",
      "source": "DB00005",
      "target": "DB01397",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00179",
      "source": "DB00005",
      "target": "DB00179",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Masoprocol.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00939",
      "source": "DB00005",
      "target": "DB00939",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00253",
      "source": "DB00005",
      "target": "DB00253",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Medrysone.",
      "name": "Medrysone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00784",
      "source": "DB00005",
      "target": "DB00784",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Mefenamic acid.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11529",
      "source": "DB00005",
      "target": "DB11529",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Melengestrol.",
      "name": "Melengestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00814",
      "source": "DB00005",
      "target": "DB00814",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00244",
      "source": "DB00005",
      "target": "DB00244",
      "description": "Etanercept may increase the nephrotoxic activities of Mesalazine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04817",
      "source": "DB00005",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Metamizole.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00563",
      "source": "DB00005",
      "target": "DB00563",
      "description": "The serum concentration of Methotrexate can be increased when it is combined with Etanercept.",
      "name": "Methotrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00232",
      "source": "DB00005",
      "target": "DB00232",
      "description": "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.",
      "name": "Methyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00959",
      "source": "DB00005",
      "target": "DB00959",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01214",
      "source": "DB00005",
      "target": "DB01214",
      "description": "Etanercept may decrease the antihypertensive activities of Metipranolol.",
      "name": "Metipranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00524",
      "source": "DB00005",
      "target": "DB00524",
      "description": "The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00264",
      "source": "DB00005",
      "target": "DB00264",
      "description": "Etanercept may decrease the antihypertensive activities of Metoprolol.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01578",
      "source": "DB00005",
      "target": "DB01578",
      "description": "Etanercept may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Metrizamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00929",
      "source": "DB00005",
      "target": "DB00929",
      "description": "The therapeutic efficacy of Misoprostol can be decreased when used in combination with Etanercept.",
      "name": "Misoprostol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00691",
      "source": "DB00005",
      "target": "DB00691",
      "description": "The risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00764",
      "source": "DB00005",
      "target": "DB00764",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.",
      "name": "Mometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09285",
      "source": "DB00005",
      "target": "DB09285",
      "description": "The risk or severity of adverse effects can be increased when Morniflumate is combined with Etanercept.",
      "name": "Morniflumate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00218",
      "source": "DB00005",
      "target": "DB00218",
      "description": "Etanercept may increase the neuroexcitatory activities of Moxifloxacin.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00688",
      "source": "DB00005",
      "target": "DB00688",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01024",
      "source": "DB00005",
      "target": "DB01024",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00461",
      "source": "DB00005",
      "target": "DB00461",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01203",
      "source": "DB00005",
      "target": "DB01203",
      "description": "Etanercept may decrease the antihypertensive activities of Nadolol.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08813",
      "source": "DB00005",
      "target": "DB08813",
      "description": "Etanercept may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00735",
      "source": "DB00005",
      "target": "DB00735",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Naftifine.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00779",
      "source": "DB00005",
      "target": "DB00779",
      "description": "Etanercept may increase the neuroexcitatory activities of Nalidixic Acid.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00788",
      "source": "DB00005",
      "target": "DB00788",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Naproxen.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00108",
      "source": "DB00005",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05822",
      "source": "DB00005",
      "target": "DB05822",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with NCX 4016.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06600",
      "source": "DB00005",
      "target": "DB06600",
      "description": "Etanercept may increase the neuroexcitatory activities of Nemonoxacin.",
      "name": "Nemonoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00994",
      "source": "DB00005",
      "target": "DB00994",
      "description": "Etanercept may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Neomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06802",
      "source": "DB00005",
      "target": "DB06802",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Nepafenac.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00955",
      "source": "DB00005",
      "target": "DB00955",
      "description": "Etanercept may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Netilmicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04552",
      "source": "DB00005",
      "target": "DB04552",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04743",
      "source": "DB00005",
      "target": "DB04743",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01059",
      "source": "DB00005",
      "target": "DB01059",
      "description": "Etanercept may increase the neuroexcitatory activities of Norfloxacin.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01165",
      "source": "DB00005",
      "target": "DB01165",
      "description": "Etanercept may increase the neuroexcitatory activities of Ofloxacin.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00275",
      "source": "DB00005",
      "target": "DB00275",
      "description": "The risk or severity of adverse effects can be increased when Olmesartan is combined with Etanercept.",
      "name": "Olmesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00768",
      "source": "DB00005",
      "target": "DB00768",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01250",
      "source": "DB00005",
      "target": "DB01250",
      "description": "Etanercept may increase the nephrotoxic activities of Olsalazine.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04865",
      "source": "DB00005",
      "target": "DB04865",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00886",
      "source": "DB00005",
      "target": "DB00886",
      "description": "The risk or severity of adverse effects can be increased when Omapatrilat is combined with Etanercept.",
      "name": "Omapatrilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11444",
      "source": "DB00005",
      "target": "DB11444",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Orgotein.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06635",
      "source": "DB00005",
      "target": "DB06635",
      "description": "Etanercept may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00991",
      "source": "DB00005",
      "target": "DB00991",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01580",
      "source": "DB00005",
      "target": "DB01580",
      "description": "Etanercept may decrease the antihypertensive activities of Oxprenolol.",
      "name": "Oxprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB03585",
      "source": "DB00005",
      "target": "DB03585",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00282",
      "source": "DB00005",
      "target": "DB00282",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Pamidronate.",
      "name": "Pamidronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01384",
      "source": "DB00005",
      "target": "DB01384",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.",
      "name": "Paramethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08439",
      "source": "DB00005",
      "target": "DB08439",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Parecoxib.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01421",
      "source": "DB00005",
      "target": "DB01421",
      "description": "Etanercept may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Paromomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00487",
      "source": "DB00005",
      "target": "DB00487",
      "description": "Etanercept may increase the neuroexcitatory activities of Pefloxacin.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01359",
      "source": "DB00005",
      "target": "DB01359",
      "description": "Etanercept may decrease the antihypertensive activities of Penbutolol.",
      "name": "Penbutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00686",
      "source": "DB00005",
      "target": "DB00686",
      "description": "Etanercept may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00790",
      "source": "DB00005",
      "target": "DB00790",
      "description": "The risk or severity of adverse effects can be increased when Perindopril is combined with Etanercept.",
      "name": "Perindopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00498",
      "source": "DB00005",
      "target": "DB00498",
      "description": "Etanercept may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00946",
      "source": "DB00005",
      "target": "DB00946",
      "description": "Etanercept may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00812",
      "source": "DB00005",
      "target": "DB00812",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00337",
      "source": "DB00005",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00960",
      "source": "DB00005",
      "target": "DB00960",
      "description": "Etanercept may decrease the antihypertensive activities of Pindolol.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB02925",
      "source": "DB00005",
      "target": "DB02925",
      "description": "Etanercept may decrease the diuretic activities of Piretanide.",
      "name": "Piretanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04951",
      "source": "DB00005",
      "target": "DB04951",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00554",
      "source": "DB00005",
      "target": "DB00554",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06810",
      "source": "DB00005",
      "target": "DB06810",
      "description": "Etanercept may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Plicamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01324",
      "source": "DB00005",
      "target": "DB01324",
      "description": "The therapeutic efficacy of Polythiazide can be decreased when used in combination with Etanercept.",
      "name": "Polythiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01297",
      "source": "DB00005",
      "target": "DB01297",
      "description": "Etanercept may decrease the antihypertensive activities of Practolol.",
      "name": "Practolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06813",
      "source": "DB00005",
      "target": "DB06813",
      "description": "The serum concentration of Pralatrexate can be increased when it is combined with Etanercept.",
      "name": "Pralatrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01130",
      "source": "DB00005",
      "target": "DB01130",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Prednicarbate.",
      "name": "Prednicarbate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00860",
      "source": "DB00005",
      "target": "DB00860",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00635",
      "source": "DB00005",
      "target": "DB00635",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB02789",
      "source": "DB00005",
      "target": "DB02789",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Pregnenolone.",
      "name": "Pregnenolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01032",
      "source": "DB00005",
      "target": "DB01032",
      "description": "The serum concentration of Etanercept can be increased when it is combined with Probenecid.",
      "name": "Probenecid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09288",
      "source": "DB00005",
      "target": "DB09288",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Propacetamol.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00571",
      "source": "DB00005",
      "target": "DB00571",
      "description": "Etanercept may decrease the antihypertensive activities of Propranolol.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08863",
      "source": "DB00005",
      "target": "DB08863",
      "description": "The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Etanercept.",
      "name": "Prostaglandin D2"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11312",
      "source": "DB00005",
      "target": "DB11312",
      "description": "Etanercept may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11268",
      "source": "DB00005",
      "target": "DB11268",
      "description": "Etanercept may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05173",
      "source": "DB00005",
      "target": "DB05173",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with PTC299.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08437",
      "source": "DB00005",
      "target": "DB08437",
      "description": "Etanercept may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Puromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00881",
      "source": "DB00005",
      "target": "DB00881",
      "description": "The risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.",
      "name": "Quinapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01325",
      "source": "DB00005",
      "target": "DB01325",
      "description": "The therapeutic efficacy of Quinethazone can be decreased when used in combination with Etanercept.",
      "name": "Quinethazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB10283",
      "source": "DB00005",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB10283",
      "source": "DB00005",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Etanercept.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00178",
      "source": "DB00005",
      "target": "DB00178",
      "description": "The risk or severity of adverse effects can be increased when Ramipril is combined with Etanercept.",
      "name": "Ramipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01180",
      "source": "DB00005",
      "target": "DB01180",
      "description": "The risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.",
      "name": "Rescinnamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB02709",
      "source": "DB00005",
      "target": "DB02709",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09259",
      "source": "DB00005",
      "target": "DB09259",
      "description": "Etanercept may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB03615",
      "source": "DB00005",
      "target": "DB03615",
      "description": "Etanercept may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Ribostamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06372",
      "source": "DB00005",
      "target": "DB06372",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept.",
      "name": "Rilonacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00896",
      "source": "DB00005",
      "target": "DB00896",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rimexolone.",
      "name": "Rimexolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00884",
      "source": "DB00005",
      "target": "DB00884",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.",
      "name": "Risedronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06228",
      "source": "DB00005",
      "target": "DB06228",
      "description": "Etanercept may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00533",
      "source": "DB00005",
      "target": "DB00533",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rofecoxib.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01656",
      "source": "DB00005",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Etanercept.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00817",
      "source": "DB00005",
      "target": "DB00817",
      "description": "Etanercept may increase the neuroexcitatory activities of Rosoxacin.",
      "name": "Rosoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09292",
      "source": "DB00005",
      "target": "DB09292",
      "description": "The risk or severity of adverse effects can be increased when Sacubitril is combined with Etanercept.",
      "name": "Sacubitril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08797",
      "source": "DB00005",
      "target": "DB08797",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00936",
      "source": "DB00005",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylic acid.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01399",
      "source": "DB00005",
      "target": "DB01399",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01347",
      "source": "DB00005",
      "target": "DB01347",
      "description": "The risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.",
      "name": "Saprisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06763",
      "source": "DB00005",
      "target": "DB06763",
      "description": "The risk or severity of adverse effects can be increased when Saralasin is combined with Etanercept.",
      "name": "Saralasin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06739",
      "source": "DB00005",
      "target": "DB06739",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Seratrodast.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06688",
      "source": "DB00005",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00489",
      "source": "DB00005",
      "target": "DB00489",
      "description": "Etanercept may decrease the antihypertensive activities of Sotalol.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01208",
      "source": "DB00005",
      "target": "DB01208",
      "description": "Etanercept may increase the neuroexcitatory activities of Sparfloxacin.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00919",
      "source": "DB00005",
      "target": "DB00919",
      "description": "Etanercept may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Spectinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01348",
      "source": "DB00005",
      "target": "DB01348",
      "description": "The risk or severity of adverse effects can be increased when Spirapril is combined with Etanercept.",
      "name": "Spirapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00421",
      "source": "DB00005",
      "target": "DB00421",
      "description": "Etanercept may decrease the antihypertensive activities of Spironolactone.",
      "name": "Spironolactone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB05073",
      "source": "DB00005",
      "target": "DB05073",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with SRT501.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01082",
      "source": "DB00005",
      "target": "DB01082",
      "description": "Etanercept may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Streptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00428",
      "source": "DB00005",
      "target": "DB00428",
      "description": "Etanercept may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00795",
      "source": "DB00005",
      "target": "DB00795",
      "description": "Etanercept may increase the nephrotoxic activities of Sulfasalazine.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00605",
      "source": "DB00005",
      "target": "DB00605",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Sulindac.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06271",
      "source": "DB00005",
      "target": "DB06271",
      "description": "Etanercept may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00870",
      "source": "DB00005",
      "target": "DB00870",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00864",
      "source": "DB00005",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etanercept.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00864",
      "source": "DB00005",
      "target": "DB00864",
      "description": "Etanercept may increase the nephrotoxic activities of Tacrolimus.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09295",
      "source": "DB00005",
      "target": "DB09295",
      "description": "The risk or severity of adverse effects can be increased when Talniflumate is combined with Etanercept.",
      "name": "Talniflumate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01349",
      "source": "DB00005",
      "target": "DB01349",
      "description": "The risk or severity of adverse effects can be increased when Tasosartan is combined with Etanercept.",
      "name": "Tasosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09138",
      "source": "DB00005",
      "target": "DB09138",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Technetium Tc-99m Medronate.",
      "name": "Technetium Tc-99m Medronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00966",
      "source": "DB00005",
      "target": "DB00966",
      "description": "The risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.",
      "name": "Telmisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01405",
      "source": "DB00005",
      "target": "DB01405",
      "description": "Etanercept may increase the neuroexcitatory activities of Temafloxacin.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08836",
      "source": "DB00005",
      "target": "DB08836",
      "description": "The risk or severity of adverse effects can be increased when Temocapril is combined with Etanercept.",
      "name": "Temocapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00300",
      "source": "DB00005",
      "target": "DB00300",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tenofovir.",
      "name": "Tenofovir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00469",
      "source": "DB00005",
      "target": "DB00469",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tenoxicam.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB11466",
      "source": "DB00005",
      "target": "DB11466",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08880",
      "source": "DB00005",
      "target": "DB08880",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01600",
      "source": "DB00005",
      "target": "DB01600",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01133",
      "source": "DB00005",
      "target": "DB01133",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tiludronate.",
      "name": "Tiludronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00373",
      "source": "DB00005",
      "target": "DB00373",
      "description": "Etanercept may decrease the antihypertensive activities of Timolol.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09091",
      "source": "DB00005",
      "target": "DB09091",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tixocortol.",
      "name": "Tixocortol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00684",
      "source": "DB00005",
      "target": "DB00684",
      "description": "Etanercept may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.",
      "name": "Tobramycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06273",
      "source": "DB00005",
      "target": "DB06273",
      "description": "Tocilizumab may increase the immunosuppressive activities of Etanercept.",
      "name": "Tocilizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB08895",
      "source": "DB00005",
      "target": "DB08895",
      "description": "Etanercept may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09216",
      "source": "DB00005",
      "target": "DB09216",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tolfenamic Acid.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00500",
      "source": "DB00005",
      "target": "DB00500",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00214",
      "source": "DB00005",
      "target": "DB00214",
      "description": "Etanercept may decrease the diuretic activities of Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00519",
      "source": "DB00005",
      "target": "DB00519",
      "description": "The risk or severity of adverse effects can be increased when Trandolapril is combined with Etanercept.",
      "name": "Trandolapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB07615",
      "source": "DB00005",
      "target": "DB07615",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00072",
      "source": "DB00005",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Etanercept.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00287",
      "source": "DB00005",
      "target": "DB00287",
      "description": "The therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.",
      "name": "Travoprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00374",
      "source": "DB00005",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00620",
      "source": "DB00005",
      "target": "DB00620",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00384",
      "source": "DB00005",
      "target": "DB00384",
      "description": "Etanercept may decrease the antihypertensive activities of Triamterene.",
      "name": "Triamterene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01021",
      "source": "DB00005",
      "target": "DB01021",
      "description": "The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etanercept.",
      "name": "Trichlormethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB01401",
      "source": "DB00005",
      "target": "DB01401",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Trisalicylate-choline.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00685",
      "source": "DB00005",
      "target": "DB00685",
      "description": "Etanercept may increase the neuroexcitatory activities of Trovafloxacin.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00580",
      "source": "DB00005",
      "target": "DB00580",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Valdecoxib.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00177",
      "source": "DB00005",
      "target": "DB00177",
      "description": "The risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.",
      "name": "Valsartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00512",
      "source": "DB00005",
      "target": "DB00512",
      "description": "The serum concentration of Vancomycin can be increased when it is combined with Etanercept.",
      "name": "Vancomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB09033",
      "source": "DB00005",
      "target": "DB09033",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Vedolizumab.",
      "name": "Vedolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00682",
      "source": "DB00005",
      "target": "DB00682",
      "description": "Etanercept may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04898",
      "source": "DB00005",
      "target": "DB04898",
      "description": "Etanercept may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB06737",
      "source": "DB00005",
      "target": "DB06737",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Zaltoprofen.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00744",
      "source": "DB00005",
      "target": "DB00744",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Zileuton.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00399",
      "source": "DB00005",
      "target": "DB00399",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Zoledronic acid.",
      "name": "Zoledronic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB04828",
      "source": "DB00005",
      "target": "DB04828",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Zomepirac.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01048",
      "source": "DB00006",
      "target": "DB01048",
      "description": "The serum concentration of Abacavir can be decreased when it is combined with Bivalirudin.",
      "name": "Abacavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00054",
      "source": "DB00006",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Bivalirudin.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06736",
      "source": "DB00006",
      "target": "DB06736",
      "description": "Aceclofenac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01418",
      "source": "DB00006",
      "target": "DB01418",
      "description": "Bivalirudin may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00945",
      "source": "DB00006",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00210",
      "source": "DB00006",
      "target": "DB00210",
      "description": "Adapalene may increase the anticoagulant activities of Bivalirudin.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00346",
      "source": "DB00006",
      "target": "DB00346",
      "description": "The serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01431",
      "source": "DB00006",
      "target": "DB01431",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Allylestrenol.",
      "name": "Allylestrenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00404",
      "source": "DB00006",
      "target": "DB00404",
      "description": "The serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.",
      "name": "Alprazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00770",
      "source": "DB00006",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00009",
      "source": "DB00006",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11372",
      "source": "DB00006",
      "target": "DB11372",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Altrenogest.",
      "name": "Altrenogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06081",
      "source": "DB00006",
      "target": "DB06081",
      "description": "ALX-0081 may increase the anticoagulant activities of Bivalirudin.",
      "name": "ALX-0081"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04836",
      "source": "DB00006",
      "target": "DB04836",
      "description": "The serum concentration of Amineptine can be increased when it is combined with Bivalirudin.",
      "name": "Amineptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01223",
      "source": "DB00006",
      "target": "DB01223",
      "description": "The serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00233",
      "source": "DB00006",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00321",
      "source": "DB00006",
      "target": "DB00321",
      "description": "The serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00261",
      "source": "DB00006",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05099",
      "source": "DB00006",
      "target": "DB05099",
      "description": "Bivalirudin may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00029",
      "source": "DB00006",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01435",
      "source": "DB00006",
      "target": "DB01435",
      "description": "Antipyrine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11598",
      "source": "DB00006",
      "target": "DB11598",
      "description": "Bivalirudin may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06605",
      "source": "DB00006",
      "target": "DB06605",
      "description": "Apixaban may increase the anticoagulant activities of Bivalirudin.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05676",
      "source": "DB00006",
      "target": "DB05676",
      "description": "Apremilast may increase the anticoagulant activities of Bivalirudin.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06692",
      "source": "DB00006",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00407",
      "source": "DB00006",
      "target": "DB00407",
      "description": "Bivalirudin may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00278",
      "source": "DB00006",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Bivalirudin.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06543",
      "source": "DB00006",
      "target": "DB06543",
      "description": "Astaxanthin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Astaxanthin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01076",
      "source": "DB00006",
      "target": "DB01076",
      "description": "The serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB07402",
      "source": "DB00006",
      "target": "DB07402",
      "description": "Azapropazone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00972",
      "source": "DB00006",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01014",
      "source": "DB00006",
      "target": "DB01014",
      "description": "Balsalazide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09005",
      "source": "DB00006",
      "target": "DB09005",
      "description": "Batroxobin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Batroxobin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06401",
      "source": "DB00006",
      "target": "DB06401",
      "description": "Bazedoxifene may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00102",
      "source": "DB00006",
      "target": "DB00102",
      "description": "Bivalirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09258",
      "source": "DB00006",
      "target": "DB09258",
      "description": "Bemiparin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04812",
      "source": "DB00006",
      "target": "DB04812",
      "description": "Benoxaprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05229",
      "source": "DB00006",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Bivalirudin.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08873",
      "source": "DB00006",
      "target": "DB08873",
      "description": "The serum concentration of Bivalirudin can be decreased when it is combined with Boceprevir.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00963",
      "source": "DB00006",
      "target": "DB00963",
      "description": "Bromfenac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01200",
      "source": "DB00006",
      "target": "DB01200",
      "description": "The serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00248",
      "source": "DB00006",
      "target": "DB00248",
      "description": "The serum concentration of Cabergoline can be increased when it is combined with Bivalirudin.",
      "name": "Cabergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06441",
      "source": "DB00006",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Bivalirudin.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00564",
      "source": "DB00006",
      "target": "DB00564",
      "description": "The metabolism of Bivalirudin can be increased when combined with Carbamazepine.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00821",
      "source": "DB00006",
      "target": "DB00821",
      "description": "Carprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01816",
      "source": "DB00006",
      "target": "DB01816",
      "description": "Castanospermine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00482",
      "source": "DB00006",
      "target": "DB00482",
      "description": "Celecoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09261",
      "source": "DB00006",
      "target": "DB09261",
      "description": "Bivalirudin may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00608",
      "source": "DB00006",
      "target": "DB00608",
      "description": "Chloroquine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00269",
      "source": "DB00006",
      "target": "DB00269",
      "description": "Chlorotrianisene may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01166",
      "source": "DB00006",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Bivalirudin.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00604",
      "source": "DB00006",
      "target": "DB00604",
      "description": "The serum concentration of Cisapride can be increased when it is combined with Bivalirudin.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04272",
      "source": "DB00006",
      "target": "DB04272",
      "description": "Bivalirudin may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01211",
      "source": "DB00006",
      "target": "DB01211",
      "description": "The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01242",
      "source": "DB00006",
      "target": "DB01242",
      "description": "The serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09218",
      "source": "DB00006",
      "target": "DB09218",
      "description": "Clonixin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00758",
      "source": "DB00006",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Bivalirudin.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11249",
      "source": "DB00006",
      "target": "DB11249",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase.",
      "name": "Collagenase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00286",
      "source": "DB00006",
      "target": "DB00286",
      "description": "Conjugated Equine Estrogens may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00924",
      "source": "DB00006",
      "target": "DB00924",
      "description": "The serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00531",
      "source": "DB00006",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00091",
      "source": "DB00006",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08921",
      "source": "DB00006",
      "target": "DB08921",
      "description": "D-Limonene may increase the anticoagulant activities of Bivalirudin.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06695",
      "source": "DB00006",
      "target": "DB06695",
      "description": "Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06779",
      "source": "DB00006",
      "target": "DB06779",
      "description": "Bivalirudin may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06754",
      "source": "DB00006",
      "target": "DB06754",
      "description": "Bivalirudin may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01254",
      "source": "DB00006",
      "target": "DB01254",
      "description": "Dasatinib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01609",
      "source": "DB00006",
      "target": "DB01609",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04932",
      "source": "DB00006",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00705",
      "source": "DB00006",
      "target": "DB00705",
      "description": "The serum concentration of Delavirdine can be decreased when it is combined with Bivalirudin.",
      "name": "Delavirdine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB03619",
      "source": "DB00006",
      "target": "DB03619",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deoxycholic Acid.",
      "name": "Deoxycholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01151",
      "source": "DB00006",
      "target": "DB01151",
      "description": "The serum concentration of Desipramine can be increased when it is combined with Bivalirudin.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11095",
      "source": "DB00006",
      "target": "DB11095",
      "description": "Bivalirudin may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04925",
      "source": "DB00006",
      "target": "DB04925",
      "description": "Desmoteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Desmoteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00304",
      "source": "DB00006",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09255",
      "source": "DB00006",
      "target": "DB09255",
      "description": "Bivalirudin may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11122",
      "source": "DB00006",
      "target": "DB11122",
      "description": "Bivalirudin may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11076",
      "source": "DB00006",
      "target": "DB11076",
      "description": "Bivalirudin may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11241",
      "source": "DB00006",
      "target": "DB11241",
      "description": "Bivalirudin may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00586",
      "source": "DB00006",
      "target": "DB00586",
      "description": "Diclofenac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00266",
      "source": "DB00006",
      "target": "DB00266",
      "description": "Bivalirudin may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00890",
      "source": "DB00006",
      "target": "DB00890",
      "description": "Dienestrol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09123",
      "source": "DB00006",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00255",
      "source": "DB00006",
      "target": "DB00255",
      "description": "Diethylstilbestrol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00861",
      "source": "DB00006",
      "target": "DB00861",
      "description": "Diflunisal may increase the anticoagulant activities of Bivalirudin.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00390",
      "source": "DB00006",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Bivalirudin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00320",
      "source": "DB00006",
      "target": "DB00320",
      "description": "The serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.",
      "name": "Dihydroergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00975",
      "source": "DB00006",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Bivalirudin.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08994",
      "source": "DB00006",
      "target": "DB08994",
      "description": "Ditazole may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ditazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09167",
      "source": "DB00006",
      "target": "DB09167",
      "description": "The serum concentration of Dosulepin can be increased when it is combined with Bivalirudin.",
      "name": "Dosulepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01142",
      "source": "DB00006",
      "target": "DB01142",
      "description": "The serum concentration of Doxepin can be increased when it is combined with Bivalirudin.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01395",
      "source": "DB00006",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00055",
      "source": "DB00006",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09215",
      "source": "DB00006",
      "target": "DB09215",
      "description": "Droxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00378",
      "source": "DB00006",
      "target": "DB00378",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dydrogesterone.",
      "name": "Dydrogesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00651",
      "source": "DB00006",
      "target": "DB00651",
      "description": "The serum concentration of Dyphylline can be decreased when it is combined with Bivalirudin.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00974",
      "source": "DB00006",
      "target": "DB00974",
      "description": "Bivalirudin may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09075",
      "source": "DB00006",
      "target": "DB09075",
      "description": "Edoxaban may increase the anticoagulant activities of Bivalirudin.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00109",
      "source": "DB00006",
      "target": "DB00109",
      "description": "The serum concentration of Enfuvirtide can be increased when it is combined with Bivalirudin.",
      "name": "Enfuvirtide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01225",
      "source": "DB00006",
      "target": "DB01225",
      "description": "Bivalirudin may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00751",
      "source": "DB00006",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08991",
      "source": "DB00006",
      "target": "DB08991",
      "description": "Epirizole may increase the anticoagulant activities of Bivalirudin.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06392",
      "source": "DB00006",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Bivalirudin.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01240",
      "source": "DB00006",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Bivalirudin.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00063",
      "source": "DB00006",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01049",
      "source": "DB00006",
      "target": "DB01049",
      "description": "The serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.",
      "name": "Ergoloid mesylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01253",
      "source": "DB00006",
      "target": "DB01253",
      "description": "The serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.",
      "name": "Ergonovine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00696",
      "source": "DB00006",
      "target": "DB00696",
      "description": "The serum concentration of Ergotamine can be increased when it is combined with Bivalirudin.",
      "name": "Ergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06678",
      "source": "DB00006",
      "target": "DB06678",
      "description": "The serum concentration of Esmirtazapine can be increased when it is combined with Bivalirudin.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00783",
      "source": "DB00006",
      "target": "DB00783",
      "description": "Estradiol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04573",
      "source": "DB00006",
      "target": "DB04573",
      "description": "Estriol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00655",
      "source": "DB00006",
      "target": "DB00655",
      "description": "Estrone may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00005",
      "source": "DB00006",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Bivalirudin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00977",
      "source": "DB00006",
      "target": "DB00977",
      "description": "Ethinyl Estradiol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08794",
      "source": "DB00006",
      "target": "DB08794",
      "description": "Bivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00823",
      "source": "DB00006",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00749",
      "source": "DB00006",
      "target": "DB00749",
      "description": "Etodolac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08984",
      "source": "DB00006",
      "target": "DB08984",
      "description": "Etofenamate may increase the anticoagulant activities of Bivalirudin.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00294",
      "source": "DB00006",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01628",
      "source": "DB00006",
      "target": "DB01628",
      "description": "Etoricoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06414",
      "source": "DB00006",
      "target": "DB06414",
      "description": "The serum concentration of Etravirine can be decreased when it is combined with Bivalirudin.",
      "name": "Etravirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11358",
      "source": "DB00006",
      "target": "DB11358",
      "description": "Evening primrose oil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06246",
      "source": "DB00006",
      "target": "DB06246",
      "description": "exisulind may increase the anticoagulant activities of Bivalirudin.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08981",
      "source": "DB00006",
      "target": "DB08981",
      "description": "Fenbufen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00573",
      "source": "DB00006",
      "target": "DB00573",
      "description": "Fenoprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08977",
      "source": "DB00006",
      "target": "DB08977",
      "description": "Fibrinolysin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Fibrinolysin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08976",
      "source": "DB00006",
      "target": "DB08976",
      "description": "Floctafenine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11518",
      "source": "DB00006",
      "target": "DB11518",
      "description": "Flunixin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00712",
      "source": "DB00006",
      "target": "DB00712",
      "description": "Flurbiprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00569",
      "source": "DB00006",
      "target": "DB00569",
      "description": "Bivalirudin may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB10532",
      "source": "DB00006",
      "target": "DB10532",
      "description": "The serum concentration of Bivalirudin can be decreased when it is combined with Garlic.",
      "name": "Garlic"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01645",
      "source": "DB00006",
      "target": "DB01645",
      "description": "Genistein may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06730",
      "source": "DB00006",
      "target": "DB06730",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestodene.",
      "name": "Gestodene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11619",
      "source": "DB00006",
      "target": "DB11619",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestrinone.",
      "name": "Gestrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB03404",
      "source": "DB00006",
      "target": "DB03404",
      "description": "Hemin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Hemin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01109",
      "source": "DB00006",
      "target": "DB01109",
      "description": "Bivalirudin may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB07931",
      "source": "DB00006",
      "target": "DB07931",
      "description": "Hexestrol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB02351",
      "source": "DB00006",
      "target": "DB02351",
      "description": "Bivalirudin may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05767",
      "source": "DB00006",
      "target": "DB05767",
      "description": "HMPL-004 may increase the anticoagulant activities of Bivalirudin.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06789",
      "source": "DB00006",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00078",
      "source": "DB00006",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09053",
      "source": "DB00006",
      "target": "DB09053",
      "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05266",
      "source": "DB00006",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01050",
      "source": "DB00006",
      "target": "DB01050",
      "description": "Ibuprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08955",
      "source": "DB00006",
      "target": "DB08955",
      "description": "Ibuproxam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06196",
      "source": "DB00006",
      "target": "DB06196",
      "description": "Icatibant may increase the anticoagulant activities of Bivalirudin.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08887",
      "source": "DB00006",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Bivalirudin.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06406",
      "source": "DB00006",
      "target": "DB06406",
      "description": "Bivalirudin may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08954",
      "source": "DB00006",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01088",
      "source": "DB00006",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Bivalirudin.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00458",
      "source": "DB00006",
      "target": "DB00458",
      "description": "The serum concentration of Imipramine can be increased when it is combined with Bivalirudin.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00328",
      "source": "DB00006",
      "target": "DB00328",
      "description": "Indomethacin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08951",
      "source": "DB00006",
      "target": "DB08951",
      "description": "Indoprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08942",
      "source": "DB00006",
      "target": "DB08942",
      "description": "Isoxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08940",
      "source": "DB00006",
      "target": "DB08940",
      "description": "Kebuzone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01009",
      "source": "DB00006",
      "target": "DB01009",
      "description": "Ketoprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00465",
      "source": "DB00006",
      "target": "DB00465",
      "description": "Ketorolac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01097",
      "source": "DB00006",
      "target": "DB01097",
      "description": "Leflunomide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00001",
      "source": "DB00006",
      "target": "DB00001",
      "description": "Lepirudin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00367",
      "source": "DB00006",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09211",
      "source": "DB00006",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06725",
      "source": "DB00006",
      "target": "DB06725",
      "description": "Lornoxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00227",
      "source": "DB00006",
      "target": "DB00227",
      "description": "The serum concentration of Lovastatin can be increased when it is combined with Bivalirudin.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09212",
      "source": "DB00006",
      "target": "DB09212",
      "description": "Loxoprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01283",
      "source": "DB00006",
      "target": "DB01283",
      "description": "Lumiracoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01397",
      "source": "DB00006",
      "target": "DB01397",
      "description": "Magnesium salicylate may increase the anticoagulant activities of Bivalirudin.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00179",
      "source": "DB00006",
      "target": "DB00179",
      "description": "Masoprocol may increase the anticoagulant activities of Bivalirudin.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00939",
      "source": "DB00006",
      "target": "DB00939",
      "description": "Meclofenamic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09124",
      "source": "DB00006",
      "target": "DB09124",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.",
      "name": "Medrogestone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00603",
      "source": "DB00006",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00784",
      "source": "DB00006",
      "target": "DB00784",
      "description": "Mefenamic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00351",
      "source": "DB00006",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00814",
      "source": "DB00006",
      "target": "DB00814",
      "description": "Meloxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00244",
      "source": "DB00006",
      "target": "DB00244",
      "description": "Mesalazine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01357",
      "source": "DB00006",
      "target": "DB01357",
      "description": "Mestranol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04817",
      "source": "DB00006",
      "target": "DB04817",
      "description": "Metamizole may increase the anticoagulant activities of Bivalirudin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00683",
      "source": "DB00006",
      "target": "DB00683",
      "description": "The serum concentration of Midazolam can be increased when it is combined with Bivalirudin.",
      "name": "Midazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00235",
      "source": "DB00006",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00370",
      "source": "DB00006",
      "target": "DB00370",
      "description": "The serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00688",
      "source": "DB00006",
      "target": "DB00688",
      "description": "Mycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01024",
      "source": "DB00006",
      "target": "DB01024",
      "description": "Mycophenolic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00461",
      "source": "DB00006",
      "target": "DB00461",
      "description": "Nabumetone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08813",
      "source": "DB00006",
      "target": "DB08813",
      "description": "Bivalirudin may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00735",
      "source": "DB00006",
      "target": "DB00735",
      "description": "Naftifine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00788",
      "source": "DB00006",
      "target": "DB00788",
      "description": "Naproxen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05822",
      "source": "DB00006",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Bivalirudin.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01149",
      "source": "DB00006",
      "target": "DB01149",
      "description": "The serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06802",
      "source": "DB00006",
      "target": "DB06802",
      "description": "Nepafenac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04552",
      "source": "DB00006",
      "target": "DB04552",
      "description": "Niflumic Acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04743",
      "source": "DB00006",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09079",
      "source": "DB00006",
      "target": "DB09079",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00717",
      "source": "DB00006",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00540",
      "source": "DB00006",
      "target": "DB00540",
      "description": "The serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08935",
      "source": "DB00006",
      "target": "DB08935",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00768",
      "source": "DB00006",
      "target": "DB00768",
      "description": "Olopatadine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01250",
      "source": "DB00006",
      "target": "DB01250",
      "description": "Olsalazine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04865",
      "source": "DB00006",
      "target": "DB04865",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11133",
      "source": "DB00006",
      "target": "DB11133",
      "description": "Omega-3 fatty acids may increase the anticoagulant activities of Bivalirudin.",
      "name": "Omega-3 fatty acids"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11444",
      "source": "DB00006",
      "target": "DB11444",
      "description": "Orgotein may increase the anticoagulant activities of Bivalirudin.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06635",
      "source": "DB00006",
      "target": "DB06635",
      "description": "Bivalirudin may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00991",
      "source": "DB00006",
      "target": "DB00991",
      "description": "Oxaprozin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB03585",
      "source": "DB00006",
      "target": "DB03585",
      "description": "Oxyphenbutazone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08439",
      "source": "DB00006",
      "target": "DB08439",
      "description": "Parecoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09260",
      "source": "DB00006",
      "target": "DB09260",
      "description": "Parnaparin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00686",
      "source": "DB00006",
      "target": "DB00686",
      "description": "Pentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00806",
      "source": "DB00006",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Bivalirudin.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00454",
      "source": "DB00006",
      "target": "DB00454",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00498",
      "source": "DB00006",
      "target": "DB00498",
      "description": "Bivalirudin may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00946",
      "source": "DB00006",
      "target": "DB00946",
      "description": "Bivalirudin may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00812",
      "source": "DB00006",
      "target": "DB00812",
      "description": "Phenylbutazone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00337",
      "source": "DB00006",
      "target": "DB00337",
      "description": "Pimecrolimus may increase the anticoagulant activities of Bivalirudin.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01100",
      "source": "DB00006",
      "target": "DB01100",
      "description": "The serum concentration of Pimozide can be increased when it is combined with Bivalirudin.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04951",
      "source": "DB00006",
      "target": "DB04951",
      "description": "Pirfenidone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00554",
      "source": "DB00006",
      "target": "DB00554",
      "description": "Piroxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05254",
      "source": "DB00006",
      "target": "DB05254",
      "description": "Plasmin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Plasmin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09369",
      "source": "DB00006",
      "target": "DB09369",
      "description": "Polyestradiol phosphate may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06209",
      "source": "DB00006",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Bivalirudin.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00396",
      "source": "DB00006",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09288",
      "source": "DB00006",
      "target": "DB09288",
      "description": "Propacetamol may increase the anticoagulant activities of Bivalirudin.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11312",
      "source": "DB00006",
      "target": "DB11312",
      "description": "Bivalirudin may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11268",
      "source": "DB00006",
      "target": "DB11268",
      "description": "Bivalirudin may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00344",
      "source": "DB00006",
      "target": "DB00344",
      "description": "The serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05173",
      "source": "DB00006",
      "target": "DB05173",
      "description": "PTC299 may increase the anticoagulant activities of Bivalirudin.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04575",
      "source": "DB00006",
      "target": "DB04575",
      "description": "Quinestrol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB02709",
      "source": "DB00006",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Bivalirudin.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00015",
      "source": "DB00006",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09259",
      "source": "DB00006",
      "target": "DB09259",
      "description": "Bivalirudin may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01207",
      "source": "DB00006",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08931",
      "source": "DB00006",
      "target": "DB08931",
      "description": "The serum concentration of Riociguat can be increased when it is combined with Bivalirudin.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06228",
      "source": "DB00006",
      "target": "DB06228",
      "description": "Bivalirudin may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00533",
      "source": "DB00006",
      "target": "DB00533",
      "description": "Rofecoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00412",
      "source": "DB00006",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01098",
      "source": "DB00006",
      "target": "DB01098",
      "description": "The serum concentration of Rosuvastatin can be increased when it is combined with Bivalirudin.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08797",
      "source": "DB00006",
      "target": "DB08797",
      "description": "Salicylamide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00936",
      "source": "DB00006",
      "target": "DB00936",
      "description": "Salicylic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01399",
      "source": "DB00006",
      "target": "DB01399",
      "description": "Salsalate may increase the anticoagulant activities of Bivalirudin.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05692",
      "source": "DB00006",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Bivalirudin.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11362",
      "source": "DB00006",
      "target": "DB11362",
      "description": "Selexipag may increase the anticoagulant activities of Bivalirudin.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06739",
      "source": "DB00006",
      "target": "DB06739",
      "description": "Seratrodast may increase the anticoagulant activities of Bivalirudin.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01236",
      "source": "DB00006",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Bivalirudin.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00203",
      "source": "DB00006",
      "target": "DB00203",
      "description": "The serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.",
      "name": "Sildenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06290",
      "source": "DB00006",
      "target": "DB06290",
      "description": "The serum concentration of Simeprevir can be increased when it is combined with Bivalirudin.",
      "name": "Simeprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00641",
      "source": "DB00006",
      "target": "DB00641",
      "description": "The serum concentration of Simvastatin can be increased when it is combined with Bivalirudin.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB05073",
      "source": "DB00006",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Bivalirudin.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01323",
      "source": "DB00006",
      "target": "DB01323",
      "description": "The metabolism of Bivalirudin can be increased when combined with St. John&#39;s Wort.",
      "name": "St. John's Wort"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00086",
      "source": "DB00006",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06206",
      "source": "DB00006",
      "target": "DB06206",
      "description": "Sugammadex may increase the anticoagulant activities of Bivalirudin.",
      "name": "Sugammadex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00795",
      "source": "DB00006",
      "target": "DB00795",
      "description": "Sulfasalazine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00605",
      "source": "DB00006",
      "target": "DB00605",
      "description": "Sulindac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06271",
      "source": "DB00006",
      "target": "DB06271",
      "description": "Bivalirudin may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00870",
      "source": "DB00006",
      "target": "DB00870",
      "description": "Suprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09317",
      "source": "DB00006",
      "target": "DB09317",
      "description": "Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09318",
      "source": "DB00006",
      "target": "DB09318",
      "description": "Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00864",
      "source": "DB00006",
      "target": "DB00864",
      "description": "The metabolism of Tacrolimus can be decreased when combined with Bivalirudin.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06287",
      "source": "DB00006",
      "target": "DB06287",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00031",
      "source": "DB00006",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00469",
      "source": "DB00006",
      "target": "DB00469",
      "description": "Tenoxicam may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11466",
      "source": "DB00006",
      "target": "DB11466",
      "description": "Tepoxalin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08880",
      "source": "DB00006",
      "target": "DB08880",
      "description": "Teriflunomide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04905",
      "source": "DB00006",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00277",
      "source": "DB00006",
      "target": "DB00277",
      "description": "The serum concentration of Theophylline can be decreased when it is combined with Bivalirudin.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09289",
      "source": "DB00006",
      "target": "DB09289",
      "description": "The serum concentration of Tianeptine can be increased when it is combined with Bivalirudin.",
      "name": "Tianeptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01600",
      "source": "DB00006",
      "target": "DB01600",
      "description": "Tiaprofenic acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09070",
      "source": "DB00006",
      "target": "DB09070",
      "description": "Tibolone may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08816",
      "source": "DB00006",
      "target": "DB08816",
      "description": "Ticagrelor may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00208",
      "source": "DB00006",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Bivalirudin.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06822",
      "source": "DB00006",
      "target": "DB06822",
      "description": "Tinzaparin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00932",
      "source": "DB00006",
      "target": "DB00932",
      "description": "The serum concentration of Bivalirudin can be decreased when it is combined with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00775",
      "source": "DB00006",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09216",
      "source": "DB00006",
      "target": "DB09216",
      "description": "Tolfenamic Acid may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00500",
      "source": "DB00006",
      "target": "DB00500",
      "description": "Tolmetin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00081",
      "source": "DB00006",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB07615",
      "source": "DB00006",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09283",
      "source": "DB00006",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00374",
      "source": "DB00006",
      "target": "DB00374",
      "description": "Treprostinil may increase the anticoagulant activities of Bivalirudin.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00897",
      "source": "DB00006",
      "target": "DB00897",
      "description": "The serum concentration of Triazolam can be increased when it is combined with Bivalirudin.",
      "name": "Triazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB08814",
      "source": "DB00006",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Bivalirudin.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00726",
      "source": "DB00006",
      "target": "DB00726",
      "description": "The serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB01401",
      "source": "DB00006",
      "target": "DB01401",
      "description": "Trisalicylate-choline may increase the anticoagulant activities of Bivalirudin.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00013",
      "source": "DB00006",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00580",
      "source": "DB00006",
      "target": "DB00580",
      "description": "Valdecoxib may increase the anticoagulant activities of Bivalirudin.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00313",
      "source": "DB00006",
      "target": "DB00313",
      "description": "The serum concentration of Valproic Acid can be decreased when it is combined with Bivalirudin.",
      "name": "Valproic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00163",
      "source": "DB00006",
      "target": "DB00163",
      "description": "Vitamin E may increase the anticoagulant activities of Bivalirudin.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB09030",
      "source": "DB00006",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Bivalirudin.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00682",
      "source": "DB00006",
      "target": "DB00682",
      "description": "Bivalirudin may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04898",
      "source": "DB00006",
      "target": "DB04898",
      "description": "Bivalirudin may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB06737",
      "source": "DB00006",
      "target": "DB06737",
      "description": "Zaltoprofen may increase the anticoagulant activities of Bivalirudin.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB11478",
      "source": "DB00006",
      "target": "DB11478",
      "description": "Zeranol may decrease the anticoagulant activities of Bivalirudin.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00495",
      "source": "DB00006",
      "target": "DB00495",
      "description": "The serum concentration of Zidovudine can be decreased when it is combined with Bivalirudin.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00744",
      "source": "DB00006",
      "target": "DB00744",
      "description": "Zileuton may increase the anticoagulant activities of Bivalirudin.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB04828",
      "source": "DB00006",
      "target": "DB04828",
      "description": "Zomepirac may increase the anticoagulant activities of Bivalirudin.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB01223",
      "source": "DB00008",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB12768",
      "source": "DB00008",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2a.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB00363",
      "source": "DB00008",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB00651",
      "source": "DB00008",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2a.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB04817",
      "source": "DB00008",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2a.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB09208",
      "source": "DB00008",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Peginterferon alfa-2a can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB01265",
      "source": "DB00008",
      "target": "DB01265",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.",
      "name": "Telbivudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB00277",
      "source": "DB00008",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB00495",
      "source": "DB00008",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00054",
      "source": "DB00009",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Alteplase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01418",
      "source": "DB00009",
      "target": "DB01418",
      "description": "Alteplase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00945",
      "source": "DB00009",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Alteplase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00770",
      "source": "DB00009",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Alteplase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00233",
      "source": "DB00009",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alteplase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00261",
      "source": "DB00009",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Alteplase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05099",
      "source": "DB00009",
      "target": "DB05099",
      "description": "Alteplase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11598",
      "source": "DB00009",
      "target": "DB11598",
      "description": "Alteplase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06605",
      "source": "DB00009",
      "target": "DB06605",
      "description": "Alteplase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06692",
      "source": "DB00009",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00407",
      "source": "DB00009",
      "target": "DB00407",
      "description": "Alteplase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00278",
      "source": "DB00009",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Alteplase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00972",
      "source": "DB00009",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Alteplase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00102",
      "source": "DB00009",
      "target": "DB00102",
      "description": "Alteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05229",
      "source": "DB00009",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Alteplase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00006",
      "source": "DB00009",
      "target": "DB00006",
      "description": "Alteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06441",
      "source": "DB00009",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Alteplase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09261",
      "source": "DB00009",
      "target": "DB09261",
      "description": "Alteplase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01166",
      "source": "DB00009",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Alteplase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB04272",
      "source": "DB00009",
      "target": "DB04272",
      "description": "Alteplase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00758",
      "source": "DB00009",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Alteplase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06695",
      "source": "DB00009",
      "target": "DB06695",
      "description": "Alteplase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06779",
      "source": "DB00009",
      "target": "DB06779",
      "description": "Alteplase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06754",
      "source": "DB00009",
      "target": "DB06754",
      "description": "Alteplase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB04932",
      "source": "DB00009",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Alteplase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11095",
      "source": "DB00009",
      "target": "DB11095",
      "description": "Alteplase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09255",
      "source": "DB00009",
      "target": "DB09255",
      "description": "Alteplase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11122",
      "source": "DB00009",
      "target": "DB11122",
      "description": "Alteplase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11076",
      "source": "DB00009",
      "target": "DB11076",
      "description": "Alteplase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11241",
      "source": "DB00009",
      "target": "DB11241",
      "description": "Alteplase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00266",
      "source": "DB00009",
      "target": "DB00266",
      "description": "Alteplase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00861",
      "source": "DB00009",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00975",
      "source": "DB00009",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Alteplase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00974",
      "source": "DB00009",
      "target": "DB00974",
      "description": "Alteplase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09075",
      "source": "DB00009",
      "target": "DB09075",
      "description": "Alteplase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01225",
      "source": "DB00009",
      "target": "DB01225",
      "description": "Alteplase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00751",
      "source": "DB00009",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Alteplase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06392",
      "source": "DB00009",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Alteplase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01240",
      "source": "DB00009",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Alteplase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00063",
      "source": "DB00009",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Alteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB08794",
      "source": "DB00009",
      "target": "DB08794",
      "description": "Alteplase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00569",
      "source": "DB00009",
      "target": "DB00569",
      "description": "Alteplase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01109",
      "source": "DB00009",
      "target": "DB01109",
      "description": "Alteplase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB02351",
      "source": "DB00009",
      "target": "DB02351",
      "description": "Alteplase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05266",
      "source": "DB00009",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Alteplase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB08887",
      "source": "DB00009",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Alteplase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06406",
      "source": "DB00009",
      "target": "DB06406",
      "description": "Alteplase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB08954",
      "source": "DB00009",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Alteplase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01088",
      "source": "DB00009",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Alteplase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00001",
      "source": "DB00009",
      "target": "DB00001",
      "description": "Alteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09211",
      "source": "DB00009",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Alteplase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00244",
      "source": "DB00009",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Alteplase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00235",
      "source": "DB00009",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Alteplase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB08813",
      "source": "DB00009",
      "target": "DB08813",
      "description": "Alteplase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05822",
      "source": "DB00009",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Alteplase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB04743",
      "source": "DB00009",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Alteplase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00727",
      "source": "DB00009",
      "target": "DB00727",
      "description": "The serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.",
      "name": "Nitroglycerin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06635",
      "source": "DB00009",
      "target": "DB06635",
      "description": "Alteplase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00686",
      "source": "DB00009",
      "target": "DB00686",
      "description": "Alteplase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00806",
      "source": "DB00009",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Alteplase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00498",
      "source": "DB00009",
      "target": "DB00498",
      "description": "Alteplase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00946",
      "source": "DB00009",
      "target": "DB00946",
      "description": "Alteplase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06209",
      "source": "DB00009",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Alteplase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11312",
      "source": "DB00009",
      "target": "DB11312",
      "description": "Alteplase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB11268",
      "source": "DB00009",
      "target": "DB11268",
      "description": "Alteplase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB02709",
      "source": "DB00009",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Alteplase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09259",
      "source": "DB00009",
      "target": "DB09259",
      "description": "Alteplase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01207",
      "source": "DB00009",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Alteplase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06228",
      "source": "DB00009",
      "target": "DB06228",
      "description": "Alteplase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00936",
      "source": "DB00009",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alteplase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05692",
      "source": "DB00009",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Alteplase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB01236",
      "source": "DB00009",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Alteplase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB05073",
      "source": "DB00009",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Alteplase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB06271",
      "source": "DB00009",
      "target": "DB06271",
      "description": "Alteplase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB04905",
      "source": "DB00009",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Alteplase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00208",
      "source": "DB00009",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Alteplase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00775",
      "source": "DB00009",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Alteplase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB07615",
      "source": "DB00009",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Alteplase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09283",
      "source": "DB00009",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Alteplase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00374",
      "source": "DB00009",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB08814",
      "source": "DB00009",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Alteplase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB09030",
      "source": "DB00009",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Alteplase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00682",
      "source": "DB00009",
      "target": "DB00682",
      "description": "Alteplase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB04898",
      "source": "DB00009",
      "target": "DB04898",
      "description": "Alteplase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00012-DB00480",
      "source": "DB00012",
      "target": "DB00480",
      "description": "Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide.",
      "name": "Lenalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00012-DB08804",
      "source": "DB00012",
      "target": "DB08804",
      "description": "Nandrolone decanoate may increase the stimulatory activities of Darbepoetin alfa.",
      "name": "Nandrolone decanoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00012-DB00984",
      "source": "DB00012",
      "target": "DB00984",
      "description": "Nandrolone phenpropionate may increase the stimulatory activities of Darbepoetin alfa.",
      "name": "Nandrolone phenpropionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00012-DB01041",
      "source": "DB00012",
      "target": "DB01041",
      "description": "Darbepoetin alfa may increase the thrombogenic activities of Thalidomide.",
      "name": "Thalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00011-DB01223",
      "source": "DB00011",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00011-DB00651",
      "source": "DB00011",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00011-DB00277",
      "source": "DB00011",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00011-DB00495",
      "source": "DB00011",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00054",
      "source": "DB00013",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Urokinase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01418",
      "source": "DB00013",
      "target": "DB01418",
      "description": "Urokinase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00945",
      "source": "DB00013",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Urokinase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00770",
      "source": "DB00013",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Urokinase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00233",
      "source": "DB00013",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Urokinase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00261",
      "source": "DB00013",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Urokinase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05099",
      "source": "DB00013",
      "target": "DB05099",
      "description": "Urokinase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11598",
      "source": "DB00013",
      "target": "DB11598",
      "description": "Urokinase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06605",
      "source": "DB00013",
      "target": "DB06605",
      "description": "Urokinase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06692",
      "source": "DB00013",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00407",
      "source": "DB00013",
      "target": "DB00407",
      "description": "Urokinase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00278",
      "source": "DB00013",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Urokinase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00972",
      "source": "DB00013",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Urokinase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00102",
      "source": "DB00013",
      "target": "DB00102",
      "description": "Urokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05229",
      "source": "DB00013",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Urokinase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00006",
      "source": "DB00013",
      "target": "DB00006",
      "description": "Urokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06441",
      "source": "DB00013",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Urokinase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09261",
      "source": "DB00013",
      "target": "DB09261",
      "description": "Urokinase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01166",
      "source": "DB00013",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Urokinase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB04272",
      "source": "DB00013",
      "target": "DB04272",
      "description": "Urokinase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00758",
      "source": "DB00013",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Urokinase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06695",
      "source": "DB00013",
      "target": "DB06695",
      "description": "Urokinase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06779",
      "source": "DB00013",
      "target": "DB06779",
      "description": "Urokinase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06754",
      "source": "DB00013",
      "target": "DB06754",
      "description": "Urokinase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB04932",
      "source": "DB00013",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Urokinase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11095",
      "source": "DB00013",
      "target": "DB11095",
      "description": "Urokinase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09255",
      "source": "DB00013",
      "target": "DB09255",
      "description": "Urokinase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11122",
      "source": "DB00013",
      "target": "DB11122",
      "description": "Urokinase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11076",
      "source": "DB00013",
      "target": "DB11076",
      "description": "Urokinase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11241",
      "source": "DB00013",
      "target": "DB11241",
      "description": "Urokinase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00266",
      "source": "DB00013",
      "target": "DB00266",
      "description": "Urokinase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00861",
      "source": "DB00013",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00975",
      "source": "DB00013",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Urokinase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00974",
      "source": "DB00013",
      "target": "DB00974",
      "description": "Urokinase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09075",
      "source": "DB00013",
      "target": "DB09075",
      "description": "Urokinase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01225",
      "source": "DB00013",
      "target": "DB01225",
      "description": "Urokinase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00751",
      "source": "DB00013",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Urokinase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06392",
      "source": "DB00013",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Urokinase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01240",
      "source": "DB00013",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Urokinase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00063",
      "source": "DB00013",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Urokinase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB08794",
      "source": "DB00013",
      "target": "DB08794",
      "description": "Urokinase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00569",
      "source": "DB00013",
      "target": "DB00569",
      "description": "Urokinase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01109",
      "source": "DB00013",
      "target": "DB01109",
      "description": "Urokinase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB02351",
      "source": "DB00013",
      "target": "DB02351",
      "description": "Urokinase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05266",
      "source": "DB00013",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Urokinase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB08887",
      "source": "DB00013",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Urokinase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06406",
      "source": "DB00013",
      "target": "DB06406",
      "description": "Urokinase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB08954",
      "source": "DB00013",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Urokinase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01088",
      "source": "DB00013",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Urokinase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00001",
      "source": "DB00013",
      "target": "DB00001",
      "description": "Urokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09211",
      "source": "DB00013",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Urokinase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00244",
      "source": "DB00013",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Urokinase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00235",
      "source": "DB00013",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Urokinase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB08813",
      "source": "DB00013",
      "target": "DB08813",
      "description": "Urokinase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05822",
      "source": "DB00013",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Urokinase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB04743",
      "source": "DB00013",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Urokinase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06635",
      "source": "DB00013",
      "target": "DB06635",
      "description": "Urokinase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00686",
      "source": "DB00013",
      "target": "DB00686",
      "description": "Urokinase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00806",
      "source": "DB00013",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Urokinase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00498",
      "source": "DB00013",
      "target": "DB00498",
      "description": "Urokinase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00946",
      "source": "DB00013",
      "target": "DB00946",
      "description": "Urokinase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06209",
      "source": "DB00013",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Urokinase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11312",
      "source": "DB00013",
      "target": "DB11312",
      "description": "Urokinase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB11268",
      "source": "DB00013",
      "target": "DB11268",
      "description": "Urokinase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB02709",
      "source": "DB00013",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Urokinase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09259",
      "source": "DB00013",
      "target": "DB09259",
      "description": "Urokinase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01207",
      "source": "DB00013",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Urokinase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06228",
      "source": "DB00013",
      "target": "DB06228",
      "description": "Urokinase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00936",
      "source": "DB00013",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Urokinase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05692",
      "source": "DB00013",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Urokinase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB01236",
      "source": "DB00013",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Urokinase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB05073",
      "source": "DB00013",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Urokinase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB06271",
      "source": "DB00013",
      "target": "DB06271",
      "description": "Urokinase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB04905",
      "source": "DB00013",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Urokinase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00208",
      "source": "DB00013",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Urokinase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00775",
      "source": "DB00013",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Urokinase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB07615",
      "source": "DB00013",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Urokinase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09283",
      "source": "DB00013",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Urokinase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00374",
      "source": "DB00013",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB08814",
      "source": "DB00013",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Urokinase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB09030",
      "source": "DB00013",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Urokinase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00682",
      "source": "DB00013",
      "target": "DB00682",
      "description": "Urokinase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB04898",
      "source": "DB00013",
      "target": "DB04898",
      "description": "Urokinase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00284",
      "source": "DB00014",
      "target": "DB00284",
      "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00414",
      "source": "DB00014",
      "target": "DB00414",
      "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00511",
      "source": "DB00014",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Goserelin.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01700",
      "source": "DB00014",
      "target": "DB01700",
      "description": "The therapeutic efficacy of Aicar can be decreased when used in combination with Goserelin.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00346",
      "source": "DB00014",
      "target": "DB00346",
      "description": "Alfuzosin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06203",
      "source": "DB00014",
      "target": "DB06203",
      "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00915",
      "source": "DB00014",
      "target": "DB00915",
      "description": "Amantadine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Amantadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01118",
      "source": "DB00014",
      "target": "DB01118",
      "description": "Goserelin may increase the QTc-prolonging activities of Amiodarone.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00321",
      "source": "DB00014",
      "target": "DB00321",
      "description": "Amitriptyline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00543",
      "source": "DB00014",
      "target": "DB00543",
      "description": "Amoxapine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Amoxapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00261",
      "source": "DB00014",
      "target": "DB00261",
      "description": "Goserelin may increase the QTc-prolonging activities of Anagrelide.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00714",
      "source": "DB00014",
      "target": "DB00714",
      "description": "Apomorphine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Apomorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01274",
      "source": "DB00014",
      "target": "DB01274",
      "description": "Arformoterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Arformoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01238",
      "source": "DB00014",
      "target": "DB01238",
      "description": "Aripiprazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01169",
      "source": "DB00014",
      "target": "DB01169",
      "description": "Goserelin may increase the QTc-prolonging activities of Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06697",
      "source": "DB00014",
      "target": "DB06697",
      "description": "Goserelin may increase the QTc-prolonging activities of Artemether.",
      "name": "Artemether"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06216",
      "source": "DB00014",
      "target": "DB06216",
      "description": "Goserelin may increase the QTc-prolonging activities of Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01072",
      "source": "DB00014",
      "target": "DB01072",
      "description": "Atazanavir may increase the QTc-prolonging activities of Goserelin.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00289",
      "source": "DB00014",
      "target": "DB00289",
      "description": "Atomoxetine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Atomoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00207",
      "source": "DB00014",
      "target": "DB00207",
      "description": "Goserelin may increase the QTc-prolonging activities of Azithromycin.",
      "name": "Azithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08903",
      "source": "DB00014",
      "target": "DB08903",
      "description": "Goserelin may increase the QTc-prolonging activities of Bedaquiline.",
      "name": "Bedaquiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00112",
      "source": "DB00014",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Goserelin.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00188",
      "source": "DB00014",
      "target": "DB00188",
      "description": "Bortezomib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Bortezomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04830",
      "source": "DB00014",
      "target": "DB04830",
      "description": "The therapeutic efficacy of Buformin can be decreased when used in combination with Goserelin.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06719",
      "source": "DB00014",
      "target": "DB06719",
      "description": "Buserelin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Buserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06772",
      "source": "DB00014",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08907",
      "source": "DB00014",
      "target": "DB08907",
      "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01816",
      "source": "DB00014",
      "target": "DB01816",
      "description": "The therapeutic efficacy of Castanospermine can be decreased when used in combination with Goserelin.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09063",
      "source": "DB00014",
      "target": "DB09063",
      "description": "Goserelin may increase the QTc-prolonging activities of Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00608",
      "source": "DB00014",
      "target": "DB00608",
      "description": "Goserelin may increase the QTc-prolonging activities of Chloroquine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00477",
      "source": "DB00014",
      "target": "DB00477",
      "description": "Goserelin may increase the QTc-prolonging activities of Chlorpromazine.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00672",
      "source": "DB00014",
      "target": "DB00672",
      "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09201",
      "source": "DB00014",
      "target": "DB09201",
      "description": "The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00537",
      "source": "DB00014",
      "target": "DB00537",
      "description": "Goserelin may increase the QTc-prolonging activities of Ciprofloxacin.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00604",
      "source": "DB00014",
      "target": "DB00604",
      "description": "Goserelin may increase the QTc-prolonging activities of Cisapride.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00215",
      "source": "DB00014",
      "target": "DB00215",
      "description": "Goserelin may increase the QTc-prolonging activities of Citalopram.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01211",
      "source": "DB00014",
      "target": "DB01211",
      "description": "Goserelin may increase the QTc-prolonging activities of Clarithromycin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01242",
      "source": "DB00014",
      "target": "DB01242",
      "description": "Clomipramine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00363",
      "source": "DB00014",
      "target": "DB00363",
      "description": "Goserelin may increase the QTc-prolonging activities of Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08865",
      "source": "DB00014",
      "target": "DB08865",
      "description": "Goserelin may increase the QTc-prolonging activities of Crizotinib.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00531",
      "source": "DB00014",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Goserelin.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08912",
      "source": "DB00014",
      "target": "DB08912",
      "description": "Dabrafenib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01254",
      "source": "DB00014",
      "target": "DB01254",
      "description": "Dasatinib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06699",
      "source": "DB00014",
      "target": "DB06699",
      "description": "Degarelix may increase the QTc-prolonging activities of Goserelin.",
      "name": "Degarelix"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01189",
      "source": "DB00014",
      "target": "DB01189",
      "description": "Desflurane may increase the QTc-prolonging activities of Goserelin.",
      "name": "Desflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01151",
      "source": "DB00014",
      "target": "DB01151",
      "description": "Desipramine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01078",
      "source": "DB00014",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Goserelin.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01396",
      "source": "DB00014",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Goserelin.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00390",
      "source": "DB00014",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Goserelin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01075",
      "source": "DB00014",
      "target": "DB01075",
      "description": "Diphenhydramine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Diphenhydramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00280",
      "source": "DB00014",
      "target": "DB00280",
      "description": "Goserelin may increase the QTc-prolonging activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01248",
      "source": "DB00014",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00204",
      "source": "DB00014",
      "target": "DB00204",
      "description": "Goserelin may increase the QTc-prolonging activities of Dofetilide.",
      "name": "Dofetilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00757",
      "source": "DB00014",
      "target": "DB00757",
      "description": "Goserelin may increase the QTc-prolonging activities of Dolasetron.",
      "name": "Dolasetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01184",
      "source": "DB00014",
      "target": "DB01184",
      "description": "Goserelin may increase the QTc-prolonging activities of Domperidone.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01142",
      "source": "DB00014",
      "target": "DB01142",
      "description": "Doxepin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04855",
      "source": "DB00014",
      "target": "DB04855",
      "description": "Goserelin may increase the QTc-prolonging activities of Dronedarone.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00450",
      "source": "DB00014",
      "target": "DB00450",
      "description": "Goserelin may increase the QTc-prolonging activities of Droperidol.",
      "name": "Droperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09045",
      "source": "DB00014",
      "target": "DB09045",
      "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09039",
      "source": "DB00014",
      "target": "DB09039",
      "description": "Goserelin may increase the QTc-prolonging activities of Eliglustat.",
      "name": "Eliglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09038",
      "source": "DB00014",
      "target": "DB09038",
      "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08871",
      "source": "DB00014",
      "target": "DB08871",
      "description": "Eribulin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Eribulin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00199",
      "source": "DB00014",
      "target": "DB00199",
      "description": "Goserelin may increase the QTc-prolonging activities of Erythromycin.",
      "name": "Erythromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01175",
      "source": "DB00014",
      "target": "DB01175",
      "description": "Goserelin may increase the QTc-prolonging activities of Escitalopram.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01276",
      "source": "DB00014",
      "target": "DB01276",
      "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04953",
      "source": "DB00014",
      "target": "DB04953",
      "description": "Ezogabine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ezogabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00927",
      "source": "DB00014",
      "target": "DB00927",
      "description": "Famotidine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Famotidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00949",
      "source": "DB00014",
      "target": "DB00949",
      "description": "Felbamate may increase the QTc-prolonging activities of Goserelin.",
      "name": "Felbamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08868",
      "source": "DB00014",
      "target": "DB08868",
      "description": "Fingolimod may increase the QTc-prolonging activities of Goserelin.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01195",
      "source": "DB00014",
      "target": "DB01195",
      "description": "Goserelin may increase the QTc-prolonging activities of Flecainide.",
      "name": "Flecainide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00196",
      "source": "DB00014",
      "target": "DB00196",
      "description": "Fluconazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Fluconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00472",
      "source": "DB00014",
      "target": "DB00472",
      "description": "Goserelin may increase the QTc-prolonging activities of Fluoxetine.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00875",
      "source": "DB00014",
      "target": "DB00875",
      "description": "Goserelin may increase the QTc-prolonging activities of Flupentixol.",
      "name": "Flupentixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00983",
      "source": "DB00014",
      "target": "DB00983",
      "description": "Formoterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Formoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00529",
      "source": "DB00014",
      "target": "DB00529",
      "description": "Foscarnet may increase the QTc-prolonging activities of Goserelin.",
      "name": "Foscarnet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00743",
      "source": "DB00014",
      "target": "DB00743",
      "description": "Goserelin may increase the QTc-prolonging activities of Gadobenic acid.",
      "name": "Gadobenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00674",
      "source": "DB00014",
      "target": "DB00674",
      "description": "Galantamine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Galantamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01155",
      "source": "DB00014",
      "target": "DB01155",
      "description": "Goserelin may increase the QTc-prolonging activities of Gemifloxacin.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08962",
      "source": "DB00014",
      "target": "DB08962",
      "description": "The therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01120",
      "source": "DB00014",
      "target": "DB01120",
      "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00222",
      "source": "DB00014",
      "target": "DB00222",
      "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01067",
      "source": "DB00014",
      "target": "DB01067",
      "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01251",
      "source": "DB00014",
      "target": "DB01251",
      "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01016",
      "source": "DB00014",
      "target": "DB01016",
      "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00889",
      "source": "DB00014",
      "target": "DB00889",
      "description": "Goserelin may increase the QTc-prolonging activities of Granisetron.",
      "name": "Granisetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00502",
      "source": "DB00014",
      "target": "DB00502",
      "description": "Goserelin may increase the QTc-prolonging activities of Haloperidol.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06788",
      "source": "DB00014",
      "target": "DB06788",
      "description": "Histrelin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Histrelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00557",
      "source": "DB00014",
      "target": "DB00557",
      "description": "Hydroxyzine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Hydroxyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00710",
      "source": "DB00014",
      "target": "DB00710",
      "description": "Ibandronate may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ibandronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00308",
      "source": "DB00014",
      "target": "DB00308",
      "description": "Goserelin may increase the QTc-prolonging activities of Ibutilide.",
      "name": "Ibutilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04946",
      "source": "DB00014",
      "target": "DB04946",
      "description": "Goserelin may increase the QTc-prolonging activities of Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00458",
      "source": "DB00014",
      "target": "DB00458",
      "description": "Imipramine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB05039",
      "source": "DB00014",
      "target": "DB05039",
      "description": "Indacaterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Indacaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00808",
      "source": "DB00014",
      "target": "DB00808",
      "description": "Indapamide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01306",
      "source": "DB00014",
      "target": "DB01306",
      "description": "The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01307",
      "source": "DB00014",
      "target": "DB01307",
      "description": "The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Goserelin.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00047",
      "source": "DB00014",
      "target": "DB00047",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01309",
      "source": "DB00014",
      "target": "DB01309",
      "description": "The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Goserelin.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00046",
      "source": "DB00014",
      "target": "DB00046",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00071",
      "source": "DB00014",
      "target": "DB00071",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00753",
      "source": "DB00014",
      "target": "DB00753",
      "description": "Isoflurane may increase the QTc-prolonging activities of Goserelin.",
      "name": "Isoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00270",
      "source": "DB00014",
      "target": "DB00270",
      "description": "Isradipine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Isradipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01167",
      "source": "DB00014",
      "target": "DB01167",
      "description": "Itraconazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Itraconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09083",
      "source": "DB00014",
      "target": "DB09083",
      "description": "Ivabradine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ivabradine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01026",
      "source": "DB00014",
      "target": "DB01026",
      "description": "Ketoconazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ketoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01259",
      "source": "DB00014",
      "target": "DB01259",
      "description": "Lapatinib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Lapatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09078",
      "source": "DB00014",
      "target": "DB09078",
      "description": "Goserelin may increase the QTc-prolonging activities of Lenvatinib.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00007",
      "source": "DB00014",
      "target": "DB00007",
      "description": "Leuprolide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01137",
      "source": "DB00014",
      "target": "DB01137",
      "description": "Goserelin may increase the QTc-prolonging activities of Levofloxacin.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08882",
      "source": "DB00014",
      "target": "DB08882",
      "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06655",
      "source": "DB00014",
      "target": "DB06655",
      "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01356",
      "source": "DB00014",
      "target": "DB01356",
      "description": "Lithium may increase the QTc-prolonging activities of Goserelin.",
      "name": "Lithium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01601",
      "source": "DB00014",
      "target": "DB01601",
      "description": "Goserelin may increase the QTc-prolonging activities of Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06708",
      "source": "DB00014",
      "target": "DB06708",
      "description": "Goserelin may increase the QTc-prolonging activities of Lumefantrine.",
      "name": "Lumefantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00934",
      "source": "DB00014",
      "target": "DB00934",
      "description": "Maprotiline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Maprotiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00358",
      "source": "DB00014",
      "target": "DB00358",
      "description": "Mefloquine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Mefloquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00331",
      "source": "DB00014",
      "target": "DB00331",
      "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00333",
      "source": "DB00014",
      "target": "DB00333",
      "description": "Goserelin may increase the QTc-prolonging activities of Methadone.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01403",
      "source": "DB00014",
      "target": "DB01403",
      "description": "Methotrimeprazine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01233",
      "source": "DB00014",
      "target": "DB01233",
      "description": "Metoclopramide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Metoclopramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00916",
      "source": "DB00014",
      "target": "DB00916",
      "description": "Metronidazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Metronidazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00834",
      "source": "DB00014",
      "target": "DB00834",
      "description": "Mifepristone may increase the QTc-prolonging activities of Goserelin.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00491",
      "source": "DB00014",
      "target": "DB00491",
      "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00419",
      "source": "DB00014",
      "target": "DB00419",
      "description": "The therapeutic efficacy of Miglustat can be decreased when used in combination with Goserelin.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08893",
      "source": "DB00014",
      "target": "DB08893",
      "description": "Mirabegron may increase the QTc-prolonging activities of Goserelin.",
      "name": "Mirabegron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00370",
      "source": "DB00014",
      "target": "DB00370",
      "description": "Mirtazapine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01252",
      "source": "DB00014",
      "target": "DB01252",
      "description": "The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Goserelin.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00691",
      "source": "DB00014",
      "target": "DB00691",
      "description": "Moexipril may increase the QTc-prolonging activities of Goserelin.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00218",
      "source": "DB00014",
      "target": "DB00218",
      "description": "Goserelin may increase the QTc-prolonging activities of Moxifloxacin.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00731",
      "source": "DB00014",
      "target": "DB00731",
      "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00220",
      "source": "DB00014",
      "target": "DB00220",
      "description": "Nelfinavir may increase the QTc-prolonging activities of Goserelin.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00622",
      "source": "DB00014",
      "target": "DB00622",
      "description": "Nicardipine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04868",
      "source": "DB00014",
      "target": "DB04868",
      "description": "Goserelin may increase the QTc-prolonging activities of Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01059",
      "source": "DB00014",
      "target": "DB01059",
      "description": "Norfloxacin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00540",
      "source": "DB00014",
      "target": "DB00540",
      "description": "Nortriptyline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00104",
      "source": "DB00014",
      "target": "DB00104",
      "description": "Octreotide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01165",
      "source": "DB00014",
      "target": "DB01165",
      "description": "Goserelin may increase the QTc-prolonging activities of Ofloxacin.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00334",
      "source": "DB00014",
      "target": "DB00334",
      "description": "Olanzapine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09080",
      "source": "DB00014",
      "target": "DB09080",
      "description": "Olodaterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Olodaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00904",
      "source": "DB00014",
      "target": "DB00904",
      "description": "Goserelin may increase the QTc-prolonging activities of Ondansetron.",
      "name": "Ondansetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01092",
      "source": "DB00014",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Goserelin.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00107",
      "source": "DB00014",
      "target": "DB00107",
      "description": "Oxytocin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Oxytocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01229",
      "source": "DB00014",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01267",
      "source": "DB00014",
      "target": "DB01267",
      "description": "Goserelin may increase the QTc-prolonging activities of Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06603",
      "source": "DB00014",
      "target": "DB06603",
      "description": "Goserelin may increase the QTc-prolonging activities of Panobinostat.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00715",
      "source": "DB00014",
      "target": "DB00715",
      "description": "Paroxetine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06663",
      "source": "DB00014",
      "target": "DB06663",
      "description": "Pasireotide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06589",
      "source": "DB00014",
      "target": "DB06589",
      "description": "Goserelin may increase the QTc-prolonging activities of Pazopanib.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00738",
      "source": "DB00014",
      "target": "DB00738",
      "description": "Goserelin may increase the QTc-prolonging activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00556",
      "source": "DB00014",
      "target": "DB00556",
      "description": "Goserelin may increase the QTc-prolonging activities of Perflutren.",
      "name": "Perflutren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00914",
      "source": "DB00014",
      "target": "DB00914",
      "description": "The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01100",
      "source": "DB00014",
      "target": "DB01100",
      "description": "Goserelin may increase the QTc-prolonging activities of Pimozide.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01132",
      "source": "DB00014",
      "target": "DB01132",
      "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01263",
      "source": "DB00014",
      "target": "DB01263",
      "description": "Posaconazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Posaconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01278",
      "source": "DB00014",
      "target": "DB01278",
      "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01087",
      "source": "DB00014",
      "target": "DB01087",
      "description": "Goserelin may increase the QTc-prolonging activities of Primaquine.",
      "name": "Primaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01035",
      "source": "DB00014",
      "target": "DB01035",
      "description": "Goserelin may increase the QTc-prolonging activities of Procainamide.",
      "name": "Procainamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00420",
      "source": "DB00014",
      "target": "DB00420",
      "description": "Goserelin may increase the QTc-prolonging activities of Promazine.",
      "name": "Promazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01069",
      "source": "DB00014",
      "target": "DB01069",
      "description": "Promethazine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Promethazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01182",
      "source": "DB00014",
      "target": "DB01182",
      "description": "Goserelin may increase the QTc-prolonging activities of Propafenone.",
      "name": "Propafenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00818",
      "source": "DB00014",
      "target": "DB00818",
      "description": "Propofol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Propofol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00344",
      "source": "DB00014",
      "target": "DB00344",
      "description": "Protriptyline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01224",
      "source": "DB00014",
      "target": "DB01224",
      "description": "Goserelin may increase the QTc-prolonging activities of Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00908",
      "source": "DB00014",
      "target": "DB00908",
      "description": "Goserelin may increase the QTc-prolonging activities of Quinidine.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00468",
      "source": "DB00014",
      "target": "DB00468",
      "description": "Goserelin may increase the QTc-prolonging activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00243",
      "source": "DB00014",
      "target": "DB00243",
      "description": "Ranolazine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ranolazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00912",
      "source": "DB00014",
      "target": "DB00912",
      "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08864",
      "source": "DB00014",
      "target": "DB08864",
      "description": "Rilpivirine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Rilpivirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00734",
      "source": "DB00014",
      "target": "DB00734",
      "description": "Risperidone may increase the QTc-prolonging activities of Goserelin.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00503",
      "source": "DB00014",
      "target": "DB00503",
      "description": "Ritonavir may increase the QTc-prolonging activities of Goserelin.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00412",
      "source": "DB00014",
      "target": "DB00412",
      "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01001",
      "source": "DB00014",
      "target": "DB01001",
      "description": "Salbutamol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Salbutamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00938",
      "source": "DB00014",
      "target": "DB00938",
      "description": "Salmeterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Salmeterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01232",
      "source": "DB00014",
      "target": "DB01232",
      "description": "Goserelin may increase the QTc-prolonging activities of Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06335",
      "source": "DB00014",
      "target": "DB06335",
      "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01104",
      "source": "DB00014",
      "target": "DB01104",
      "description": "Sertraline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01236",
      "source": "DB00014",
      "target": "DB01236",
      "description": "Sevoflurane may increase the QTc-prolonging activities of Goserelin.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01261",
      "source": "DB00014",
      "target": "DB01261",
      "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01591",
      "source": "DB00014",
      "target": "DB01591",
      "description": "Solifenacin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00398",
      "source": "DB00014",
      "target": "DB00398",
      "description": "Sorafenib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Sorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00489",
      "source": "DB00014",
      "target": "DB00489",
      "description": "Goserelin may increase the QTc-prolonging activities of Sotalol.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01015",
      "source": "DB00014",
      "target": "DB01015",
      "description": "Sulfamethoxazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00263",
      "source": "DB00014",
      "target": "DB00263",
      "description": "Goserelin may increase the QTc-prolonging activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06271",
      "source": "DB00014",
      "target": "DB06271",
      "description": "The therapeutic efficacy of Sulodexide can be decreased when used in combination with Goserelin.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01268",
      "source": "DB00014",
      "target": "DB01268",
      "description": "Sunitinib may increase the QTc-prolonging activities of Goserelin.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00675",
      "source": "DB00014",
      "target": "DB00675",
      "description": "Tamoxifen may increase the QTc-prolonging activities of Goserelin.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06402",
      "source": "DB00014",
      "target": "DB06402",
      "description": "Goserelin may increase the QTc-prolonging activities of Telavancin.",
      "name": "Telavancin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00976",
      "source": "DB00014",
      "target": "DB00976",
      "description": "Goserelin may increase the QTc-prolonging activities of Telithromycin.",
      "name": "Telithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00871",
      "source": "DB00014",
      "target": "DB00871",
      "description": "Terbutaline may increase the QTc-prolonging activities of Goserelin.",
      "name": "Terbutaline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04844",
      "source": "DB00014",
      "target": "DB04844",
      "description": "Goserelin may increase the QTc-prolonging activities of Tetrabenazine.",
      "name": "Tetrabenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00679",
      "source": "DB00014",
      "target": "DB00679",
      "description": "Goserelin may increase the QTc-prolonging activities of Thioridazine.",
      "name": "Thioridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01623",
      "source": "DB00014",
      "target": "DB01623",
      "description": "Thiothixene may increase the QTc-prolonging activities of Goserelin.",
      "name": "Thiothixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00697",
      "source": "DB00014",
      "target": "DB00697",
      "description": "Tizanidine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Tizanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00839",
      "source": "DB00014",
      "target": "DB00839",
      "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01124",
      "source": "DB00014",
      "target": "DB01124",
      "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01036",
      "source": "DB00014",
      "target": "DB01036",
      "description": "Tolterodine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00539",
      "source": "DB00014",
      "target": "DB00539",
      "description": "Goserelin may increase the QTc-prolonging activities of Toremifene.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00072",
      "source": "DB00014",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Goserelin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00656",
      "source": "DB00014",
      "target": "DB00656",
      "description": "Trazodone may increase the QTc-prolonging activities of Goserelin.",
      "name": "Trazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00374",
      "source": "DB00014",
      "target": "DB00374",
      "description": "Treprostinil may increase the QTc-prolonging activities of Goserelin.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00440",
      "source": "DB00014",
      "target": "DB00440",
      "description": "Trimethoprim may increase the QTc-prolonging activities of Goserelin.",
      "name": "Trimethoprim"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00726",
      "source": "DB00014",
      "target": "DB00726",
      "description": "Trimipramine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB06825",
      "source": "DB00014",
      "target": "DB06825",
      "description": "Triptorelin may increase the QTc-prolonging activities of Goserelin.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00197",
      "source": "DB00014",
      "target": "DB00197",
      "description": "The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB05294",
      "source": "DB00014",
      "target": "DB05294",
      "description": "Goserelin may increase the QTc-prolonging activities of Vandetanib.",
      "name": "Vandetanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00862",
      "source": "DB00014",
      "target": "DB00862",
      "description": "Vardenafil may increase the QTc-prolonging activities of Goserelin.",
      "name": "Vardenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB08881",
      "source": "DB00014",
      "target": "DB08881",
      "description": "Goserelin may increase the QTc-prolonging activities of Vemurafenib.",
      "name": "Vemurafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00285",
      "source": "DB00014",
      "target": "DB00285",
      "description": "Venlafaxine may increase the QTc-prolonging activities of Goserelin.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB09082",
      "source": "DB00014",
      "target": "DB09082",
      "description": "Vilanterol may increase the QTc-prolonging activities of Goserelin.",
      "name": "Vilanterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04876",
      "source": "DB00014",
      "target": "DB04876",
      "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB04878",
      "source": "DB00014",
      "target": "DB04878",
      "description": "The therapeutic efficacy of Voglibose can be decreased when used in combination with Goserelin.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00582",
      "source": "DB00014",
      "target": "DB00582",
      "description": "Voriconazole may increase the QTc-prolonging activities of Goserelin.",
      "name": "Voriconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB02546",
      "source": "DB00014",
      "target": "DB02546",
      "description": "Vorinostat may increase the QTc-prolonging activities of Goserelin.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00246",
      "source": "DB00014",
      "target": "DB00246",
      "description": "Goserelin may increase the QTc-prolonging activities of Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB01624",
      "source": "DB00014",
      "target": "DB01624",
      "description": "Goserelin may increase the QTc-prolonging activities of Zuclopenthixol.",
      "name": "Zuclopenthixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00054",
      "source": "DB00015",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Reteplase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01418",
      "source": "DB00015",
      "target": "DB01418",
      "description": "Reteplase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00945",
      "source": "DB00015",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Reteplase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00770",
      "source": "DB00015",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Reteplase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00233",
      "source": "DB00015",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Reteplase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00261",
      "source": "DB00015",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Reteplase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05099",
      "source": "DB00015",
      "target": "DB05099",
      "description": "Reteplase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11598",
      "source": "DB00015",
      "target": "DB11598",
      "description": "Reteplase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06605",
      "source": "DB00015",
      "target": "DB06605",
      "description": "Reteplase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06692",
      "source": "DB00015",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00407",
      "source": "DB00015",
      "target": "DB00407",
      "description": "Reteplase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00278",
      "source": "DB00015",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Reteplase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00972",
      "source": "DB00015",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Reteplase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00102",
      "source": "DB00015",
      "target": "DB00102",
      "description": "Reteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05229",
      "source": "DB00015",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Reteplase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00006",
      "source": "DB00015",
      "target": "DB00006",
      "description": "Reteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06441",
      "source": "DB00015",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Reteplase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09261",
      "source": "DB00015",
      "target": "DB09261",
      "description": "Reteplase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01166",
      "source": "DB00015",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Reteplase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB04272",
      "source": "DB00015",
      "target": "DB04272",
      "description": "Reteplase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00758",
      "source": "DB00015",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Reteplase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06695",
      "source": "DB00015",
      "target": "DB06695",
      "description": "Reteplase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06779",
      "source": "DB00015",
      "target": "DB06779",
      "description": "Reteplase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06754",
      "source": "DB00015",
      "target": "DB06754",
      "description": "Reteplase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB04932",
      "source": "DB00015",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Reteplase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11095",
      "source": "DB00015",
      "target": "DB11095",
      "description": "Reteplase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09255",
      "source": "DB00015",
      "target": "DB09255",
      "description": "Reteplase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11122",
      "source": "DB00015",
      "target": "DB11122",
      "description": "Reteplase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11076",
      "source": "DB00015",
      "target": "DB11076",
      "description": "Reteplase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11241",
      "source": "DB00015",
      "target": "DB11241",
      "description": "Reteplase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00266",
      "source": "DB00015",
      "target": "DB00266",
      "description": "Reteplase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00861",
      "source": "DB00015",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00975",
      "source": "DB00015",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Reteplase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00974",
      "source": "DB00015",
      "target": "DB00974",
      "description": "Reteplase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09075",
      "source": "DB00015",
      "target": "DB09075",
      "description": "Reteplase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01225",
      "source": "DB00015",
      "target": "DB01225",
      "description": "Reteplase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00751",
      "source": "DB00015",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Reteplase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06392",
      "source": "DB00015",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Reteplase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01240",
      "source": "DB00015",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Reteplase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00063",
      "source": "DB00015",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Reteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB08794",
      "source": "DB00015",
      "target": "DB08794",
      "description": "Reteplase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00569",
      "source": "DB00015",
      "target": "DB00569",
      "description": "Reteplase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01109",
      "source": "DB00015",
      "target": "DB01109",
      "description": "Reteplase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB02351",
      "source": "DB00015",
      "target": "DB02351",
      "description": "Reteplase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05266",
      "source": "DB00015",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Reteplase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB08887",
      "source": "DB00015",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Reteplase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06406",
      "source": "DB00015",
      "target": "DB06406",
      "description": "Reteplase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB08954",
      "source": "DB00015",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Reteplase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01088",
      "source": "DB00015",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Reteplase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00001",
      "source": "DB00015",
      "target": "DB00001",
      "description": "Reteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09211",
      "source": "DB00015",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00244",
      "source": "DB00015",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Reteplase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00235",
      "source": "DB00015",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Reteplase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB08813",
      "source": "DB00015",
      "target": "DB08813",
      "description": "Reteplase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05822",
      "source": "DB00015",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Reteplase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB04743",
      "source": "DB00015",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Reteplase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06635",
      "source": "DB00015",
      "target": "DB06635",
      "description": "Reteplase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00686",
      "source": "DB00015",
      "target": "DB00686",
      "description": "Reteplase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00806",
      "source": "DB00015",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Reteplase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00498",
      "source": "DB00015",
      "target": "DB00498",
      "description": "Reteplase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00946",
      "source": "DB00015",
      "target": "DB00946",
      "description": "Reteplase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06209",
      "source": "DB00015",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Reteplase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11312",
      "source": "DB00015",
      "target": "DB11312",
      "description": "Reteplase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB11268",
      "source": "DB00015",
      "target": "DB11268",
      "description": "Reteplase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB02709",
      "source": "DB00015",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Reteplase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09259",
      "source": "DB00015",
      "target": "DB09259",
      "description": "Reteplase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01207",
      "source": "DB00015",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Reteplase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06228",
      "source": "DB00015",
      "target": "DB06228",
      "description": "Reteplase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00936",
      "source": "DB00015",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Reteplase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05692",
      "source": "DB00015",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Reteplase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB01236",
      "source": "DB00015",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Reteplase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB05073",
      "source": "DB00015",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Reteplase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB06271",
      "source": "DB00015",
      "target": "DB06271",
      "description": "Reteplase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB04905",
      "source": "DB00015",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Reteplase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00208",
      "source": "DB00015",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Reteplase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00775",
      "source": "DB00015",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Reteplase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB07615",
      "source": "DB00015",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Reteplase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09283",
      "source": "DB00015",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Reteplase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00374",
      "source": "DB00015",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB08814",
      "source": "DB00015",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Reteplase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB09030",
      "source": "DB00015",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Reteplase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00682",
      "source": "DB00015",
      "target": "DB00682",
      "description": "Reteplase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB04898",
      "source": "DB00015",
      "target": "DB04898",
      "description": "Reteplase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00016-DB00480",
      "source": "DB00016",
      "target": "DB00480",
      "description": "Erythropoietin may increase the thrombogenic activities of Lenalidomide.",
      "name": "Lenalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00016-DB08804",
      "source": "DB00016",
      "target": "DB08804",
      "description": "Nandrolone decanoate may increase the stimulatory activities of Erythropoietin.",
      "name": "Nandrolone decanoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00016-DB00984",
      "source": "DB00016",
      "target": "DB00984",
      "description": "Nandrolone phenpropionate may increase the stimulatory activities of Erythropoietin.",
      "name": "Nandrolone phenpropionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00016-DB01041",
      "source": "DB00016",
      "target": "DB01041",
      "description": "Erythropoietin may increase the thrombogenic activities of Thalidomide.",
      "name": "Thalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00018-DB12768",
      "source": "DB00018",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Interferon alfa-n3.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00018-DB00363",
      "source": "DB00018",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00018-DB04817",
      "source": "DB00018",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfa-n3.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00019-DB09208",
      "source": "DB00019",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00020-DB00290",
      "source": "DB00020",
      "target": "DB00290",
      "description": "The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.",
      "name": "Bleomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00020-DB00531",
      "source": "DB00020",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB08897",
      "source": "DB00021",
      "target": "DB08897",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.",
      "name": "Aclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00517",
      "source": "DB00021",
      "target": "DB00517",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Anisotropine Methylbromide.",
      "name": "Anisotropine Methylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00732",
      "source": "DB00021",
      "target": "DB00732",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.",
      "name": "Atracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00572",
      "source": "DB00021",
      "target": "DB00572",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Atropine.",
      "name": "Atropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB09023",
      "source": "DB00021",
      "target": "DB09023",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Benactyzine.",
      "name": "Benactyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00245",
      "source": "DB00021",
      "target": "DB00245",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine.",
      "name": "Benzatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00810",
      "source": "DB00021",
      "target": "DB00810",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.",
      "name": "Biperiden"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB09007",
      "source": "DB00021",
      "target": "DB09007",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenoxamine.",
      "name": "Chlorphenoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00979",
      "source": "DB00021",
      "target": "DB00979",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate.",
      "name": "Cyclopentolate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00496",
      "source": "DB00021",
      "target": "DB00496",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00967",
      "source": "DB00021",
      "target": "DB00967",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB08997",
      "source": "DB00021",
      "target": "DB08997",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Dexetimide.",
      "name": "Dexetimide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00804",
      "source": "DB00021",
      "target": "DB00804",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.",
      "name": "Dicyclomine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00392",
      "source": "DB00021",
      "target": "DB00392",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Ethopropazine.",
      "name": "Ethopropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB06702",
      "source": "DB00021",
      "target": "DB06702",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00483",
      "source": "DB00021",
      "target": "DB00483",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Gallamine Triethiodide.",
      "name": "Gallamine Triethiodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00986",
      "source": "DB00021",
      "target": "DB00986",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Glycopyrronium.",
      "name": "Glycopyrronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB08960",
      "source": "DB00021",
      "target": "DB08960",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Hexamethonium.",
      "name": "Hexamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB11181",
      "source": "DB00021",
      "target": "DB11181",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.",
      "name": "Homatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00424",
      "source": "DB00021",
      "target": "DB00424",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine.",
      "name": "Hyoscyamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00332",
      "source": "DB00021",
      "target": "DB00332",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00657",
      "source": "DB00021",
      "target": "DB00657",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00940",
      "source": "DB00021",
      "target": "DB00940",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Methantheline.",
      "name": "Methantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00340",
      "source": "DB00021",
      "target": "DB00340",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Metixene.",
      "name": "Metixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB11535",
      "source": "DB00021",
      "target": "DB11535",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with N-butylscopolammonium bromide.",
      "name": "N-butylscopolammonium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB06583",
      "source": "DB00021",
      "target": "DB06583",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with NVA237.",
      "name": "NVA237"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01173",
      "source": "DB00021",
      "target": "DB01173",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.",
      "name": "Orphenadrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01062",
      "source": "DB00021",
      "target": "DB01062",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.",
      "name": "Oxybutynin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00219",
      "source": "DB00021",
      "target": "DB00219",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Oxyphenonium.",
      "name": "Oxyphenonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01337",
      "source": "DB00021",
      "target": "DB01337",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.",
      "name": "Pancuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01090",
      "source": "DB00021",
      "target": "DB01090",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pentolinium.",
      "name": "Pentolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01338",
      "source": "DB00021",
      "target": "DB01338",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.",
      "name": "Pipecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00670",
      "source": "DB00021",
      "target": "DB00670",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.",
      "name": "Pirenzepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00387",
      "source": "DB00021",
      "target": "DB00387",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.",
      "name": "Procyclidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00782",
      "source": "DB00021",
      "target": "DB00782",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline.",
      "name": "Propantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00908",
      "source": "DB00021",
      "target": "DB00908",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00747",
      "source": "DB00021",
      "target": "DB00747",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.",
      "name": "Scopolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB09300",
      "source": "DB00021",
      "target": "DB09300",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide.",
      "name": "Scopolamine butylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01591",
      "source": "DB00021",
      "target": "DB01591",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01409",
      "source": "DB00021",
      "target": "DB01409",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tiotropium.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01036",
      "source": "DB00021",
      "target": "DB01036",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00376",
      "source": "DB00021",
      "target": "DB00376",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl.",
      "name": "Trihexyphenidyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01116",
      "source": "DB00021",
      "target": "DB01116",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan.",
      "name": "Trimethaphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00809",
      "source": "DB00021",
      "target": "DB00809",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tropicamide.",
      "name": "Tropicamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB00209",
      "source": "DB00021",
      "target": "DB00209",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trospium.",
      "name": "Trospium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01199",
      "source": "DB00021",
      "target": "DB01199",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.",
      "name": "Tubocurarine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB09076",
      "source": "DB00021",
      "target": "DB09076",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Umeclidinium.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00021-DB01339",
      "source": "DB00021",
      "target": "DB01339",
      "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01472",
      "source": "DB00022",
      "target": "DB01472",
      "description": "The serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "4-Methoxyamphetamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01418",
      "source": "DB00022",
      "target": "DB01418",
      "description": "The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00316",
      "source": "DB00022",
      "target": "DB00316",
      "description": "The serum concentration of Acetaminophen can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Acetaminophen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB03128",
      "source": "DB00022",
      "target": "DB03128",
      "description": "The serum concentration of Acetylcholine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Acetylcholine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01426",
      "source": "DB00022",
      "target": "DB01426",
      "description": "The serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ajmaline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00518",
      "source": "DB00022",
      "target": "DB00518",
      "description": "The serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Albendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00918",
      "source": "DB00022",
      "target": "DB00918",
      "description": "The serum concentration of Almotriptan can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Almotriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06203",
      "source": "DB00022",
      "target": "DB06203",
      "description": "The serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00969",
      "source": "DB00022",
      "target": "DB00969",
      "description": "The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Alosetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00866",
      "source": "DB00022",
      "target": "DB00866",
      "description": "The serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Alprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01424",
      "source": "DB00022",
      "target": "DB01424",
      "description": "The serum concentration of Aminophenazone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Aminophenazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01223",
      "source": "DB00022",
      "target": "DB01223",
      "description": "The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01118",
      "source": "DB00022",
      "target": "DB01118",
      "description": "The serum concentration of Amiodarone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00321",
      "source": "DB00022",
      "target": "DB00321",
      "description": "The serum concentration of Amitriptyline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00543",
      "source": "DB00022",
      "target": "DB00543",
      "description": "The serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Amoxapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00182",
      "source": "DB00022",
      "target": "DB00182",
      "description": "The serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Amphetamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00701",
      "source": "DB00022",
      "target": "DB00701",
      "description": "The serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Amprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00276",
      "source": "DB00022",
      "target": "DB00276",
      "description": "The serum concentration of Amsacrine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Amsacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00261",
      "source": "DB00022",
      "target": "DB00261",
      "description": "The serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01435",
      "source": "DB00022",
      "target": "DB01435",
      "description": "The serum concentration of Antipyrine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06605",
      "source": "DB00022",
      "target": "DB06605",
      "description": "The serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00673",
      "source": "DB00022",
      "target": "DB00673",
      "description": "The serum concentration of Aprepitant can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Aprepitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01429",
      "source": "DB00022",
      "target": "DB01429",
      "description": "The serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Aprindine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01274",
      "source": "DB00022",
      "target": "DB01274",
      "description": "The serum concentration of Arformoterol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Arformoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01238",
      "source": "DB00022",
      "target": "DB01238",
      "description": "The serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06697",
      "source": "DB00022",
      "target": "DB06697",
      "description": "The serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Artemether"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06235",
      "source": "DB00022",
      "target": "DB06235",
      "description": "The serum concentration of ASA404 can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "ASA404"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06216",
      "source": "DB00022",
      "target": "DB06216",
      "description": "The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00637",
      "source": "DB00022",
      "target": "DB00637",
      "description": "The serum concentration of Astemizole can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Astemizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00289",
      "source": "DB00022",
      "target": "DB00289",
      "description": "The serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Atomoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06264",
      "source": "DB00022",
      "target": "DB06264",
      "description": "The serum concentration of AV650 can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "AV650"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06626",
      "source": "DB00022",
      "target": "DB06626",
      "description": "The serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Axitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00972",
      "source": "DB00022",
      "target": "DB00972",
      "description": "The serum concentration of Azelastine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB12768",
      "source": "DB00022",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2b.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06769",
      "source": "DB00022",
      "target": "DB06769",
      "description": "The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Bendamustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00245",
      "source": "DB00022",
      "target": "DB00245",
      "description": "The serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Benzatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06770",
      "source": "DB00022",
      "target": "DB06770",
      "description": "The serum concentration of Benzyl alcohol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Benzyl alcohol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01244",
      "source": "DB00022",
      "target": "DB01244",
      "description": "The serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Bepridil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00195",
      "source": "DB00022",
      "target": "DB00195",
      "description": "The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00612",
      "source": "DB00022",
      "target": "DB00612",
      "description": "The serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00188",
      "source": "DB00022",
      "target": "DB00188",
      "description": "The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Bortezomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09128",
      "source": "DB00022",
      "target": "DB09128",
      "description": "The serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Brexpiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01558",
      "source": "DB00022",
      "target": "DB01558",
      "description": "The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Bromazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00835",
      "source": "DB00022",
      "target": "DB00835",
      "description": "The serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Brompheniramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06726",
      "source": "DB00022",
      "target": "DB06726",
      "description": "The serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Bufuralol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00297",
      "source": "DB00022",
      "target": "DB00297",
      "description": "The serum concentration of Bupivacaine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Bupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00921",
      "source": "DB00022",
      "target": "DB00921",
      "description": "The serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Buprenorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01156",
      "source": "DB00022",
      "target": "DB01156",
      "description": "The serum concentration of Bupropion can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Bupropion"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00490",
      "source": "DB00022",
      "target": "DB00490",
      "description": "The serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Buspirone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00201",
      "source": "DB00022",
      "target": "DB00201",
      "description": "The serum concentration of Caffeine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Caffeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00201",
      "source": "DB00022",
      "target": "DB00201",
      "description": "The serum concentration of Caffeine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Caffeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01197",
      "source": "DB00022",
      "target": "DB01197",
      "description": "The serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Captopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00564",
      "source": "DB00022",
      "target": "DB00564",
      "description": "The serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06016",
      "source": "DB00022",
      "target": "DB06016",
      "description": "The serum concentration of Cariprazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Cariprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00262",
      "source": "DB00022",
      "target": "DB00262",
      "description": "The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Carmustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00521",
      "source": "DB00022",
      "target": "DB00521",
      "description": "The serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01136",
      "source": "DB00022",
      "target": "DB01136",
      "description": "The serum concentration of Carvedilol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00567",
      "source": "DB00022",
      "target": "DB00567",
      "description": "The serum concentration of Cephalexin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Cephalexin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00185",
      "source": "DB00022",
      "target": "DB00185",
      "description": "The serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Cevimeline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00475",
      "source": "DB00022",
      "target": "DB00475",
      "description": "The serum concentration of Chlordiazepoxide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Chlordiazepoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00608",
      "source": "DB00022",
      "target": "DB00608",
      "description": "The serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01114",
      "source": "DB00022",
      "target": "DB01114",
      "description": "The serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Chlorphenamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00477",
      "source": "DB00022",
      "target": "DB00477",
      "description": "The serum concentration of Chlorpromazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00356",
      "source": "DB00022",
      "target": "DB00356",
      "description": "The serum concentration of Chlorzoxazone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Chlorzoxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01166",
      "source": "DB00022",
      "target": "DB01166",
      "description": "The serum concentration of Cilostazol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01012",
      "source": "DB00022",
      "target": "DB01012",
      "description": "The serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Cinacalcet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00568",
      "source": "DB00022",
      "target": "DB00568",
      "description": "The serum concentration of Cinnarizine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Cinnarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00604",
      "source": "DB00022",
      "target": "DB00604",
      "description": "The serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00215",
      "source": "DB00022",
      "target": "DB00215",
      "description": "The serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01407",
      "source": "DB00022",
      "target": "DB01407",
      "description": "The serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Clenbuterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04920",
      "source": "DB00022",
      "target": "DB04920",
      "description": "The serum concentration of Clevidipine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Clevidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01242",
      "source": "DB00022",
      "target": "DB01242",
      "description": "The serum concentration of Clomipramine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00575",
      "source": "DB00022",
      "target": "DB00575",
      "description": "The serum concentration of Clonidine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00758",
      "source": "DB00022",
      "target": "DB00758",
      "description": "The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00363",
      "source": "DB00022",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00318",
      "source": "DB00022",
      "target": "DB00318",
      "description": "The serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Codeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00286",
      "source": "DB00022",
      "target": "DB00286",
      "description": "The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00924",
      "source": "DB00022",
      "target": "DB00924",
      "description": "The serum concentration of Cyclobenzaprine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00531",
      "source": "DB00022",
      "target": "DB00531",
      "description": "The serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00851",
      "source": "DB00022",
      "target": "DB00851",
      "description": "The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Dacarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06292",
      "source": "DB00022",
      "target": "DB06292",
      "description": "The serum concentration of Dapagliflozin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Dapagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00496",
      "source": "DB00022",
      "target": "DB00496",
      "description": "The serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09183",
      "source": "DB00022",
      "target": "DB09183",
      "description": "The serum concentration of Dasabuvir can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dasabuvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01254",
      "source": "DB00022",
      "target": "DB01254",
      "description": "The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00694",
      "source": "DB00022",
      "target": "DB00694",
      "description": "The serum concentration of Daunorubicin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04840",
      "source": "DB00022",
      "target": "DB04840",
      "description": "The serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Debrisoquin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00705",
      "source": "DB00022",
      "target": "DB00705",
      "description": "The serum concentration of Delavirdine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Delavirdine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01151",
      "source": "DB00022",
      "target": "DB01151",
      "description": "The serum concentration of Desipramine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01191",
      "source": "DB00022",
      "target": "DB01191",
      "description": "The serum concentration of Dexfenfluramine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Dexfenfluramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06701",
      "source": "DB00022",
      "target": "DB06701",
      "description": "The serum concentration of Dexmethylphenidate can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dexmethylphenidate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01576",
      "source": "DB00022",
      "target": "DB01576",
      "description": "The serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dextroamphetamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00514",
      "source": "DB00022",
      "target": "DB00514",
      "description": "The serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dextromethorphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00829",
      "source": "DB00022",
      "target": "DB00829",
      "description": "The serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Diazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00586",
      "source": "DB00022",
      "target": "DB00586",
      "description": "The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01551",
      "source": "DB00022",
      "target": "DB01551",
      "description": "The serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dihydrocodeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00343",
      "source": "DB00022",
      "target": "DB00343",
      "description": "The serum concentration of Diltiazem can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00917",
      "source": "DB00022",
      "target": "DB00917",
      "description": "The serum concentration of Dinoprostone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Dinoprostone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01075",
      "source": "DB00022",
      "target": "DB01075",
      "description": "The serum concentration of Diphenhydramine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Diphenhydramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00757",
      "source": "DB00022",
      "target": "DB00757",
      "description": "The serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dolasetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01184",
      "source": "DB00022",
      "target": "DB01184",
      "description": "The serum concentration of Domperidone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00843",
      "source": "DB00022",
      "target": "DB00843",
      "description": "The serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Donepezil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00988",
      "source": "DB00022",
      "target": "DB00988",
      "description": "The serum concentration of Dopamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dopamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00590",
      "source": "DB00022",
      "target": "DB00590",
      "description": "The serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Doxazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01142",
      "source": "DB00022",
      "target": "DB01142",
      "description": "The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00997",
      "source": "DB00022",
      "target": "DB00997",
      "description": "The serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04855",
      "source": "DB00022",
      "target": "DB04855",
      "description": "The serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00476",
      "source": "DB00022",
      "target": "DB00476",
      "description": "The serum concentration of Duloxetine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00651",
      "source": "DB00022",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00216",
      "source": "DB00022",
      "target": "DB00216",
      "description": "The serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Eletriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09039",
      "source": "DB00022",
      "target": "DB09039",
      "description": "The serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Eliglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06210",
      "source": "DB00022",
      "target": "DB06210",
      "description": "The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Eltrombopag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01228",
      "source": "DB00022",
      "target": "DB01228",
      "description": "The serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Encainide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06735",
      "source": "DB00022",
      "target": "DB06735",
      "description": "The serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Enclomiphene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00751",
      "source": "DB00022",
      "target": "DB00751",
      "description": "The serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00696",
      "source": "DB00022",
      "target": "DB00696",
      "description": "The serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00530",
      "source": "DB00022",
      "target": "DB00530",
      "description": "The serum concentration of Erlotinib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Erlotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01175",
      "source": "DB00022",
      "target": "DB01175",
      "description": "The serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06678",
      "source": "DB00022",
      "target": "DB06678",
      "description": "The serum concentration of Esmirtazapine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00783",
      "source": "DB00022",
      "target": "DB00783",
      "description": "The serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00655",
      "source": "DB00022",
      "target": "DB00655",
      "description": "The serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04574",
      "source": "DB00022",
      "target": "DB04574",
      "description": "The serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Estrone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00898",
      "source": "DB00022",
      "target": "DB00898",
      "description": "The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ethanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01466",
      "source": "DB00022",
      "target": "DB01466",
      "description": "The serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ethylmorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00773",
      "source": "DB00022",
      "target": "DB00773",
      "description": "The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Etoposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01628",
      "source": "DB00022",
      "target": "DB01628",
      "description": "The serum concentration of Etoricoxib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06702",
      "source": "DB00022",
      "target": "DB06702",
      "description": "The serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08868",
      "source": "DB00022",
      "target": "DB08868",
      "description": "The serum concentration of Fingolimod can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01195",
      "source": "DB00022",
      "target": "DB01195",
      "description": "The serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Flecainide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04841",
      "source": "DB00022",
      "target": "DB04841",
      "description": "The serum concentration of Flunarizine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Flunarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01544",
      "source": "DB00022",
      "target": "DB01544",
      "description": "The serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Flunitrazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00544",
      "source": "DB00022",
      "target": "DB00544",
      "description": "The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Fluorouracil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00472",
      "source": "DB00022",
      "target": "DB00472",
      "description": "The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00623",
      "source": "DB00022",
      "target": "DB00623",
      "description": "The serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Fluphenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00499",
      "source": "DB00022",
      "target": "DB00499",
      "description": "The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Flutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01095",
      "source": "DB00022",
      "target": "DB01095",
      "description": "The serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Fluvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00176",
      "source": "DB00022",
      "target": "DB00176",
      "description": "The serum concentration of Fluvoxamine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00983",
      "source": "DB00022",
      "target": "DB00983",
      "description": "The serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Formoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00998",
      "source": "DB00022",
      "target": "DB00998",
      "description": "The serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Frovatriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00674",
      "source": "DB00022",
      "target": "DB00674",
      "description": "The serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Galantamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00317",
      "source": "DB00022",
      "target": "DB00317",
      "description": "The serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Gefitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01645",
      "source": "DB00022",
      "target": "DB01645",
      "description": "The serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00889",
      "source": "DB00022",
      "target": "DB00889",
      "description": "The serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Granisetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00365",
      "source": "DB00022",
      "target": "DB00365",
      "description": "The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00629",
      "source": "DB00022",
      "target": "DB00629",
      "description": "The serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Guanabenz"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01218",
      "source": "DB00022",
      "target": "DB01218",
      "description": "The serum concentration of Halofantrine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Halofantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00502",
      "source": "DB00022",
      "target": "DB00502",
      "description": "The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01159",
      "source": "DB00022",
      "target": "DB01159",
      "description": "The serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Halothane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01094",
      "source": "DB00022",
      "target": "DB01094",
      "description": "The serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Hesperetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01355",
      "source": "DB00022",
      "target": "DB01355",
      "description": "The serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Hexobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00956",
      "source": "DB00022",
      "target": "DB00956",
      "description": "The serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Hydrocodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00327",
      "source": "DB00022",
      "target": "DB00327",
      "description": "The serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Hydromorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09053",
      "source": "DB00022",
      "target": "DB09053",
      "description": "The serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01177",
      "source": "DB00022",
      "target": "DB01177",
      "description": "The serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04946",
      "source": "DB00022",
      "target": "DB04946",
      "description": "The serum concentration of Iloperidone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00619",
      "source": "DB00022",
      "target": "DB00619",
      "description": "The serum concentration of Imatinib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Imatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00458",
      "source": "DB00022",
      "target": "DB00458",
      "description": "The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00724",
      "source": "DB00022",
      "target": "DB00724",
      "description": "The serum concentration of Imiquimod can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Imiquimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00332",
      "source": "DB00022",
      "target": "DB00332",
      "description": "The serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09570",
      "source": "DB00022",
      "target": "DB09570",
      "description": "The serum concentration of Ixazomib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ixazomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00598",
      "source": "DB00022",
      "target": "DB00598",
      "description": "The serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01097",
      "source": "DB00022",
      "target": "DB01097",
      "description": "The serum concentration of Leflunomide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01002",
      "source": "DB00022",
      "target": "DB01002",
      "description": "The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Levobupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01235",
      "source": "DB00022",
      "target": "DB01235",
      "description": "The serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Levodopa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08918",
      "source": "DB00022",
      "target": "DB08918",
      "description": "The serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00281",
      "source": "DB00022",
      "target": "DB00281",
      "description": "The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Lidocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00589",
      "source": "DB00022",
      "target": "DB00589",
      "description": "The serum concentration of Lisuride can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Lisuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00978",
      "source": "DB00022",
      "target": "DB00978",
      "description": "The serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01206",
      "source": "DB00022",
      "target": "DB01206",
      "description": "The serum concentration of Lomustine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Lomustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00836",
      "source": "DB00022",
      "target": "DB00836",
      "description": "The serum concentration of Loperamide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Loperamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00455",
      "source": "DB00022",
      "target": "DB00455",
      "description": "The serum concentration of Loratadine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Loratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04871",
      "source": "DB00022",
      "target": "DB04871",
      "description": "The serum concentration of Lorcaserin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Lorcaserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01283",
      "source": "DB00022",
      "target": "DB01283",
      "description": "The serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00772",
      "source": "DB00022",
      "target": "DB00772",
      "description": "The serum concentration of Malathion can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Malathion"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00934",
      "source": "DB00022",
      "target": "DB00934",
      "description": "The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Maprotiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01065",
      "source": "DB00022",
      "target": "DB01065",
      "description": "The serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Melatonin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00170",
      "source": "DB00022",
      "target": "DB00170",
      "description": "The serum concentration of Menadione can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Menadione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00532",
      "source": "DB00022",
      "target": "DB00532",
      "description": "The serum concentration of Mephenytoin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Mephenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01071",
      "source": "DB00022",
      "target": "DB01071",
      "description": "The serum concentration of Mequitazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Mequitazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00933",
      "source": "DB00022",
      "target": "DB00933",
      "description": "The serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Mesoridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04817",
      "source": "DB00022",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00333",
      "source": "DB00022",
      "target": "DB00333",
      "description": "The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01577",
      "source": "DB00022",
      "target": "DB01577",
      "description": "The serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Methamphetamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01403",
      "source": "DB00022",
      "target": "DB01403",
      "description": "The serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01028",
      "source": "DB00022",
      "target": "DB01028",
      "description": "The serum concentration of Methoxyflurane can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Methoxyflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00422",
      "source": "DB00022",
      "target": "DB00422",
      "description": "The serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Methylphenidate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01107",
      "source": "DB00022",
      "target": "DB01107",
      "description": "The serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Methyprylon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01233",
      "source": "DB00022",
      "target": "DB01233",
      "description": "The serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Metoclopramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00264",
      "source": "DB00022",
      "target": "DB00264",
      "description": "The serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00379",
      "source": "DB00022",
      "target": "DB00379",
      "description": "The serum concentration of Mexiletine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Mexiletine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06148",
      "source": "DB00022",
      "target": "DB06148",
      "description": "The serum concentration of Mianserin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Mianserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00805",
      "source": "DB00022",
      "target": "DB00805",
      "description": "The serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Minaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08893",
      "source": "DB00022",
      "target": "DB08893",
      "description": "The serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Mirabegron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00370",
      "source": "DB00022",
      "target": "DB00370",
      "description": "The serum concentration of Mirtazapine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01171",
      "source": "DB00022",
      "target": "DB01171",
      "description": "The serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00295",
      "source": "DB00022",
      "target": "DB00295",
      "description": "The serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Morphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06510",
      "source": "DB00022",
      "target": "DB06510",
      "description": "The serum concentration of muraglitazar can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "muraglitazar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00461",
      "source": "DB00022",
      "target": "DB00461",
      "description": "The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00788",
      "source": "DB00022",
      "target": "DB00788",
      "description": "The serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00731",
      "source": "DB00022",
      "target": "DB00731",
      "description": "The serum concentration of Nateglinide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04861",
      "source": "DB00022",
      "target": "DB04861",
      "description": "The serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nebivolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01149",
      "source": "DB00022",
      "target": "DB01149",
      "description": "The serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09048",
      "source": "DB00022",
      "target": "DB09048",
      "description": "The serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Netupitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00238",
      "source": "DB00022",
      "target": "DB00238",
      "description": "The serum concentration of Nevirapine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nevirapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00622",
      "source": "DB00022",
      "target": "DB00622",
      "description": "The serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00699",
      "source": "DB00022",
      "target": "DB00699",
      "description": "The serum concentration of Nicergoline can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nicergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00184",
      "source": "DB00022",
      "target": "DB00184",
      "description": "The serum concentration of Nicotine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Nicotine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01115",
      "source": "DB00022",
      "target": "DB01115",
      "description": "The serum concentration of Nifedipine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Nifedipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00435",
      "source": "DB00022",
      "target": "DB00435",
      "description": "The serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Nitric Oxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00336",
      "source": "DB00022",
      "target": "DB00336",
      "description": "The serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Nitrofural"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00540",
      "source": "DB00022",
      "target": "DB00540",
      "description": "The serum concentration of Nortriptyline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00334",
      "source": "DB00022",
      "target": "DB00334",
      "description": "The serum concentration of Olanzapine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00338",
      "source": "DB00022",
      "target": "DB00338",
      "description": "The serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Omeprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00904",
      "source": "DB00022",
      "target": "DB00904",
      "description": "The serum concentration of Ondansetron can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ondansetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00526",
      "source": "DB00022",
      "target": "DB00526",
      "description": "The serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Oxaliplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01303",
      "source": "DB00022",
      "target": "DB01303",
      "description": "The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Oxtriphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00497",
      "source": "DB00022",
      "target": "DB00497",
      "description": "The serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Oxycodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01192",
      "source": "DB00022",
      "target": "DB01192",
      "description": "The serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Oxymorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00377",
      "source": "DB00022",
      "target": "DB00377",
      "description": "The serum concentration of Palonosetron can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Palonosetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00213",
      "source": "DB00022",
      "target": "DB00213",
      "description": "The serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pantoprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00715",
      "source": "DB00022",
      "target": "DB00715",
      "description": "The serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06589",
      "source": "DB00022",
      "target": "DB06589",
      "description": "The serum concentration of Pazopanib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09208",
      "source": "DB00022",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00738",
      "source": "DB00022",
      "target": "DB00738",
      "description": "The serum concentration of Pentamidine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00806",
      "source": "DB00022",
      "target": "DB00806",
      "description": "The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01074",
      "source": "DB00022",
      "target": "DB01074",
      "description": "The serum concentration of Perhexiline can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Perhexiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00850",
      "source": "DB00022",
      "target": "DB00850",
      "description": "The serum concentration of Perphenazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Perphenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00454",
      "source": "DB00022",
      "target": "DB00454",
      "description": "The serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB03783",
      "source": "DB00022",
      "target": "DB03783",
      "description": "The serum concentration of Phenacetin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Phenacetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00914",
      "source": "DB00022",
      "target": "DB00914",
      "description": "The serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01100",
      "source": "DB00022",
      "target": "DB01100",
      "description": "The serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00960",
      "source": "DB00022",
      "target": "DB00960",
      "description": "The serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00592",
      "source": "DB00022",
      "target": "DB00592",
      "description": "The serum concentration of Piperazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Piperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01621",
      "source": "DB00022",
      "target": "DB01621",
      "description": "The serum concentration of Pipotiazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pipotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08910",
      "source": "DB00022",
      "target": "DB08910",
      "description": "The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pomalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08901",
      "source": "DB00022",
      "target": "DB08901",
      "description": "The serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ponatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01058",
      "source": "DB00022",
      "target": "DB01058",
      "description": "The serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Praziquantel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01087",
      "source": "DB00022",
      "target": "DB01087",
      "description": "The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Primaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01035",
      "source": "DB00022",
      "target": "DB01035",
      "description": "The serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Procainamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00433",
      "source": "DB00022",
      "target": "DB00433",
      "description": "The serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Prochlorperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00396",
      "source": "DB00022",
      "target": "DB00396",
      "description": "The serum concentration of Progesterone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01131",
      "source": "DB00022",
      "target": "DB01131",
      "description": "The serum concentration of Proguanil can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Proguanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00420",
      "source": "DB00022",
      "target": "DB00420",
      "description": "The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Promazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01069",
      "source": "DB00022",
      "target": "DB01069",
      "description": "The serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Promethazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01182",
      "source": "DB00022",
      "target": "DB01182",
      "description": "The serum concentration of Propafenone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Propafenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00818",
      "source": "DB00022",
      "target": "DB00818",
      "description": "The serum concentration of Propofol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Propofol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00571",
      "source": "DB00022",
      "target": "DB00571",
      "description": "The serum concentration of Propranolol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00344",
      "source": "DB00022",
      "target": "DB00344",
      "description": "The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00852",
      "source": "DB00022",
      "target": "DB00852",
      "description": "The serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Pseudoephedrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00339",
      "source": "DB00022",
      "target": "DB00339",
      "description": "The serum concentration of Pyrazinamide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Pyrazinamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01224",
      "source": "DB00022",
      "target": "DB01224",
      "description": "The serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00468",
      "source": "DB00022",
      "target": "DB00468",
      "description": "The serum concentration of Quinine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00980",
      "source": "DB00022",
      "target": "DB00980",
      "description": "The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ramelteon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00863",
      "source": "DB00022",
      "target": "DB00863",
      "description": "The serum concentration of Ranitidine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ranitidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01367",
      "source": "DB00022",
      "target": "DB01367",
      "description": "The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Rasagiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00409",
      "source": "DB00022",
      "target": "DB00409",
      "description": "The serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Remoxipride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06506",
      "source": "DB00022",
      "target": "DB06506",
      "description": "The serum concentration of repinotan can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "repinotan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB02709",
      "source": "DB00022",
      "target": "DB02709",
      "description": "The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00615",
      "source": "DB00022",
      "target": "DB00615",
      "description": "The serum concentration of Rifabutin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Rifabutin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00740",
      "source": "DB00022",
      "target": "DB00740",
      "description": "The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Riluzole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00734",
      "source": "DB00022",
      "target": "DB00734",
      "description": "The serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00503",
      "source": "DB00022",
      "target": "DB00503",
      "description": "The serum concentration of Ritonavir can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00953",
      "source": "DB00022",
      "target": "DB00953",
      "description": "The serum concentration of Rizatriptan can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Rizatriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00533",
      "source": "DB00022",
      "target": "DB00533",
      "description": "The serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00268",
      "source": "DB00022",
      "target": "DB00268",
      "description": "The serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ropinirole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00296",
      "source": "DB00022",
      "target": "DB00296",
      "description": "The serum concentration of Ropivacaine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ropivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB05271",
      "source": "DB00022",
      "target": "DB05271",
      "description": "The serum concentration of Rotigotine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Rotigotine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01232",
      "source": "DB00022",
      "target": "DB01232",
      "description": "The serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01037",
      "source": "DB00022",
      "target": "DB01037",
      "description": "The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06144",
      "source": "DB00022",
      "target": "DB06144",
      "description": "The serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Sertindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01104",
      "source": "DB00022",
      "target": "DB01104",
      "description": "The serum concentration of Sertraline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00203",
      "source": "DB00022",
      "target": "DB00203",
      "description": "The serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Sildenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00641",
      "source": "DB00022",
      "target": "DB00641",
      "description": "The serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06727",
      "source": "DB00022",
      "target": "DB06727",
      "description": "The serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Sparteine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00382",
      "source": "DB00022",
      "target": "DB00382",
      "description": "The serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Tacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00675",
      "source": "DB00022",
      "target": "DB00675",
      "description": "The serum concentration of Tamoxifen can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00706",
      "source": "DB00022",
      "target": "DB00706",
      "description": "The serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tamsulosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06204",
      "source": "DB00022",
      "target": "DB06204",
      "description": "The serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tapentadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01079",
      "source": "DB00022",
      "target": "DB01079",
      "description": "The serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tegaserod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01265",
      "source": "DB00022",
      "target": "DB01265",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.",
      "name": "Telbivudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00976",
      "source": "DB00022",
      "target": "DB00976",
      "description": "The serum concentration of Telithromycin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Telithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01405",
      "source": "DB00022",
      "target": "DB01405",
      "description": "The serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00857",
      "source": "DB00022",
      "target": "DB00857",
      "description": "The serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Terbinafine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00342",
      "source": "DB00022",
      "target": "DB00342",
      "description": "The serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Terfenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04905",
      "source": "DB00022",
      "target": "DB04905",
      "description": "The serum concentration of Tesmilifene can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB04844",
      "source": "DB00022",
      "target": "DB04844",
      "description": "The serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tetrabenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01041",
      "source": "DB00022",
      "target": "DB01041",
      "description": "The serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Thalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01412",
      "source": "DB00022",
      "target": "DB01412",
      "description": "The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Theobromine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00277",
      "source": "DB00022",
      "target": "DB00277",
      "description": "The serum concentration of Theophylline can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00730",
      "source": "DB00022",
      "target": "DB00730",
      "description": "The serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Thiabendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00679",
      "source": "DB00022",
      "target": "DB00679",
      "description": "The serum concentration of Thioridazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Thioridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01623",
      "source": "DB00022",
      "target": "DB01623",
      "description": "The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Thiothixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00208",
      "source": "DB00022",
      "target": "DB00208",
      "description": "The serum concentration of Ticlopidine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00373",
      "source": "DB00022",
      "target": "DB00373",
      "description": "The serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01409",
      "source": "DB00022",
      "target": "DB01409",
      "description": "The serum concentration of Tiotropium can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00932",
      "source": "DB00022",
      "target": "DB00932",
      "description": "The serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00697",
      "source": "DB00022",
      "target": "DB00697",
      "description": "The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Tizanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01036",
      "source": "DB00022",
      "target": "DB01036",
      "description": "The serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00539",
      "source": "DB00022",
      "target": "DB00539",
      "description": "The serum concentration of Toremifene can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB05109",
      "source": "DB00022",
      "target": "DB05109",
      "description": "The serum concentration of Trabectedin can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Trabectedin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00193",
      "source": "DB00022",
      "target": "DB00193",
      "description": "The serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Tramadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00656",
      "source": "DB00022",
      "target": "DB00656",
      "description": "The serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Trazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00384",
      "source": "DB00022",
      "target": "DB00384",
      "description": "The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Triamterene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00831",
      "source": "DB00022",
      "target": "DB00831",
      "description": "The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Trifluoperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00726",
      "source": "DB00022",
      "target": "DB00726",
      "description": "The serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB08867",
      "source": "DB00022",
      "target": "DB08867",
      "description": "The serum concentration of Ulipristal can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ulipristal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09076",
      "source": "DB00022",
      "target": "DB09076",
      "description": "The serum concentration of Umeclidinium can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00285",
      "source": "DB00022",
      "target": "DB00285",
      "description": "The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00661",
      "source": "DB00022",
      "target": "DB00661",
      "description": "The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Verapamil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB06684",
      "source": "DB00022",
      "target": "DB06684",
      "description": "The serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Vilazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00570",
      "source": "DB00022",
      "target": "DB00570",
      "description": "The serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Vinblastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00361",
      "source": "DB00022",
      "target": "DB00361",
      "description": "The serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Vinorelbine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB09068",
      "source": "DB00022",
      "target": "DB09068",
      "description": "The serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Vortioxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00682",
      "source": "DB00022",
      "target": "DB00682",
      "description": "The serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01392",
      "source": "DB00022",
      "target": "DB01392",
      "description": "The serum concentration of Yohimbine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Yohimbine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00943",
      "source": "DB00022",
      "target": "DB00943",
      "description": "The serum concentration of Zalcitabine can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Zalcitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00495",
      "source": "DB00022",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00744",
      "source": "DB00022",
      "target": "DB00744",
      "description": "The serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00246",
      "source": "DB00022",
      "target": "DB00246",
      "description": "The serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00315",
      "source": "DB00022",
      "target": "DB00315",
      "description": "The serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Zolmitriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00425",
      "source": "DB00022",
      "target": "DB00425",
      "description": "The serum concentration of Zolpidem can be increased when it is combined with Peginterferon alfa-2b.",
      "name": "Zolpidem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB01624",
      "source": "DB00022",
      "target": "DB01624",
      "description": "The serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.",
      "name": "Zuclopenthixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00511",
      "source": "DB00023",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Asparaginase.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00112",
      "source": "DB00023",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Asparaginase.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB06772",
      "source": "DB00023",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00531",
      "source": "DB00023",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Asparaginase.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01078",
      "source": "DB00023",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Asparaginase.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01234",
      "source": "DB00023",
      "target": "DB01234",
      "description": "The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01396",
      "source": "DB00023",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Asparaginase.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00390",
      "source": "DB00023",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Asparaginase.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01248",
      "source": "DB00023",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01092",
      "source": "DB00023",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Asparaginase.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB01229",
      "source": "DB00023",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00072",
      "source": "DB00023",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Asparaginase.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01193",
      "source": "DB00027",
      "target": "DB01193",
      "description": "The serum concentration of Acebutolol can be increased when it is combined with Gramicidin D.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00316",
      "source": "DB00027",
      "target": "DB00316",
      "description": "The serum concentration of Acetaminophen can be increased when it is combined with Gramicidin D.",
      "name": "Acetaminophen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00945",
      "source": "DB00027",
      "target": "DB00945",
      "description": "The serum concentration of Acetylsalicylic acid can be increased when it is combined with Gramicidin D.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08916",
      "source": "DB00027",
      "target": "DB08916",
      "description": "The serum concentration of Afatinib can be increased when it is combined with Gramicidin D.",
      "name": "Afatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04630",
      "source": "DB00027",
      "target": "DB04630",
      "description": "The serum concentration of Aldosterone can be increased when it is combined with Gramicidin D.",
      "name": "Aldosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00523",
      "source": "DB00027",
      "target": "DB00523",
      "description": "The serum concentration of Alitretinoin can be increased when it is combined with Gramicidin D.",
      "name": "Alitretinoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06403",
      "source": "DB00027",
      "target": "DB06403",
      "description": "The serum concentration of Ambrisentan can be increased when it is combined with Gramicidin D.",
      "name": "Ambrisentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00321",
      "source": "DB00027",
      "target": "DB00321",
      "description": "The serum concentration of Amitriptyline can be increased when it is combined with Gramicidin D.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06605",
      "source": "DB00027",
      "target": "DB06605",
      "description": "The serum concentration of Apixaban can be increased when it is combined with Gramicidin D.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01169",
      "source": "DB00027",
      "target": "DB01169",
      "description": "The serum concentration of Arsenic trioxide can be increased when it is combined with Gramicidin D.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01072",
      "source": "DB00027",
      "target": "DB01072",
      "description": "The serum concentration of Atazanavir can be increased when it is combined with Gramicidin D.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00335",
      "source": "DB00027",
      "target": "DB00335",
      "description": "The serum concentration of Atenolol can be increased when it is combined with Gramicidin D.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06626",
      "source": "DB00027",
      "target": "DB06626",
      "description": "The serum concentration of Axitinib can be increased when it is combined with Gramicidin D.",
      "name": "Axitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB12768",
      "source": "DB00027",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Gramicidin D.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00443",
      "source": "DB00027",
      "target": "DB00443",
      "description": "The serum concentration of Betamethasone can be increased when it is combined with Gramicidin D.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08873",
      "source": "DB00027",
      "target": "DB08873",
      "description": "The serum concentration of Boceprevir can be increased when it is combined with Gramicidin D.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06616",
      "source": "DB00027",
      "target": "DB06616",
      "description": "The serum concentration of Bosutinib can be increased when it is combined with Gramicidin D.",
      "name": "Bosutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08870",
      "source": "DB00027",
      "target": "DB08870",
      "description": "The serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.",
      "name": "Brentuximab vedotin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01200",
      "source": "DB00027",
      "target": "DB01200",
      "description": "The serum concentration of Bromocriptine can be increased when it is combined with Gramicidin D.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06772",
      "source": "DB00027",
      "target": "DB06772",
      "description": "The serum concentration of Cabazitaxel can be increased when it is combined with Gramicidin D.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00201",
      "source": "DB00027",
      "target": "DB00201",
      "description": "The serum concentration of Caffeine can be increased when it is combined with Gramicidin D.",
      "name": "Caffeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04690",
      "source": "DB00027",
      "target": "DB04690",
      "description": "The serum concentration of Camptothecin can be increased when it is combined with Gramicidin D.",
      "name": "Camptothecin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08907",
      "source": "DB00027",
      "target": "DB08907",
      "description": "The serum concentration of Canagliflozin can be increased when it is combined with Gramicidin D.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00564",
      "source": "DB00027",
      "target": "DB00564",
      "description": "The serum concentration of Carbamazepine can be increased when it is combined with Gramicidin D.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08889",
      "source": "DB00027",
      "target": "DB08889",
      "description": "The serum concentration of Carfilzomib can be increased when it is combined with Gramicidin D.",
      "name": "Carfilzomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09063",
      "source": "DB00027",
      "target": "DB09063",
      "description": "The serum concentration of Ceritinib can be increased when it is combined with Gramicidin D.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00439",
      "source": "DB00027",
      "target": "DB00439",
      "description": "The serum concentration of Cerivastatin can be increased when it is combined with Gramicidin D.",
      "name": "Cerivastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00477",
      "source": "DB00027",
      "target": "DB00477",
      "description": "The serum concentration of Chlorpromazine can be increased when it is combined with Gramicidin D.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00501",
      "source": "DB00027",
      "target": "DB00501",
      "description": "The serum concentration of Cimetidine can be increased when it is combined with Gramicidin D.",
      "name": "Cimetidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00537",
      "source": "DB00027",
      "target": "DB00537",
      "description": "The serum concentration of Ciprofloxacin can be increased when it is combined with Gramicidin D.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00515",
      "source": "DB00027",
      "target": "DB00515",
      "description": "The serum concentration of Cisplatin can be increased when it is combined with Gramicidin D.",
      "name": "Cisplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00215",
      "source": "DB00027",
      "target": "DB00215",
      "description": "The serum concentration of Citalopram can be increased when it is combined with Gramicidin D.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01211",
      "source": "DB00027",
      "target": "DB01211",
      "description": "The serum concentration of Clarithromycin can be increased when it is combined with Gramicidin D.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00349",
      "source": "DB00027",
      "target": "DB00349",
      "description": "The serum concentration of Clobazam can be increased when it is combined with Gramicidin D.",
      "name": "Clobazam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00882",
      "source": "DB00027",
      "target": "DB00882",
      "description": "The serum concentration of Clomifene can be increased when it is combined with Gramicidin D.",
      "name": "Clomifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00575",
      "source": "DB00027",
      "target": "DB00575",
      "description": "The serum concentration of Clonidine can be increased when it is combined with Gramicidin D.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00758",
      "source": "DB00027",
      "target": "DB00758",
      "description": "The serum concentration of Clopidogrel can be increased when it is combined with Gramicidin D.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00363",
      "source": "DB00027",
      "target": "DB00363",
      "description": "The serum concentration of Clozapine can be increased when it is combined with Gramicidin D.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB05239",
      "source": "DB00027",
      "target": "DB05239",
      "description": "The serum concentration of Cobimetinib can be increased when it is combined with Gramicidin D.",
      "name": "Cobimetinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01394",
      "source": "DB00027",
      "target": "DB01394",
      "description": "The serum concentration of Colchicine can be increased when it is combined with Gramicidin D.",
      "name": "Colchicine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00286",
      "source": "DB00027",
      "target": "DB00286",
      "description": "The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Gramicidin D.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08865",
      "source": "DB00027",
      "target": "DB08865",
      "description": "The serum concentration of Crizotinib can be increased when it is combined with Gramicidin D.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00091",
      "source": "DB00027",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06695",
      "source": "DB00027",
      "target": "DB06695",
      "description": "The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08912",
      "source": "DB00027",
      "target": "DB08912",
      "description": "The serum concentration of Dabrafenib can be increased when it is combined with Gramicidin D.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00970",
      "source": "DB00027",
      "target": "DB00970",
      "description": "The serum concentration of Dactinomycin can be increased when it is combined with Gramicidin D.",
      "name": "Dactinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06292",
      "source": "DB00027",
      "target": "DB06292",
      "description": "The serum concentration of Dapagliflozin can be increased when it is combined with Gramicidin D.",
      "name": "Dapagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01254",
      "source": "DB00027",
      "target": "DB01254",
      "description": "The serum concentration of Dasatinib can be increased when it is combined with Gramicidin D.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00694",
      "source": "DB00027",
      "target": "DB00694",
      "description": "The serum concentration of Daunorubicin can be increased when it is combined with Gramicidin D.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04840",
      "source": "DB00027",
      "target": "DB04840",
      "description": "The serum concentration of Debrisoquin can be increased when it is combined with Gramicidin D.",
      "name": "Debrisoquin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01234",
      "source": "DB00027",
      "target": "DB01234",
      "description": "The serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00829",
      "source": "DB00027",
      "target": "DB00829",
      "description": "The serum concentration of Diazepam can be increased when it is combined with Gramicidin D.",
      "name": "Diazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00255",
      "source": "DB00027",
      "target": "DB00255",
      "description": "The serum concentration of Diethylstilbestrol can be increased when it is combined with Gramicidin D.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01396",
      "source": "DB00027",
      "target": "DB01396",
      "description": "The serum concentration of Digitoxin can be increased when it is combined with Gramicidin D.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00390",
      "source": "DB00027",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Gramicidin D.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB02901",
      "source": "DB00027",
      "target": "DB02901",
      "description": "The serum concentration of Dihydrotestosterone can be increased when it is combined with Gramicidin D.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00343",
      "source": "DB00027",
      "target": "DB00343",
      "description": "The serum concentration of Diltiazem can be increased when it is combined with Gramicidin D.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00975",
      "source": "DB00027",
      "target": "DB00975",
      "description": "The serum concentration of Dipyridamole can be increased when it is combined with Gramicidin D.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01248",
      "source": "DB00027",
      "target": "DB01248",
      "description": "The serum concentration of Docetaxel can be increased when it is combined with Gramicidin D.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01184",
      "source": "DB00027",
      "target": "DB01184",
      "description": "The serum concentration of Domperidone can be increased when it is combined with Gramicidin D.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00997",
      "source": "DB00027",
      "target": "DB00997",
      "description": "The serum concentration of Doxorubicin can be increased when it is combined with Gramicidin D.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09075",
      "source": "DB00027",
      "target": "DB09075",
      "description": "The serum concentration of Edoxaban can be increased when it is combined with Gramicidin D.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00216",
      "source": "DB00027",
      "target": "DB00216",
      "description": "The serum concentration of Eletriptan can be increased when it is combined with Gramicidin D.",
      "name": "Eletriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00751",
      "source": "DB00027",
      "target": "DB00751",
      "description": "The serum concentration of Epinastine can be increased when it is combined with Gramicidin D.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00530",
      "source": "DB00027",
      "target": "DB00530",
      "description": "The serum concentration of Erlotinib can be increased when it is combined with Gramicidin D.",
      "name": "Erlotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00199",
      "source": "DB00027",
      "target": "DB00199",
      "description": "The serum concentration of Erythromycin can be increased when it is combined with Gramicidin D.",
      "name": "Erythromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00783",
      "source": "DB00027",
      "target": "DB00783",
      "description": "The serum concentration of Estradiol can be increased when it is combined with Gramicidin D.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04573",
      "source": "DB00027",
      "target": "DB04573",
      "description": "The serum concentration of Estriol can be increased when it is combined with Gramicidin D.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00655",
      "source": "DB00027",
      "target": "DB00655",
      "description": "The serum concentration of Estrone can be increased when it is combined with Gramicidin D.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00977",
      "source": "DB00027",
      "target": "DB00977",
      "description": "The serum concentration of Ethinyl Estradiol can be increased when it is combined with Gramicidin D.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00773",
      "source": "DB00027",
      "target": "DB00773",
      "description": "The serum concentration of Etoposide can be increased when it is combined with Gramicidin D.",
      "name": "Etoposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01590",
      "source": "DB00027",
      "target": "DB01590",
      "description": "The serum concentration of Everolimus can be increased when it is combined with Gramicidin D.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00973",
      "source": "DB00027",
      "target": "DB00973",
      "description": "The serum concentration of Ezetimibe can be increased when it is combined with Gramicidin D.",
      "name": "Ezetimibe"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06702",
      "source": "DB00027",
      "target": "DB06702",
      "description": "The serum concentration of Fesoterodine can be increased when it is combined with Gramicidin D.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00950",
      "source": "DB00027",
      "target": "DB00950",
      "description": "The serum concentration of Fexofenadine can be increased when it is combined with Gramicidin D.",
      "name": "Fexofenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08874",
      "source": "DB00027",
      "target": "DB08874",
      "description": "The serum concentration of Fidaxomicin can be increased when it is combined with Gramicidin D.",
      "name": "Fidaxomicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08906",
      "source": "DB00027",
      "target": "DB08906",
      "description": "The serum concentration of Fluticasone furoate can be increased when it is combined with Gramicidin D.",
      "name": "Fluticasone furoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00317",
      "source": "DB00027",
      "target": "DB00317",
      "description": "The serum concentration of Gefitinib can be increased when it is combined with Gramicidin D.",
      "name": "Gefitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00441",
      "source": "DB00027",
      "target": "DB00441",
      "description": "The serum concentration of Gemcitabine can be increased when it is combined with Gramicidin D.",
      "name": "Gemcitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB11575",
      "source": "DB00027",
      "target": "DB11575",
      "description": "The serum concentration of Grazoprevir can be increased when it is combined with Gramicidin D.",
      "name": "Grazoprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00365",
      "source": "DB00027",
      "target": "DB00365",
      "description": "The serum concentration of Grepafloxacin can be increased when it is combined with Gramicidin D.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00502",
      "source": "DB00027",
      "target": "DB00502",
      "description": "The serum concentration of Haloperidol can be increased when it is combined with Gramicidin D.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00741",
      "source": "DB00027",
      "target": "DB00741",
      "description": "The serum concentration of Hydrocortisone can be increased when it is combined with Gramicidin D.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01050",
      "source": "DB00027",
      "target": "DB01050",
      "description": "The serum concentration of Ibuprofen can be increased when it is combined with Gramicidin D.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09054",
      "source": "DB00027",
      "target": "DB09054",
      "description": "The serum concentration of Idelalisib can be increased when it is combined with Gramicidin D.",
      "name": "Idelalisib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00619",
      "source": "DB00027",
      "target": "DB00619",
      "description": "The serum concentration of Imatinib can be increased when it is combined with Gramicidin D.",
      "name": "Imatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00458",
      "source": "DB00027",
      "target": "DB00458",
      "description": "The serum concentration of Imipramine can be increased when it is combined with Gramicidin D.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB05039",
      "source": "DB00027",
      "target": "DB05039",
      "description": "The serum concentration of Indacaterol can be increased when it is combined with Gramicidin D.",
      "name": "Indacaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00224",
      "source": "DB00027",
      "target": "DB00224",
      "description": "The serum concentration of Indinavir can be increased when it is combined with Gramicidin D.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00328",
      "source": "DB00027",
      "target": "DB00328",
      "description": "The serum concentration of Indomethacin can be increased when it is combined with Gramicidin D.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00762",
      "source": "DB00027",
      "target": "DB00762",
      "description": "The serum concentration of Irinotecan can be increased when it is combined with Gramicidin D.",
      "name": "Irinotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00602",
      "source": "DB00027",
      "target": "DB00602",
      "description": "The serum concentration of Ivermectin can be increased when it is combined with Gramicidin D.",
      "name": "Ivermectin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01587",
      "source": "DB00027",
      "target": "DB01587",
      "description": "The serum concentration of Ketazolam can be increased when it is combined with Gramicidin D.",
      "name": "Ketazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01026",
      "source": "DB00027",
      "target": "DB01026",
      "description": "The serum concentration of Ketoconazole can be increased when it is combined with Gramicidin D.",
      "name": "Ketoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00709",
      "source": "DB00027",
      "target": "DB00709",
      "description": "The serum concentration of Lamivudine can be increased when it is combined with Gramicidin D.",
      "name": "Lamivudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00555",
      "source": "DB00027",
      "target": "DB00555",
      "description": "The serum concentration of Lamotrigine can be increased when it is combined with Gramicidin D.",
      "name": "Lamotrigine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00448",
      "source": "DB00027",
      "target": "DB00448",
      "description": "The serum concentration of Lansoprazole can be increased when it is combined with Gramicidin D.",
      "name": "Lansoprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09027",
      "source": "DB00027",
      "target": "DB09027",
      "description": "The serum concentration of Ledipasvir can be increased when it is combined with Gramicidin D.",
      "name": "Ledipasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00480",
      "source": "DB00027",
      "target": "DB00480",
      "description": "The serum concentration of Lenalidomide can be increased when it is combined with Gramicidin D.",
      "name": "Lenalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09078",
      "source": "DB00027",
      "target": "DB09078",
      "description": "The serum concentration of Lenvatinib can be increased when it is combined with Gramicidin D.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01202",
      "source": "DB00027",
      "target": "DB01202",
      "description": "The serum concentration of Levetiracetam can be increased when it is combined with Gramicidin D.",
      "name": "Levetiracetam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01137",
      "source": "DB00027",
      "target": "DB01137",
      "description": "The serum concentration of Levofloxacin can be increased when it is combined with Gramicidin D.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08918",
      "source": "DB00027",
      "target": "DB08918",
      "description": "The serum concentration of Levomilnacipran can be increased when it is combined with Gramicidin D.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08882",
      "source": "DB00027",
      "target": "DB08882",
      "description": "The serum concentration of Linagliptin can be increased when it is combined with Gramicidin D.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00836",
      "source": "DB00027",
      "target": "DB00836",
      "description": "The serum concentration of Loperamide can be increased when it is combined with Gramicidin D.",
      "name": "Loperamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00678",
      "source": "DB00027",
      "target": "DB00678",
      "description": "The serum concentration of Losartan can be increased when it is combined with Gramicidin D.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00742",
      "source": "DB00027",
      "target": "DB00742",
      "description": "The serum concentration of Mannitol can be increased when it is combined with Gramicidin D.",
      "name": "Mannitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00563",
      "source": "DB00027",
      "target": "DB00563",
      "description": "The serum concentration of Methotrexate can be increased when it is combined with Gramicidin D.",
      "name": "Methotrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00959",
      "source": "DB00027",
      "target": "DB00959",
      "description": "The serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00264",
      "source": "DB00027",
      "target": "DB00264",
      "description": "The serum concentration of Metoprolol can be increased when it is combined with Gramicidin D.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00683",
      "source": "DB00027",
      "target": "DB00683",
      "description": "The serum concentration of Midazolam can be increased when it is combined with Gramicidin D.",
      "name": "Midazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08893",
      "source": "DB00027",
      "target": "DB08893",
      "description": "The serum concentration of Mirabegron can be increased when it is combined with Gramicidin D.",
      "name": "Mirabegron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01204",
      "source": "DB00027",
      "target": "DB01204",
      "description": "The serum concentration of Mitoxantrone can be increased when it is combined with Gramicidin D.",
      "name": "Mitoxantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00295",
      "source": "DB00027",
      "target": "DB00295",
      "description": "The serum concentration of Morphine can be increased when it is combined with Gramicidin D.",
      "name": "Morphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00688",
      "source": "DB00027",
      "target": "DB00688",
      "description": "The serum concentration of Mycophenolate mofetil can be increased when it is combined with Gramicidin D.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01203",
      "source": "DB00027",
      "target": "DB01203",
      "description": "The serum concentration of Nadolol can be increased when it is combined with Gramicidin D.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09049",
      "source": "DB00027",
      "target": "DB09049",
      "description": "The serum concentration of Naloxegol can be increased when it is combined with Gramicidin D.",
      "name": "Naloxegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01183",
      "source": "DB00027",
      "target": "DB01183",
      "description": "The serum concentration of Naloxone can be increased when it is combined with Gramicidin D.",
      "name": "Naloxone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00220",
      "source": "DB00027",
      "target": "DB00220",
      "description": "The serum concentration of Nelfinavir can be increased when it is combined with Gramicidin D.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00622",
      "source": "DB00027",
      "target": "DB00622",
      "description": "The serum concentration of Nicardipine can be increased when it is combined with Gramicidin D.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01115",
      "source": "DB00027",
      "target": "DB01115",
      "description": "The serum concentration of Nifedipine can be increased when it is combined with Gramicidin D.",
      "name": "Nifedipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04868",
      "source": "DB00027",
      "target": "DB04868",
      "description": "The serum concentration of Nilotinib can be increased when it is combined with Gramicidin D.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09079",
      "source": "DB00027",
      "target": "DB09079",
      "description": "The serum concentration of Nintedanib can be increased when it is combined with Gramicidin D.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00585",
      "source": "DB00027",
      "target": "DB00585",
      "description": "The serum concentration of Nizatidine can be increased when it is combined with Gramicidin D.",
      "name": "Nizatidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00334",
      "source": "DB00027",
      "target": "DB00334",
      "description": "The serum concentration of Olanzapine can be increased when it is combined with Gramicidin D.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09296",
      "source": "DB00027",
      "target": "DB09296",
      "description": "The serum concentration of Ombitasvir can be increased when it is combined with Gramicidin D.",
      "name": "Ombitasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09330",
      "source": "DB00027",
      "target": "DB09330",
      "description": "The serum concentration of Osimertinib can be increased when it is combined with Gramicidin D.",
      "name": "Osimertinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01229",
      "source": "DB00027",
      "target": "DB01229",
      "description": "The serum concentration of Paclitaxel can be increased when it is combined with Gramicidin D.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06603",
      "source": "DB00027",
      "target": "DB06603",
      "description": "The serum concentration of Panobinostat can be increased when it is combined with Gramicidin D.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06589",
      "source": "DB00027",
      "target": "DB06589",
      "description": "The serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01174",
      "source": "DB00027",
      "target": "DB01174",
      "description": "The serum concentration of Phenobarbital can be increased when it is combined with Gramicidin D.",
      "name": "Phenobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00252",
      "source": "DB00027",
      "target": "DB00252",
      "description": "The serum concentration of Phenytoin can be increased when it is combined with Gramicidin D.",
      "name": "Phenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09268",
      "source": "DB00027",
      "target": "DB09268",
      "description": "The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gramicidin D.",
      "name": "Picosulfuric acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08860",
      "source": "DB00027",
      "target": "DB08860",
      "description": "The serum concentration of Pitavastatin can be increased when it is combined with Gramicidin D.",
      "name": "Pitavastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08910",
      "source": "DB00027",
      "target": "DB08910",
      "description": "The serum concentration of Pomalidomide can be increased when it is combined with Gramicidin D.",
      "name": "Pomalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08901",
      "source": "DB00027",
      "target": "DB08901",
      "description": "The serum concentration of Ponatinib can be increased when it is combined with Gramicidin D.",
      "name": "Ponatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00175",
      "source": "DB00027",
      "target": "DB00175",
      "description": "The serum concentration of Pravastatin can be increased when it is combined with Gramicidin D.",
      "name": "Pravastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00457",
      "source": "DB00027",
      "target": "DB00457",
      "description": "The serum concentration of Prazosin can be increased when it is combined with Gramicidin D.",
      "name": "Prazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00860",
      "source": "DB00027",
      "target": "DB00860",
      "description": "The serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00635",
      "source": "DB00027",
      "target": "DB00635",
      "description": "The serum concentration of Prednisone can be increased when it is combined with Gramicidin D.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00396",
      "source": "DB00027",
      "target": "DB00396",
      "description": "The serum concentration of Progesterone can be increased when it is combined with Gramicidin D.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00571",
      "source": "DB00027",
      "target": "DB00571",
      "description": "The serum concentration of Propranolol can be increased when it is combined with Gramicidin D.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06480",
      "source": "DB00027",
      "target": "DB06480",
      "description": "The serum concentration of Prucalopride can be increased when it is combined with Gramicidin D.",
      "name": "Prucalopride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01224",
      "source": "DB00027",
      "target": "DB01224",
      "description": "The serum concentration of Quetiapine can be increased when it is combined with Gramicidin D.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00908",
      "source": "DB00027",
      "target": "DB00908",
      "description": "The serum concentration of Quinidine can be increased when it is combined with Gramicidin D.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00468",
      "source": "DB00027",
      "target": "DB00468",
      "description": "The serum concentration of Quinine can be increased when it is combined with Gramicidin D.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00863",
      "source": "DB00027",
      "target": "DB00863",
      "description": "The serum concentration of Ranitidine can be increased when it is combined with Gramicidin D.",
      "name": "Ranitidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00243",
      "source": "DB00027",
      "target": "DB00243",
      "description": "The serum concentration of Ranolazine can be increased when it is combined with Gramicidin D.",
      "name": "Ranolazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00206",
      "source": "DB00027",
      "target": "DB00206",
      "description": "The serum concentration of Reserpine can be increased when it is combined with Gramicidin D.",
      "name": "Reserpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01045",
      "source": "DB00027",
      "target": "DB01045",
      "description": "The serum concentration of Rifampicin can be increased when it is combined with Gramicidin D.",
      "name": "Rifampicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01220",
      "source": "DB00027",
      "target": "DB01220",
      "description": "The serum concentration of Rifaximin can be increased when it is combined with Gramicidin D.",
      "name": "Rifaximin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00734",
      "source": "DB00027",
      "target": "DB00734",
      "description": "The serum concentration of Risperidone can be increased when it is combined with Gramicidin D.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00503",
      "source": "DB00027",
      "target": "DB00503",
      "description": "The serum concentration of Ritonavir can be increased when it is combined with Gramicidin D.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06228",
      "source": "DB00027",
      "target": "DB06228",
      "description": "The serum concentration of Rivaroxaban can be increased when it is combined with Gramicidin D.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06176",
      "source": "DB00027",
      "target": "DB06176",
      "description": "The serum concentration of Romidepsin can be increased when it is combined with Gramicidin D.",
      "name": "Romidepsin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00936",
      "source": "DB00027",
      "target": "DB00936",
      "description": "The serum concentration of Salicylic acid can be increased when it is combined with Gramicidin D.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01232",
      "source": "DB00027",
      "target": "DB01232",
      "description": "The serum concentration of Saquinavir can be increased when it is combined with Gramicidin D.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB11362",
      "source": "DB00027",
      "target": "DB11362",
      "description": "The serum concentration of Selexipag can be increased when it is combined with Gramicidin D.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06207",
      "source": "DB00027",
      "target": "DB06207",
      "description": "The serum concentration of Silodosin can be increased when it is combined with Gramicidin D.",
      "name": "Silodosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06290",
      "source": "DB00027",
      "target": "DB06290",
      "description": "The serum concentration of Simeprevir can be increased when it is combined with Gramicidin D.",
      "name": "Simeprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01261",
      "source": "DB00027",
      "target": "DB01261",
      "description": "The serum concentration of Sitagliptin can be increased when it is combined with Gramicidin D.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08934",
      "source": "DB00027",
      "target": "DB08934",
      "description": "The serum concentration of Sofosbuvir can be increased when it is combined with Gramicidin D.",
      "name": "Sofosbuvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00398",
      "source": "DB00027",
      "target": "DB00398",
      "description": "The serum concentration of Sorafenib can be increased when it is combined with Gramicidin D.",
      "name": "Sorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01208",
      "source": "DB00027",
      "target": "DB01208",
      "description": "The serum concentration of Sparfloxacin can be increased when it is combined with Gramicidin D.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB03203",
      "source": "DB00027",
      "target": "DB03203",
      "description": "The serum concentration of Sphingosine can be increased when it is combined with Gramicidin D.",
      "name": "Sphingosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00864",
      "source": "DB00027",
      "target": "DB00864",
      "description": "The serum concentration of Tacrolimus can be increased when it is combined with Gramicidin D.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00675",
      "source": "DB00027",
      "target": "DB00675",
      "description": "The serum concentration of Tamoxifen can be increased when it is combined with Gramicidin D.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB04348",
      "source": "DB00027",
      "target": "DB04348",
      "description": "The serum concentration of Taurocholic Acid can be increased when it is combined with Gramicidin D.",
      "name": "Taurocholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09161",
      "source": "DB00027",
      "target": "DB09161",
      "description": "The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Gramicidin D.",
      "name": "Technetium Tc-99m sestamibi"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB05521",
      "source": "DB00027",
      "target": "DB05521",
      "description": "The serum concentration of Telaprevir can be increased when it is combined with Gramicidin D.",
      "name": "Telaprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06287",
      "source": "DB00027",
      "target": "DB06287",
      "description": "The serum concentration of Temsirolimus can be increased when it is combined with Gramicidin D.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08816",
      "source": "DB00027",
      "target": "DB08816",
      "description": "The serum concentration of Ticagrelor can be increased when it is combined with Gramicidin D.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00373",
      "source": "DB00027",
      "target": "DB00373",
      "description": "The serum concentration of Timolol can be increased when it is combined with Gramicidin D.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB06212",
      "source": "DB00027",
      "target": "DB06212",
      "description": "The serum concentration of Tolvaptan can be increased when it is combined with Gramicidin D.",
      "name": "Tolvaptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01030",
      "source": "DB00027",
      "target": "DB01030",
      "description": "The serum concentration of Topotecan can be increased when it is combined with Gramicidin D.",
      "name": "Topotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00539",
      "source": "DB00027",
      "target": "DB00539",
      "description": "The serum concentration of Toremifene can be increased when it is combined with Gramicidin D.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB05773",
      "source": "DB00027",
      "target": "DB05773",
      "description": "The serum concentration of Trastuzumab emtansine can be increased when it is combined with Gramicidin D.",
      "name": "Trastuzumab emtansine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08867",
      "source": "DB00027",
      "target": "DB08867",
      "description": "The serum concentration of Ulipristal can be increased when it is combined with Gramicidin D.",
      "name": "Ulipristal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB09076",
      "source": "DB00027",
      "target": "DB09076",
      "description": "The serum concentration of Umeclidinium can be increased when it is combined with Gramicidin D.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB01339",
      "source": "DB00027",
      "target": "DB01339",
      "description": "The serum concentration of Vecuronium can be increased when it is combined with Gramicidin D.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB11581",
      "source": "DB00027",
      "target": "DB11581",
      "description": "The serum concentration of Venetoclax can be increased when it is combined with Gramicidin D.",
      "name": "Venetoclax"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00285",
      "source": "DB00027",
      "target": "DB00285",
      "description": "The serum concentration of Venlafaxine can be increased when it is combined with Gramicidin D.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00661",
      "source": "DB00027",
      "target": "DB00661",
      "description": "The serum concentration of Verapamil can be increased when it is combined with Gramicidin D.",
      "name": "Verapamil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00570",
      "source": "DB00027",
      "target": "DB00570",
      "description": "The serum concentration of Vinblastine can be increased when it is combined with Gramicidin D.",
      "name": "Vinblastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00541",
      "source": "DB00027",
      "target": "DB00541",
      "description": "The serum concentration of Vincristine can be increased when it is combined with Gramicidin D.",
      "name": "Vincristine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB08828",
      "source": "DB00027",
      "target": "DB08828",
      "description": "The serum concentration of Vismodegib can be increased when it is combined with Gramicidin D.",
      "name": "Vismodegib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00495",
      "source": "DB00027",
      "target": "DB00495",
      "description": "The serum concentration of Zidovudine can be increased when it is combined with Gramicidin D.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB01281",
      "source": "DB00026",
      "target": "DB01281",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00051",
      "source": "DB00026",
      "target": "DB00051",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB04956",
      "source": "DB00026",
      "target": "DB04956",
      "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.",
      "name": "Afelimomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB12768",
      "source": "DB00026",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Anakinra.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB06168",
      "source": "DB00026",
      "target": "DB06168",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Canakinumab.",
      "name": "Canakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB08904",
      "source": "DB00026",
      "target": "DB08904",
      "description": "The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB06643",
      "source": "DB00026",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00005",
      "source": "DB00026",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB08868",
      "source": "DB00026",
      "target": "DB08868",
      "description": "Anakinra may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB06674",
      "source": "DB00026",
      "target": "DB06674",
      "description": "The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.",
      "name": "Golimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00065",
      "source": "DB00026",
      "target": "DB00065",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB01097",
      "source": "DB00026",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00108",
      "source": "DB00026",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00337",
      "source": "DB00026",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB04951",
      "source": "DB00026",
      "target": "DB04951",
      "description": "The risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB10283",
      "source": "DB00026",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB10283",
      "source": "DB00026",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Anakinra.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB01656",
      "source": "DB00026",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Anakinra.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB06688",
      "source": "DB00026",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00864",
      "source": "DB00026",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB08895",
      "source": "DB00026",
      "target": "DB08895",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00072",
      "source": "DB00026",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Anakinra.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00054",
      "source": "DB00029",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Anistreplase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01418",
      "source": "DB00029",
      "target": "DB01418",
      "description": "Anistreplase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00945",
      "source": "DB00029",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Anistreplase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00770",
      "source": "DB00029",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Anistreplase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00233",
      "source": "DB00029",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anistreplase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00261",
      "source": "DB00029",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Anistreplase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05099",
      "source": "DB00029",
      "target": "DB05099",
      "description": "Anistreplase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11598",
      "source": "DB00029",
      "target": "DB11598",
      "description": "Anistreplase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06605",
      "source": "DB00029",
      "target": "DB06605",
      "description": "Anistreplase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06692",
      "source": "DB00029",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00407",
      "source": "DB00029",
      "target": "DB00407",
      "description": "Anistreplase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00278",
      "source": "DB00029",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Anistreplase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00972",
      "source": "DB00029",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Anistreplase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00102",
      "source": "DB00029",
      "target": "DB00102",
      "description": "Anistreplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05229",
      "source": "DB00029",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Anistreplase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00006",
      "source": "DB00029",
      "target": "DB00006",
      "description": "Anistreplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06441",
      "source": "DB00029",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Anistreplase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09261",
      "source": "DB00029",
      "target": "DB09261",
      "description": "Anistreplase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01166",
      "source": "DB00029",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Anistreplase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB04272",
      "source": "DB00029",
      "target": "DB04272",
      "description": "Anistreplase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00758",
      "source": "DB00029",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Anistreplase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06695",
      "source": "DB00029",
      "target": "DB06695",
      "description": "Anistreplase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06779",
      "source": "DB00029",
      "target": "DB06779",
      "description": "Anistreplase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06754",
      "source": "DB00029",
      "target": "DB06754",
      "description": "Anistreplase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB04932",
      "source": "DB00029",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Anistreplase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11095",
      "source": "DB00029",
      "target": "DB11095",
      "description": "Anistreplase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09255",
      "source": "DB00029",
      "target": "DB09255",
      "description": "Anistreplase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11122",
      "source": "DB00029",
      "target": "DB11122",
      "description": "Anistreplase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11076",
      "source": "DB00029",
      "target": "DB11076",
      "description": "Anistreplase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11241",
      "source": "DB00029",
      "target": "DB11241",
      "description": "Anistreplase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00266",
      "source": "DB00029",
      "target": "DB00266",
      "description": "Anistreplase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00861",
      "source": "DB00029",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00975",
      "source": "DB00029",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Anistreplase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00974",
      "source": "DB00029",
      "target": "DB00974",
      "description": "Anistreplase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09075",
      "source": "DB00029",
      "target": "DB09075",
      "description": "Anistreplase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01225",
      "source": "DB00029",
      "target": "DB01225",
      "description": "Anistreplase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00751",
      "source": "DB00029",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Anistreplase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06392",
      "source": "DB00029",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Anistreplase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01240",
      "source": "DB00029",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Anistreplase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00063",
      "source": "DB00029",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Anistreplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB08794",
      "source": "DB00029",
      "target": "DB08794",
      "description": "Anistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00569",
      "source": "DB00029",
      "target": "DB00569",
      "description": "Anistreplase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01109",
      "source": "DB00029",
      "target": "DB01109",
      "description": "Anistreplase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB02351",
      "source": "DB00029",
      "target": "DB02351",
      "description": "Anistreplase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05266",
      "source": "DB00029",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Anistreplase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB08887",
      "source": "DB00029",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Anistreplase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06406",
      "source": "DB00029",
      "target": "DB06406",
      "description": "Anistreplase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB08954",
      "source": "DB00029",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Anistreplase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01088",
      "source": "DB00029",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Anistreplase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00001",
      "source": "DB00029",
      "target": "DB00001",
      "description": "Anistreplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09211",
      "source": "DB00029",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Anistreplase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00244",
      "source": "DB00029",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Anistreplase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00235",
      "source": "DB00029",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Anistreplase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB08813",
      "source": "DB00029",
      "target": "DB08813",
      "description": "Anistreplase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05822",
      "source": "DB00029",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Anistreplase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB04743",
      "source": "DB00029",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Anistreplase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06635",
      "source": "DB00029",
      "target": "DB06635",
      "description": "Anistreplase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00686",
      "source": "DB00029",
      "target": "DB00686",
      "description": "Anistreplase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00806",
      "source": "DB00029",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Anistreplase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00498",
      "source": "DB00029",
      "target": "DB00498",
      "description": "Anistreplase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00946",
      "source": "DB00029",
      "target": "DB00946",
      "description": "Anistreplase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06209",
      "source": "DB00029",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Anistreplase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11312",
      "source": "DB00029",
      "target": "DB11312",
      "description": "Anistreplase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB11268",
      "source": "DB00029",
      "target": "DB11268",
      "description": "Anistreplase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB02709",
      "source": "DB00029",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Anistreplase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09259",
      "source": "DB00029",
      "target": "DB09259",
      "description": "Anistreplase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01207",
      "source": "DB00029",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Anistreplase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06228",
      "source": "DB00029",
      "target": "DB06228",
      "description": "Anistreplase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00936",
      "source": "DB00029",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Anistreplase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05692",
      "source": "DB00029",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Anistreplase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB01236",
      "source": "DB00029",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Anistreplase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB05073",
      "source": "DB00029",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Anistreplase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB06271",
      "source": "DB00029",
      "target": "DB06271",
      "description": "Anistreplase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB04905",
      "source": "DB00029",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Anistreplase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00208",
      "source": "DB00029",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Anistreplase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00775",
      "source": "DB00029",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Anistreplase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB07615",
      "source": "DB00029",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Anistreplase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09283",
      "source": "DB00029",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Anistreplase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00374",
      "source": "DB00029",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB08814",
      "source": "DB00029",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Anistreplase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB09030",
      "source": "DB00029",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Anistreplase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00682",
      "source": "DB00029",
      "target": "DB00682",
      "description": "Anistreplase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB04898",
      "source": "DB00029",
      "target": "DB04898",
      "description": "Anistreplase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00028-DB10283",
      "source": "DB00028",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Immune Globulin Human.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00054",
      "source": "DB00031",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Tenecteplase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01418",
      "source": "DB00031",
      "target": "DB01418",
      "description": "Tenecteplase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00945",
      "source": "DB00031",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Tenecteplase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00770",
      "source": "DB00031",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Tenecteplase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00233",
      "source": "DB00031",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tenecteplase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00261",
      "source": "DB00031",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05099",
      "source": "DB00031",
      "target": "DB05099",
      "description": "Tenecteplase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11598",
      "source": "DB00031",
      "target": "DB11598",
      "description": "Tenecteplase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06605",
      "source": "DB00031",
      "target": "DB06605",
      "description": "Tenecteplase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06692",
      "source": "DB00031",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00407",
      "source": "DB00031",
      "target": "DB00407",
      "description": "Tenecteplase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00278",
      "source": "DB00031",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Tenecteplase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00972",
      "source": "DB00031",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Tenecteplase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00102",
      "source": "DB00031",
      "target": "DB00102",
      "description": "Tenecteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05229",
      "source": "DB00031",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Tenecteplase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00006",
      "source": "DB00031",
      "target": "DB00006",
      "description": "Tenecteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06441",
      "source": "DB00031",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Tenecteplase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09261",
      "source": "DB00031",
      "target": "DB09261",
      "description": "Tenecteplase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01166",
      "source": "DB00031",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Tenecteplase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB04272",
      "source": "DB00031",
      "target": "DB04272",
      "description": "Tenecteplase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00758",
      "source": "DB00031",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Tenecteplase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06695",
      "source": "DB00031",
      "target": "DB06695",
      "description": "Tenecteplase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06779",
      "source": "DB00031",
      "target": "DB06779",
      "description": "Tenecteplase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06754",
      "source": "DB00031",
      "target": "DB06754",
      "description": "Tenecteplase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB04932",
      "source": "DB00031",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11095",
      "source": "DB00031",
      "target": "DB11095",
      "description": "Tenecteplase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09255",
      "source": "DB00031",
      "target": "DB09255",
      "description": "Tenecteplase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11122",
      "source": "DB00031",
      "target": "DB11122",
      "description": "Tenecteplase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11076",
      "source": "DB00031",
      "target": "DB11076",
      "description": "Tenecteplase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11241",
      "source": "DB00031",
      "target": "DB11241",
      "description": "Tenecteplase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00266",
      "source": "DB00031",
      "target": "DB00266",
      "description": "Tenecteplase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00861",
      "source": "DB00031",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00975",
      "source": "DB00031",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Tenecteplase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00974",
      "source": "DB00031",
      "target": "DB00974",
      "description": "Tenecteplase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09075",
      "source": "DB00031",
      "target": "DB09075",
      "description": "Tenecteplase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01225",
      "source": "DB00031",
      "target": "DB01225",
      "description": "Tenecteplase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00751",
      "source": "DB00031",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Tenecteplase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06392",
      "source": "DB00031",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Tenecteplase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01240",
      "source": "DB00031",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Tenecteplase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00063",
      "source": "DB00031",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB08794",
      "source": "DB00031",
      "target": "DB08794",
      "description": "Tenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00569",
      "source": "DB00031",
      "target": "DB00569",
      "description": "Tenecteplase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01109",
      "source": "DB00031",
      "target": "DB01109",
      "description": "Tenecteplase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB02351",
      "source": "DB00031",
      "target": "DB02351",
      "description": "Tenecteplase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05266",
      "source": "DB00031",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Tenecteplase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB08887",
      "source": "DB00031",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Tenecteplase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06406",
      "source": "DB00031",
      "target": "DB06406",
      "description": "Tenecteplase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB08954",
      "source": "DB00031",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Tenecteplase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01088",
      "source": "DB00031",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Tenecteplase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00001",
      "source": "DB00031",
      "target": "DB00001",
      "description": "Tenecteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09211",
      "source": "DB00031",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Tenecteplase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00244",
      "source": "DB00031",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Tenecteplase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00235",
      "source": "DB00031",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Tenecteplase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB08813",
      "source": "DB00031",
      "target": "DB08813",
      "description": "Tenecteplase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05822",
      "source": "DB00031",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Tenecteplase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB04743",
      "source": "DB00031",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06635",
      "source": "DB00031",
      "target": "DB06635",
      "description": "Tenecteplase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00686",
      "source": "DB00031",
      "target": "DB00686",
      "description": "Tenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00806",
      "source": "DB00031",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Tenecteplase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00498",
      "source": "DB00031",
      "target": "DB00498",
      "description": "Tenecteplase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00946",
      "source": "DB00031",
      "target": "DB00946",
      "description": "Tenecteplase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06209",
      "source": "DB00031",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Tenecteplase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11312",
      "source": "DB00031",
      "target": "DB11312",
      "description": "Tenecteplase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB11268",
      "source": "DB00031",
      "target": "DB11268",
      "description": "Tenecteplase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB02709",
      "source": "DB00031",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Tenecteplase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09259",
      "source": "DB00031",
      "target": "DB09259",
      "description": "Tenecteplase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01207",
      "source": "DB00031",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Tenecteplase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06228",
      "source": "DB00031",
      "target": "DB06228",
      "description": "Tenecteplase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00936",
      "source": "DB00031",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenecteplase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05692",
      "source": "DB00031",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Tenecteplase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB01236",
      "source": "DB00031",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Tenecteplase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB05073",
      "source": "DB00031",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Tenecteplase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB06271",
      "source": "DB00031",
      "target": "DB06271",
      "description": "Tenecteplase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB04905",
      "source": "DB00031",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00208",
      "source": "DB00031",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Tenecteplase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00775",
      "source": "DB00031",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB07615",
      "source": "DB00031",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09283",
      "source": "DB00031",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Tenecteplase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00374",
      "source": "DB00031",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB08814",
      "source": "DB00031",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Tenecteplase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB09030",
      "source": "DB00031",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Tenecteplase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00682",
      "source": "DB00031",
      "target": "DB00682",
      "description": "Tenecteplase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB04898",
      "source": "DB00031",
      "target": "DB04898",
      "description": "Tenecteplase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08550",
      "source": "DB00030",
      "target": "DB08550",
      "description": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Insulin Human.",
      "name": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00284",
      "source": "DB00030",
      "target": "DB00284",
      "description": "Acarbose may increase the hypoglycemic activities of Insulin Human.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00414",
      "source": "DB00030",
      "target": "DB00414",
      "description": "Acetohexamide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00945",
      "source": "DB00030",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01700",
      "source": "DB00030",
      "target": "DB01700",
      "description": "Aicar may increase the hypoglycemic activities of Insulin Human.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06203",
      "source": "DB00030",
      "target": "DB06203",
      "description": "Alogliptin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00233",
      "source": "DB00030",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09246",
      "source": "DB00030",
      "target": "DB09246",
      "description": "Benmoxin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Benmoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04830",
      "source": "DB00030",
      "target": "DB04830",
      "description": "Buformin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08907",
      "source": "DB00030",
      "target": "DB08907",
      "description": "Canagliflozin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09254",
      "source": "DB00030",
      "target": "DB09254",
      "description": "Caroxazone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Caroxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01816",
      "source": "DB00030",
      "target": "DB01816",
      "description": "Castanospermine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00672",
      "source": "DB00030",
      "target": "DB00672",
      "description": "Chlorpropamide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09201",
      "source": "DB00030",
      "target": "DB09201",
      "description": "Ciglitazone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00827",
      "source": "DB00030",
      "target": "DB00827",
      "description": "Cinoxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00537",
      "source": "DB00030",
      "target": "DB00537",
      "description": "Ciprofloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00215",
      "source": "DB00030",
      "target": "DB00215",
      "description": "Citalopram may increase the hypoglycemic activities of Insulin Human.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04884",
      "source": "DB00030",
      "target": "DB04884",
      "description": "Dapoxetine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06700",
      "source": "DB00030",
      "target": "DB06700",
      "description": "Desvenlafaxine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00861",
      "source": "DB00030",
      "target": "DB00861",
      "description": "Diflunisal may increase the hypoglycemic activities of Insulin Human.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB02901",
      "source": "DB00030",
      "target": "DB02901",
      "description": "Dihydrotestosterone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00280",
      "source": "DB00030",
      "target": "DB00280",
      "description": "Insulin Human may increase the hypoglycemic activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09045",
      "source": "DB00030",
      "target": "DB09045",
      "description": "Dulaglutide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00476",
      "source": "DB00030",
      "target": "DB00476",
      "description": "Duloxetine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09038",
      "source": "DB00030",
      "target": "DB09038",
      "description": "Empagliflozin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00467",
      "source": "DB00030",
      "target": "DB00467",
      "description": "Enoxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01175",
      "source": "DB00030",
      "target": "DB01175",
      "description": "Escitalopram may increase the hypoglycemic activities of Insulin Human.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09194",
      "source": "DB00030",
      "target": "DB09194",
      "description": "Etoperidone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Etoperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01276",
      "source": "DB00030",
      "target": "DB01276",
      "description": "Exenatide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04576",
      "source": "DB00030",
      "target": "DB04576",
      "description": "Fleroxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08972",
      "source": "DB00030",
      "target": "DB08972",
      "description": "Flumequine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00472",
      "source": "DB00030",
      "target": "DB00472",
      "description": "Fluoxetine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01185",
      "source": "DB00030",
      "target": "DB01185",
      "description": "Fluoxymesterone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Fluoxymesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00176",
      "source": "DB00030",
      "target": "DB00176",
      "description": "Fluvoxamine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00614",
      "source": "DB00030",
      "target": "DB00614",
      "description": "Furazolidone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Furazolidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06160",
      "source": "DB00030",
      "target": "DB06160",
      "description": "Garenoxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01044",
      "source": "DB00030",
      "target": "DB01044",
      "description": "Gatifloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01155",
      "source": "DB00030",
      "target": "DB01155",
      "description": "Gemifloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08962",
      "source": "DB00030",
      "target": "DB08962",
      "description": "Glibornuride may increase the hypoglycemic activities of Insulin Human.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01120",
      "source": "DB00030",
      "target": "DB01120",
      "description": "Gliclazide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00222",
      "source": "DB00030",
      "target": "DB00222",
      "description": "Glimepiride may increase the hypoglycemic activities of Insulin Human.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01067",
      "source": "DB00030",
      "target": "DB01067",
      "description": "Glipizide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01251",
      "source": "DB00030",
      "target": "DB01251",
      "description": "Gliquidone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01016",
      "source": "DB00030",
      "target": "DB01016",
      "description": "Glyburide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00365",
      "source": "DB00030",
      "target": "DB00365",
      "description": "Grepafloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09243",
      "source": "DB00030",
      "target": "DB09243",
      "description": "Hydracarbazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Hydracarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08953",
      "source": "DB00030",
      "target": "DB08953",
      "description": "Indalpine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Indalpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01306",
      "source": "DB00030",
      "target": "DB01306",
      "description": "Insulin Aspart may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01307",
      "source": "DB00030",
      "target": "DB01307",
      "description": "Insulin Detemir may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00047",
      "source": "DB00030",
      "target": "DB00047",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01309",
      "source": "DB00030",
      "target": "DB01309",
      "description": "Insulin Glulisine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00046",
      "source": "DB00030",
      "target": "DB00046",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00071",
      "source": "DB00030",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09247",
      "source": "DB00030",
      "target": "DB09247",
      "description": "Iproclozide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Iproclozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04818",
      "source": "DB00030",
      "target": "DB04818",
      "description": "Iproniazid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Iproniazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01247",
      "source": "DB00030",
      "target": "DB01247",
      "description": "Isocarboxazid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Isocarboxazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06791",
      "source": "DB00030",
      "target": "DB06791",
      "description": "Insulin Human may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01137",
      "source": "DB00030",
      "target": "DB01137",
      "description": "Levofloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08918",
      "source": "DB00030",
      "target": "DB08918",
      "description": "Levomilnacipran may increase the hypoglycemic activities of Insulin Human.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB08882",
      "source": "DB00030",
      "target": "DB08882",
      "description": "Linagliptin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06655",
      "source": "DB00030",
      "target": "DB06655",
      "description": "Liraglutide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00978",
      "source": "DB00030",
      "target": "DB00978",
      "description": "Lomefloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09248",
      "source": "DB00030",
      "target": "DB09248",
      "description": "Mebanazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Mebanazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01277",
      "source": "DB00030",
      "target": "DB01277",
      "description": "Insulin Human may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00244",
      "source": "DB00030",
      "target": "DB00244",
      "description": "Mesalazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00331",
      "source": "DB00030",
      "target": "DB00331",
      "description": "Metformin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09241",
      "source": "DB00030",
      "target": "DB09241",
      "description": "Methylene blue may increase the hypoglycemic activities of Insulin Human.",
      "name": "Methylene blue"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06710",
      "source": "DB00030",
      "target": "DB06710",
      "description": "Methyltestosterone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00834",
      "source": "DB00030",
      "target": "DB00834",
      "description": "Insulin Human may increase the hypoglycemic activities of Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00491",
      "source": "DB00030",
      "target": "DB00491",
      "description": "Miglitol may increase the hypoglycemic activities of Insulin Human.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00419",
      "source": "DB00030",
      "target": "DB00419",
      "description": "Miglustat may increase the hypoglycemic activities of Insulin Human.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04896",
      "source": "DB00030",
      "target": "DB04896",
      "description": "Milnacipran may increase the hypoglycemic activities of Insulin Human.",
      "name": "Milnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00805",
      "source": "DB00030",
      "target": "DB00805",
      "description": "Minaprine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Minaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01252",
      "source": "DB00030",
      "target": "DB01252",
      "description": "Mitiglinide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01171",
      "source": "DB00030",
      "target": "DB01171",
      "description": "Moclobemide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00218",
      "source": "DB00030",
      "target": "DB00218",
      "description": "Moxifloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00779",
      "source": "DB00030",
      "target": "DB00779",
      "description": "Nalidixic Acid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00731",
      "source": "DB00030",
      "target": "DB00731",
      "description": "Nateglinide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01149",
      "source": "DB00030",
      "target": "DB01149",
      "description": "Nefazodone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06600",
      "source": "DB00030",
      "target": "DB06600",
      "description": "Nemonoxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Nemonoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04820",
      "source": "DB00030",
      "target": "DB04820",
      "description": "Nialamide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Nialamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01059",
      "source": "DB00030",
      "target": "DB01059",
      "description": "Norfloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09249",
      "source": "DB00030",
      "target": "DB09249",
      "description": "Octamoxin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Octamoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00104",
      "source": "DB00030",
      "target": "DB00104",
      "description": "Insulin Human may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01165",
      "source": "DB00030",
      "target": "DB01165",
      "description": "Ofloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00621",
      "source": "DB00030",
      "target": "DB00621",
      "description": "Oxandrolone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Oxandrolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06412",
      "source": "DB00030",
      "target": "DB06412",
      "description": "Oxymetholone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Oxymetholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01626",
      "source": "DB00030",
      "target": "DB01626",
      "description": "Pargyline may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pargyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00715",
      "source": "DB00030",
      "target": "DB00715",
      "description": "Paroxetine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06663",
      "source": "DB00030",
      "target": "DB06663",
      "description": "Insulin Human may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00487",
      "source": "DB00030",
      "target": "DB00487",
      "description": "Pefloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00082",
      "source": "DB00030",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00738",
      "source": "DB00030",
      "target": "DB00738",
      "description": "Insulin Human may increase the hypoglycemic activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00780",
      "source": "DB00030",
      "target": "DB00780",
      "description": "Phenelzine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Phenelzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00914",
      "source": "DB00030",
      "target": "DB00914",
      "description": "Phenformin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09250",
      "source": "DB00030",
      "target": "DB09250",
      "description": "Pheniprazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pheniprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09251",
      "source": "DB00030",
      "target": "DB09251",
      "description": "Phenoxypropazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Phenoxypropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01132",
      "source": "DB00030",
      "target": "DB01132",
      "description": "Pioglitazone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09244",
      "source": "DB00030",
      "target": "DB09244",
      "description": "Pirlindole may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pirlindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09252",
      "source": "DB00030",
      "target": "DB09252",
      "description": "Pivhydrazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pivhydrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01278",
      "source": "DB00030",
      "target": "DB01278",
      "description": "Pramlintide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00468",
      "source": "DB00030",
      "target": "DB00468",
      "description": "Insulin Human may increase the hypoglycemic activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01367",
      "source": "DB00030",
      "target": "DB01367",
      "description": "Rasagiline may increase the hypoglycemic activities of Insulin Human.",
      "name": "Rasagiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00912",
      "source": "DB00030",
      "target": "DB00912",
      "description": "Repaglinide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00412",
      "source": "DB00030",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00817",
      "source": "DB00030",
      "target": "DB00817",
      "description": "Rosoxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Rosoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09253",
      "source": "DB00030",
      "target": "DB09253",
      "description": "Safrazine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Safrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00936",
      "source": "DB00030",
      "target": "DB00936",
      "description": "Salicylic acid may increase the hypoglycemic activities of Insulin Human.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06335",
      "source": "DB00030",
      "target": "DB06335",
      "description": "Saxagliptin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01037",
      "source": "DB00030",
      "target": "DB01037",
      "description": "Selegiline may increase the hypoglycemic activities of Insulin Human.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01104",
      "source": "DB00030",
      "target": "DB01104",
      "description": "Sertraline may increase the hypoglycemic activities of Insulin Human.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01261",
      "source": "DB00030",
      "target": "DB01261",
      "description": "Sitagliptin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01208",
      "source": "DB00030",
      "target": "DB01208",
      "description": "Sparfloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06718",
      "source": "DB00030",
      "target": "DB06718",
      "description": "Stanozolol may increase the hypoglycemic activities of Insulin Human.",
      "name": "Stanozolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00359",
      "source": "DB00030",
      "target": "DB00359",
      "description": "Insulin Human may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01015",
      "source": "DB00030",
      "target": "DB01015",
      "description": "Insulin Human may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00263",
      "source": "DB00030",
      "target": "DB00263",
      "description": "Insulin Human may increase the hypoglycemic activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB06271",
      "source": "DB00030",
      "target": "DB06271",
      "description": "Sulodexide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01268",
      "source": "DB00030",
      "target": "DB01268",
      "description": "Insulin Human may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01405",
      "source": "DB00030",
      "target": "DB01405",
      "description": "Temafloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00624",
      "source": "DB00030",
      "target": "DB00624",
      "description": "Testosterone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00839",
      "source": "DB00030",
      "target": "DB00839",
      "description": "Tolazamide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB01124",
      "source": "DB00030",
      "target": "DB01124",
      "description": "Tolbutamide may increase the hypoglycemic activities of Insulin Human.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB09245",
      "source": "DB00030",
      "target": "DB09245",
      "description": "Toloxatone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Toloxatone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB02665",
      "source": "DB00030",
      "target": "DB02665",
      "description": "Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Trans-2-Phenylcyclopropylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00752",
      "source": "DB00030",
      "target": "DB00752",
      "description": "Tranylcypromine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Tranylcypromine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00197",
      "source": "DB00030",
      "target": "DB00197",
      "description": "Troglitazone may increase the hypoglycemic activities of Insulin Human.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00685",
      "source": "DB00030",
      "target": "DB00685",
      "description": "Trovafloxacin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00285",
      "source": "DB00030",
      "target": "DB00285",
      "description": "Venlafaxine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04876",
      "source": "DB00030",
      "target": "DB04876",
      "description": "Vildagliptin may increase the hypoglycemic activities of Insulin Human.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04878",
      "source": "DB00030",
      "target": "DB04878",
      "description": "Voglibose may increase the hypoglycemic activities of Insulin Human.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB04832",
      "source": "DB00030",
      "target": "DB04832",
      "description": "Zimelidine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00034-DB01223",
      "source": "DB00034",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00034-DB00651",
      "source": "DB00034",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2a, Recombinant.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00034-DB00277",
      "source": "DB00034",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00034-DB00495",
      "source": "DB00034",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00511",
      "source": "DB00038",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00112",
      "source": "DB00038",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB06772",
      "source": "DB00038",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00531",
      "source": "DB00038",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB01078",
      "source": "DB00038",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Oprelvekin.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB01396",
      "source": "DB00038",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Oprelvekin.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00390",
      "source": "DB00038",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Oprelvekin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB01248",
      "source": "DB00038",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB01092",
      "source": "DB00038",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Oprelvekin.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB01229",
      "source": "DB00038",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00072",
      "source": "DB00038",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01418",
      "source": "DB00040",
      "target": "DB01418",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB08897",
      "source": "DB00040",
      "target": "DB08897",
      "description": "The risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.",
      "name": "Aclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00517",
      "source": "DB00040",
      "target": "DB00517",
      "description": "The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Glucagon recombinant.",
      "name": "Anisotropine Methylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00732",
      "source": "DB00040",
      "target": "DB00732",
      "description": "The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.",
      "name": "Atracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00572",
      "source": "DB00040",
      "target": "DB00572",
      "description": "The risk or severity of adverse effects can be increased when Atropine is combined with Glucagon recombinant.",
      "name": "Atropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB09023",
      "source": "DB00040",
      "target": "DB09023",
      "description": "The risk or severity of adverse effects can be increased when Benactyzine is combined with Glucagon recombinant.",
      "name": "Benactyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00245",
      "source": "DB00040",
      "target": "DB00245",
      "description": "The risk or severity of adverse effects can be increased when Benzatropine is combined with Glucagon recombinant.",
      "name": "Benzatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00810",
      "source": "DB00040",
      "target": "DB00810",
      "description": "The risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.",
      "name": "Biperiden"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB09007",
      "source": "DB00040",
      "target": "DB09007",
      "description": "The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glucagon recombinant.",
      "name": "Chlorphenoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00979",
      "source": "DB00040",
      "target": "DB00979",
      "description": "The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glucagon recombinant.",
      "name": "Cyclopentolate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00496",
      "source": "DB00040",
      "target": "DB00496",
      "description": "The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00967",
      "source": "DB00040",
      "target": "DB00967",
      "description": "The risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB08997",
      "source": "DB00040",
      "target": "DB08997",
      "description": "The risk or severity of adverse effects can be increased when Dexetimide is combined with Glucagon recombinant.",
      "name": "Dexetimide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00266",
      "source": "DB00040",
      "target": "DB00266",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00804",
      "source": "DB00040",
      "target": "DB00804",
      "description": "The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.",
      "name": "Dicyclomine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00392",
      "source": "DB00040",
      "target": "DB00392",
      "description": "The risk or severity of adverse effects can be increased when Ethopropazine is combined with Glucagon recombinant.",
      "name": "Ethopropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB08794",
      "source": "DB00040",
      "target": "DB08794",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB06702",
      "source": "DB00040",
      "target": "DB06702",
      "description": "The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00483",
      "source": "DB00040",
      "target": "DB00483",
      "description": "The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Glucagon recombinant.",
      "name": "Gallamine Triethiodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00986",
      "source": "DB00040",
      "target": "DB00986",
      "description": "The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Glucagon recombinant.",
      "name": "Glycopyrronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB08960",
      "source": "DB00040",
      "target": "DB08960",
      "description": "The risk or severity of adverse effects can be increased when Hexamethonium is combined with Glucagon recombinant.",
      "name": "Hexamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB11181",
      "source": "DB00040",
      "target": "DB11181",
      "description": "The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.",
      "name": "Homatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00424",
      "source": "DB00040",
      "target": "DB00424",
      "description": "The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glucagon recombinant.",
      "name": "Hyoscyamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00328",
      "source": "DB00040",
      "target": "DB00328",
      "description": "The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00332",
      "source": "DB00040",
      "target": "DB00332",
      "description": "The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00657",
      "source": "DB00040",
      "target": "DB00657",
      "description": "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00940",
      "source": "DB00040",
      "target": "DB00940",
      "description": "The risk or severity of adverse effects can be increased when Methantheline is combined with Glucagon recombinant.",
      "name": "Methantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00340",
      "source": "DB00040",
      "target": "DB00340",
      "description": "The risk or severity of adverse effects can be increased when Metixene is combined with Glucagon recombinant.",
      "name": "Metixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB11535",
      "source": "DB00040",
      "target": "DB11535",
      "description": "The risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Glucagon recombinant.",
      "name": "N-butylscopolammonium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB06583",
      "source": "DB00040",
      "target": "DB06583",
      "description": "The risk or severity of adverse effects can be increased when NVA237 is combined with Glucagon recombinant.",
      "name": "NVA237"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01173",
      "source": "DB00040",
      "target": "DB01173",
      "description": "The risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.",
      "name": "Orphenadrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01062",
      "source": "DB00040",
      "target": "DB01062",
      "description": "The risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.",
      "name": "Oxybutynin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00219",
      "source": "DB00040",
      "target": "DB00219",
      "description": "The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glucagon recombinant.",
      "name": "Oxyphenonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01337",
      "source": "DB00040",
      "target": "DB01337",
      "description": "The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.",
      "name": "Pancuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01090",
      "source": "DB00040",
      "target": "DB01090",
      "description": "The risk or severity of adverse effects can be increased when Pentolinium is combined with Glucagon recombinant.",
      "name": "Pentolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00498",
      "source": "DB00040",
      "target": "DB00498",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00946",
      "source": "DB00040",
      "target": "DB00946",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01338",
      "source": "DB00040",
      "target": "DB01338",
      "description": "The risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.",
      "name": "Pipecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00670",
      "source": "DB00040",
      "target": "DB00670",
      "description": "The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.",
      "name": "Pirenzepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00387",
      "source": "DB00040",
      "target": "DB00387",
      "description": "The risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.",
      "name": "Procyclidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00782",
      "source": "DB00040",
      "target": "DB00782",
      "description": "The risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.",
      "name": "Propantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00908",
      "source": "DB00040",
      "target": "DB00908",
      "description": "The risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00747",
      "source": "DB00040",
      "target": "DB00747",
      "description": "The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.",
      "name": "Scopolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB09300",
      "source": "DB00040",
      "target": "DB09300",
      "description": "The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Glucagon recombinant.",
      "name": "Scopolamine butylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01591",
      "source": "DB00040",
      "target": "DB01591",
      "description": "The risk or severity of adverse effects can be increased when Solifenacin is combined with Glucagon recombinant.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01409",
      "source": "DB00040",
      "target": "DB01409",
      "description": "The risk or severity of adverse effects can be increased when Tiotropium is combined with Glucagon recombinant.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01036",
      "source": "DB00040",
      "target": "DB01036",
      "description": "The risk or severity of adverse effects can be increased when Tolterodine is combined with Glucagon recombinant.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00376",
      "source": "DB00040",
      "target": "DB00376",
      "description": "The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.",
      "name": "Trihexyphenidyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01116",
      "source": "DB00040",
      "target": "DB01116",
      "description": "The risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant.",
      "name": "Trimethaphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00809",
      "source": "DB00040",
      "target": "DB00809",
      "description": "The risk or severity of adverse effects can be increased when Tropicamide is combined with Glucagon recombinant.",
      "name": "Tropicamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00209",
      "source": "DB00040",
      "target": "DB00209",
      "description": "The risk or severity of adverse effects can be increased when Trospium is combined with Glucagon recombinant.",
      "name": "Trospium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01199",
      "source": "DB00040",
      "target": "DB01199",
      "description": "The risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.",
      "name": "Tubocurarine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB09076",
      "source": "DB00040",
      "target": "DB09076",
      "description": "The risk or severity of adverse effects can be increased when Umeclidinium is combined with Glucagon recombinant.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB01339",
      "source": "DB00040",
      "target": "DB01339",
      "description": "The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00040-DB00682",
      "source": "DB00040",
      "target": "DB00682",
      "description": "Glucagon recombinant may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06736",
      "source": "DB00035",
      "target": "DB06736",
      "description": "The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00945",
      "source": "DB00035",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00210",
      "source": "DB00035",
      "target": "DB00210",
      "description": "The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00802",
      "source": "DB00035",
      "target": "DB00802",
      "description": "The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.",
      "name": "Alfentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01555",
      "source": "DB00035",
      "target": "DB01555",
      "description": "The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.",
      "name": "Alphacetylmethadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04836",
      "source": "DB00035",
      "target": "DB04836",
      "description": "The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.",
      "name": "Amineptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00321",
      "source": "DB00035",
      "target": "DB00321",
      "description": "The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01435",
      "source": "DB00035",
      "target": "DB01435",
      "description": "The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB05676",
      "source": "DB00035",
      "target": "DB05676",
      "description": "The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB07402",
      "source": "DB00035",
      "target": "DB07402",
      "description": "The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00972",
      "source": "DB00035",
      "target": "DB00972",
      "description": "The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01014",
      "source": "DB00035",
      "target": "DB01014",
      "description": "The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04812",
      "source": "DB00035",
      "target": "DB04812",
      "description": "The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01459",
      "source": "DB00035",
      "target": "DB01459",
      "description": "The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.",
      "name": "Bezitramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00963",
      "source": "DB00035",
      "target": "DB00963",
      "description": "The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00921",
      "source": "DB00035",
      "target": "DB00921",
      "description": "The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.",
      "name": "Buprenorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00611",
      "source": "DB00035",
      "target": "DB00611",
      "description": "The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.",
      "name": "Butorphanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00564",
      "source": "DB00035",
      "target": "DB00564",
      "description": "The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01535",
      "source": "DB00035",
      "target": "DB01535",
      "description": "The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.",
      "name": "Carfentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00821",
      "source": "DB00035",
      "target": "DB00821",
      "description": "The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01816",
      "source": "DB00035",
      "target": "DB01816",
      "description": "The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00482",
      "source": "DB00035",
      "target": "DB00482",
      "description": "The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00608",
      "source": "DB00035",
      "target": "DB00608",
      "description": "The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00477",
      "source": "DB00035",
      "target": "DB00477",
      "description": "The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00215",
      "source": "DB00035",
      "target": "DB00215",
      "description": "The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01242",
      "source": "DB00035",
      "target": "DB01242",
      "description": "The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09218",
      "source": "DB00035",
      "target": "DB09218",
      "description": "The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00318",
      "source": "DB00035",
      "target": "DB00318",
      "description": "The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.",
      "name": "Codeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00924",
      "source": "DB00035",
      "target": "DB00924",
      "description": "The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08921",
      "source": "DB00035",
      "target": "DB08921",
      "description": "The risk or severity of adverse effects can be increased when D-Limonene is combined with Desmopressin.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04884",
      "source": "DB00035",
      "target": "DB04884",
      "description": "The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00618",
      "source": "DB00035",
      "target": "DB00618",
      "description": "The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.",
      "name": "Demeclocycline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01151",
      "source": "DB00035",
      "target": "DB01151",
      "description": "The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06700",
      "source": "DB00035",
      "target": "DB06700",
      "description": "The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01529",
      "source": "DB00035",
      "target": "DB01529",
      "description": "The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.",
      "name": "Dextromoramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00647",
      "source": "DB00035",
      "target": "DB00647",
      "description": "The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.",
      "name": "Dextropropoxyphene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01209",
      "source": "DB00035",
      "target": "DB01209",
      "description": "The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.",
      "name": "Dezocine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00586",
      "source": "DB00035",
      "target": "DB00586",
      "description": "The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00861",
      "source": "DB00035",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01551",
      "source": "DB00035",
      "target": "DB01551",
      "description": "The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.",
      "name": "Dihydrocodeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01450",
      "source": "DB00035",
      "target": "DB01450",
      "description": "The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.",
      "name": "Dihydroetorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01565",
      "source": "DB00035",
      "target": "DB01565",
      "description": "The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.",
      "name": "Dihydromorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01081",
      "source": "DB00035",
      "target": "DB01081",
      "description": "The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.",
      "name": "Diphenoxylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09167",
      "source": "DB00035",
      "target": "DB09167",
      "description": "The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.",
      "name": "Dosulepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01142",
      "source": "DB00035",
      "target": "DB01142",
      "description": "The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08861",
      "source": "DB00035",
      "target": "DB08861",
      "description": "The risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.",
      "name": "DPDPE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09215",
      "source": "DB00035",
      "target": "DB09215",
      "description": "The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00476",
      "source": "DB00035",
      "target": "DB00476",
      "description": "The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08991",
      "source": "DB00035",
      "target": "DB08991",
      "description": "The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01175",
      "source": "DB00035",
      "target": "DB01175",
      "description": "The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06678",
      "source": "DB00035",
      "target": "DB06678",
      "description": "The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00005",
      "source": "DB00035",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01466",
      "source": "DB00035",
      "target": "DB01466",
      "description": "The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.",
      "name": "Ethylmorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00749",
      "source": "DB00035",
      "target": "DB00749",
      "description": "The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08984",
      "source": "DB00035",
      "target": "DB08984",
      "description": "The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09194",
      "source": "DB00035",
      "target": "DB09194",
      "description": "The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.",
      "name": "Etoperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01628",
      "source": "DB00035",
      "target": "DB01628",
      "description": "The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01497",
      "source": "DB00035",
      "target": "DB01497",
      "description": "The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.",
      "name": "Etorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11358",
      "source": "DB00035",
      "target": "DB11358",
      "description": "The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06246",
      "source": "DB00035",
      "target": "DB06246",
      "description": "The risk or severity of adverse effects can be increased when exisulind is combined with Desmopressin.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08981",
      "source": "DB00035",
      "target": "DB08981",
      "description": "The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00573",
      "source": "DB00035",
      "target": "DB00573",
      "description": "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00813",
      "source": "DB00035",
      "target": "DB00813",
      "description": "The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.",
      "name": "Fentanyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08976",
      "source": "DB00035",
      "target": "DB08976",
      "description": "The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11518",
      "source": "DB00035",
      "target": "DB11518",
      "description": "The risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00472",
      "source": "DB00035",
      "target": "DB00472",
      "description": "The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00712",
      "source": "DB00035",
      "target": "DB00712",
      "description": "The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00176",
      "source": "DB00035",
      "target": "DB00176",
      "description": "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01452",
      "source": "DB00035",
      "target": "DB01452",
      "description": "The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.",
      "name": "Heroin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB05767",
      "source": "DB00035",
      "target": "DB05767",
      "description": "The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00956",
      "source": "DB00035",
      "target": "DB00956",
      "description": "The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.",
      "name": "Hydrocodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00327",
      "source": "DB00035",
      "target": "DB00327",
      "description": "The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.",
      "name": "Hydromorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01050",
      "source": "DB00035",
      "target": "DB01050",
      "description": "The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08955",
      "source": "DB00035",
      "target": "DB08955",
      "description": "The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06196",
      "source": "DB00035",
      "target": "DB06196",
      "description": "The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00458",
      "source": "DB00035",
      "target": "DB00458",
      "description": "The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08953",
      "source": "DB00035",
      "target": "DB08953",
      "description": "The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.",
      "name": "Indalpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00328",
      "source": "DB00035",
      "target": "DB00328",
      "description": "The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08951",
      "source": "DB00035",
      "target": "DB08951",
      "description": "The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08942",
      "source": "DB00035",
      "target": "DB08942",
      "description": "The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08940",
      "source": "DB00035",
      "target": "DB08940",
      "description": "The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06738",
      "source": "DB00035",
      "target": "DB06738",
      "description": "The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.",
      "name": "Ketobemidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01009",
      "source": "DB00035",
      "target": "DB01009",
      "description": "The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00465",
      "source": "DB00035",
      "target": "DB00465",
      "description": "The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00555",
      "source": "DB00035",
      "target": "DB00555",
      "description": "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.",
      "name": "Lamotrigine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01097",
      "source": "DB00035",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01227",
      "source": "DB00035",
      "target": "DB01227",
      "description": "The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.",
      "name": "Levomethadyl Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08918",
      "source": "DB00035",
      "target": "DB08918",
      "description": "The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00854",
      "source": "DB00035",
      "target": "DB00854",
      "description": "The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.",
      "name": "Levorphanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01356",
      "source": "DB00035",
      "target": "DB01356",
      "description": "The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.",
      "name": "Lithium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09174",
      "source": "DB00035",
      "target": "DB09174",
      "description": "The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.",
      "name": "Lofentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06725",
      "source": "DB00035",
      "target": "DB06725",
      "description": "The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09212",
      "source": "DB00035",
      "target": "DB09212",
      "description": "The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01283",
      "source": "DB00035",
      "target": "DB01283",
      "description": "The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01397",
      "source": "DB00035",
      "target": "DB01397",
      "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00179",
      "source": "DB00035",
      "target": "DB00179",
      "description": "The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00939",
      "source": "DB00035",
      "target": "DB00939",
      "description": "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00784",
      "source": "DB00035",
      "target": "DB00784",
      "description": "The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00814",
      "source": "DB00035",
      "target": "DB00814",
      "description": "The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00244",
      "source": "DB00035",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04817",
      "source": "DB00035",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00333",
      "source": "DB00035",
      "target": "DB00333",
      "description": "The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01433",
      "source": "DB00035",
      "target": "DB01433",
      "description": "The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.",
      "name": "Methadyl Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04896",
      "source": "DB00035",
      "target": "DB04896",
      "description": "The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.",
      "name": "Milnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00370",
      "source": "DB00035",
      "target": "DB00370",
      "description": "The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00295",
      "source": "DB00035",
      "target": "DB00295",
      "description": "The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.",
      "name": "Morphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00688",
      "source": "DB00035",
      "target": "DB00688",
      "description": "The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01024",
      "source": "DB00035",
      "target": "DB01024",
      "description": "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00461",
      "source": "DB00035",
      "target": "DB00461",
      "description": "The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00735",
      "source": "DB00035",
      "target": "DB00735",
      "description": "The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00844",
      "source": "DB00035",
      "target": "DB00844",
      "description": "The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.",
      "name": "Nalbuphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00788",
      "source": "DB00035",
      "target": "DB00788",
      "description": "The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB05822",
      "source": "DB00035",
      "target": "DB05822",
      "description": "The risk or severity of adverse effects can be increased when NCX 4016 is combined with Desmopressin.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01149",
      "source": "DB00035",
      "target": "DB01149",
      "description": "The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06802",
      "source": "DB00035",
      "target": "DB06802",
      "description": "The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04552",
      "source": "DB00035",
      "target": "DB04552",
      "description": "The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04743",
      "source": "DB00035",
      "target": "DB04743",
      "description": "The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11609",
      "source": "DB00035",
      "target": "DB11609",
      "description": "The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.",
      "name": "Normethadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00540",
      "source": "DB00035",
      "target": "DB00540",
      "description": "The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00768",
      "source": "DB00035",
      "target": "DB00768",
      "description": "The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01250",
      "source": "DB00035",
      "target": "DB01250",
      "description": "The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11130",
      "source": "DB00035",
      "target": "DB11130",
      "description": "The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.",
      "name": "Opium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11444",
      "source": "DB00035",
      "target": "DB11444",
      "description": "The risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00991",
      "source": "DB00035",
      "target": "DB00991",
      "description": "The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00497",
      "source": "DB00035",
      "target": "DB00497",
      "description": "The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.",
      "name": "Oxycodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01192",
      "source": "DB00035",
      "target": "DB01192",
      "description": "The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.",
      "name": "Oxymorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB03585",
      "source": "DB00035",
      "target": "DB03585",
      "description": "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08439",
      "source": "DB00035",
      "target": "DB08439",
      "description": "The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00715",
      "source": "DB00035",
      "target": "DB00715",
      "description": "The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00652",
      "source": "DB00035",
      "target": "DB00652",
      "description": "The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.",
      "name": "Pentazocine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00454",
      "source": "DB00035",
      "target": "DB00454",
      "description": "The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00812",
      "source": "DB00035",
      "target": "DB00812",
      "description": "The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00337",
      "source": "DB00035",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04951",
      "source": "DB00035",
      "target": "DB04951",
      "description": "The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00554",
      "source": "DB00035",
      "target": "DB00554",
      "description": "The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09288",
      "source": "DB00035",
      "target": "DB09288",
      "description": "The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00344",
      "source": "DB00035",
      "target": "DB00344",
      "description": "The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB05173",
      "source": "DB00035",
      "target": "DB05173",
      "description": "The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00899",
      "source": "DB00035",
      "target": "DB00899",
      "description": "The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.",
      "name": "Remifentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB02709",
      "source": "DB00035",
      "target": "DB02709",
      "description": "The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00533",
      "source": "DB00035",
      "target": "DB00533",
      "description": "The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08797",
      "source": "DB00035",
      "target": "DB08797",
      "description": "The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00936",
      "source": "DB00035",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01399",
      "source": "DB00035",
      "target": "DB01399",
      "description": "The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06739",
      "source": "DB00035",
      "target": "DB06739",
      "description": "The risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01104",
      "source": "DB00035",
      "target": "DB01104",
      "description": "The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB05073",
      "source": "DB00035",
      "target": "DB05073",
      "description": "The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00708",
      "source": "DB00035",
      "target": "DB00708",
      "description": "The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.",
      "name": "Sufentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00795",
      "source": "DB00035",
      "target": "DB00795",
      "description": "The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00605",
      "source": "DB00035",
      "target": "DB00605",
      "description": "The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00870",
      "source": "DB00035",
      "target": "DB00870",
      "description": "The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06204",
      "source": "DB00035",
      "target": "DB06204",
      "description": "The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.",
      "name": "Tapentadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00469",
      "source": "DB00035",
      "target": "DB00469",
      "description": "The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB11466",
      "source": "DB00035",
      "target": "DB11466",
      "description": "The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB08880",
      "source": "DB00035",
      "target": "DB08880",
      "description": "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09289",
      "source": "DB00035",
      "target": "DB09289",
      "description": "The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.",
      "name": "Tianeptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01600",
      "source": "DB00035",
      "target": "DB01600",
      "description": "The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB09216",
      "source": "DB00035",
      "target": "DB09216",
      "description": "The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00500",
      "source": "DB00035",
      "target": "DB00500",
      "description": "The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06212",
      "source": "DB00035",
      "target": "DB06212",
      "description": "The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.",
      "name": "Tolvaptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00193",
      "source": "DB00035",
      "target": "DB00193",
      "description": "The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.",
      "name": "Tramadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB07615",
      "source": "DB00035",
      "target": "DB07615",
      "description": "The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00726",
      "source": "DB00035",
      "target": "DB00726",
      "description": "The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB01401",
      "source": "DB00035",
      "target": "DB01401",
      "description": "The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00580",
      "source": "DB00035",
      "target": "DB00580",
      "description": "The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00285",
      "source": "DB00035",
      "target": "DB00285",
      "description": "The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB06737",
      "source": "DB00035",
      "target": "DB06737",
      "description": "The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00744",
      "source": "DB00035",
      "target": "DB00744",
      "description": "The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04832",
      "source": "DB00035",
      "target": "DB04832",
      "description": "The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB04828",
      "source": "DB00035",
      "target": "DB04828",
      "description": "The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB00407",
      "source": "DB00039",
      "target": "DB00407",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB09258",
      "source": "DB00039",
      "target": "DB09258",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Bemiparin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB09261",
      "source": "DB00039",
      "target": "DB09261",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB06779",
      "source": "DB00039",
      "target": "DB06779",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB01225",
      "source": "DB00039",
      "target": "DB01225",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB01109",
      "source": "DB00039",
      "target": "DB01109",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB08813",
      "source": "DB00039",
      "target": "DB08813",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB09260",
      "source": "DB00039",
      "target": "DB09260",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Parnaparin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB09259",
      "source": "DB00039",
      "target": "DB09259",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00039-DB06822",
      "source": "DB00039",
      "target": "DB06822",
      "description": "The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00043-DB08879",
      "source": "DB00043",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Omalizumab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00043-DB10283",
      "source": "DB00043",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Omalizumab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11617",
      "source": "DB00042",
      "target": "DB11617",
      "description": "Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Aclarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB08897",
      "source": "DB00042",
      "target": "DB08897",
      "description": "Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Aclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00479",
      "source": "DB00042",
      "target": "DB00479",
      "description": "Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Amikacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00517",
      "source": "DB00042",
      "target": "DB00517",
      "description": "Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Anisotropine Methylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00732",
      "source": "DB00042",
      "target": "DB00732",
      "description": "Atracurium besylate may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Atracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00572",
      "source": "DB00042",
      "target": "DB00572",
      "description": "Atropine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Atropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB09023",
      "source": "DB00042",
      "target": "DB09023",
      "description": "Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Benactyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00245",
      "source": "DB00042",
      "target": "DB00245",
      "description": "Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Benzatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00810",
      "source": "DB00042",
      "target": "DB00810",
      "description": "Biperiden may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Biperiden"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00083",
      "source": "DB00042",
      "target": "DB00083",
      "description": "Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.",
      "name": "Botulinum Toxin Type A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB09007",
      "source": "DB00042",
      "target": "DB09007",
      "description": "Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Chlorphenoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00565",
      "source": "DB00042",
      "target": "DB00565",
      "description": "Cisatracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Cisatracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00979",
      "source": "DB00042",
      "target": "DB00979",
      "description": "Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Cyclopentolate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00496",
      "source": "DB00042",
      "target": "DB00496",
      "description": "Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00694",
      "source": "DB00042",
      "target": "DB00694",
      "description": "Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01245",
      "source": "DB00042",
      "target": "DB01245",
      "description": "Decamethonium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Decamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00967",
      "source": "DB00042",
      "target": "DB00967",
      "description": "Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB08997",
      "source": "DB00042",
      "target": "DB08997",
      "description": "Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Dexetimide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00804",
      "source": "DB00042",
      "target": "DB00804",
      "description": "Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Dicyclomine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11512",
      "source": "DB00042",
      "target": "DB11512",
      "description": "Dihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Dihydrostreptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB02852",
      "source": "DB00042",
      "target": "DB02852",
      "description": "Domoic Acid may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Domoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01135",
      "source": "DB00042",
      "target": "DB01135",
      "description": "Doxacurium chloride may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Doxacurium chloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00997",
      "source": "DB00042",
      "target": "DB00997",
      "description": "Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00445",
      "source": "DB00042",
      "target": "DB00445",
      "description": "Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Epirubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00392",
      "source": "DB00042",
      "target": "DB00392",
      "description": "Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Ethopropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB06702",
      "source": "DB00042",
      "target": "DB06702",
      "description": "Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00452",
      "source": "DB00042",
      "target": "DB00452",
      "description": "Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Framycetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00483",
      "source": "DB00042",
      "target": "DB00483",
      "description": "Gallamine Triethiodide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Gallamine Triethiodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00798",
      "source": "DB00042",
      "target": "DB00798",
      "description": "Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Gentamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00986",
      "source": "DB00042",
      "target": "DB00986",
      "description": "Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Glycopyrronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB08960",
      "source": "DB00042",
      "target": "DB08960",
      "description": "Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Hexamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11181",
      "source": "DB00042",
      "target": "DB11181",
      "description": "Homatropine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Homatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11520",
      "source": "DB00042",
      "target": "DB11520",
      "description": "Hygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Hygromycin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00424",
      "source": "DB00042",
      "target": "DB00424",
      "description": "Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Hyoscyamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01177",
      "source": "DB00042",
      "target": "DB01177",
      "description": "Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00332",
      "source": "DB00042",
      "target": "DB00332",
      "description": "Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01172",
      "source": "DB00042",
      "target": "DB01172",
      "description": "Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Kanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00657",
      "source": "DB00042",
      "target": "DB00657",
      "description": "Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00940",
      "source": "DB00042",
      "target": "DB00940",
      "description": "Methantheline may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Methantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00340",
      "source": "DB00042",
      "target": "DB00340",
      "description": "Metixene may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Metixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01336",
      "source": "DB00042",
      "target": "DB01336",
      "description": "Metocurine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Metocurine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00416",
      "source": "DB00042",
      "target": "DB00416",
      "description": "Metocurine Iodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Metocurine Iodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01578",
      "source": "DB00042",
      "target": "DB01578",
      "description": "Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Metrizamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01226",
      "source": "DB00042",
      "target": "DB01226",
      "description": "Mivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Mivacurium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11535",
      "source": "DB00042",
      "target": "DB11535",
      "description": "N-butylscopolammonium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "N-butylscopolammonium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00994",
      "source": "DB00042",
      "target": "DB00994",
      "description": "Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Neomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00955",
      "source": "DB00042",
      "target": "DB00955",
      "description": "Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Netilmicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB06583",
      "source": "DB00042",
      "target": "DB06583",
      "description": "NVA237 may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "NVA237"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01173",
      "source": "DB00042",
      "target": "DB01173",
      "description": "Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Orphenadrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01062",
      "source": "DB00042",
      "target": "DB01062",
      "description": "Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Oxybutynin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00219",
      "source": "DB00042",
      "target": "DB00219",
      "description": "Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Oxyphenonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01337",
      "source": "DB00042",
      "target": "DB01337",
      "description": "Pancuronium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Pancuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01421",
      "source": "DB00042",
      "target": "DB01421",
      "description": "Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Paromomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01090",
      "source": "DB00042",
      "target": "DB01090",
      "description": "Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Pentolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01338",
      "source": "DB00042",
      "target": "DB01338",
      "description": "Pipecuronium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Pipecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00670",
      "source": "DB00042",
      "target": "DB00670",
      "description": "Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Pirenzepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB06810",
      "source": "DB00042",
      "target": "DB06810",
      "description": "Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Plicamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00387",
      "source": "DB00042",
      "target": "DB00387",
      "description": "Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Procyclidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00782",
      "source": "DB00042",
      "target": "DB00782",
      "description": "Propantheline may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Propantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB08437",
      "source": "DB00042",
      "target": "DB08437",
      "description": "Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Puromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB11156",
      "source": "DB00042",
      "target": "DB11156",
      "description": "Pyrantel may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Pyrantel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00908",
      "source": "DB00042",
      "target": "DB00908",
      "description": "Quinidine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB04834",
      "source": "DB00042",
      "target": "DB04834",
      "description": "Rapacuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Rapacuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB03615",
      "source": "DB00042",
      "target": "DB03615",
      "description": "Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Ribostamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00728",
      "source": "DB00042",
      "target": "DB00728",
      "description": "Rocuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Rocuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00747",
      "source": "DB00042",
      "target": "DB00747",
      "description": "Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Scopolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB09300",
      "source": "DB00042",
      "target": "DB09300",
      "description": "Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Scopolamine butylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01591",
      "source": "DB00042",
      "target": "DB01591",
      "description": "Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00919",
      "source": "DB00042",
      "target": "DB00919",
      "description": "Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Spectinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01082",
      "source": "DB00042",
      "target": "DB01082",
      "description": "Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Streptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00428",
      "source": "DB00042",
      "target": "DB00428",
      "description": "Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00202",
      "source": "DB00042",
      "target": "DB00202",
      "description": "Succinylcholine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Succinylcholine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01409",
      "source": "DB00042",
      "target": "DB01409",
      "description": "Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00684",
      "source": "DB00042",
      "target": "DB00684",
      "description": "Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.",
      "name": "Tobramycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01036",
      "source": "DB00042",
      "target": "DB01036",
      "description": "Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00376",
      "source": "DB00042",
      "target": "DB00376",
      "description": "Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Trihexyphenidyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01116",
      "source": "DB00042",
      "target": "DB01116",
      "description": "Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Trimethaphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00809",
      "source": "DB00042",
      "target": "DB00809",
      "description": "Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Tropicamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00209",
      "source": "DB00042",
      "target": "DB00209",
      "description": "Trospium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Trospium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01199",
      "source": "DB00042",
      "target": "DB01199",
      "description": "Tubocurarine may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Tubocurarine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB09076",
      "source": "DB00042",
      "target": "DB09076",
      "description": "Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB01339",
      "source": "DB00042",
      "target": "DB01339",
      "description": "Vecuronium may increase the anticholinergic activities of Botulinum Toxin Type B.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01536",
      "source": "DB00041",
      "target": "DB01536",
      "description": "4-Androstenedione may decrease the antineoplastic activities of Aldesleukin.",
      "name": "4-Androstenedione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01193",
      "source": "DB00041",
      "target": "DB01193",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00819",
      "source": "DB00041",
      "target": "DB00819",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acetazolamide.",
      "name": "Acetazolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00511",
      "source": "DB00041",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00240",
      "source": "DB00041",
      "target": "DB00240",
      "description": "Alclometasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Alclometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04630",
      "source": "DB00041",
      "target": "DB04630",
      "description": "Aldosterone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Aldosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09026",
      "source": "DB00041",
      "target": "DB09026",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.",
      "name": "Aliskiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00288",
      "source": "DB00041",
      "target": "DB00288",
      "description": "Amcinonide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Amcinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00594",
      "source": "DB00041",
      "target": "DB00594",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.",
      "name": "Amiloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00381",
      "source": "DB00041",
      "target": "DB00381",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.",
      "name": "Amlodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01351",
      "source": "DB00041",
      "target": "DB01351",
      "description": "Amobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Amobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01612",
      "source": "DB00041",
      "target": "DB01612",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.",
      "name": "Amyl Nitrite"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00964",
      "source": "DB00041",
      "target": "DB00964",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.",
      "name": "Apraclonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01238",
      "source": "DB00041",
      "target": "DB01238",
      "description": "Aripiprazole may increase the hypotensive activities of Aldesleukin.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00335",
      "source": "DB00041",
      "target": "DB00335",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08822",
      "source": "DB00041",
      "target": "DB08822",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.",
      "name": "Azilsartan medoxomil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01483",
      "source": "DB00041",
      "target": "DB01483",
      "description": "Barbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Barbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB12768",
      "source": "DB00041",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Aldesleukin.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00394",
      "source": "DB00041",
      "target": "DB00394",
      "description": "Beclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Beclomethasone dipropionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00542",
      "source": "DB00041",
      "target": "DB00542",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.",
      "name": "Benazepril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00436",
      "source": "DB00041",
      "target": "DB00436",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00443",
      "source": "DB00041",
      "target": "DB00443",
      "description": "Betamethasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00195",
      "source": "DB00041",
      "target": "DB00195",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00112",
      "source": "DB00041",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00612",
      "source": "DB00041",
      "target": "DB00612",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01158",
      "source": "DB00041",
      "target": "DB01158",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.",
      "name": "Bretylium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00484",
      "source": "DB00041",
      "target": "DB00484",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.",
      "name": "Brimonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01222",
      "source": "DB00041",
      "target": "DB01222",
      "description": "Budesonide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00887",
      "source": "DB00041",
      "target": "DB00887",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB06772",
      "source": "DB00041",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08907",
      "source": "DB00041",
      "target": "DB08907",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00796",
      "source": "DB00041",
      "target": "DB00796",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.",
      "name": "Candesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01197",
      "source": "DB00041",
      "target": "DB01197",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.",
      "name": "Captopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00521",
      "source": "DB00041",
      "target": "DB00521",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01136",
      "source": "DB00041",
      "target": "DB01136",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00880",
      "source": "DB00041",
      "target": "DB00880",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00310",
      "source": "DB00041",
      "target": "DB00310",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01410",
      "source": "DB00041",
      "target": "DB01410",
      "description": "Ciclesonide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Ciclesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01340",
      "source": "DB00041",
      "target": "DB01340",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.",
      "name": "Cilazapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04920",
      "source": "DB00041",
      "target": "DB04920",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.",
      "name": "Clevidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01013",
      "source": "DB00041",
      "target": "DB01013",
      "description": "Clobetasol propionate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Clobetasol propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00838",
      "source": "DB00041",
      "target": "DB00838",
      "description": "Clocortolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Clocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00575",
      "source": "DB00041",
      "target": "DB00575",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00363",
      "source": "DB00041",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01380",
      "source": "DB00041",
      "target": "DB01380",
      "description": "Cortisone acetate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00531",
      "source": "DB00041",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB06292",
      "source": "DB00041",
      "target": "DB06292",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.",
      "name": "Dapagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01708",
      "source": "DB00041",
      "target": "DB01708",
      "description": "Dehydroepiandrosterone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Dehydroepiandrosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB05804",
      "source": "DB00041",
      "target": "DB05804",
      "description": "dehydroepiandrosterone sulfate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "dehydroepiandrosterone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01078",
      "source": "DB00041",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Aldesleukin.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00547",
      "source": "DB00041",
      "target": "DB00547",
      "description": "Desoximetasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Desoximetasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB06780",
      "source": "DB00041",
      "target": "DB06780",
      "description": "Desoxycorticosterone acetate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Desoxycorticosterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01234",
      "source": "DB00041",
      "target": "DB01234",
      "description": "Dexamethasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB11487",
      "source": "DB00041",
      "target": "DB11487",
      "description": "Dexamethasone isonicotinate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Dexamethasone isonicotinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00633",
      "source": "DB00041",
      "target": "DB00633",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.",
      "name": "Dexmedetomidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00271",
      "source": "DB00041",
      "target": "DB00271",
      "description": "The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.",
      "name": "Diatrizoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01144",
      "source": "DB00041",
      "target": "DB01144",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.",
      "name": "Diclofenamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00223",
      "source": "DB00041",
      "target": "DB00223",
      "description": "Diflorasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Diflorasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09095",
      "source": "DB00041",
      "target": "DB09095",
      "description": "Difluocortolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Difluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB06781",
      "source": "DB00041",
      "target": "DB06781",
      "description": "Difluprednate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Difluprednate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01396",
      "source": "DB00041",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Aldesleukin.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00390",
      "source": "DB00041",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Aldesleukin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00343",
      "source": "DB00041",
      "target": "DB00343",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09077",
      "source": "DB00041",
      "target": "DB09077",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.",
      "name": "Dinutuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00975",
      "source": "DB00041",
      "target": "DB00975",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01248",
      "source": "DB00041",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00590",
      "source": "DB00041",
      "target": "DB00590",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.",
      "name": "Doxazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00476",
      "source": "DB00041",
      "target": "DB00476",
      "description": "Aldesleukin may increase the orthostatic hypotensive activities of Duloxetine.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09038",
      "source": "DB00041",
      "target": "DB09038",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00584",
      "source": "DB00041",
      "target": "DB00584",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.",
      "name": "Enalapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00700",
      "source": "DB00041",
      "target": "DB00700",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.",
      "name": "Eplerenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00876",
      "source": "DB00041",
      "target": "DB00876",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.",
      "name": "Eprosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB03515",
      "source": "DB00041",
      "target": "DB03515",
      "description": "Equilenin may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Equilenin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB02187",
      "source": "DB00041",
      "target": "DB02187",
      "description": "Equilin may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Equilin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00187",
      "source": "DB00041",
      "target": "DB00187",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.",
      "name": "Esmolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00655",
      "source": "DB00041",
      "target": "DB00655",
      "description": "Estrone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00903",
      "source": "DB00041",
      "target": "DB00903",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00965",
      "source": "DB00041",
      "target": "DB00965",
      "description": "The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.",
      "name": "Ethiodized oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01023",
      "source": "DB00041",
      "target": "DB01023",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.",
      "name": "Felodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00687",
      "source": "DB00041",
      "target": "DB00687",
      "description": "Fludrocortisone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00663",
      "source": "DB00041",
      "target": "DB00663",
      "description": "Flumethasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Flumethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00180",
      "source": "DB00041",
      "target": "DB00180",
      "description": "Flunisolide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Flunisolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00591",
      "source": "DB00041",
      "target": "DB00591",
      "description": "Fluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluocinolone Acetonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01047",
      "source": "DB00041",
      "target": "DB01047",
      "description": "Fluocinonide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluocinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08971",
      "source": "DB00041",
      "target": "DB08971",
      "description": "Fluocortolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00324",
      "source": "DB00041",
      "target": "DB00324",
      "description": "Fluorometholone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluorometholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08970",
      "source": "DB00041",
      "target": "DB08970",
      "description": "Fluprednidene may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluprednidene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09378",
      "source": "DB00041",
      "target": "DB09378",
      "description": "Fluprednisolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00846",
      "source": "DB00041",
      "target": "DB00846",
      "description": "Flurandrenolide may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Flurandrenolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08906",
      "source": "DB00041",
      "target": "DB08906",
      "description": "Fluticasone furoate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluticasone furoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00588",
      "source": "DB00041",
      "target": "DB00588",
      "description": "Fluticasone Propionate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Fluticasone Propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00492",
      "source": "DB00041",
      "target": "DB00492",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.",
      "name": "Fosinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00695",
      "source": "DB00041",
      "target": "DB00695",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01018",
      "source": "DB00041",
      "target": "DB01018",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.",
      "name": "Guanfacine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01355",
      "source": "DB00041",
      "target": "DB01355",
      "description": "Hexobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Hexobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01275",
      "source": "DB00041",
      "target": "DB01275",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.",
      "name": "Hydralazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00999",
      "source": "DB00041",
      "target": "DB00999",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00741",
      "source": "DB00041",
      "target": "DB00741",
      "description": "Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00808",
      "source": "DB00041",
      "target": "DB00808",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04711",
      "source": "DB00041",
      "target": "DB04711",
      "description": "The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.",
      "name": "Iodipamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01249",
      "source": "DB00041",
      "target": "DB01249",
      "description": "The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.",
      "name": "Iodixanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01362",
      "source": "DB00041",
      "target": "DB01362",
      "description": "The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.",
      "name": "Iohexol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08947",
      "source": "DB00041",
      "target": "DB08947",
      "description": "The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.",
      "name": "Iopamidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09156",
      "source": "DB00041",
      "target": "DB09156",
      "description": "The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.",
      "name": "Iopromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09134",
      "source": "DB00041",
      "target": "DB09134",
      "description": "The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.",
      "name": "Ioversol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09135",
      "source": "DB00041",
      "target": "DB09135",
      "description": "The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.",
      "name": "Ioxilan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01029",
      "source": "DB00041",
      "target": "DB01029",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.",
      "name": "Irbesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00883",
      "source": "DB00041",
      "target": "DB00883",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.",
      "name": "Isosorbide Dinitrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01020",
      "source": "DB00041",
      "target": "DB01020",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.",
      "name": "Isosorbide Mononitrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08941",
      "source": "DB00041",
      "target": "DB08941",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.",
      "name": "Isoxsuprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00270",
      "source": "DB00041",
      "target": "DB00270",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.",
      "name": "Isradipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00598",
      "source": "DB00041",
      "target": "DB00598",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01210",
      "source": "DB00041",
      "target": "DB01210",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.",
      "name": "Levobunolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01235",
      "source": "DB00041",
      "target": "DB01235",
      "description": "Aldesleukin may increase the orthostatic hypotensive activities of Levodopa.",
      "name": "Levodopa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00722",
      "source": "DB00041",
      "target": "DB00722",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.",
      "name": "Lisinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00678",
      "source": "DB00041",
      "target": "DB00678",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00742",
      "source": "DB00041",
      "target": "DB00742",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.",
      "name": "Mannitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00657",
      "source": "DB00041",
      "target": "DB00657",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00253",
      "source": "DB00041",
      "target": "DB00253",
      "description": "Medrysone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Medrysone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB11529",
      "source": "DB00041",
      "target": "DB11529",
      "description": "Melengestrol may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Melengestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04817",
      "source": "DB00041",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Aldesleukin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00703",
      "source": "DB00041",
      "target": "DB00703",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.",
      "name": "Methazolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00474",
      "source": "DB00041",
      "target": "DB00474",
      "description": "Methohexital may increase the hypotensive activities of Aldesleukin.",
      "name": "Methohexital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00232",
      "source": "DB00041",
      "target": "DB00232",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.",
      "name": "Methyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00968",
      "source": "DB00041",
      "target": "DB00968",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.",
      "name": "Methyldopa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00849",
      "source": "DB00041",
      "target": "DB00849",
      "description": "Methylphenobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Methylphenobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00959",
      "source": "DB00041",
      "target": "DB00959",
      "description": "Methylprednisolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01214",
      "source": "DB00041",
      "target": "DB01214",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.",
      "name": "Metipranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00524",
      "source": "DB00041",
      "target": "DB00524",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00264",
      "source": "DB00041",
      "target": "DB00264",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00350",
      "source": "DB00041",
      "target": "DB00350",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.",
      "name": "Minoxidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00691",
      "source": "DB00041",
      "target": "DB00691",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00764",
      "source": "DB00041",
      "target": "DB00764",
      "description": "Mometasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Mometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01203",
      "source": "DB00041",
      "target": "DB01203",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04861",
      "source": "DB00041",
      "target": "DB04861",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.",
      "name": "Nebivolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB04899",
      "source": "DB00041",
      "target": "DB04899",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.",
      "name": "Nesiritide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00622",
      "source": "DB00041",
      "target": "DB00622",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09220",
      "source": "DB00041",
      "target": "DB09220",
      "description": "Nicorandil may increase the hypotensive activities of Aldesleukin.",
      "name": "Nicorandil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01115",
      "source": "DB00041",
      "target": "DB01115",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.",
      "name": "Nifedipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00393",
      "source": "DB00041",
      "target": "DB00393",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.",
      "name": "Nimodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00401",
      "source": "DB00041",
      "target": "DB00401",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.",
      "name": "Nisoldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00727",
      "source": "DB00041",
      "target": "DB00727",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.",
      "name": "Nitroglycerin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00325",
      "source": "DB00041",
      "target": "DB00325",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.",
      "name": "Nitroprusside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00275",
      "source": "DB00041",
      "target": "DB00275",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.",
      "name": "Olmesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01092",
      "source": "DB00041",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Aldesleukin.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01229",
      "source": "DB00041",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01113",
      "source": "DB00041",
      "target": "DB01113",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.",
      "name": "Papaverine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01384",
      "source": "DB00041",
      "target": "DB01384",
      "description": "Paramethasone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Paramethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01359",
      "source": "DB00041",
      "target": "DB01359",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.",
      "name": "Penbutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00312",
      "source": "DB00041",
      "target": "DB00312",
      "description": "Pentobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Pentobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00790",
      "source": "DB00041",
      "target": "DB00790",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.",
      "name": "Perindopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01174",
      "source": "DB00041",
      "target": "DB01174",
      "description": "Phenobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Phenobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00960",
      "source": "DB00041",
      "target": "DB00960",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00457",
      "source": "DB00041",
      "target": "DB00457",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.",
      "name": "Prazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01130",
      "source": "DB00041",
      "target": "DB01130",
      "description": "Prednicarbate may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Prednicarbate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00860",
      "source": "DB00041",
      "target": "DB00860",
      "description": "Prednisolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00635",
      "source": "DB00041",
      "target": "DB00635",
      "description": "Prednisone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB02789",
      "source": "DB00041",
      "target": "DB02789",
      "description": "Pregnenolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Pregnenolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00794",
      "source": "DB00041",
      "target": "DB00794",
      "description": "Primidone may increase the hypotensive activities of Aldesleukin.",
      "name": "Primidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00571",
      "source": "DB00041",
      "target": "DB00571",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01224",
      "source": "DB00041",
      "target": "DB01224",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00881",
      "source": "DB00041",
      "target": "DB00881",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.",
      "name": "Quinapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00178",
      "source": "DB00041",
      "target": "DB00178",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.",
      "name": "Ramipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00206",
      "source": "DB00041",
      "target": "DB00206",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.",
      "name": "Reserpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00896",
      "source": "DB00041",
      "target": "DB00896",
      "description": "Rimexolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Rimexolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB08931",
      "source": "DB00041",
      "target": "DB08931",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00734",
      "source": "DB00041",
      "target": "DB00734",
      "description": "Aldesleukin may increase the hypotensive activities of Risperidone.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00418",
      "source": "DB00041",
      "target": "DB00418",
      "description": "Secobarbital may increase the hypotensive activities of Aldesleukin.",
      "name": "Secobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00489",
      "source": "DB00041",
      "target": "DB00489",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00421",
      "source": "DB00041",
      "target": "DB00421",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.",
      "name": "Spironolactone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00966",
      "source": "DB00041",
      "target": "DB00966",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.",
      "name": "Telmisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01162",
      "source": "DB00041",
      "target": "DB01162",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.",
      "name": "Terazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB01154",
      "source": "DB00041",
      "target": "DB01154",
      "description": "Thiamylal may increase the hypotensive activities of Aldesleukin.",
      "name": "Thiamylal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00599",
      "source": "DB00041",
      "target": "DB00599",
      "description": "Thiopental may increase the hypotensive activities of Aldesleukin.",
      "name": "Thiopental"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00373",
      "source": "DB00041",
      "target": "DB00373",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB09091",
      "source": "DB00041",
      "target": "DB09091",
      "description": "Tixocortol may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Tixocortol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00697",
      "source": "DB00041",
      "target": "DB00697",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.",
      "name": "Tizanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00214",
      "source": "DB00041",
      "target": "DB00214",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00519",
      "source": "DB00041",
      "target": "DB00519",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.",
      "name": "Trandolapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00072",
      "source": "DB00041",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00620",
      "source": "DB00041",
      "target": "DB00620",
      "description": "Triamcinolone may decrease the antineoplastic activities of Aldesleukin.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00384",
      "source": "DB00041",
      "target": "DB00384",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.",
      "name": "Triamterene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00177",
      "source": "DB00041",
      "target": "DB00177",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.",
      "name": "Valsartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00661",
      "source": "DB00041",
      "target": "DB00661",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.",
      "name": "Verapamil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08550",
      "source": "DB00046",
      "target": "DB08550",
      "description": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00284",
      "source": "DB00046",
      "target": "DB00284",
      "description": "Acarbose may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00414",
      "source": "DB00046",
      "target": "DB00414",
      "description": "Acetohexamide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00945",
      "source": "DB00046",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01700",
      "source": "DB00046",
      "target": "DB01700",
      "description": "Aicar may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06203",
      "source": "DB00046",
      "target": "DB06203",
      "description": "Alogliptin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00233",
      "source": "DB00046",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01238",
      "source": "DB00046",
      "target": "DB01238",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01169",
      "source": "DB00046",
      "target": "DB01169",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09009",
      "source": "DB00046",
      "target": "DB09009",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Articaine.",
      "name": "Articaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06216",
      "source": "DB00046",
      "target": "DB06216",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01072",
      "source": "DB00046",
      "target": "DB01072",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Atazanavir.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00436",
      "source": "DB00046",
      "target": "DB00436",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bendroflumethiazide.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09246",
      "source": "DB00046",
      "target": "DB09246",
      "description": "Benmoxin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Benmoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00443",
      "source": "DB00046",
      "target": "DB00443",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09128",
      "source": "DB00046",
      "target": "DB09128",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.",
      "name": "Brexpiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04830",
      "source": "DB00046",
      "target": "DB04830",
      "description": "Buformin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00887",
      "source": "DB00046",
      "target": "DB00887",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06719",
      "source": "DB00046",
      "target": "DB06719",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Buserelin.",
      "name": "Buserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08907",
      "source": "DB00046",
      "target": "DB08907",
      "description": "Canagliflozin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09254",
      "source": "DB00046",
      "target": "DB09254",
      "description": "Caroxazone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Caroxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01816",
      "source": "DB00046",
      "target": "DB01816",
      "description": "Castanospermine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09063",
      "source": "DB00046",
      "target": "DB09063",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00880",
      "source": "DB00046",
      "target": "DB00880",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00672",
      "source": "DB00046",
      "target": "DB00672",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Chlorpropamide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00310",
      "source": "DB00046",
      "target": "DB00310",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorthalidone.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09201",
      "source": "DB00046",
      "target": "DB09201",
      "description": "Ciglitazone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00827",
      "source": "DB00046",
      "target": "DB00827",
      "description": "Cinoxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00537",
      "source": "DB00046",
      "target": "DB00537",
      "description": "Ciprofloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00215",
      "source": "DB00046",
      "target": "DB00215",
      "description": "Citalopram may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00363",
      "source": "DB00046",
      "target": "DB00363",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01285",
      "source": "DB00046",
      "target": "DB01285",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Corticotropin.",
      "name": "Corticotropin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01380",
      "source": "DB00046",
      "target": "DB01380",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04839",
      "source": "DB00046",
      "target": "DB04839",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cyproterone acetate.",
      "name": "Cyproterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08912",
      "source": "DB00046",
      "target": "DB08912",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dabrafenib.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01406",
      "source": "DB00046",
      "target": "DB01406",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Danazol.",
      "name": "Danazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04884",
      "source": "DB00046",
      "target": "DB04884",
      "description": "Dapoxetine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01264",
      "source": "DB00046",
      "target": "DB01264",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Darunavir.",
      "name": "Darunavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00304",
      "source": "DB00046",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06700",
      "source": "DB00046",
      "target": "DB06700",
      "description": "Desvenlafaxine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01234",
      "source": "DB00046",
      "target": "DB01234",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01119",
      "source": "DB00046",
      "target": "DB01119",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Diazoxide.",
      "name": "Diazoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09123",
      "source": "DB00046",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00861",
      "source": "DB00046",
      "target": "DB00861",
      "description": "Diflunisal may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB02901",
      "source": "DB00046",
      "target": "DB02901",
      "description": "Dihydrotestosterone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00280",
      "source": "DB00046",
      "target": "DB00280",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01395",
      "source": "DB00046",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09045",
      "source": "DB00046",
      "target": "DB09045",
      "description": "Dulaglutide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00476",
      "source": "DB00046",
      "target": "DB00476",
      "description": "Duloxetine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09038",
      "source": "DB00046",
      "target": "DB09038",
      "description": "Empagliflozin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00467",
      "source": "DB00046",
      "target": "DB00467",
      "description": "Enoxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00668",
      "source": "DB00046",
      "target": "DB00668",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Epinephrine.",
      "name": "Epinephrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01175",
      "source": "DB00046",
      "target": "DB01175",
      "description": "Escitalopram may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00783",
      "source": "DB00046",
      "target": "DB00783",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estradiol.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04574",
      "source": "DB00046",
      "target": "DB04574",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estrone sulfate.",
      "name": "Estrone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00903",
      "source": "DB00046",
      "target": "DB00903",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00977",
      "source": "DB00046",
      "target": "DB00977",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethinyl Estradiol.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00823",
      "source": "DB00046",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00294",
      "source": "DB00046",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09194",
      "source": "DB00046",
      "target": "DB09194",
      "description": "Etoperidone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Etoperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01590",
      "source": "DB00046",
      "target": "DB01590",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01276",
      "source": "DB00046",
      "target": "DB01276",
      "description": "Exenatide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04576",
      "source": "DB00046",
      "target": "DB04576",
      "description": "Fleroxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00687",
      "source": "DB00046",
      "target": "DB00687",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08972",
      "source": "DB00046",
      "target": "DB08972",
      "description": "Flumequine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00472",
      "source": "DB00046",
      "target": "DB00472",
      "description": "Fluoxetine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01185",
      "source": "DB00046",
      "target": "DB01185",
      "description": "Fluoxymesterone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Fluoxymesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00176",
      "source": "DB00046",
      "target": "DB00176",
      "description": "Fluvoxamine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01319",
      "source": "DB00046",
      "target": "DB01319",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fosamprenavir.",
      "name": "Fosamprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00614",
      "source": "DB00046",
      "target": "DB00614",
      "description": "Furazolidone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Furazolidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00695",
      "source": "DB00046",
      "target": "DB00695",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06160",
      "source": "DB00046",
      "target": "DB06160",
      "description": "Garenoxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01044",
      "source": "DB00046",
      "target": "DB01044",
      "description": "Gatifloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01155",
      "source": "DB00046",
      "target": "DB01155",
      "description": "Gemifloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08962",
      "source": "DB00046",
      "target": "DB08962",
      "description": "Glibornuride may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01120",
      "source": "DB00046",
      "target": "DB01120",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Gliclazide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00222",
      "source": "DB00046",
      "target": "DB00222",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Glimepiride.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01067",
      "source": "DB00046",
      "target": "DB01067",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Glipizide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01251",
      "source": "DB00046",
      "target": "DB01251",
      "description": "Gliquidone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01016",
      "source": "DB00046",
      "target": "DB01016",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Glyburide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00014",
      "source": "DB00046",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00365",
      "source": "DB00046",
      "target": "DB00365",
      "description": "Grepafloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06788",
      "source": "DB00046",
      "target": "DB06788",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Histrelin.",
      "name": "Histrelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09243",
      "source": "DB00046",
      "target": "DB09243",
      "description": "Hydracarbazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Hydracarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00999",
      "source": "DB00046",
      "target": "DB00999",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00741",
      "source": "DB00046",
      "target": "DB00741",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00774",
      "source": "DB00046",
      "target": "DB00774",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroflumethiazide.",
      "name": "Hydroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06789",
      "source": "DB00046",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04946",
      "source": "DB00046",
      "target": "DB04946",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08953",
      "source": "DB00046",
      "target": "DB08953",
      "description": "Indalpine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Indalpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00808",
      "source": "DB00046",
      "target": "DB00808",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00224",
      "source": "DB00046",
      "target": "DB00224",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indinavir.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01306",
      "source": "DB00046",
      "target": "DB01306",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Aspart.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01307",
      "source": "DB00046",
      "target": "DB01307",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Detemir.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00047",
      "source": "DB00046",
      "target": "DB00047",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01309",
      "source": "DB00046",
      "target": "DB01309",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Glulisine.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00030",
      "source": "DB00046",
      "target": "DB00030",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00071",
      "source": "DB00046",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09247",
      "source": "DB00046",
      "target": "DB09247",
      "description": "Iproclozide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Iproclozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04818",
      "source": "DB00046",
      "target": "DB04818",
      "description": "Iproniazid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Iproniazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01247",
      "source": "DB00046",
      "target": "DB01247",
      "description": "Isocarboxazid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Isocarboxazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06791",
      "source": "DB00046",
      "target": "DB06791",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00007",
      "source": "DB00046",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01137",
      "source": "DB00046",
      "target": "DB01137",
      "description": "Levofloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08918",
      "source": "DB00046",
      "target": "DB08918",
      "description": "Levomilnacipran may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00367",
      "source": "DB00046",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08882",
      "source": "DB00046",
      "target": "DB08882",
      "description": "Linagliptin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00166",
      "source": "DB00046",
      "target": "DB00166",
      "description": "Lipoic Acid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Lipoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06655",
      "source": "DB00046",
      "target": "DB06655",
      "description": "Liraglutide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00978",
      "source": "DB00046",
      "target": "DB00978",
      "description": "Lomefloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01601",
      "source": "DB00046",
      "target": "DB01601",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB08815",
      "source": "DB00046",
      "target": "DB08815",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.",
      "name": "Lurasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09248",
      "source": "DB00046",
      "target": "DB09248",
      "description": "Mebanazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Mebanazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01277",
      "source": "DB00046",
      "target": "DB01277",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00603",
      "source": "DB00046",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00351",
      "source": "DB00046",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00244",
      "source": "DB00046",
      "target": "DB00244",
      "description": "Mesalazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01357",
      "source": "DB00046",
      "target": "DB01357",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Mestranol.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00331",
      "source": "DB00046",
      "target": "DB00331",
      "description": "Metformin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01403",
      "source": "DB00046",
      "target": "DB01403",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00232",
      "source": "DB00046",
      "target": "DB00232",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.",
      "name": "Methyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09241",
      "source": "DB00046",
      "target": "DB09241",
      "description": "Methylene blue may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Methylene blue"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00959",
      "source": "DB00046",
      "target": "DB00959",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06710",
      "source": "DB00046",
      "target": "DB06710",
      "description": "Methyltestosterone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00524",
      "source": "DB00046",
      "target": "DB00524",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00834",
      "source": "DB00046",
      "target": "DB00834",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00491",
      "source": "DB00046",
      "target": "DB00491",
      "description": "Miglitol may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00419",
      "source": "DB00046",
      "target": "DB00419",
      "description": "Miglustat may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04896",
      "source": "DB00046",
      "target": "DB04896",
      "description": "Milnacipran may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Milnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00805",
      "source": "DB00046",
      "target": "DB00805",
      "description": "Minaprine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Minaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01252",
      "source": "DB00046",
      "target": "DB01252",
      "description": "Mitiglinide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01171",
      "source": "DB00046",
      "target": "DB01171",
      "description": "Moclobemide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00218",
      "source": "DB00046",
      "target": "DB00218",
      "description": "Moxifloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00779",
      "source": "DB00046",
      "target": "DB00779",
      "description": "Nalidixic Acid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00731",
      "source": "DB00046",
      "target": "DB00731",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Nateglinide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01149",
      "source": "DB00046",
      "target": "DB01149",
      "description": "Nefazodone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00220",
      "source": "DB00046",
      "target": "DB00220",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06600",
      "source": "DB00046",
      "target": "DB06600",
      "description": "Nemonoxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Nemonoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00627",
      "source": "DB00046",
      "target": "DB00627",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Niacin.",
      "name": "Niacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04820",
      "source": "DB00046",
      "target": "DB04820",
      "description": "Nialamide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Nialamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04868",
      "source": "DB00046",
      "target": "DB04868",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00717",
      "source": "DB00046",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01059",
      "source": "DB00046",
      "target": "DB01059",
      "description": "Norfloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00957",
      "source": "DB00046",
      "target": "DB00957",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norgestimate.",
      "name": "Norgestimate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09249",
      "source": "DB00046",
      "target": "DB09249",
      "description": "Octamoxin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Octamoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00104",
      "source": "DB00046",
      "target": "DB00104",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01165",
      "source": "DB00046",
      "target": "DB01165",
      "description": "Ofloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00334",
      "source": "DB00046",
      "target": "DB00334",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00621",
      "source": "DB00046",
      "target": "DB00621",
      "description": "Oxandrolone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Oxandrolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06412",
      "source": "DB00046",
      "target": "DB06412",
      "description": "Oxymetholone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Oxymetholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01267",
      "source": "DB00046",
      "target": "DB01267",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01626",
      "source": "DB00046",
      "target": "DB01626",
      "description": "Pargyline may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pargyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00715",
      "source": "DB00046",
      "target": "DB00715",
      "description": "Paroxetine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06663",
      "source": "DB00046",
      "target": "DB06663",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00487",
      "source": "DB00046",
      "target": "DB00487",
      "description": "Pefloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00082",
      "source": "DB00046",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00738",
      "source": "DB00046",
      "target": "DB00738",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00780",
      "source": "DB00046",
      "target": "DB00780",
      "description": "Phenelzine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Phenelzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00914",
      "source": "DB00046",
      "target": "DB00914",
      "description": "Phenformin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09250",
      "source": "DB00046",
      "target": "DB09250",
      "description": "Pheniprazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pheniprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09251",
      "source": "DB00046",
      "target": "DB09251",
      "description": "Phenoxypropazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Phenoxypropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01132",
      "source": "DB00046",
      "target": "DB01132",
      "description": "Pioglitazone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00592",
      "source": "DB00046",
      "target": "DB00592",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Piperazine.",
      "name": "Piperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01621",
      "source": "DB00046",
      "target": "DB01621",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pipotiazine.",
      "name": "Pipotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09244",
      "source": "DB00046",
      "target": "DB09244",
      "description": "Pirlindole may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pirlindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09252",
      "source": "DB00046",
      "target": "DB09252",
      "description": "Pivhydrazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pivhydrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01324",
      "source": "DB00046",
      "target": "DB01324",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Polythiazide.",
      "name": "Polythiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01278",
      "source": "DB00046",
      "target": "DB01278",
      "description": "Pramlintide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00860",
      "source": "DB00046",
      "target": "DB00860",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00635",
      "source": "DB00046",
      "target": "DB00635",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00396",
      "source": "DB00046",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01224",
      "source": "DB00046",
      "target": "DB01224",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01325",
      "source": "DB00046",
      "target": "DB01325",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quinethazone.",
      "name": "Quinethazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00468",
      "source": "DB00046",
      "target": "DB00468",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01367",
      "source": "DB00046",
      "target": "DB01367",
      "description": "Rasagiline may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Rasagiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00912",
      "source": "DB00046",
      "target": "DB00912",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Repaglinide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00734",
      "source": "DB00046",
      "target": "DB00734",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00503",
      "source": "DB00046",
      "target": "DB00503",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ritonavir.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00412",
      "source": "DB00046",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00817",
      "source": "DB00046",
      "target": "DB00817",
      "description": "Rosoxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Rosoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09253",
      "source": "DB00046",
      "target": "DB09253",
      "description": "Safrazine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Safrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00936",
      "source": "DB00046",
      "target": "DB00936",
      "description": "Salicylic acid may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01232",
      "source": "DB00046",
      "target": "DB01232",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06335",
      "source": "DB00046",
      "target": "DB06335",
      "description": "Saxagliptin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01037",
      "source": "DB00046",
      "target": "DB01037",
      "description": "Selegiline may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01104",
      "source": "DB00046",
      "target": "DB01104",
      "description": "Sertraline may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00877",
      "source": "DB00046",
      "target": "DB00877",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Sirolimus.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01261",
      "source": "DB00046",
      "target": "DB01261",
      "description": "Sitagliptin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01208",
      "source": "DB00046",
      "target": "DB01208",
      "description": "Sparfloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06718",
      "source": "DB00046",
      "target": "DB06718",
      "description": "Stanozolol may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Stanozolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00359",
      "source": "DB00046",
      "target": "DB00359",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01015",
      "source": "DB00046",
      "target": "DB01015",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00263",
      "source": "DB00046",
      "target": "DB00263",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06271",
      "source": "DB00046",
      "target": "DB06271",
      "description": "Sulodexide may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01268",
      "source": "DB00046",
      "target": "DB01268",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00864",
      "source": "DB00046",
      "target": "DB00864",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01405",
      "source": "DB00046",
      "target": "DB01405",
      "description": "Temafloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06287",
      "source": "DB00046",
      "target": "DB06287",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00624",
      "source": "DB00046",
      "target": "DB00624",
      "description": "Testosterone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00932",
      "source": "DB00046",
      "target": "DB00932",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00839",
      "source": "DB00046",
      "target": "DB00839",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Tolazamide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01124",
      "source": "DB00046",
      "target": "DB01124",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Tolbutamide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB09245",
      "source": "DB00046",
      "target": "DB09245",
      "description": "Toloxatone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Toloxatone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00214",
      "source": "DB00046",
      "target": "DB00214",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB02665",
      "source": "DB00046",
      "target": "DB02665",
      "description": "Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Trans-2-Phenylcyclopropylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00752",
      "source": "DB00046",
      "target": "DB00752",
      "description": "Tranylcypromine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Tranylcypromine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00620",
      "source": "DB00046",
      "target": "DB00620",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB01021",
      "source": "DB00046",
      "target": "DB01021",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.",
      "name": "Trichlormethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB06825",
      "source": "DB00046",
      "target": "DB06825",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triptorelin.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00197",
      "source": "DB00046",
      "target": "DB00197",
      "description": "Troglitazone may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00685",
      "source": "DB00046",
      "target": "DB00685",
      "description": "Trovafloxacin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00285",
      "source": "DB00046",
      "target": "DB00285",
      "description": "Venlafaxine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04876",
      "source": "DB00046",
      "target": "DB04876",
      "description": "Vildagliptin may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04878",
      "source": "DB00046",
      "target": "DB04878",
      "description": "Voglibose may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB02546",
      "source": "DB00046",
      "target": "DB02546",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB04832",
      "source": "DB00046",
      "target": "DB04832",
      "description": "Zimelidine may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00246",
      "source": "DB00046",
      "target": "DB00246",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08550",
      "source": "DB00047",
      "target": "DB08550",
      "description": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00284",
      "source": "DB00047",
      "target": "DB00284",
      "description": "Acarbose may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00414",
      "source": "DB00047",
      "target": "DB00414",
      "description": "Acetohexamide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00945",
      "source": "DB00047",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01700",
      "source": "DB00047",
      "target": "DB01700",
      "description": "Aicar may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06203",
      "source": "DB00047",
      "target": "DB06203",
      "description": "Alogliptin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00233",
      "source": "DB00047",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01238",
      "source": "DB00047",
      "target": "DB01238",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01169",
      "source": "DB00047",
      "target": "DB01169",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09009",
      "source": "DB00047",
      "target": "DB09009",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Articaine.",
      "name": "Articaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06216",
      "source": "DB00047",
      "target": "DB06216",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01072",
      "source": "DB00047",
      "target": "DB01072",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Atazanavir.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00436",
      "source": "DB00047",
      "target": "DB00436",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bendroflumethiazide.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09246",
      "source": "DB00047",
      "target": "DB09246",
      "description": "Benmoxin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Benmoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00443",
      "source": "DB00047",
      "target": "DB00443",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09128",
      "source": "DB00047",
      "target": "DB09128",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Brexpiprazole.",
      "name": "Brexpiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04830",
      "source": "DB00047",
      "target": "DB04830",
      "description": "Buformin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00887",
      "source": "DB00047",
      "target": "DB00887",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06719",
      "source": "DB00047",
      "target": "DB06719",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Buserelin.",
      "name": "Buserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08907",
      "source": "DB00047",
      "target": "DB08907",
      "description": "Canagliflozin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09254",
      "source": "DB00047",
      "target": "DB09254",
      "description": "Caroxazone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Caroxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01816",
      "source": "DB00047",
      "target": "DB01816",
      "description": "Castanospermine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09063",
      "source": "DB00047",
      "target": "DB09063",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00880",
      "source": "DB00047",
      "target": "DB00880",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00672",
      "source": "DB00047",
      "target": "DB00672",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Chlorpropamide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00310",
      "source": "DB00047",
      "target": "DB00310",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorthalidone.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09201",
      "source": "DB00047",
      "target": "DB09201",
      "description": "Ciglitazone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00827",
      "source": "DB00047",
      "target": "DB00827",
      "description": "Cinoxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00537",
      "source": "DB00047",
      "target": "DB00537",
      "description": "Ciprofloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00215",
      "source": "DB00047",
      "target": "DB00215",
      "description": "Citalopram may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00363",
      "source": "DB00047",
      "target": "DB00363",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01285",
      "source": "DB00047",
      "target": "DB01285",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Corticotropin.",
      "name": "Corticotropin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01380",
      "source": "DB00047",
      "target": "DB01380",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04839",
      "source": "DB00047",
      "target": "DB04839",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cyproterone acetate.",
      "name": "Cyproterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08912",
      "source": "DB00047",
      "target": "DB08912",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dabrafenib.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01406",
      "source": "DB00047",
      "target": "DB01406",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Danazol.",
      "name": "Danazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04884",
      "source": "DB00047",
      "target": "DB04884",
      "description": "Dapoxetine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01264",
      "source": "DB00047",
      "target": "DB01264",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Darunavir.",
      "name": "Darunavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00304",
      "source": "DB00047",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06700",
      "source": "DB00047",
      "target": "DB06700",
      "description": "Desvenlafaxine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01234",
      "source": "DB00047",
      "target": "DB01234",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01119",
      "source": "DB00047",
      "target": "DB01119",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Diazoxide.",
      "name": "Diazoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09123",
      "source": "DB00047",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00861",
      "source": "DB00047",
      "target": "DB00861",
      "description": "Diflunisal may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB02901",
      "source": "DB00047",
      "target": "DB02901",
      "description": "Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00280",
      "source": "DB00047",
      "target": "DB00280",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01395",
      "source": "DB00047",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09045",
      "source": "DB00047",
      "target": "DB09045",
      "description": "Dulaglutide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00476",
      "source": "DB00047",
      "target": "DB00476",
      "description": "Duloxetine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09038",
      "source": "DB00047",
      "target": "DB09038",
      "description": "Empagliflozin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00467",
      "source": "DB00047",
      "target": "DB00467",
      "description": "Enoxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00668",
      "source": "DB00047",
      "target": "DB00668",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Epinephrine.",
      "name": "Epinephrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01175",
      "source": "DB00047",
      "target": "DB01175",
      "description": "Escitalopram may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00783",
      "source": "DB00047",
      "target": "DB00783",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estradiol.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04574",
      "source": "DB00047",
      "target": "DB04574",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estrone sulfate.",
      "name": "Estrone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00903",
      "source": "DB00047",
      "target": "DB00903",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00977",
      "source": "DB00047",
      "target": "DB00977",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethinyl Estradiol.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00823",
      "source": "DB00047",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00294",
      "source": "DB00047",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09194",
      "source": "DB00047",
      "target": "DB09194",
      "description": "Etoperidone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Etoperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01590",
      "source": "DB00047",
      "target": "DB01590",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Everolimus.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01276",
      "source": "DB00047",
      "target": "DB01276",
      "description": "Exenatide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04576",
      "source": "DB00047",
      "target": "DB04576",
      "description": "Fleroxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00687",
      "source": "DB00047",
      "target": "DB00687",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08972",
      "source": "DB00047",
      "target": "DB08972",
      "description": "Flumequine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00472",
      "source": "DB00047",
      "target": "DB00472",
      "description": "Fluoxetine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01185",
      "source": "DB00047",
      "target": "DB01185",
      "description": "Fluoxymesterone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Fluoxymesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00176",
      "source": "DB00047",
      "target": "DB00176",
      "description": "Fluvoxamine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01319",
      "source": "DB00047",
      "target": "DB01319",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fosamprenavir.",
      "name": "Fosamprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00614",
      "source": "DB00047",
      "target": "DB00614",
      "description": "Furazolidone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Furazolidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00695",
      "source": "DB00047",
      "target": "DB00695",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06160",
      "source": "DB00047",
      "target": "DB06160",
      "description": "Garenoxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01044",
      "source": "DB00047",
      "target": "DB01044",
      "description": "Gatifloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01155",
      "source": "DB00047",
      "target": "DB01155",
      "description": "Gemifloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08962",
      "source": "DB00047",
      "target": "DB08962",
      "description": "Glibornuride may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01120",
      "source": "DB00047",
      "target": "DB01120",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Gliclazide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00222",
      "source": "DB00047",
      "target": "DB00222",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Glimepiride.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01067",
      "source": "DB00047",
      "target": "DB01067",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Glipizide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01251",
      "source": "DB00047",
      "target": "DB01251",
      "description": "Gliquidone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01016",
      "source": "DB00047",
      "target": "DB01016",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Glyburide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00014",
      "source": "DB00047",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00365",
      "source": "DB00047",
      "target": "DB00365",
      "description": "Grepafloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06788",
      "source": "DB00047",
      "target": "DB06788",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Histrelin.",
      "name": "Histrelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09243",
      "source": "DB00047",
      "target": "DB09243",
      "description": "Hydracarbazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Hydracarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00999",
      "source": "DB00047",
      "target": "DB00999",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrochlorothiazide.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00741",
      "source": "DB00047",
      "target": "DB00741",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00774",
      "source": "DB00047",
      "target": "DB00774",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroflumethiazide.",
      "name": "Hydroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06789",
      "source": "DB00047",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04946",
      "source": "DB00047",
      "target": "DB04946",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08953",
      "source": "DB00047",
      "target": "DB08953",
      "description": "Indalpine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Indalpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00808",
      "source": "DB00047",
      "target": "DB00808",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00224",
      "source": "DB00047",
      "target": "DB00224",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indinavir.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01306",
      "source": "DB00047",
      "target": "DB01306",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Insulin Aspart.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01307",
      "source": "DB00047",
      "target": "DB01307",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Insulin Detemir.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01309",
      "source": "DB00047",
      "target": "DB01309",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Insulin Glulisine.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00030",
      "source": "DB00047",
      "target": "DB00030",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00046",
      "source": "DB00047",
      "target": "DB00046",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00071",
      "source": "DB00047",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09247",
      "source": "DB00047",
      "target": "DB09247",
      "description": "Iproclozide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Iproclozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04818",
      "source": "DB00047",
      "target": "DB04818",
      "description": "Iproniazid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Iproniazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01247",
      "source": "DB00047",
      "target": "DB01247",
      "description": "Isocarboxazid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Isocarboxazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06791",
      "source": "DB00047",
      "target": "DB06791",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00007",
      "source": "DB00047",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01137",
      "source": "DB00047",
      "target": "DB01137",
      "description": "Levofloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08918",
      "source": "DB00047",
      "target": "DB08918",
      "description": "Levomilnacipran may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00367",
      "source": "DB00047",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08882",
      "source": "DB00047",
      "target": "DB08882",
      "description": "Linagliptin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00166",
      "source": "DB00047",
      "target": "DB00166",
      "description": "Lipoic Acid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Lipoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06655",
      "source": "DB00047",
      "target": "DB06655",
      "description": "Liraglutide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00978",
      "source": "DB00047",
      "target": "DB00978",
      "description": "Lomefloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01601",
      "source": "DB00047",
      "target": "DB01601",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB08815",
      "source": "DB00047",
      "target": "DB08815",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.",
      "name": "Lurasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09248",
      "source": "DB00047",
      "target": "DB09248",
      "description": "Mebanazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Mebanazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01277",
      "source": "DB00047",
      "target": "DB01277",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00603",
      "source": "DB00047",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00351",
      "source": "DB00047",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00244",
      "source": "DB00047",
      "target": "DB00244",
      "description": "Mesalazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01357",
      "source": "DB00047",
      "target": "DB01357",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Mestranol.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00331",
      "source": "DB00047",
      "target": "DB00331",
      "description": "Metformin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01403",
      "source": "DB00047",
      "target": "DB01403",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methotrimeprazine.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00232",
      "source": "DB00047",
      "target": "DB00232",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.",
      "name": "Methyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09241",
      "source": "DB00047",
      "target": "DB09241",
      "description": "Methylene blue may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Methylene blue"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00959",
      "source": "DB00047",
      "target": "DB00959",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06710",
      "source": "DB00047",
      "target": "DB06710",
      "description": "Methyltestosterone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00524",
      "source": "DB00047",
      "target": "DB00524",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00834",
      "source": "DB00047",
      "target": "DB00834",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00491",
      "source": "DB00047",
      "target": "DB00491",
      "description": "Miglitol may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00419",
      "source": "DB00047",
      "target": "DB00419",
      "description": "Miglustat may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04896",
      "source": "DB00047",
      "target": "DB04896",
      "description": "Milnacipran may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Milnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00805",
      "source": "DB00047",
      "target": "DB00805",
      "description": "Minaprine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Minaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01252",
      "source": "DB00047",
      "target": "DB01252",
      "description": "Mitiglinide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01171",
      "source": "DB00047",
      "target": "DB01171",
      "description": "Moclobemide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00218",
      "source": "DB00047",
      "target": "DB00218",
      "description": "Moxifloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00779",
      "source": "DB00047",
      "target": "DB00779",
      "description": "Nalidixic Acid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00731",
      "source": "DB00047",
      "target": "DB00731",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Nateglinide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01149",
      "source": "DB00047",
      "target": "DB01149",
      "description": "Nefazodone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00220",
      "source": "DB00047",
      "target": "DB00220",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06600",
      "source": "DB00047",
      "target": "DB06600",
      "description": "Nemonoxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Nemonoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00627",
      "source": "DB00047",
      "target": "DB00627",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Niacin.",
      "name": "Niacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04820",
      "source": "DB00047",
      "target": "DB04820",
      "description": "Nialamide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Nialamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04868",
      "source": "DB00047",
      "target": "DB04868",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00717",
      "source": "DB00047",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01059",
      "source": "DB00047",
      "target": "DB01059",
      "description": "Norfloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00957",
      "source": "DB00047",
      "target": "DB00957",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Norgestimate.",
      "name": "Norgestimate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09249",
      "source": "DB00047",
      "target": "DB09249",
      "description": "Octamoxin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Octamoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00104",
      "source": "DB00047",
      "target": "DB00104",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01165",
      "source": "DB00047",
      "target": "DB01165",
      "description": "Ofloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00334",
      "source": "DB00047",
      "target": "DB00334",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00621",
      "source": "DB00047",
      "target": "DB00621",
      "description": "Oxandrolone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Oxandrolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06412",
      "source": "DB00047",
      "target": "DB06412",
      "description": "Oxymetholone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Oxymetholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01267",
      "source": "DB00047",
      "target": "DB01267",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01626",
      "source": "DB00047",
      "target": "DB01626",
      "description": "Pargyline may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pargyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00715",
      "source": "DB00047",
      "target": "DB00715",
      "description": "Paroxetine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06663",
      "source": "DB00047",
      "target": "DB06663",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00487",
      "source": "DB00047",
      "target": "DB00487",
      "description": "Pefloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00082",
      "source": "DB00047",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00738",
      "source": "DB00047",
      "target": "DB00738",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00780",
      "source": "DB00047",
      "target": "DB00780",
      "description": "Phenelzine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Phenelzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00914",
      "source": "DB00047",
      "target": "DB00914",
      "description": "Phenformin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09250",
      "source": "DB00047",
      "target": "DB09250",
      "description": "Pheniprazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pheniprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09251",
      "source": "DB00047",
      "target": "DB09251",
      "description": "Phenoxypropazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Phenoxypropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01132",
      "source": "DB00047",
      "target": "DB01132",
      "description": "Pioglitazone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00592",
      "source": "DB00047",
      "target": "DB00592",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Piperazine.",
      "name": "Piperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01621",
      "source": "DB00047",
      "target": "DB01621",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Pipotiazine.",
      "name": "Pipotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09244",
      "source": "DB00047",
      "target": "DB09244",
      "description": "Pirlindole may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pirlindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09252",
      "source": "DB00047",
      "target": "DB09252",
      "description": "Pivhydrazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pivhydrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01324",
      "source": "DB00047",
      "target": "DB01324",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Polythiazide.",
      "name": "Polythiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01278",
      "source": "DB00047",
      "target": "DB01278",
      "description": "Pramlintide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00860",
      "source": "DB00047",
      "target": "DB00860",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00635",
      "source": "DB00047",
      "target": "DB00635",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00396",
      "source": "DB00047",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01224",
      "source": "DB00047",
      "target": "DB01224",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01325",
      "source": "DB00047",
      "target": "DB01325",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quinethazone.",
      "name": "Quinethazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00468",
      "source": "DB00047",
      "target": "DB00468",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01367",
      "source": "DB00047",
      "target": "DB01367",
      "description": "Rasagiline may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Rasagiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00912",
      "source": "DB00047",
      "target": "DB00912",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Repaglinide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00734",
      "source": "DB00047",
      "target": "DB00734",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00503",
      "source": "DB00047",
      "target": "DB00503",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ritonavir.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00412",
      "source": "DB00047",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00817",
      "source": "DB00047",
      "target": "DB00817",
      "description": "Rosoxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Rosoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09253",
      "source": "DB00047",
      "target": "DB09253",
      "description": "Safrazine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Safrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00936",
      "source": "DB00047",
      "target": "DB00936",
      "description": "Salicylic acid may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01232",
      "source": "DB00047",
      "target": "DB01232",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06335",
      "source": "DB00047",
      "target": "DB06335",
      "description": "Saxagliptin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01037",
      "source": "DB00047",
      "target": "DB01037",
      "description": "Selegiline may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01104",
      "source": "DB00047",
      "target": "DB01104",
      "description": "Sertraline may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00877",
      "source": "DB00047",
      "target": "DB00877",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Sirolimus.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01261",
      "source": "DB00047",
      "target": "DB01261",
      "description": "Sitagliptin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01208",
      "source": "DB00047",
      "target": "DB01208",
      "description": "Sparfloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06718",
      "source": "DB00047",
      "target": "DB06718",
      "description": "Stanozolol may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Stanozolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00359",
      "source": "DB00047",
      "target": "DB00359",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01015",
      "source": "DB00047",
      "target": "DB01015",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00263",
      "source": "DB00047",
      "target": "DB00263",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06271",
      "source": "DB00047",
      "target": "DB06271",
      "description": "Sulodexide may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01268",
      "source": "DB00047",
      "target": "DB01268",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00864",
      "source": "DB00047",
      "target": "DB00864",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tacrolimus.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01405",
      "source": "DB00047",
      "target": "DB01405",
      "description": "Temafloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06287",
      "source": "DB00047",
      "target": "DB06287",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00624",
      "source": "DB00047",
      "target": "DB00624",
      "description": "Testosterone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00932",
      "source": "DB00047",
      "target": "DB00932",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00839",
      "source": "DB00047",
      "target": "DB00839",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Tolazamide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01124",
      "source": "DB00047",
      "target": "DB01124",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Tolbutamide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB09245",
      "source": "DB00047",
      "target": "DB09245",
      "description": "Toloxatone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Toloxatone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00214",
      "source": "DB00047",
      "target": "DB00214",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB02665",
      "source": "DB00047",
      "target": "DB02665",
      "description": "Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Trans-2-Phenylcyclopropylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00752",
      "source": "DB00047",
      "target": "DB00752",
      "description": "Tranylcypromine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Tranylcypromine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00620",
      "source": "DB00047",
      "target": "DB00620",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB01021",
      "source": "DB00047",
      "target": "DB01021",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Trichlormethiazide.",
      "name": "Trichlormethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB06825",
      "source": "DB00047",
      "target": "DB06825",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triptorelin.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00197",
      "source": "DB00047",
      "target": "DB00197",
      "description": "Troglitazone may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00685",
      "source": "DB00047",
      "target": "DB00685",
      "description": "Trovafloxacin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00285",
      "source": "DB00047",
      "target": "DB00285",
      "description": "Venlafaxine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04876",
      "source": "DB00047",
      "target": "DB04876",
      "description": "Vildagliptin may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04878",
      "source": "DB00047",
      "target": "DB04878",
      "description": "Voglibose may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB02546",
      "source": "DB00047",
      "target": "DB02546",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Vorinostat.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB04832",
      "source": "DB00047",
      "target": "DB04832",
      "description": "Zimelidine may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00246",
      "source": "DB00047",
      "target": "DB00246",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB01281",
      "source": "DB00051",
      "target": "DB01281",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB01223",
      "source": "DB00051",
      "target": "DB01223",
      "description": "The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00026",
      "source": "DB00051",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB12768",
      "source": "DB00051",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Adalimumab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB08879",
      "source": "DB00051",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB06168",
      "source": "DB00051",
      "target": "DB06168",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Canakinumab.",
      "name": "Canakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB08904",
      "source": "DB00051",
      "target": "DB08904",
      "description": "Adalimumab may increase the immunosuppressive activities of Certolizumab pegol.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00091",
      "source": "DB00051",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB06643",
      "source": "DB00051",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00651",
      "source": "DB00051",
      "target": "DB00651",
      "description": "The serum concentration of Dyphylline can be decreased when it is combined with Adalimumab.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB08868",
      "source": "DB00051",
      "target": "DB08868",
      "description": "Adalimumab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00065",
      "source": "DB00051",
      "target": "DB00065",
      "description": "Adalimumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB01097",
      "source": "DB00051",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00108",
      "source": "DB00051",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00337",
      "source": "DB00051",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB10283",
      "source": "DB00051",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB10283",
      "source": "DB00051",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Adalimumab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB06372",
      "source": "DB00051",
      "target": "DB06372",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilonacept.",
      "name": "Rilonacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB01656",
      "source": "DB00051",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Adalimumab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB06688",
      "source": "DB00051",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00864",
      "source": "DB00051",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00277",
      "source": "DB00051",
      "target": "DB00277",
      "description": "The serum concentration of Theophylline can be decreased when it is combined with Adalimumab.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB06273",
      "source": "DB00051",
      "target": "DB06273",
      "description": "Tocilizumab may increase the immunosuppressive activities of Adalimumab.",
      "name": "Tocilizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB08895",
      "source": "DB00051",
      "target": "DB08895",
      "description": "Adalimumab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00072",
      "source": "DB00051",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Adalimumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB09033",
      "source": "DB00051",
      "target": "DB09033",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Vedolizumab.",
      "name": "Vedolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00682",
      "source": "DB00051",
      "target": "DB00682",
      "description": "The serum concentration of Warfarin can be decreased when it is combined with Adalimumab.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB06401",
      "source": "DB00052",
      "target": "DB06401",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Bazedoxifene.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00269",
      "source": "DB00052",
      "target": "DB00269",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Chlorotrianisene.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00286",
      "source": "DB00052",
      "target": "DB00286",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Conjugated Equine Estrogens.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB01380",
      "source": "DB00052",
      "target": "DB01380",
      "description": "The therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatropin recombinant.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00890",
      "source": "DB00052",
      "target": "DB00890",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Dienestrol.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00255",
      "source": "DB00052",
      "target": "DB00255",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Diethylstilbestrol.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00783",
      "source": "DB00052",
      "target": "DB00783",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estradiol.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB04573",
      "source": "DB00052",
      "target": "DB04573",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estriol.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00655",
      "source": "DB00052",
      "target": "DB00655",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estrone.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00977",
      "source": "DB00052",
      "target": "DB00977",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Ethinyl Estradiol.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB01645",
      "source": "DB00052",
      "target": "DB01645",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Genistein.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB07931",
      "source": "DB00052",
      "target": "DB07931",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Hexestrol.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB01357",
      "source": "DB00052",
      "target": "DB01357",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Mestranol.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB09369",
      "source": "DB00052",
      "target": "DB09369",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Polyestradiol phosphate.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB00635",
      "source": "DB00052",
      "target": "DB00635",
      "description": "The therapeutic efficacy of Prednisone can be decreased when used in combination with Somatropin recombinant.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB04575",
      "source": "DB00052",
      "target": "DB04575",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Quinestrol.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB09317",
      "source": "DB00052",
      "target": "DB09317",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Synthetic Conjugated Estrogens, A.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB09318",
      "source": "DB00052",
      "target": "DB09318",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Synthetic Conjugated Estrogens, B.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB09070",
      "source": "DB00052",
      "target": "DB09070",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Tibolone.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00052-DB11478",
      "source": "DB00052",
      "target": "DB11478",
      "description": "The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Zeranol.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06736",
      "source": "DB00054",
      "target": "DB06736",
      "description": "Aceclofenac may increase the anticoagulant activities of Abciximab.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01418",
      "source": "DB00054",
      "target": "DB01418",
      "description": "Abciximab may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00945",
      "source": "DB00054",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Acetylsalicylic acid.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00210",
      "source": "DB00054",
      "target": "DB00210",
      "description": "Adapalene may increase the anticoagulant activities of Abciximab.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01431",
      "source": "DB00054",
      "target": "DB01431",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Allylestrenol.",
      "name": "Allylestrenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00770",
      "source": "DB00054",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Abciximab.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00009",
      "source": "DB00054",
      "target": "DB00009",
      "description": "Abciximab may increase the anticoagulant activities of Alteplase.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11372",
      "source": "DB00054",
      "target": "DB11372",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Altrenogest.",
      "name": "Altrenogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06081",
      "source": "DB00054",
      "target": "DB06081",
      "description": "Abciximab may increase the anticoagulant activities of ALX-0081.",
      "name": "ALX-0081"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00233",
      "source": "DB00054",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Aminosalicylic Acid.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00261",
      "source": "DB00054",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Abciximab.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05099",
      "source": "DB00054",
      "target": "DB05099",
      "description": "Abciximab may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00029",
      "source": "DB00054",
      "target": "DB00029",
      "description": "Abciximab may increase the anticoagulant activities of Anistreplase.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01435",
      "source": "DB00054",
      "target": "DB01435",
      "description": "Antipyrine may increase the anticoagulant activities of Abciximab.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11598",
      "source": "DB00054",
      "target": "DB11598",
      "description": "Abciximab may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06605",
      "source": "DB00054",
      "target": "DB06605",
      "description": "Apixaban may increase the anticoagulant activities of Abciximab.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05676",
      "source": "DB00054",
      "target": "DB05676",
      "description": "Apremilast may increase the anticoagulant activities of Abciximab.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06692",
      "source": "DB00054",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00407",
      "source": "DB00054",
      "target": "DB00407",
      "description": "Abciximab may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00278",
      "source": "DB00054",
      "target": "DB00278",
      "description": "Abciximab may increase the anticoagulant activities of Argatroban.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06543",
      "source": "DB00054",
      "target": "DB06543",
      "description": "Abciximab may increase the anticoagulant activities of Astaxanthin.",
      "name": "Astaxanthin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB07402",
      "source": "DB00054",
      "target": "DB07402",
      "description": "Azapropazone may increase the anticoagulant activities of Abciximab.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00972",
      "source": "DB00054",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Abciximab.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01014",
      "source": "DB00054",
      "target": "DB01014",
      "description": "Balsalazide may increase the anticoagulant activities of Abciximab.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09005",
      "source": "DB00054",
      "target": "DB09005",
      "description": "Abciximab may increase the anticoagulant activities of Batroxobin.",
      "name": "Batroxobin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06401",
      "source": "DB00054",
      "target": "DB06401",
      "description": "Bazedoxifene may decrease the anticoagulant activities of Abciximab.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00102",
      "source": "DB00054",
      "target": "DB00102",
      "description": "Abciximab may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09258",
      "source": "DB00054",
      "target": "DB09258",
      "description": "Abciximab may increase the anticoagulant activities of Bemiparin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04812",
      "source": "DB00054",
      "target": "DB04812",
      "description": "Benoxaprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05229",
      "source": "DB00054",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Abciximab.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00006",
      "source": "DB00054",
      "target": "DB00006",
      "description": "Abciximab may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00963",
      "source": "DB00054",
      "target": "DB00963",
      "description": "Bromfenac may increase the anticoagulant activities of Abciximab.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06441",
      "source": "DB00054",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Abciximab.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00821",
      "source": "DB00054",
      "target": "DB00821",
      "description": "Carprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01816",
      "source": "DB00054",
      "target": "DB01816",
      "description": "Castanospermine may increase the anticoagulant activities of Abciximab.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00482",
      "source": "DB00054",
      "target": "DB00482",
      "description": "Celecoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09261",
      "source": "DB00054",
      "target": "DB09261",
      "description": "Abciximab may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00608",
      "source": "DB00054",
      "target": "DB00608",
      "description": "Chloroquine may increase the anticoagulant activities of Abciximab.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00269",
      "source": "DB00054",
      "target": "DB00269",
      "description": "Chlorotrianisene may decrease the anticoagulant activities of Abciximab.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01166",
      "source": "DB00054",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Abciximab.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04272",
      "source": "DB00054",
      "target": "DB04272",
      "description": "Abciximab may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09218",
      "source": "DB00054",
      "target": "DB09218",
      "description": "Clonixin may increase the anticoagulant activities of Abciximab.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00758",
      "source": "DB00054",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Abciximab.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11249",
      "source": "DB00054",
      "target": "DB11249",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Collagenase.",
      "name": "Collagenase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00286",
      "source": "DB00054",
      "target": "DB00286",
      "description": "Conjugated Equine Estrogens may decrease the anticoagulant activities of Abciximab.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08921",
      "source": "DB00054",
      "target": "DB08921",
      "description": "D-Limonene may increase the anticoagulant activities of Abciximab.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06695",
      "source": "DB00054",
      "target": "DB06695",
      "description": "Dabigatran etexilate may increase the anticoagulant activities of Abciximab.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06779",
      "source": "DB00054",
      "target": "DB06779",
      "description": "Abciximab may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06754",
      "source": "DB00054",
      "target": "DB06754",
      "description": "Abciximab may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01254",
      "source": "DB00054",
      "target": "DB01254",
      "description": "Dasatinib may increase the anticoagulant activities of Abciximab.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01609",
      "source": "DB00054",
      "target": "DB01609",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04932",
      "source": "DB00054",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Abciximab.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB03619",
      "source": "DB00054",
      "target": "DB03619",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Deoxycholic Acid.",
      "name": "Deoxycholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11095",
      "source": "DB00054",
      "target": "DB11095",
      "description": "Abciximab may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04925",
      "source": "DB00054",
      "target": "DB04925",
      "description": "Abciximab may increase the anticoagulant activities of Desmoteplase.",
      "name": "Desmoteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00304",
      "source": "DB00054",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09255",
      "source": "DB00054",
      "target": "DB09255",
      "description": "Dextran may increase the anticoagulant activities of Abciximab.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11122",
      "source": "DB00054",
      "target": "DB11122",
      "description": "Abciximab may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11076",
      "source": "DB00054",
      "target": "DB11076",
      "description": "Abciximab may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11241",
      "source": "DB00054",
      "target": "DB11241",
      "description": "Abciximab may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00586",
      "source": "DB00054",
      "target": "DB00586",
      "description": "Diclofenac may increase the anticoagulant activities of Abciximab.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00266",
      "source": "DB00054",
      "target": "DB00266",
      "description": "Abciximab may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00890",
      "source": "DB00054",
      "target": "DB00890",
      "description": "Dienestrol may decrease the anticoagulant activities of Abciximab.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09123",
      "source": "DB00054",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00255",
      "source": "DB00054",
      "target": "DB00255",
      "description": "Diethylstilbestrol may decrease the anticoagulant activities of Abciximab.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00861",
      "source": "DB00054",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Diflunisal.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00975",
      "source": "DB00054",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Abciximab.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08994",
      "source": "DB00054",
      "target": "DB08994",
      "description": "Abciximab may increase the anticoagulant activities of Ditazole.",
      "name": "Ditazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01395",
      "source": "DB00054",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00055",
      "source": "DB00054",
      "target": "DB00055",
      "description": "Abciximab may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09215",
      "source": "DB00054",
      "target": "DB09215",
      "description": "Droxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00378",
      "source": "DB00054",
      "target": "DB00378",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Dydrogesterone.",
      "name": "Dydrogesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00974",
      "source": "DB00054",
      "target": "DB00974",
      "description": "Abciximab may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09075",
      "source": "DB00054",
      "target": "DB09075",
      "description": "Edoxaban may increase the anticoagulant activities of Abciximab.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01225",
      "source": "DB00054",
      "target": "DB01225",
      "description": "Abciximab may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00751",
      "source": "DB00054",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Abciximab.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08991",
      "source": "DB00054",
      "target": "DB08991",
      "description": "Epirizole may increase the anticoagulant activities of Abciximab.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06392",
      "source": "DB00054",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Abciximab.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01240",
      "source": "DB00054",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Abciximab.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00063",
      "source": "DB00054",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Abciximab.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00783",
      "source": "DB00054",
      "target": "DB00783",
      "description": "Estradiol may decrease the anticoagulant activities of Abciximab.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04573",
      "source": "DB00054",
      "target": "DB04573",
      "description": "Estriol may decrease the anticoagulant activities of Abciximab.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00655",
      "source": "DB00054",
      "target": "DB00655",
      "description": "Estrone may decrease the anticoagulant activities of Abciximab.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00005",
      "source": "DB00054",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Abciximab.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00977",
      "source": "DB00054",
      "target": "DB00977",
      "description": "Ethinyl Estradiol may decrease the anticoagulant activities of Abciximab.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08794",
      "source": "DB00054",
      "target": "DB08794",
      "description": "Abciximab may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00823",
      "source": "DB00054",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00749",
      "source": "DB00054",
      "target": "DB00749",
      "description": "Etodolac may increase the anticoagulant activities of Abciximab.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08984",
      "source": "DB00054",
      "target": "DB08984",
      "description": "Etofenamate may increase the anticoagulant activities of Abciximab.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00294",
      "source": "DB00054",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01628",
      "source": "DB00054",
      "target": "DB01628",
      "description": "Etoricoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11358",
      "source": "DB00054",
      "target": "DB11358",
      "description": "Evening primrose oil may increase the anticoagulant activities of Abciximab.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06246",
      "source": "DB00054",
      "target": "DB06246",
      "description": "exisulind may increase the anticoagulant activities of Abciximab.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08981",
      "source": "DB00054",
      "target": "DB08981",
      "description": "Fenbufen may increase the anticoagulant activities of Abciximab.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00573",
      "source": "DB00054",
      "target": "DB00573",
      "description": "Fenoprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08977",
      "source": "DB00054",
      "target": "DB08977",
      "description": "Abciximab may increase the anticoagulant activities of Fibrinolysin.",
      "name": "Fibrinolysin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08976",
      "source": "DB00054",
      "target": "DB08976",
      "description": "Floctafenine may increase the anticoagulant activities of Abciximab.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11518",
      "source": "DB00054",
      "target": "DB11518",
      "description": "Flunixin may increase the anticoagulant activities of Abciximab.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00712",
      "source": "DB00054",
      "target": "DB00712",
      "description": "Flurbiprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00569",
      "source": "DB00054",
      "target": "DB00569",
      "description": "Abciximab may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01645",
      "source": "DB00054",
      "target": "DB01645",
      "description": "Genistein may decrease the anticoagulant activities of Abciximab.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06730",
      "source": "DB00054",
      "target": "DB06730",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Gestodene.",
      "name": "Gestodene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11619",
      "source": "DB00054",
      "target": "DB11619",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Gestrinone.",
      "name": "Gestrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01296",
      "source": "DB00054",
      "target": "DB01296",
      "description": "Glucosamine may increase the antiplatelet activities of Abciximab.",
      "name": "Glucosamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB03404",
      "source": "DB00054",
      "target": "DB03404",
      "description": "Hemin may increase the anticoagulant activities of Abciximab.",
      "name": "Hemin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01109",
      "source": "DB00054",
      "target": "DB01109",
      "description": "Abciximab may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB07931",
      "source": "DB00054",
      "target": "DB07931",
      "description": "Hexestrol may decrease the anticoagulant activities of Abciximab.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB02351",
      "source": "DB00054",
      "target": "DB02351",
      "description": "Abciximab may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05767",
      "source": "DB00054",
      "target": "DB05767",
      "description": "HMPL-004 may increase the anticoagulant activities of Abciximab.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06789",
      "source": "DB00054",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00078",
      "source": "DB00054",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09053",
      "source": "DB00054",
      "target": "DB09053",
      "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Abciximab.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05266",
      "source": "DB00054",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Abciximab.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01050",
      "source": "DB00054",
      "target": "DB01050",
      "description": "Ibuprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08955",
      "source": "DB00054",
      "target": "DB08955",
      "description": "Ibuproxam may increase the anticoagulant activities of Abciximab.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06196",
      "source": "DB00054",
      "target": "DB06196",
      "description": "Icatibant may increase the anticoagulant activities of Abciximab.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08887",
      "source": "DB00054",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Abciximab.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06406",
      "source": "DB00054",
      "target": "DB06406",
      "description": "Abciximab may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08954",
      "source": "DB00054",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Abciximab.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01088",
      "source": "DB00054",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Abciximab.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00328",
      "source": "DB00054",
      "target": "DB00328",
      "description": "Indomethacin may increase the anticoagulant activities of Abciximab.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08951",
      "source": "DB00054",
      "target": "DB08951",
      "description": "Indoprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08942",
      "source": "DB00054",
      "target": "DB08942",
      "description": "Isoxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08940",
      "source": "DB00054",
      "target": "DB08940",
      "description": "Kebuzone may increase the anticoagulant activities of Abciximab.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01009",
      "source": "DB00054",
      "target": "DB01009",
      "description": "Ketoprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00465",
      "source": "DB00054",
      "target": "DB00465",
      "description": "Ketorolac may increase the anticoagulant activities of Abciximab.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01097",
      "source": "DB00054",
      "target": "DB01097",
      "description": "Leflunomide may increase the anticoagulant activities of Abciximab.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00001",
      "source": "DB00054",
      "target": "DB00001",
      "description": "Abciximab may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00367",
      "source": "DB00054",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09211",
      "source": "DB00054",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Abciximab.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06725",
      "source": "DB00054",
      "target": "DB06725",
      "description": "Lornoxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09212",
      "source": "DB00054",
      "target": "DB09212",
      "description": "Loxoprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01283",
      "source": "DB00054",
      "target": "DB01283",
      "description": "Lumiracoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01397",
      "source": "DB00054",
      "target": "DB01397",
      "description": "Magnesium salicylate may increase the anticoagulant activities of Abciximab.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00179",
      "source": "DB00054",
      "target": "DB00179",
      "description": "Masoprocol may increase the anticoagulant activities of Abciximab.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00939",
      "source": "DB00054",
      "target": "DB00939",
      "description": "Meclofenamic acid may increase the anticoagulant activities of Abciximab.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09124",
      "source": "DB00054",
      "target": "DB09124",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Medrogestone.",
      "name": "Medrogestone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00603",
      "source": "DB00054",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00784",
      "source": "DB00054",
      "target": "DB00784",
      "description": "Mefenamic acid may increase the anticoagulant activities of Abciximab.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00351",
      "source": "DB00054",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00814",
      "source": "DB00054",
      "target": "DB00814",
      "description": "Meloxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00244",
      "source": "DB00054",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Mesalazine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01357",
      "source": "DB00054",
      "target": "DB01357",
      "description": "Mestranol may decrease the anticoagulant activities of Abciximab.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04817",
      "source": "DB00054",
      "target": "DB04817",
      "description": "Metamizole may increase the anticoagulant activities of Abciximab.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00235",
      "source": "DB00054",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Abciximab.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00688",
      "source": "DB00054",
      "target": "DB00688",
      "description": "Mycophenolate mofetil may increase the anticoagulant activities of Abciximab.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01024",
      "source": "DB00054",
      "target": "DB01024",
      "description": "Mycophenolic acid may increase the anticoagulant activities of Abciximab.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00461",
      "source": "DB00054",
      "target": "DB00461",
      "description": "Nabumetone may increase the anticoagulant activities of Abciximab.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08813",
      "source": "DB00054",
      "target": "DB08813",
      "description": "Abciximab may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00735",
      "source": "DB00054",
      "target": "DB00735",
      "description": "Naftifine may increase the anticoagulant activities of Abciximab.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00788",
      "source": "DB00054",
      "target": "DB00788",
      "description": "Naproxen may increase the anticoagulant activities of Abciximab.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05822",
      "source": "DB00054",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Abciximab.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06802",
      "source": "DB00054",
      "target": "DB06802",
      "description": "Nepafenac may increase the anticoagulant activities of Abciximab.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04552",
      "source": "DB00054",
      "target": "DB04552",
      "description": "Niflumic Acid may increase the anticoagulant activities of Abciximab.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04743",
      "source": "DB00054",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Abciximab.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09079",
      "source": "DB00054",
      "target": "DB09079",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Nintedanib.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00717",
      "source": "DB00054",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08935",
      "source": "DB00054",
      "target": "DB08935",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00768",
      "source": "DB00054",
      "target": "DB00768",
      "description": "Olopatadine may increase the anticoagulant activities of Abciximab.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01250",
      "source": "DB00054",
      "target": "DB01250",
      "description": "Olsalazine may increase the anticoagulant activities of Abciximab.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04865",
      "source": "DB00054",
      "target": "DB04865",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11133",
      "source": "DB00054",
      "target": "DB11133",
      "description": "Omega-3 fatty acids may increase the anticoagulant activities of Abciximab.",
      "name": "Omega-3 fatty acids"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11444",
      "source": "DB00054",
      "target": "DB11444",
      "description": "Orgotein may increase the anticoagulant activities of Abciximab.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06635",
      "source": "DB00054",
      "target": "DB06635",
      "description": "Abciximab may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00991",
      "source": "DB00054",
      "target": "DB00991",
      "description": "Oxaprozin may increase the anticoagulant activities of Abciximab.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB03585",
      "source": "DB00054",
      "target": "DB03585",
      "description": "Oxyphenbutazone may increase the anticoagulant activities of Abciximab.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08439",
      "source": "DB00054",
      "target": "DB08439",
      "description": "Parecoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09260",
      "source": "DB00054",
      "target": "DB09260",
      "description": "Abciximab may increase the anticoagulant activities of Parnaparin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00686",
      "source": "DB00054",
      "target": "DB00686",
      "description": "Pentosan Polysulfate may increase the anticoagulant activities of Abciximab.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00806",
      "source": "DB00054",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the antiplatelet activities of Abciximab.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00498",
      "source": "DB00054",
      "target": "DB00498",
      "description": "Abciximab may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00946",
      "source": "DB00054",
      "target": "DB00946",
      "description": "Abciximab may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00812",
      "source": "DB00054",
      "target": "DB00812",
      "description": "Phenylbutazone may increase the anticoagulant activities of Abciximab.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00337",
      "source": "DB00054",
      "target": "DB00337",
      "description": "Pimecrolimus may increase the anticoagulant activities of Abciximab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04951",
      "source": "DB00054",
      "target": "DB04951",
      "description": "Pirfenidone may increase the anticoagulant activities of Abciximab.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00554",
      "source": "DB00054",
      "target": "DB00554",
      "description": "Piroxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05254",
      "source": "DB00054",
      "target": "DB05254",
      "description": "Abciximab may increase the anticoagulant activities of Plasmin.",
      "name": "Plasmin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09369",
      "source": "DB00054",
      "target": "DB09369",
      "description": "Polyestradiol phosphate may decrease the anticoagulant activities of Abciximab.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06209",
      "source": "DB00054",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Abciximab.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00396",
      "source": "DB00054",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Abciximab can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09288",
      "source": "DB00054",
      "target": "DB09288",
      "description": "Propacetamol may increase the anticoagulant activities of Abciximab.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11312",
      "source": "DB00054",
      "target": "DB11312",
      "description": "Abciximab may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11268",
      "source": "DB00054",
      "target": "DB11268",
      "description": "Abciximab may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05173",
      "source": "DB00054",
      "target": "DB05173",
      "description": "PTC299 may increase the anticoagulant activities of Abciximab.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04575",
      "source": "DB00054",
      "target": "DB04575",
      "description": "Quinestrol may decrease the anticoagulant activities of Abciximab.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB02709",
      "source": "DB00054",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Abciximab.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00015",
      "source": "DB00054",
      "target": "DB00015",
      "description": "Abciximab may increase the anticoagulant activities of Reteplase.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09259",
      "source": "DB00054",
      "target": "DB09259",
      "description": "Abciximab may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01207",
      "source": "DB00054",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Abciximab.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06228",
      "source": "DB00054",
      "target": "DB06228",
      "description": "Abciximab may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00533",
      "source": "DB00054",
      "target": "DB00533",
      "description": "Rofecoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00412",
      "source": "DB00054",
      "target": "DB00412",
      "description": "Abciximab may increase the anticoagulant activities of Rosiglitazone.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08797",
      "source": "DB00054",
      "target": "DB08797",
      "description": "Salicylamide may increase the anticoagulant activities of Abciximab.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00936",
      "source": "DB00054",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Salicylic acid.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01399",
      "source": "DB00054",
      "target": "DB01399",
      "description": "Salsalate may increase the anticoagulant activities of Abciximab.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05692",
      "source": "DB00054",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Abciximab.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11362",
      "source": "DB00054",
      "target": "DB11362",
      "description": "Abciximab may increase the anticoagulant activities of Selexipag.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06739",
      "source": "DB00054",
      "target": "DB06739",
      "description": "Seratrodast may increase the anticoagulant activities of Abciximab.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01236",
      "source": "DB00054",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Abciximab.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB05073",
      "source": "DB00054",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Abciximab.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00086",
      "source": "DB00054",
      "target": "DB00086",
      "description": "Abciximab may increase the anticoagulant activities of Streptokinase.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06206",
      "source": "DB00054",
      "target": "DB06206",
      "description": "Sugammadex may increase the anticoagulant activities of Abciximab.",
      "name": "Sugammadex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00795",
      "source": "DB00054",
      "target": "DB00795",
      "description": "Sulfasalazine may increase the anticoagulant activities of Abciximab.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00605",
      "source": "DB00054",
      "target": "DB00605",
      "description": "Sulindac may increase the anticoagulant activities of Abciximab.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06271",
      "source": "DB00054",
      "target": "DB06271",
      "description": "Abciximab may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00870",
      "source": "DB00054",
      "target": "DB00870",
      "description": "Suprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09317",
      "source": "DB00054",
      "target": "DB09317",
      "description": "Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Abciximab.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09318",
      "source": "DB00054",
      "target": "DB09318",
      "description": "Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Abciximab.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00031",
      "source": "DB00054",
      "target": "DB00031",
      "description": "Abciximab may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00469",
      "source": "DB00054",
      "target": "DB00469",
      "description": "Tenoxicam may increase the anticoagulant activities of Abciximab.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11466",
      "source": "DB00054",
      "target": "DB11466",
      "description": "Tepoxalin may increase the anticoagulant activities of Abciximab.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08880",
      "source": "DB00054",
      "target": "DB08880",
      "description": "Teriflunomide may increase the anticoagulant activities of Abciximab.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04905",
      "source": "DB00054",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Abciximab.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01600",
      "source": "DB00054",
      "target": "DB01600",
      "description": "Tiaprofenic acid may increase the anticoagulant activities of Abciximab.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09070",
      "source": "DB00054",
      "target": "DB09070",
      "description": "Tibolone may increase the anticoagulant activities of Abciximab.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08816",
      "source": "DB00054",
      "target": "DB08816",
      "description": "Abciximab may increase the anticoagulant activities of Ticagrelor.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00208",
      "source": "DB00054",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Abciximab.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06822",
      "source": "DB00054",
      "target": "DB06822",
      "description": "Abciximab may increase the anticoagulant activities of Tinzaparin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00932",
      "source": "DB00054",
      "target": "DB00932",
      "description": "Tipranavir may increase the antiplatelet activities of Abciximab.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00775",
      "source": "DB00054",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Abciximab.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09216",
      "source": "DB00054",
      "target": "DB09216",
      "description": "Tolfenamic Acid may increase the anticoagulant activities of Abciximab.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00500",
      "source": "DB00054",
      "target": "DB00500",
      "description": "Tolmetin may increase the anticoagulant activities of Abciximab.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00081",
      "source": "DB00054",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB07615",
      "source": "DB00054",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Abciximab.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09283",
      "source": "DB00054",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Abciximab.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00374",
      "source": "DB00054",
      "target": "DB00374",
      "description": "Abciximab may increase the anticoagulant activities of Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB08814",
      "source": "DB00054",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Abciximab.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB01401",
      "source": "DB00054",
      "target": "DB01401",
      "description": "Trisalicylate-choline may increase the anticoagulant activities of Abciximab.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00013",
      "source": "DB00054",
      "target": "DB00013",
      "description": "Abciximab may increase the anticoagulant activities of Urokinase.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00580",
      "source": "DB00054",
      "target": "DB00580",
      "description": "Valdecoxib may increase the anticoagulant activities of Abciximab.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00163",
      "source": "DB00054",
      "target": "DB00163",
      "description": "Vitamin E may increase the antiplatelet activities of Abciximab.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00163",
      "source": "DB00054",
      "target": "DB00163",
      "description": "Vitamin E may increase the anticoagulant activities of Abciximab.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB09030",
      "source": "DB00054",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Abciximab.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00682",
      "source": "DB00054",
      "target": "DB00682",
      "description": "Abciximab may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04898",
      "source": "DB00054",
      "target": "DB04898",
      "description": "Abciximab may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB06737",
      "source": "DB00054",
      "target": "DB06737",
      "description": "Zaltoprofen may increase the anticoagulant activities of Abciximab.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB11478",
      "source": "DB00054",
      "target": "DB11478",
      "description": "Zeranol may decrease the anticoagulant activities of Abciximab.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00744",
      "source": "DB00054",
      "target": "DB00744",
      "description": "Zileuton may increase the anticoagulant activities of Abciximab.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB04828",
      "source": "DB00054",
      "target": "DB04828",
      "description": "Zomepirac may increase the anticoagulant activities of Abciximab.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00511",
      "source": "DB00056",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB12768",
      "source": "DB00056",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Gemtuzumab ozogamicin.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00112",
      "source": "DB00056",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB06772",
      "source": "DB00056",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemtuzumab ozogamicin.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00363",
      "source": "DB00056",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00531",
      "source": "DB00056",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB06643",
      "source": "DB00056",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01078",
      "source": "DB00056",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01396",
      "source": "DB00056",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00390",
      "source": "DB00056",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01248",
      "source": "DB00056",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB08868",
      "source": "DB00056",
      "target": "DB08868",
      "description": "Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01097",
      "source": "DB00056",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB04817",
      "source": "DB00056",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Gemtuzumab ozogamicin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00108",
      "source": "DB00056",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01092",
      "source": "DB00056",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01229",
      "source": "DB00056",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemtuzumab ozogamicin.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00337",
      "source": "DB00056",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB10283",
      "source": "DB00056",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB10283",
      "source": "DB00056",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB01656",
      "source": "DB00056",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB06688",
      "source": "DB00056",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00864",
      "source": "DB00056",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemtuzumab ozogamicin.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB08895",
      "source": "DB00056",
      "target": "DB08895",
      "description": "Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00072",
      "source": "DB00056",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01048",
      "source": "DB00058",
      "target": "DB01048",
      "description": "The serum concentration of Abacavir can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Abacavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00346",
      "source": "DB00058",
      "target": "DB00346",
      "description": "The serum concentration of Alfuzosin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00404",
      "source": "DB00058",
      "target": "DB00404",
      "description": "The serum concentration of Alprazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Alprazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB04836",
      "source": "DB00058",
      "target": "DB04836",
      "description": "The serum concentration of Amineptine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Amineptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01223",
      "source": "DB00058",
      "target": "DB01223",
      "description": "The serum concentration of Aminophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00321",
      "source": "DB00058",
      "target": "DB00321",
      "description": "The serum concentration of Amitriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01076",
      "source": "DB00058",
      "target": "DB01076",
      "description": "The serum concentration of Atorvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB08873",
      "source": "DB00058",
      "target": "DB08873",
      "description": "The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Boceprevir.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01200",
      "source": "DB00058",
      "target": "DB01200",
      "description": "The serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00248",
      "source": "DB00058",
      "target": "DB00248",
      "description": "The serum concentration of Cabergoline can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Cabergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00564",
      "source": "DB00058",
      "target": "DB00564",
      "description": "The metabolism of Alpha-1-proteinase inhibitor can be increased when combined with Carbamazepine.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00604",
      "source": "DB00058",
      "target": "DB00604",
      "description": "The serum concentration of Cisapride can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01211",
      "source": "DB00058",
      "target": "DB01211",
      "description": "The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alpha-1-proteinase inhibitor.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01242",
      "source": "DB00058",
      "target": "DB01242",
      "description": "The serum concentration of Clomipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00924",
      "source": "DB00058",
      "target": "DB00924",
      "description": "The serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00531",
      "source": "DB00058",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00091",
      "source": "DB00058",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00705",
      "source": "DB00058",
      "target": "DB00705",
      "description": "The serum concentration of Delavirdine can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Delavirdine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01151",
      "source": "DB00058",
      "target": "DB01151",
      "description": "The serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00390",
      "source": "DB00058",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00320",
      "source": "DB00058",
      "target": "DB00320",
      "description": "The serum concentration of Dihydroergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Dihydroergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB09167",
      "source": "DB00058",
      "target": "DB09167",
      "description": "The serum concentration of Dosulepin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Dosulepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01142",
      "source": "DB00058",
      "target": "DB01142",
      "description": "The serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00651",
      "source": "DB00058",
      "target": "DB00651",
      "description": "The serum concentration of Dyphylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00109",
      "source": "DB00058",
      "target": "DB00109",
      "description": "The serum concentration of Enfuvirtide can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Enfuvirtide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01049",
      "source": "DB00058",
      "target": "DB01049",
      "description": "The serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Ergoloid mesylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01253",
      "source": "DB00058",
      "target": "DB01253",
      "description": "The serum concentration of Ergonovine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Ergonovine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00696",
      "source": "DB00058",
      "target": "DB00696",
      "description": "The serum concentration of Ergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Ergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB06678",
      "source": "DB00058",
      "target": "DB06678",
      "description": "The serum concentration of Esmirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB06414",
      "source": "DB00058",
      "target": "DB06414",
      "description": "The serum concentration of Etravirine can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Etravirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB10532",
      "source": "DB00058",
      "target": "DB10532",
      "description": "The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Garlic.",
      "name": "Garlic"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00458",
      "source": "DB00058",
      "target": "DB00458",
      "description": "The serum concentration of Imipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00227",
      "source": "DB00058",
      "target": "DB00227",
      "description": "The serum concentration of Lovastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00683",
      "source": "DB00058",
      "target": "DB00683",
      "description": "The serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Midazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00370",
      "source": "DB00058",
      "target": "DB00370",
      "description": "The serum concentration of Mirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01149",
      "source": "DB00058",
      "target": "DB01149",
      "description": "The serum concentration of Nefazodone can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00540",
      "source": "DB00058",
      "target": "DB00540",
      "description": "The serum concentration of Nortriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00454",
      "source": "DB00058",
      "target": "DB00454",
      "description": "The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Pethidine.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01100",
      "source": "DB00058",
      "target": "DB01100",
      "description": "The serum concentration of Pimozide can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00344",
      "source": "DB00058",
      "target": "DB00344",
      "description": "The serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB08931",
      "source": "DB00058",
      "target": "DB08931",
      "description": "The serum concentration of Riociguat can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01098",
      "source": "DB00058",
      "target": "DB01098",
      "description": "The serum concentration of Rosuvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00203",
      "source": "DB00058",
      "target": "DB00203",
      "description": "The serum concentration of Sildenafil can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Sildenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB06290",
      "source": "DB00058",
      "target": "DB06290",
      "description": "The serum concentration of Simeprevir can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Simeprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00641",
      "source": "DB00058",
      "target": "DB00641",
      "description": "The serum concentration of Simvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB01323",
      "source": "DB00058",
      "target": "DB01323",
      "description": "The metabolism of Alpha-1-proteinase inhibitor can be increased when combined with St. John&#39;s Wort.",
      "name": "St. John's Wort"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00864",
      "source": "DB00058",
      "target": "DB00864",
      "description": "The metabolism of Tacrolimus can be decreased when combined with Alpha-1-proteinase inhibitor.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB06287",
      "source": "DB00058",
      "target": "DB06287",
      "description": "The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00277",
      "source": "DB00058",
      "target": "DB00277",
      "description": "The serum concentration of Theophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB09289",
      "source": "DB00058",
      "target": "DB09289",
      "description": "The serum concentration of Tianeptine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Tianeptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00932",
      "source": "DB00058",
      "target": "DB00932",
      "description": "The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00897",
      "source": "DB00058",
      "target": "DB00897",
      "description": "The serum concentration of Triazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Triazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00726",
      "source": "DB00058",
      "target": "DB00726",
      "description": "The serum concentration of Trimipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00313",
      "source": "DB00058",
      "target": "DB00313",
      "description": "The serum concentration of Valproic Acid can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Valproic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00495",
      "source": "DB00058",
      "target": "DB00495",
      "description": "The serum concentration of Zidovudine can be decreased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00054",
      "source": "DB00055",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01418",
      "source": "DB00055",
      "target": "DB01418",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00945",
      "source": "DB00055",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00770",
      "source": "DB00055",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00233",
      "source": "DB00055",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Drotrecogin alfa.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00261",
      "source": "DB00055",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05099",
      "source": "DB00055",
      "target": "DB05099",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11598",
      "source": "DB00055",
      "target": "DB11598",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06605",
      "source": "DB00055",
      "target": "DB06605",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06692",
      "source": "DB00055",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00407",
      "source": "DB00055",
      "target": "DB00407",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00278",
      "source": "DB00055",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00972",
      "source": "DB00055",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00102",
      "source": "DB00055",
      "target": "DB00102",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05229",
      "source": "DB00055",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00006",
      "source": "DB00055",
      "target": "DB00006",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06441",
      "source": "DB00055",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09261",
      "source": "DB00055",
      "target": "DB09261",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01166",
      "source": "DB00055",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB04272",
      "source": "DB00055",
      "target": "DB04272",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00758",
      "source": "DB00055",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06695",
      "source": "DB00055",
      "target": "DB06695",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06779",
      "source": "DB00055",
      "target": "DB06779",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06754",
      "source": "DB00055",
      "target": "DB06754",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB04932",
      "source": "DB00055",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11095",
      "source": "DB00055",
      "target": "DB11095",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09255",
      "source": "DB00055",
      "target": "DB09255",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11122",
      "source": "DB00055",
      "target": "DB11122",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11076",
      "source": "DB00055",
      "target": "DB11076",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11241",
      "source": "DB00055",
      "target": "DB11241",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00266",
      "source": "DB00055",
      "target": "DB00266",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00861",
      "source": "DB00055",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Drotrecogin alfa.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00975",
      "source": "DB00055",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00974",
      "source": "DB00055",
      "target": "DB00974",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09075",
      "source": "DB00055",
      "target": "DB09075",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01225",
      "source": "DB00055",
      "target": "DB01225",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00751",
      "source": "DB00055",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06392",
      "source": "DB00055",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01240",
      "source": "DB00055",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00063",
      "source": "DB00055",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB08794",
      "source": "DB00055",
      "target": "DB08794",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00569",
      "source": "DB00055",
      "target": "DB00569",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01109",
      "source": "DB00055",
      "target": "DB01109",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB02351",
      "source": "DB00055",
      "target": "DB02351",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05266",
      "source": "DB00055",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB08887",
      "source": "DB00055",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06406",
      "source": "DB00055",
      "target": "DB06406",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB08954",
      "source": "DB00055",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01088",
      "source": "DB00055",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00001",
      "source": "DB00055",
      "target": "DB00001",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09211",
      "source": "DB00055",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Drotrecogin alfa.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00244",
      "source": "DB00055",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Drotrecogin alfa.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00235",
      "source": "DB00055",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB08813",
      "source": "DB00055",
      "target": "DB08813",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05822",
      "source": "DB00055",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB04743",
      "source": "DB00055",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06635",
      "source": "DB00055",
      "target": "DB06635",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00686",
      "source": "DB00055",
      "target": "DB00686",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00806",
      "source": "DB00055",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00498",
      "source": "DB00055",
      "target": "DB00498",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00946",
      "source": "DB00055",
      "target": "DB00946",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06209",
      "source": "DB00055",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11312",
      "source": "DB00055",
      "target": "DB11312",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB11268",
      "source": "DB00055",
      "target": "DB11268",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB02709",
      "source": "DB00055",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09259",
      "source": "DB00055",
      "target": "DB09259",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01207",
      "source": "DB00055",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06228",
      "source": "DB00055",
      "target": "DB06228",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00936",
      "source": "DB00055",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Drotrecogin alfa.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05692",
      "source": "DB00055",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB01236",
      "source": "DB00055",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB05073",
      "source": "DB00055",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB06271",
      "source": "DB00055",
      "target": "DB06271",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB04905",
      "source": "DB00055",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00208",
      "source": "DB00055",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00775",
      "source": "DB00055",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB07615",
      "source": "DB00055",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09283",
      "source": "DB00055",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00374",
      "source": "DB00055",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB08814",
      "source": "DB00055",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB09030",
      "source": "DB00055",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00682",
      "source": "DB00055",
      "target": "DB00682",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB04898",
      "source": "DB00055",
      "target": "DB04898",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00511",
      "source": "DB00059",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Pegaspargase.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB12768",
      "source": "DB00059",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Pegaspargase.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00112",
      "source": "DB00059",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB06772",
      "source": "DB00059",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegaspargase.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00531",
      "source": "DB00059",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB06643",
      "source": "DB00059",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01078",
      "source": "DB00059",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Pegaspargase.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01396",
      "source": "DB00059",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Pegaspargase.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00390",
      "source": "DB00059",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Pegaspargase.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01248",
      "source": "DB00059",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB08868",
      "source": "DB00059",
      "target": "DB08868",
      "description": "Pegaspargase may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01097",
      "source": "DB00059",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00108",
      "source": "DB00059",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01092",
      "source": "DB00059",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Pegaspargase.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01229",
      "source": "DB00059",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegaspargase.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB09208",
      "source": "DB00059",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00337",
      "source": "DB00059",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB10283",
      "source": "DB00059",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB10283",
      "source": "DB00059",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Pegaspargase.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB01656",
      "source": "DB00059",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Pegaspargase.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB06688",
      "source": "DB00059",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00864",
      "source": "DB00059",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pegaspargase.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB08895",
      "source": "DB00059",
      "target": "DB08895",
      "description": "Pegaspargase may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00072",
      "source": "DB00059",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00511",
      "source": "DB00060",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01223",
      "source": "DB00060",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00112",
      "source": "DB00060",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB06772",
      "source": "DB00060",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00531",
      "source": "DB00060",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01078",
      "source": "DB00060",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Interferon beta-1a.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01396",
      "source": "DB00060",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Interferon beta-1a.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00390",
      "source": "DB00060",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Interferon beta-1a.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01248",
      "source": "DB00060",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00651",
      "source": "DB00060",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01092",
      "source": "DB00060",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Interferon beta-1a.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB01229",
      "source": "DB00060",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00277",
      "source": "DB00060",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Interferon beta-1a.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00072",
      "source": "DB00060",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00495",
      "source": "DB00060",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00061-DB09208",
      "source": "DB00061",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Pegademase bovine can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00061-DB00552",
      "source": "DB00061",
      "target": "DB00552",
      "description": "The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase bovine.",
      "name": "Pentostatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00054",
      "source": "DB00063",
      "target": "DB00054",
      "description": "Eptifibatide may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01418",
      "source": "DB00063",
      "target": "DB01418",
      "description": "Eptifibatide may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00945",
      "source": "DB00063",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Acetylsalicylic acid.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00770",
      "source": "DB00063",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Eptifibatide.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00009",
      "source": "DB00063",
      "target": "DB00009",
      "description": "Eptifibatide may increase the anticoagulant activities of Alteplase.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06081",
      "source": "DB00063",
      "target": "DB06081",
      "description": "Eptifibatide may increase the anticoagulant activities of ALX-0081.",
      "name": "ALX-0081"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00233",
      "source": "DB00063",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00261",
      "source": "DB00063",
      "target": "DB00261",
      "description": "Eptifibatide may increase the anticoagulant activities of Anagrelide.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05099",
      "source": "DB00063",
      "target": "DB05099",
      "description": "Eptifibatide may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00029",
      "source": "DB00063",
      "target": "DB00029",
      "description": "Eptifibatide may increase the anticoagulant activities of Anistreplase.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11598",
      "source": "DB00063",
      "target": "DB11598",
      "description": "Eptifibatide may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06605",
      "source": "DB00063",
      "target": "DB06605",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06692",
      "source": "DB00063",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Eptifibatide can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00407",
      "source": "DB00063",
      "target": "DB00407",
      "description": "Eptifibatide may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00278",
      "source": "DB00063",
      "target": "DB00278",
      "description": "Eptifibatide may increase the anticoagulant activities of Argatroban.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06543",
      "source": "DB00063",
      "target": "DB06543",
      "description": "Eptifibatide may increase the anticoagulant activities of Astaxanthin.",
      "name": "Astaxanthin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00972",
      "source": "DB00063",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Eptifibatide.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09005",
      "source": "DB00063",
      "target": "DB09005",
      "description": "Eptifibatide may increase the anticoagulant activities of Batroxobin.",
      "name": "Batroxobin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00102",
      "source": "DB00063",
      "target": "DB00102",
      "description": "Eptifibatide may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09258",
      "source": "DB00063",
      "target": "DB09258",
      "description": "Eptifibatide may increase the anticoagulant activities of Bemiparin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05229",
      "source": "DB00063",
      "target": "DB05229",
      "description": "Eptifibatide may increase the anticoagulant activities of Beraprost.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00006",
      "source": "DB00063",
      "target": "DB00006",
      "description": "Eptifibatide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06441",
      "source": "DB00063",
      "target": "DB06441",
      "description": "Eptifibatide may increase the anticoagulant activities of Cangrelor.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09261",
      "source": "DB00063",
      "target": "DB09261",
      "description": "Eptifibatide may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01166",
      "source": "DB00063",
      "target": "DB01166",
      "description": "Eptifibatide may increase the anticoagulant activities of Cilostazol.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04272",
      "source": "DB00063",
      "target": "DB04272",
      "description": "Eptifibatide may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00758",
      "source": "DB00063",
      "target": "DB00758",
      "description": "Eptifibatide may increase the anticoagulant activities of Clopidogrel.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11249",
      "source": "DB00063",
      "target": "DB11249",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Collagenase.",
      "name": "Collagenase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06695",
      "source": "DB00063",
      "target": "DB06695",
      "description": "Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06779",
      "source": "DB00063",
      "target": "DB06779",
      "description": "Eptifibatide may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06754",
      "source": "DB00063",
      "target": "DB06754",
      "description": "Eptifibatide may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01254",
      "source": "DB00063",
      "target": "DB01254",
      "description": "Dasatinib may increase the anticoagulant activities of Eptifibatide.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04932",
      "source": "DB00063",
      "target": "DB04932",
      "description": "Eptifibatide may increase the anticoagulant activities of Defibrotide.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB03619",
      "source": "DB00063",
      "target": "DB03619",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic Acid.",
      "name": "Deoxycholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11095",
      "source": "DB00063",
      "target": "DB11095",
      "description": "Eptifibatide may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04925",
      "source": "DB00063",
      "target": "DB04925",
      "description": "Eptifibatide may increase the anticoagulant activities of Desmoteplase.",
      "name": "Desmoteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09255",
      "source": "DB00063",
      "target": "DB09255",
      "description": "Eptifibatide may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11122",
      "source": "DB00063",
      "target": "DB11122",
      "description": "Eptifibatide may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11076",
      "source": "DB00063",
      "target": "DB11076",
      "description": "Eptifibatide may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11241",
      "source": "DB00063",
      "target": "DB11241",
      "description": "Eptifibatide may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00266",
      "source": "DB00063",
      "target": "DB00266",
      "description": "Eptifibatide may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00861",
      "source": "DB00063",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Diflunisal.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00975",
      "source": "DB00063",
      "target": "DB00975",
      "description": "Eptifibatide may increase the anticoagulant activities of Dipyridamole.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08994",
      "source": "DB00063",
      "target": "DB08994",
      "description": "Eptifibatide may increase the anticoagulant activities of Ditazole.",
      "name": "Ditazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00055",
      "source": "DB00063",
      "target": "DB00055",
      "description": "Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00974",
      "source": "DB00063",
      "target": "DB00974",
      "description": "Eptifibatide may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09075",
      "source": "DB00063",
      "target": "DB09075",
      "description": "Eptifibatide may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01225",
      "source": "DB00063",
      "target": "DB01225",
      "description": "Eptifibatide may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00751",
      "source": "DB00063",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Eptifibatide.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06392",
      "source": "DB00063",
      "target": "DB06392",
      "description": "Eptifibatide may increase the anticoagulant activities of eplivanserine.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01240",
      "source": "DB00063",
      "target": "DB01240",
      "description": "Eptifibatide may increase the anticoagulant activities of Epoprostenol.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08794",
      "source": "DB00063",
      "target": "DB08794",
      "description": "Eptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08977",
      "source": "DB00063",
      "target": "DB08977",
      "description": "Eptifibatide may increase the anticoagulant activities of Fibrinolysin.",
      "name": "Fibrinolysin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00569",
      "source": "DB00063",
      "target": "DB00569",
      "description": "Eptifibatide may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01296",
      "source": "DB00063",
      "target": "DB01296",
      "description": "Glucosamine may increase the antiplatelet activities of Eptifibatide.",
      "name": "Glucosamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01109",
      "source": "DB00063",
      "target": "DB01109",
      "description": "Eptifibatide may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB02351",
      "source": "DB00063",
      "target": "DB02351",
      "description": "Eptifibatide may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00078",
      "source": "DB00063",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09053",
      "source": "DB00063",
      "target": "DB09053",
      "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05266",
      "source": "DB00063",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Eptifibatide.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08887",
      "source": "DB00063",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Eptifibatide.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06406",
      "source": "DB00063",
      "target": "DB06406",
      "description": "Eptifibatide may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08954",
      "source": "DB00063",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Eptifibatide.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01088",
      "source": "DB00063",
      "target": "DB01088",
      "description": "Eptifibatide may increase the anticoagulant activities of Iloprost.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00001",
      "source": "DB00063",
      "target": "DB00001",
      "description": "Eptifibatide may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09211",
      "source": "DB00063",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Eptifibatide.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00244",
      "source": "DB00063",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Mesalazine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00235",
      "source": "DB00063",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Eptifibatide.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08813",
      "source": "DB00063",
      "target": "DB08813",
      "description": "Eptifibatide may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05822",
      "source": "DB00063",
      "target": "DB05822",
      "description": "Eptifibatide may increase the anticoagulant activities of NCX 4016.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04743",
      "source": "DB00063",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Eptifibatide.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08935",
      "source": "DB00063",
      "target": "DB08935",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11133",
      "source": "DB00063",
      "target": "DB11133",
      "description": "Omega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.",
      "name": "Omega-3 fatty acids"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06635",
      "source": "DB00063",
      "target": "DB06635",
      "description": "Eptifibatide may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09260",
      "source": "DB00063",
      "target": "DB09260",
      "description": "Eptifibatide may increase the anticoagulant activities of Parnaparin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00686",
      "source": "DB00063",
      "target": "DB00686",
      "description": "The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00806",
      "source": "DB00063",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the antiplatelet activities of Eptifibatide.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00498",
      "source": "DB00063",
      "target": "DB00498",
      "description": "Eptifibatide may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00946",
      "source": "DB00063",
      "target": "DB00946",
      "description": "Eptifibatide may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05254",
      "source": "DB00063",
      "target": "DB05254",
      "description": "Eptifibatide may increase the anticoagulant activities of Plasmin.",
      "name": "Plasmin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06209",
      "source": "DB00063",
      "target": "DB06209",
      "description": "Eptifibatide may increase the anticoagulant activities of Prasugrel.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11312",
      "source": "DB00063",
      "target": "DB11312",
      "description": "Eptifibatide may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11268",
      "source": "DB00063",
      "target": "DB11268",
      "description": "Eptifibatide may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB02709",
      "source": "DB00063",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Eptifibatide.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00015",
      "source": "DB00063",
      "target": "DB00015",
      "description": "Eptifibatide may increase the anticoagulant activities of Reteplase.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09259",
      "source": "DB00063",
      "target": "DB09259",
      "description": "Eptifibatide may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01207",
      "source": "DB00063",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Eptifibatide.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06228",
      "source": "DB00063",
      "target": "DB06228",
      "description": "Eptifibatide may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00412",
      "source": "DB00063",
      "target": "DB00412",
      "description": "Eptifibatide may increase the anticoagulant activities of Rosiglitazone.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00936",
      "source": "DB00063",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Salicylic acid.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05692",
      "source": "DB00063",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Eptifibatide.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB11362",
      "source": "DB00063",
      "target": "DB11362",
      "description": "Eptifibatide may increase the anticoagulant activities of Selexipag.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB01236",
      "source": "DB00063",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Eptifibatide.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB05073",
      "source": "DB00063",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Eptifibatide.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00086",
      "source": "DB00063",
      "target": "DB00086",
      "description": "Eptifibatide may increase the anticoagulant activities of Streptokinase.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06271",
      "source": "DB00063",
      "target": "DB06271",
      "description": "Eptifibatide may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00031",
      "source": "DB00063",
      "target": "DB00031",
      "description": "Eptifibatide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04905",
      "source": "DB00063",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Eptifibatide.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08816",
      "source": "DB00063",
      "target": "DB08816",
      "description": "Eptifibatide may increase the anticoagulant activities of Ticagrelor.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00208",
      "source": "DB00063",
      "target": "DB00208",
      "description": "Eptifibatide may increase the anticoagulant activities of Ticlopidine.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB06822",
      "source": "DB00063",
      "target": "DB06822",
      "description": "Eptifibatide may increase the anticoagulant activities of Tinzaparin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00932",
      "source": "DB00063",
      "target": "DB00932",
      "description": "Tipranavir may increase the antiplatelet activities of Eptifibatide.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00775",
      "source": "DB00063",
      "target": "DB00775",
      "description": "Eptifibatide may increase the anticoagulant activities of Tirofiban.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00081",
      "source": "DB00063",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB07615",
      "source": "DB00063",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Eptifibatide.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09283",
      "source": "DB00063",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Eptifibatide.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00374",
      "source": "DB00063",
      "target": "DB00374",
      "description": "Eptifibatide may increase the anticoagulant activities of Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB08814",
      "source": "DB00063",
      "target": "DB08814",
      "description": "Eptifibatide may increase the anticoagulant activities of Triflusal.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00013",
      "source": "DB00063",
      "target": "DB00013",
      "description": "Eptifibatide may increase the anticoagulant activities of Urokinase.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00163",
      "source": "DB00063",
      "target": "DB00163",
      "description": "Vitamin E may increase the antiplatelet activities of Eptifibatide.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB09030",
      "source": "DB00063",
      "target": "DB09030",
      "description": "Eptifibatide may increase the anticoagulant activities of Vorapaxar.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00682",
      "source": "DB00063",
      "target": "DB00682",
      "description": "Eptifibatide may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB04898",
      "source": "DB00063",
      "target": "DB04898",
      "description": "Eptifibatide may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB01281",
      "source": "DB00065",
      "target": "DB01281",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00051",
      "source": "DB00065",
      "target": "DB00051",
      "description": "Adalimumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00026",
      "source": "DB00065",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB12768",
      "source": "DB00065",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Infliximab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB08879",
      "source": "DB00065",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06168",
      "source": "DB00065",
      "target": "DB06168",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Canakinumab.",
      "name": "Canakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB08904",
      "source": "DB00065",
      "target": "DB08904",
      "description": "Infliximab may increase the immunosuppressive activities of Certolizumab pegol.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06643",
      "source": "DB00065",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00005",
      "source": "DB00065",
      "target": "DB00005",
      "description": "Etanercept may increase the immunosuppressive activities of Infliximab.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB08868",
      "source": "DB00065",
      "target": "DB08868",
      "description": "Infliximab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06674",
      "source": "DB00065",
      "target": "DB06674",
      "description": "Golimumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Golimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB01097",
      "source": "DB00065",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00108",
      "source": "DB00065",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00337",
      "source": "DB00065",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB10283",
      "source": "DB00065",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB10283",
      "source": "DB00065",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Infliximab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06372",
      "source": "DB00065",
      "target": "DB06372",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.",
      "name": "Rilonacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB01656",
      "source": "DB00065",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Infliximab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06688",
      "source": "DB00065",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00864",
      "source": "DB00065",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB06273",
      "source": "DB00065",
      "target": "DB06273",
      "description": "Tocilizumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Tocilizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB08895",
      "source": "DB00065",
      "target": "DB08895",
      "description": "Infliximab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00072",
      "source": "DB00065",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Infliximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB05679",
      "source": "DB00065",
      "target": "DB05679",
      "description": "Ustekinumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Ustekinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB09033",
      "source": "DB00065",
      "target": "DB09033",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Vedolizumab.",
      "name": "Vedolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00511",
      "source": "DB00068",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1b.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01223",
      "source": "DB00068",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00112",
      "source": "DB00068",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB06772",
      "source": "DB00068",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1b.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00531",
      "source": "DB00068",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01078",
      "source": "DB00068",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Interferon beta-1b.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01396",
      "source": "DB00068",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Interferon beta-1b.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00390",
      "source": "DB00068",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Interferon beta-1b.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01248",
      "source": "DB00068",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1b.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00651",
      "source": "DB00068",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01092",
      "source": "DB00068",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Interferon beta-1b.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB01229",
      "source": "DB00068",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1b.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00277",
      "source": "DB00068",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Interferon beta-1b.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00072",
      "source": "DB00068",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00495",
      "source": "DB00068",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB01223",
      "source": "DB00069",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB12768",
      "source": "DB00069",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Interferon alfacon-1.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB00363",
      "source": "DB00069",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB00651",
      "source": "DB00069",
      "target": "DB00651",
      "description": "The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.",
      "name": "Dyphylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB04817",
      "source": "DB00069",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfacon-1.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB00277",
      "source": "DB00069",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB00495",
      "source": "DB00069",
      "target": "DB00495",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01193",
      "source": "DB00071",
      "target": "DB01193",
      "description": "Acebutolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09043",
      "source": "DB00071",
      "target": "DB09043",
      "description": "Albiglutide may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Albiglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06203",
      "source": "DB00071",
      "target": "DB06203",
      "description": "Alogliptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00866",
      "source": "DB00071",
      "target": "DB00866",
      "description": "Alprenolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Alprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01238",
      "source": "DB00071",
      "target": "DB01238",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09204",
      "source": "DB00071",
      "target": "DB09204",
      "description": "Arotinolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Arotinolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01169",
      "source": "DB00071",
      "target": "DB01169",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09009",
      "source": "DB00071",
      "target": "DB09009",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Articaine.",
      "name": "Articaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06216",
      "source": "DB00071",
      "target": "DB06216",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01072",
      "source": "DB00071",
      "target": "DB01072",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Atazanavir.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00335",
      "source": "DB00071",
      "target": "DB00335",
      "description": "Atenolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01076",
      "source": "DB00071",
      "target": "DB01076",
      "description": "Atorvastatin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09013",
      "source": "DB00071",
      "target": "DB09013",
      "description": "Befunolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Befunolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00436",
      "source": "DB00071",
      "target": "DB00436",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bendroflumethiazide.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00443",
      "source": "DB00071",
      "target": "DB00443",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00195",
      "source": "DB00071",
      "target": "DB00195",
      "description": "Betaxolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01295",
      "source": "DB00071",
      "target": "DB01295",
      "description": "Bevantolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Bevantolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00612",
      "source": "DB00071",
      "target": "DB00612",
      "description": "Bisoprolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08807",
      "source": "DB00071",
      "target": "DB08807",
      "description": "Bopindolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Bopindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09128",
      "source": "DB00071",
      "target": "DB09128",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Brexpiprazole.",
      "name": "Brexpiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06726",
      "source": "DB00071",
      "target": "DB06726",
      "description": "Bufuralol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Bufuralol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00887",
      "source": "DB00071",
      "target": "DB00887",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08808",
      "source": "DB00071",
      "target": "DB08808",
      "description": "Bupranolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Bupranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06719",
      "source": "DB00071",
      "target": "DB06719",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Buserelin.",
      "name": "Buserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08907",
      "source": "DB00071",
      "target": "DB08907",
      "description": "Canagliflozin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00521",
      "source": "DB00071",
      "target": "DB00521",
      "description": "Carteolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01136",
      "source": "DB00071",
      "target": "DB01136",
      "description": "Carvedilol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04846",
      "source": "DB00071",
      "target": "DB04846",
      "description": "Celiprolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Celiprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09063",
      "source": "DB00071",
      "target": "DB09063",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00880",
      "source": "DB00071",
      "target": "DB00880",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00672",
      "source": "DB00071",
      "target": "DB00672",
      "description": "Insulin Pork may increase the hypoglycemic activities of Chlorpropamide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00310",
      "source": "DB00071",
      "target": "DB00310",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorthalidone.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00363",
      "source": "DB00071",
      "target": "DB00363",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01285",
      "source": "DB00071",
      "target": "DB01285",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Corticotropin.",
      "name": "Corticotropin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01380",
      "source": "DB00071",
      "target": "DB01380",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04839",
      "source": "DB00071",
      "target": "DB04839",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cyproterone acetate.",
      "name": "Cyproterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08912",
      "source": "DB00071",
      "target": "DB08912",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dabrafenib.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01406",
      "source": "DB00071",
      "target": "DB01406",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Danazol.",
      "name": "Danazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01264",
      "source": "DB00071",
      "target": "DB01264",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Darunavir.",
      "name": "Darunavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00304",
      "source": "DB00071",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01234",
      "source": "DB00071",
      "target": "DB01234",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01119",
      "source": "DB00071",
      "target": "DB01119",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Diazoxide.",
      "name": "Diazoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09123",
      "source": "DB00071",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00280",
      "source": "DB00071",
      "target": "DB00280",
      "description": "Insulin Pork may increase the hypoglycemic activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01395",
      "source": "DB00071",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09045",
      "source": "DB00071",
      "target": "DB09045",
      "description": "Dulaglutide may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00974",
      "source": "DB00071",
      "target": "DB00974",
      "description": "Edetic Acid may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09038",
      "source": "DB00071",
      "target": "DB09038",
      "description": "Empagliflozin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00668",
      "source": "DB00071",
      "target": "DB00668",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Epinephrine.",
      "name": "Epinephrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00187",
      "source": "DB00071",
      "target": "DB00187",
      "description": "Esmolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Esmolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00783",
      "source": "DB00071",
      "target": "DB00783",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estradiol.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04574",
      "source": "DB00071",
      "target": "DB04574",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estrone sulfate.",
      "name": "Estrone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00903",
      "source": "DB00071",
      "target": "DB00903",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00977",
      "source": "DB00071",
      "target": "DB00977",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethinyl Estradiol.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00823",
      "source": "DB00071",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00294",
      "source": "DB00071",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01590",
      "source": "DB00071",
      "target": "DB01590",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Everolimus.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01276",
      "source": "DB00071",
      "target": "DB01276",
      "description": "Exenatide may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00687",
      "source": "DB00071",
      "target": "DB00687",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01319",
      "source": "DB00071",
      "target": "DB01319",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fosamprenavir.",
      "name": "Fosamprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00695",
      "source": "DB00071",
      "target": "DB00695",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01120",
      "source": "DB00071",
      "target": "DB01120",
      "description": "Insulin Pork may increase the hypoglycemic activities of Gliclazide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00222",
      "source": "DB00071",
      "target": "DB00222",
      "description": "Insulin Pork may increase the hypoglycemic activities of Glimepiride.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01067",
      "source": "DB00071",
      "target": "DB01067",
      "description": "Insulin Pork may increase the hypoglycemic activities of Glipizide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01016",
      "source": "DB00071",
      "target": "DB01016",
      "description": "Insulin Pork may increase the hypoglycemic activities of Glyburide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00014",
      "source": "DB00071",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06788",
      "source": "DB00071",
      "target": "DB06788",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Histrelin.",
      "name": "Histrelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00999",
      "source": "DB00071",
      "target": "DB00999",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrochlorothiazide.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00741",
      "source": "DB00071",
      "target": "DB00741",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00774",
      "source": "DB00071",
      "target": "DB00774",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroflumethiazide.",
      "name": "Hydroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06789",
      "source": "DB00071",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04946",
      "source": "DB00071",
      "target": "DB04946",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00808",
      "source": "DB00071",
      "target": "DB00808",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indapamide.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08952",
      "source": "DB00071",
      "target": "DB08952",
      "description": "Indenolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Indenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00224",
      "source": "DB00071",
      "target": "DB00224",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indinavir.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01306",
      "source": "DB00071",
      "target": "DB01306",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Aspart.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01307",
      "source": "DB00071",
      "target": "DB01307",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Detemir.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00047",
      "source": "DB00071",
      "target": "DB00047",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01309",
      "source": "DB00071",
      "target": "DB01309",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Glulisine.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00030",
      "source": "DB00071",
      "target": "DB00030",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00046",
      "source": "DB00071",
      "target": "DB00046",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00598",
      "source": "DB00071",
      "target": "DB00598",
      "description": "Labetalol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06791",
      "source": "DB00071",
      "target": "DB06791",
      "description": "Insulin Pork may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00007",
      "source": "DB00071",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00367",
      "source": "DB00071",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08882",
      "source": "DB00071",
      "target": "DB08882",
      "description": "Linagliptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00166",
      "source": "DB00071",
      "target": "DB00166",
      "description": "Lipoic Acid may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Lipoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06655",
      "source": "DB00071",
      "target": "DB06655",
      "description": "Liraglutide may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01601",
      "source": "DB00071",
      "target": "DB01601",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB08815",
      "source": "DB00071",
      "target": "DB08815",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.",
      "name": "Lurasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01277",
      "source": "DB00071",
      "target": "DB01277",
      "description": "Insulin Pork may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00603",
      "source": "DB00071",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00351",
      "source": "DB00071",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01357",
      "source": "DB00071",
      "target": "DB01357",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Mestranol.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01403",
      "source": "DB00071",
      "target": "DB01403",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methotrimeprazine.",
      "name": "Methotrimeprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00232",
      "source": "DB00071",
      "target": "DB00232",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.",
      "name": "Methyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00959",
      "source": "DB00071",
      "target": "DB00959",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00524",
      "source": "DB00071",
      "target": "DB00524",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00264",
      "source": "DB00071",
      "target": "DB00264",
      "description": "Metoprolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB09046",
      "source": "DB00071",
      "target": "DB09046",
      "description": "Metreleptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Metreleptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00834",
      "source": "DB00071",
      "target": "DB00834",
      "description": "Insulin Pork may increase the hypoglycemic activities of Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01203",
      "source": "DB00071",
      "target": "DB01203",
      "description": "Nadolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00731",
      "source": "DB00071",
      "target": "DB00731",
      "description": "Insulin Pork may increase the hypoglycemic activities of Nateglinide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00220",
      "source": "DB00071",
      "target": "DB00220",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00627",
      "source": "DB00071",
      "target": "DB00627",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Niacin.",
      "name": "Niacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04868",
      "source": "DB00071",
      "target": "DB04868",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00717",
      "source": "DB00071",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00957",
      "source": "DB00071",
      "target": "DB00957",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Norgestimate.",
      "name": "Norgestimate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00104",
      "source": "DB00071",
      "target": "DB00104",
      "description": "Insulin Pork may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00334",
      "source": "DB00071",
      "target": "DB00334",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01580",
      "source": "DB00071",
      "target": "DB01580",
      "description": "Oxprenolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Oxprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01267",
      "source": "DB00071",
      "target": "DB01267",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06663",
      "source": "DB00071",
      "target": "DB06663",
      "description": "Insulin Pork may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01359",
      "source": "DB00071",
      "target": "DB01359",
      "description": "Penbutolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Penbutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00738",
      "source": "DB00071",
      "target": "DB00738",
      "description": "Insulin Pork may increase the hypoglycemic activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00960",
      "source": "DB00071",
      "target": "DB00960",
      "description": "Pindolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01132",
      "source": "DB00071",
      "target": "DB01132",
      "description": "The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin Pork.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00592",
      "source": "DB00071",
      "target": "DB00592",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Piperazine.",
      "name": "Piperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01621",
      "source": "DB00071",
      "target": "DB01621",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pipotiazine.",
      "name": "Pipotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01324",
      "source": "DB00071",
      "target": "DB01324",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Polythiazide.",
      "name": "Polythiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01297",
      "source": "DB00071",
      "target": "DB01297",
      "description": "Practolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Practolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01278",
      "source": "DB00071",
      "target": "DB01278",
      "description": "Pramlintide may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00860",
      "source": "DB00071",
      "target": "DB00860",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00635",
      "source": "DB00071",
      "target": "DB00635",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00396",
      "source": "DB00071",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00571",
      "source": "DB00071",
      "target": "DB00571",
      "description": "Propranolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01224",
      "source": "DB00071",
      "target": "DB01224",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01325",
      "source": "DB00071",
      "target": "DB01325",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quinethazone.",
      "name": "Quinethazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00468",
      "source": "DB00071",
      "target": "DB00468",
      "description": "Insulin Pork may increase the hypoglycemic activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00912",
      "source": "DB00071",
      "target": "DB00912",
      "description": "Insulin Pork may increase the hypoglycemic activities of Repaglinide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00734",
      "source": "DB00071",
      "target": "DB00734",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00503",
      "source": "DB00071",
      "target": "DB00503",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ritonavir.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00412",
      "source": "DB00071",
      "target": "DB00412",
      "description": "The risk or severity of adverse effects can be increased when Insulin Pork is combined with Rosiglitazone.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01232",
      "source": "DB00071",
      "target": "DB01232",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06335",
      "source": "DB00071",
      "target": "DB06335",
      "description": "Saxagliptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00877",
      "source": "DB00071",
      "target": "DB00877",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Sirolimus.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01261",
      "source": "DB00071",
      "target": "DB01261",
      "description": "Sitagliptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00489",
      "source": "DB00071",
      "target": "DB00489",
      "description": "Sotalol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00359",
      "source": "DB00071",
      "target": "DB00359",
      "description": "Insulin Pork may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01015",
      "source": "DB00071",
      "target": "DB01015",
      "description": "Insulin Pork may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00263",
      "source": "DB00071",
      "target": "DB00263",
      "description": "Insulin Pork may increase the hypoglycemic activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01268",
      "source": "DB00071",
      "target": "DB01268",
      "description": "Insulin Pork may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00864",
      "source": "DB00071",
      "target": "DB00864",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tacrolimus.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06287",
      "source": "DB00071",
      "target": "DB06287",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00373",
      "source": "DB00071",
      "target": "DB00373",
      "description": "Timolol may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00932",
      "source": "DB00071",
      "target": "DB00932",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00839",
      "source": "DB00071",
      "target": "DB00839",
      "description": "Insulin Pork may increase the hypoglycemic activities of Tolazamide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01124",
      "source": "DB00071",
      "target": "DB01124",
      "description": "Insulin Pork may increase the hypoglycemic activities of Tolbutamide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00214",
      "source": "DB00071",
      "target": "DB00214",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00620",
      "source": "DB00071",
      "target": "DB00620",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB01021",
      "source": "DB00071",
      "target": "DB01021",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Trichlormethiazide.",
      "name": "Trichlormethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB06825",
      "source": "DB00071",
      "target": "DB06825",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triptorelin.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB04876",
      "source": "DB00071",
      "target": "DB04876",
      "description": "Vildagliptin may increase the hypoglycemic activities of Insulin Pork.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB02546",
      "source": "DB00071",
      "target": "DB02546",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Vorinostat.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00246",
      "source": "DB00071",
      "target": "DB00246",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01536",
      "source": "DB00070",
      "target": "DB01536",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 4-Androstenedione.",
      "name": "4-Androstenedione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00945",
      "source": "DB00070",
      "target": "DB00945",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09488",
      "source": "DB00070",
      "target": "DB09488",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acrivastine.",
      "name": "Acrivastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06766",
      "source": "DB00070",
      "target": "DB06766",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alcaftadine.",
      "name": "Alcaftadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00240",
      "source": "DB00070",
      "target": "DB00240",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alclometasone.",
      "name": "Alclometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04630",
      "source": "DB00070",
      "target": "DB04630",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.",
      "name": "Aldosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01246",
      "source": "DB00070",
      "target": "DB01246",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alimemazine.",
      "name": "Alimemazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00288",
      "source": "DB00070",
      "target": "DB00288",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amcinonide.",
      "name": "Amcinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00233",
      "source": "DB00070",
      "target": "DB00233",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aminosalicylic Acid.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08799",
      "source": "DB00070",
      "target": "DB08799",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.",
      "name": "Antazoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09009",
      "source": "DB00070",
      "target": "DB09009",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Articaine.",
      "name": "Articaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00637",
      "source": "DB00070",
      "target": "DB00637",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Astemizole.",
      "name": "Astemizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00719",
      "source": "DB00070",
      "target": "DB00719",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azatadine.",
      "name": "Azatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00972",
      "source": "DB00070",
      "target": "DB00972",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06401",
      "source": "DB00070",
      "target": "DB06401",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Bazedoxifene.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00394",
      "source": "DB00070",
      "target": "DB00394",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Beclomethasone dipropionate.",
      "name": "Beclomethasone dipropionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01086",
      "source": "DB00070",
      "target": "DB01086",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzocaine.",
      "name": "Benzocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06770",
      "source": "DB00070",
      "target": "DB06770",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzyl alcohol.",
      "name": "Benzyl alcohol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00443",
      "source": "DB00070",
      "target": "DB00443",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00835",
      "source": "DB00070",
      "target": "DB00835",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.",
      "name": "Brompheniramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00354",
      "source": "DB00070",
      "target": "DB00354",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Buclizine.",
      "name": "Buclizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01222",
      "source": "DB00070",
      "target": "DB01222",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00297",
      "source": "DB00070",
      "target": "DB00297",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bupivacaine.",
      "name": "Bupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11502",
      "source": "DB00070",
      "target": "DB11502",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butacaine.",
      "name": "Butacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11148",
      "source": "DB00070",
      "target": "DB11148",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butamben.",
      "name": "Butamben"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB03568",
      "source": "DB00070",
      "target": "DB03568",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butanoic Acid.",
      "name": "Butanoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06774",
      "source": "DB00070",
      "target": "DB06774",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Capsaicin.",
      "name": "Capsaicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00748",
      "source": "DB00070",
      "target": "DB00748",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbinoxamine.",
      "name": "Carbinoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00341",
      "source": "DB00070",
      "target": "DB00341",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.",
      "name": "Cetirizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01161",
      "source": "DB00070",
      "target": "DB01161",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Chloroprocaine.",
      "name": "Chloroprocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08800",
      "source": "DB00070",
      "target": "DB08800",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chloropyramine.",
      "name": "Chloropyramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00269",
      "source": "DB00070",
      "target": "DB00269",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01114",
      "source": "DB00070",
      "target": "DB01114",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine.",
      "name": "Chlorphenamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09007",
      "source": "DB00070",
      "target": "DB09007",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.",
      "name": "Chlorphenoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01410",
      "source": "DB00070",
      "target": "DB01410",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ciclesonide.",
      "name": "Ciclesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00501",
      "source": "DB00070",
      "target": "DB00501",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.",
      "name": "Cimetidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00527",
      "source": "DB00070",
      "target": "DB00527",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cinchocaine.",
      "name": "Cinchocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00568",
      "source": "DB00070",
      "target": "DB00568",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cinnarizine.",
      "name": "Cinnarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00283",
      "source": "DB00070",
      "target": "DB00283",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.",
      "name": "Clemastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01013",
      "source": "DB00070",
      "target": "DB01013",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasol propionate.",
      "name": "Clobetasol propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00838",
      "source": "DB00070",
      "target": "DB00838",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone.",
      "name": "Clocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00907",
      "source": "DB00070",
      "target": "DB00907",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cocaine.",
      "name": "Cocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00286",
      "source": "DB00070",
      "target": "DB00286",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated Equine Estrogens.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01380",
      "source": "DB00070",
      "target": "DB01380",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01176",
      "source": "DB00070",
      "target": "DB01176",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.",
      "name": "Cyclizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00434",
      "source": "DB00070",
      "target": "DB00434",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyproheptadine.",
      "name": "Cyproheptadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01708",
      "source": "DB00070",
      "target": "DB01708",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dehydroepiandrosterone.",
      "name": "Dehydroepiandrosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB05804",
      "source": "DB00070",
      "target": "DB05804",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with dehydroepiandrosterone sulfate.",
      "name": "dehydroepiandrosterone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00967",
      "source": "DB00070",
      "target": "DB00967",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00547",
      "source": "DB00070",
      "target": "DB00547",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoximetasone.",
      "name": "Desoximetasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06780",
      "source": "DB00070",
      "target": "DB06780",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycorticosterone acetate.",
      "name": "Desoxycorticosterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01234",
      "source": "DB00070",
      "target": "DB01234",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11487",
      "source": "DB00070",
      "target": "DB11487",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone isonicotinate.",
      "name": "Dexamethasone isonicotinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00405",
      "source": "DB00070",
      "target": "DB00405",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine.",
      "name": "Dexbrompheniramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09555",
      "source": "DB00070",
      "target": "DB09555",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexchlorpheniramine maleate.",
      "name": "Dexchlorpheniramine maleate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00890",
      "source": "DB00070",
      "target": "DB00890",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dienestrol.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00255",
      "source": "DB00070",
      "target": "DB00255",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00223",
      "source": "DB00070",
      "target": "DB00223",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflorasone.",
      "name": "Diflorasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00861",
      "source": "DB00070",
      "target": "DB00861",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflunisal.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09095",
      "source": "DB00070",
      "target": "DB09095",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluocortolone.",
      "name": "Difluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06781",
      "source": "DB00070",
      "target": "DB06781",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluprednate.",
      "name": "Difluprednate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00985",
      "source": "DB00070",
      "target": "DB00985",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.",
      "name": "Dimenhydrinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08801",
      "source": "DB00070",
      "target": "DB08801",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene.",
      "name": "Dimetindene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08967",
      "source": "DB00070",
      "target": "DB08967",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetotiazine.",
      "name": "Dimetotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01075",
      "source": "DB00070",
      "target": "DB01075",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diphenhydramine.",
      "name": "Diphenhydramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00988",
      "source": "DB00070",
      "target": "DB00988",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.",
      "name": "Dopamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01142",
      "source": "DB00070",
      "target": "DB01142",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00366",
      "source": "DB00070",
      "target": "DB00366",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxylamine.",
      "name": "Doxylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00645",
      "source": "DB00070",
      "target": "DB00645",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.",
      "name": "Dyclonine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01084",
      "source": "DB00070",
      "target": "DB01084",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Emedastine.",
      "name": "Emedastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00751",
      "source": "DB00070",
      "target": "DB00751",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB03515",
      "source": "DB00070",
      "target": "DB03515",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilenin.",
      "name": "Equilenin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB02187",
      "source": "DB00070",
      "target": "DB02187",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilin.",
      "name": "Equilin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06678",
      "source": "DB00070",
      "target": "DB06678",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Esmirtazapine.",
      "name": "Esmirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00783",
      "source": "DB00070",
      "target": "DB00783",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04573",
      "source": "DB00070",
      "target": "DB04573",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00655",
      "source": "DB00070",
      "target": "DB00655",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00977",
      "source": "DB00070",
      "target": "DB00977",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinyl Estradiol.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00392",
      "source": "DB00070",
      "target": "DB00392",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethopropazine.",
      "name": "Ethopropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08987",
      "source": "DB00070",
      "target": "DB08987",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etidocaine.",
      "name": "Etidocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00927",
      "source": "DB00070",
      "target": "DB00927",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.",
      "name": "Famotidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00950",
      "source": "DB00070",
      "target": "DB00950",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fexofenadine.",
      "name": "Fexofenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00687",
      "source": "DB00070",
      "target": "DB00687",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00663",
      "source": "DB00070",
      "target": "DB00663",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flumethasone.",
      "name": "Flumethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04841",
      "source": "DB00070",
      "target": "DB04841",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunarizine.",
      "name": "Flunarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00180",
      "source": "DB00070",
      "target": "DB00180",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunisolide.",
      "name": "Flunisolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00591",
      "source": "DB00070",
      "target": "DB00591",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone Acetonide.",
      "name": "Fluocinolone Acetonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01047",
      "source": "DB00070",
      "target": "DB01047",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinonide.",
      "name": "Fluocinonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08971",
      "source": "DB00070",
      "target": "DB08971",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocortolone.",
      "name": "Fluocortolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00324",
      "source": "DB00070",
      "target": "DB00324",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.",
      "name": "Fluorometholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08970",
      "source": "DB00070",
      "target": "DB08970",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.",
      "name": "Fluprednidene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09378",
      "source": "DB00070",
      "target": "DB09378",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednisolone.",
      "name": "Fluprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00846",
      "source": "DB00070",
      "target": "DB00846",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.",
      "name": "Flurandrenolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08906",
      "source": "DB00070",
      "target": "DB08906",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone furoate.",
      "name": "Fluticasone furoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00588",
      "source": "DB00070",
      "target": "DB00588",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone Propionate.",
      "name": "Fluticasone Propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01645",
      "source": "DB00070",
      "target": "DB01645",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Genistein.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB07931",
      "source": "DB00070",
      "target": "DB07931",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hexestrol.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00741",
      "source": "DB00070",
      "target": "DB00741",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00557",
      "source": "DB00070",
      "target": "DB00557",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.",
      "name": "Hydroxyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08802",
      "source": "DB00070",
      "target": "DB08802",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Isothipendyl.",
      "name": "Isothipendyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00920",
      "source": "DB00070",
      "target": "DB00920",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ketotifen.",
      "name": "Ketotifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01002",
      "source": "DB00070",
      "target": "DB01002",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Levobupivacaine.",
      "name": "Levobupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01106",
      "source": "DB00070",
      "target": "DB01106",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Levocabastine.",
      "name": "Levocabastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06282",
      "source": "DB00070",
      "target": "DB06282",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Levocetirizine.",
      "name": "Levocetirizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00281",
      "source": "DB00070",
      "target": "DB00281",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Lidocaine.",
      "name": "Lidocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06794",
      "source": "DB00070",
      "target": "DB06794",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Lodoxamide.",
      "name": "Lodoxamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00455",
      "source": "DB00070",
      "target": "DB00455",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Loratadine.",
      "name": "Loratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00737",
      "source": "DB00070",
      "target": "DB00737",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meclizine.",
      "name": "Meclizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00253",
      "source": "DB00070",
      "target": "DB00253",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Medrysone.",
      "name": "Medrysone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11529",
      "source": "DB00070",
      "target": "DB11529",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Melengestrol.",
      "name": "Melengestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00961",
      "source": "DB00070",
      "target": "DB00961",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mepivacaine.",
      "name": "Mepivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06691",
      "source": "DB00070",
      "target": "DB06691",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mepyramine.",
      "name": "Mepyramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01071",
      "source": "DB00070",
      "target": "DB01071",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mequitazine.",
      "name": "Mequitazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00244",
      "source": "DB00070",
      "target": "DB00244",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mesalazine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01357",
      "source": "DB00070",
      "target": "DB01357",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mestranol.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04819",
      "source": "DB00070",
      "target": "DB04819",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.",
      "name": "Methapyrilene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00959",
      "source": "DB00070",
      "target": "DB00959",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08805",
      "source": "DB00070",
      "target": "DB08805",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Metiamide.",
      "name": "Metiamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06148",
      "source": "DB00070",
      "target": "DB06148",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mianserin.",
      "name": "Mianserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00370",
      "source": "DB00070",
      "target": "DB00370",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00764",
      "source": "DB00070",
      "target": "DB00764",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone.",
      "name": "Mometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00585",
      "source": "DB00070",
      "target": "DB00585",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.",
      "name": "Nizatidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00768",
      "source": "DB00070",
      "target": "DB00768",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00892",
      "source": "DB00070",
      "target": "DB00892",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxybuprocaine.",
      "name": "Oxybuprocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01384",
      "source": "DB00070",
      "target": "DB01384",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.",
      "name": "Paramethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00885",
      "source": "DB00070",
      "target": "DB00885",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pemirolast.",
      "name": "Pemirolast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01619",
      "source": "DB00070",
      "target": "DB01619",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenindamine.",
      "name": "Phenindamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01620",
      "source": "DB00070",
      "target": "DB01620",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.",
      "name": "Pheniramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB03255",
      "source": "DB00070",
      "target": "DB03255",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Phenol.",
      "name": "Phenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00388",
      "source": "DB00070",
      "target": "DB00388",
      "description": "Hyaluronidase may increase the vasoconstricting activities of Phenylephrine.",
      "name": "Phenylephrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09369",
      "source": "DB00070",
      "target": "DB09369",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09345",
      "source": "DB00070",
      "target": "DB09345",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Pramocaine.",
      "name": "Pramocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01130",
      "source": "DB00070",
      "target": "DB01130",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednicarbate.",
      "name": "Prednicarbate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00860",
      "source": "DB00070",
      "target": "DB00860",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00635",
      "source": "DB00070",
      "target": "DB00635",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB02789",
      "source": "DB00070",
      "target": "DB02789",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pregnenolone.",
      "name": "Pregnenolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00750",
      "source": "DB00070",
      "target": "DB00750",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Prilocaine.",
      "name": "Prilocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00721",
      "source": "DB00070",
      "target": "DB00721",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Procaine.",
      "name": "Procaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB01069",
      "source": "DB00070",
      "target": "DB01069",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.",
      "name": "Promethazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00807",
      "source": "DB00070",
      "target": "DB00807",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Proparacaine.",
      "name": "Proparacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09342",
      "source": "DB00070",
      "target": "DB09342",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Propoxycaine.",
      "name": "Propoxycaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB06671",
      "source": "DB00070",
      "target": "DB06671",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with PSD502.",
      "name": "PSD502"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04575",
      "source": "DB00070",
      "target": "DB04575",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Quinestrol.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00863",
      "source": "DB00070",
      "target": "DB00863",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.",
      "name": "Ranitidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00896",
      "source": "DB00070",
      "target": "DB00896",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Rimexolone.",
      "name": "Rimexolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00296",
      "source": "DB00070",
      "target": "DB00296",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine.",
      "name": "Ropivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08806",
      "source": "DB00070",
      "target": "DB08806",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Roxatidine acetate.",
      "name": "Roxatidine acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00936",
      "source": "DB00070",
      "target": "DB00936",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB08835",
      "source": "DB00070",
      "target": "DB08835",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Spaglumic Acid.",
      "name": "Spaglumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09317",
      "source": "DB00070",
      "target": "DB09317",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, A.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09318",
      "source": "DB00070",
      "target": "DB09318",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, B.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00342",
      "source": "DB00070",
      "target": "DB00342",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Terfenadine.",
      "name": "Terfenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB04905",
      "source": "DB00070",
      "target": "DB04905",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tesmilifene.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09085",
      "source": "DB00070",
      "target": "DB09085",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetracaine.",
      "name": "Tetracaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB05232",
      "source": "DB00070",
      "target": "DB05232",
      "description": "The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetrodotoxin.",
      "name": "Tetrodotoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11235",
      "source": "DB00070",
      "target": "DB11235",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Thonzylamine.",
      "name": "Thonzylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09070",
      "source": "DB00070",
      "target": "DB09070",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tibolone.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB09091",
      "source": "DB00070",
      "target": "DB09091",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tixocortol.",
      "name": "Tixocortol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB07615",
      "source": "DB00070",
      "target": "DB07615",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tranilast.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00620",
      "source": "DB00070",
      "target": "DB00620",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00792",
      "source": "DB00070",
      "target": "DB00792",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tripelennamine.",
      "name": "Tripelennamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB00427",
      "source": "DB00070",
      "target": "DB00427",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triprolidine.",
      "name": "Triprolidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00070-DB11478",
      "source": "DB00070",
      "target": "DB11478",
      "description": "The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zeranol.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB12768",
      "source": "DB00075",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Muromonab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB08879",
      "source": "DB00075",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB06643",
      "source": "DB00075",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB08868",
      "source": "DB00075",
      "target": "DB08868",
      "description": "Muromonab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB01097",
      "source": "DB00075",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB00108",
      "source": "DB00075",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB00337",
      "source": "DB00075",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB10283",
      "source": "DB00075",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB10283",
      "source": "DB00075",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Muromonab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB01656",
      "source": "DB00075",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Muromonab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB06688",
      "source": "DB00075",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB00864",
      "source": "DB00075",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Muromonab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB08895",
      "source": "DB00075",
      "target": "DB08895",
      "description": "Muromonab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB00072",
      "source": "DB00075",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Muromonab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01281",
      "source": "DB00073",
      "target": "DB01281",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01193",
      "source": "DB00073",
      "target": "DB01193",
      "description": "Acebutolol may increase the hypotensive activities of Rituximab.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00511",
      "source": "DB00073",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Rituximab.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09026",
      "source": "DB00073",
      "target": "DB09026",
      "description": "Aliskiren may increase the hypotensive activities of Rituximab.",
      "name": "Aliskiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00866",
      "source": "DB00073",
      "target": "DB00866",
      "description": "Alprenolol may increase the hypotensive activities of Rituximab.",
      "name": "Alprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06403",
      "source": "DB00073",
      "target": "DB06403",
      "description": "Ambrisentan may increase the hypotensive activities of Rituximab.",
      "name": "Ambrisentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00381",
      "source": "DB00073",
      "target": "DB00381",
      "description": "Amlodipine may increase the hypotensive activities of Rituximab.",
      "name": "Amlodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00335",
      "source": "DB00073",
      "target": "DB00335",
      "description": "Atenolol may increase the hypotensive activities of Rituximab.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB12768",
      "source": "DB00073",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Rituximab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08879",
      "source": "DB00073",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00542",
      "source": "DB00073",
      "target": "DB00542",
      "description": "Benazepril may increase the hypotensive activities of Rituximab.",
      "name": "Benazepril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00436",
      "source": "DB00073",
      "target": "DB00436",
      "description": "Bendroflumethiazide may increase the hypotensive activities of Rituximab.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01244",
      "source": "DB00073",
      "target": "DB01244",
      "description": "Bepridil may increase the hypotensive activities of Rituximab.",
      "name": "Bepridil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00195",
      "source": "DB00073",
      "target": "DB00195",
      "description": "Betaxolol may increase the hypotensive activities of Rituximab.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00217",
      "source": "DB00073",
      "target": "DB00217",
      "description": "Bethanidine may increase the hypotensive activities of Rituximab.",
      "name": "Bethanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00112",
      "source": "DB00073",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Rituximab.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00905",
      "source": "DB00073",
      "target": "DB00905",
      "description": "Bimatoprost may increase the hypotensive activities of Rituximab.",
      "name": "Bimatoprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00612",
      "source": "DB00073",
      "target": "DB00612",
      "description": "Bisoprolol may increase the hypotensive activities of Rituximab.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00559",
      "source": "DB00073",
      "target": "DB00559",
      "description": "Bosentan may increase the hypotensive activities of Rituximab.",
      "name": "Bosentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01158",
      "source": "DB00073",
      "target": "DB01158",
      "description": "Bretylium may increase the hypotensive activities of Rituximab.",
      "name": "Bretylium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00484",
      "source": "DB00073",
      "target": "DB00484",
      "description": "Brimonidine may increase the hypotensive activities of Rituximab.",
      "name": "Brimonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08808",
      "source": "DB00073",
      "target": "DB08808",
      "description": "Bupranolol may increase the hypotensive activities of Rituximab.",
      "name": "Bupranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06772",
      "source": "DB00073",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rituximab.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00796",
      "source": "DB00073",
      "target": "DB00796",
      "description": "Candesartan may increase the hypotensive activities of Rituximab.",
      "name": "Candesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00616",
      "source": "DB00073",
      "target": "DB00616",
      "description": "Candoxatril may increase the hypotensive activities of Rituximab.",
      "name": "Candoxatril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01197",
      "source": "DB00073",
      "target": "DB01197",
      "description": "Captopril may increase the hypotensive activities of Rituximab.",
      "name": "Captopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00521",
      "source": "DB00073",
      "target": "DB00521",
      "description": "Carteolol may increase the hypotensive activities of Rituximab.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01136",
      "source": "DB00073",
      "target": "DB01136",
      "description": "Carvedilol may increase the hypotensive activities of Rituximab.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04846",
      "source": "DB00073",
      "target": "DB04846",
      "description": "Celiprolol may increase the hypotensive activities of Rituximab.",
      "name": "Celiprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08904",
      "source": "DB00073",
      "target": "DB08904",
      "description": "Rituximab may increase the immunosuppressive activities of Certolizumab pegol.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00880",
      "source": "DB00073",
      "target": "DB00880",
      "description": "Chlorothiazide may increase the hypotensive activities of Rituximab.",
      "name": "Chlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00310",
      "source": "DB00073",
      "target": "DB00310",
      "description": "Chlorthalidone may increase the hypotensive activities of Rituximab.",
      "name": "Chlorthalidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01340",
      "source": "DB00073",
      "target": "DB01340",
      "description": "Cilazapril may increase the hypotensive activities of Rituximab.",
      "name": "Cilazapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00575",
      "source": "DB00073",
      "target": "DB00575",
      "description": "Clonidine may increase the hypotensive activities of Rituximab.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00363",
      "source": "DB00073",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00785",
      "source": "DB00073",
      "target": "DB00785",
      "description": "Cryptenamine may increase the hypotensive activities of Rituximab.",
      "name": "Cryptenamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00531",
      "source": "DB00073",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Rituximab.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00606",
      "source": "DB00073",
      "target": "DB00606",
      "description": "Cyclothiazide may increase the hypotensive activities of Rituximab.",
      "name": "Cyclothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04840",
      "source": "DB00073",
      "target": "DB04840",
      "description": "Debrisoquin may increase the hypotensive activities of Rituximab.",
      "name": "Debrisoquin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06643",
      "source": "DB00073",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01089",
      "source": "DB00073",
      "target": "DB01089",
      "description": "Deserpidine may increase the hypotensive activities of Rituximab.",
      "name": "Deserpidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01078",
      "source": "DB00073",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Rituximab.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01119",
      "source": "DB00073",
      "target": "DB01119",
      "description": "Diazoxide may increase the hypotensive activities of Rituximab.",
      "name": "Diazoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01396",
      "source": "DB00073",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Rituximab.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00390",
      "source": "DB00073",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Rituximab.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00343",
      "source": "DB00073",
      "target": "DB00343",
      "description": "Diltiazem may increase the hypotensive activities of Rituximab.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01248",
      "source": "DB00073",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00869",
      "source": "DB00073",
      "target": "DB00869",
      "description": "Dorzolamide may increase the hypotensive activities of Rituximab.",
      "name": "Dorzolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00590",
      "source": "DB00073",
      "target": "DB00590",
      "description": "Doxazosin may increase the hypotensive activities of Rituximab.",
      "name": "Doxazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09235",
      "source": "DB00073",
      "target": "DB09235",
      "description": "Efonidipine may increase the hypotensive activities of Rituximab.",
      "name": "Efonidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00584",
      "source": "DB00073",
      "target": "DB00584",
      "description": "Enalapril may increase the hypotensive activities of Rituximab.",
      "name": "Enalapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09477",
      "source": "DB00073",
      "target": "DB09477",
      "description": "Enalaprilat may increase the hypotensive activities of Rituximab.",
      "name": "Enalaprilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01240",
      "source": "DB00073",
      "target": "DB01240",
      "description": "Epoprostenol may increase the hypotensive activities of Rituximab.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00876",
      "source": "DB00073",
      "target": "DB00876",
      "description": "Eprosartan may increase the hypotensive activities of Rituximab.",
      "name": "Eprosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01023",
      "source": "DB00073",
      "target": "DB01023",
      "description": "Felodipine may increase the hypotensive activities of Rituximab.",
      "name": "Felodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00800",
      "source": "DB00073",
      "target": "DB00800",
      "description": "Fenoldopam may increase the hypotensive activities of Rituximab.",
      "name": "Fenoldopam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08868",
      "source": "DB00073",
      "target": "DB08868",
      "description": "Rituximab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00492",
      "source": "DB00073",
      "target": "DB00492",
      "description": "Fosinopril may increase the hypotensive activities of Rituximab.",
      "name": "Fosinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00629",
      "source": "DB00073",
      "target": "DB00629",
      "description": "Guanabenz may increase the hypotensive activities of Rituximab.",
      "name": "Guanabenz"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00226",
      "source": "DB00073",
      "target": "DB00226",
      "description": "Guanadrel may increase the hypotensive activities of Rituximab.",
      "name": "Guanadrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01170",
      "source": "DB00073",
      "target": "DB01170",
      "description": "Guanethidine may increase the hypotensive activities of Rituximab.",
      "name": "Guanethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01018",
      "source": "DB00073",
      "target": "DB01018",
      "description": "Guanfacine may increase the hypotensive activities of Rituximab.",
      "name": "Guanfacine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08960",
      "source": "DB00073",
      "target": "DB08960",
      "description": "Hexamethonium may increase the hypotensive activities of Rituximab.",
      "name": "Hexamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01275",
      "source": "DB00073",
      "target": "DB01275",
      "description": "Hydralazine may increase the hypotensive activities of Rituximab.",
      "name": "Hydralazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00999",
      "source": "DB00073",
      "target": "DB00999",
      "description": "Hydrochlorothiazide may increase the hypotensive activities of Rituximab.",
      "name": "Hydrochlorothiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00774",
      "source": "DB00073",
      "target": "DB00774",
      "description": "Hydroflumethiazide may increase the hypotensive activities of Rituximab.",
      "name": "Hydroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00808",
      "source": "DB00073",
      "target": "DB00808",
      "description": "Indapamide may increase the hypotensive activities of Rituximab.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08952",
      "source": "DB00073",
      "target": "DB08952",
      "description": "Indenolol may increase the hypotensive activities of Rituximab.",
      "name": "Indenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08950",
      "source": "DB00073",
      "target": "DB08950",
      "description": "Indoramin may increase the hypotensive activities of Rituximab.",
      "name": "Indoramin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01029",
      "source": "DB00073",
      "target": "DB01029",
      "description": "Irbesartan may increase the hypotensive activities of Rituximab.",
      "name": "Irbesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00270",
      "source": "DB00073",
      "target": "DB00270",
      "description": "Isradipine may increase the hypotensive activities of Rituximab.",
      "name": "Isradipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00598",
      "source": "DB00073",
      "target": "DB00598",
      "description": "Labetalol may increase the hypotensive activities of Rituximab.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09236",
      "source": "DB00073",
      "target": "DB09236",
      "description": "Lacidipine may increase the hypotensive activities of Rituximab.",
      "name": "Lacidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00654",
      "source": "DB00073",
      "target": "DB00654",
      "description": "Latanoprost may increase the hypotensive activities of Rituximab.",
      "name": "Latanoprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01097",
      "source": "DB00073",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00528",
      "source": "DB00073",
      "target": "DB00528",
      "description": "Lercanidipine may increase the hypotensive activities of Rituximab.",
      "name": "Lercanidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00722",
      "source": "DB00073",
      "target": "DB00722",
      "description": "Lisinopril may increase the hypotensive activities of Rituximab.",
      "name": "Lisinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04948",
      "source": "DB00073",
      "target": "DB04948",
      "description": "Lofexidine may increase the hypotensive activities of Rituximab.",
      "name": "Lofexidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00678",
      "source": "DB00073",
      "target": "DB00678",
      "description": "Losartan may increase the hypotensive activities of Rituximab.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08932",
      "source": "DB00073",
      "target": "DB08932",
      "description": "Macitentan may increase the hypotensive activities of Rituximab.",
      "name": "Macitentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09238",
      "source": "DB00073",
      "target": "DB09238",
      "description": "Manidipine may increase the hypotensive activities of Rituximab.",
      "name": "Manidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00657",
      "source": "DB00073",
      "target": "DB00657",
      "description": "Mecamylamine may increase the hypotensive activities of Rituximab.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04817",
      "source": "DB00073",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Rituximab.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00968",
      "source": "DB00073",
      "target": "DB00968",
      "description": "Methyldopa may increase the hypotensive activities of Rituximab.",
      "name": "Methyldopa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01214",
      "source": "DB00073",
      "target": "DB01214",
      "description": "Metipranolol may increase the hypotensive activities of Rituximab.",
      "name": "Metipranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00524",
      "source": "DB00073",
      "target": "DB00524",
      "description": "Metolazone may increase the hypotensive activities of Rituximab.",
      "name": "Metolazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00264",
      "source": "DB00073",
      "target": "DB00264",
      "description": "Metoprolol may increase the hypotensive activities of Rituximab.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00765",
      "source": "DB00073",
      "target": "DB00765",
      "description": "Metyrosine may increase the hypotensive activities of Rituximab.",
      "name": "Metyrosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01388",
      "source": "DB00073",
      "target": "DB01388",
      "description": "Mibefradil may increase the hypotensive activities of Rituximab.",
      "name": "Mibefradil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00350",
      "source": "DB00073",
      "target": "DB00350",
      "description": "Minoxidil may increase the hypotensive activities of Rituximab.",
      "name": "Minoxidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00691",
      "source": "DB00073",
      "target": "DB00691",
      "description": "Moexipril may increase the hypotensive activities of Rituximab.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09242",
      "source": "DB00073",
      "target": "DB09242",
      "description": "Moxonidine may increase the hypotensive activities of Rituximab.",
      "name": "Moxonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01203",
      "source": "DB00073",
      "target": "DB01203",
      "description": "Nadolol may increase the hypotensive activities of Rituximab.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00108",
      "source": "DB00073",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04861",
      "source": "DB00073",
      "target": "DB04861",
      "description": "Nebivolol may increase the hypotensive activities of Rituximab.",
      "name": "Nebivolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00622",
      "source": "DB00073",
      "target": "DB00622",
      "description": "Nicardipine may increase the hypotensive activities of Rituximab.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09220",
      "source": "DB00073",
      "target": "DB09220",
      "description": "Nicorandil may increase the hypotensive activities of Rituximab.",
      "name": "Nicorandil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09239",
      "source": "DB00073",
      "target": "DB09239",
      "description": "Niguldipine may increase the hypotensive activities of Rituximab.",
      "name": "Niguldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06712",
      "source": "DB00073",
      "target": "DB06712",
      "description": "Nilvadipine may increase the hypotensive activities of Rituximab.",
      "name": "Nilvadipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00393",
      "source": "DB00073",
      "target": "DB00393",
      "description": "Nimodipine may increase the hypotensive activities of Rituximab.",
      "name": "Nimodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00401",
      "source": "DB00073",
      "target": "DB00401",
      "description": "Nisoldipine may increase the hypotensive activities of Rituximab.",
      "name": "Nisoldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01054",
      "source": "DB00073",
      "target": "DB01054",
      "description": "Nitrendipine may increase the hypotensive activities of Rituximab.",
      "name": "Nitrendipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00325",
      "source": "DB00073",
      "target": "DB00325",
      "description": "Nitroprusside may increase the hypotensive activities of Rituximab.",
      "name": "Nitroprusside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00275",
      "source": "DB00073",
      "target": "DB00275",
      "description": "Olmesartan may increase the hypotensive activities of Rituximab.",
      "name": "Olmesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00886",
      "source": "DB00073",
      "target": "DB00886",
      "description": "Omapatrilat may increase the hypotensive activities of Rituximab.",
      "name": "Omapatrilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01092",
      "source": "DB00073",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Rituximab.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01580",
      "source": "DB00073",
      "target": "DB01580",
      "description": "Oxprenolol may increase the hypotensive activities of Rituximab.",
      "name": "Oxprenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01229",
      "source": "DB00073",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rituximab.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01626",
      "source": "DB00073",
      "target": "DB01626",
      "description": "Pargyline may increase the hypotensive activities of Rituximab.",
      "name": "Pargyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01359",
      "source": "DB00073",
      "target": "DB01359",
      "description": "Penbutolol may increase the hypotensive activities of Rituximab.",
      "name": "Penbutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01090",
      "source": "DB00073",
      "target": "DB01090",
      "description": "Pentolinium may increase the hypotensive activities of Rituximab.",
      "name": "Pentolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00790",
      "source": "DB00073",
      "target": "DB00790",
      "description": "Perindopril may increase the hypotensive activities of Rituximab.",
      "name": "Perindopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00925",
      "source": "DB00073",
      "target": "DB00925",
      "description": "Phenoxybenzamine may increase the hypotensive activities of Rituximab.",
      "name": "Phenoxybenzamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00692",
      "source": "DB00073",
      "target": "DB00692",
      "description": "Phentolamine may increase the hypotensive activities of Rituximab.",
      "name": "Phentolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00337",
      "source": "DB00073",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06762",
      "source": "DB00073",
      "target": "DB06762",
      "description": "Pinacidil may increase the hypotensive activities of Rituximab.",
      "name": "Pinacidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00960",
      "source": "DB00073",
      "target": "DB00960",
      "description": "Pindolol may increase the hypotensive activities of Rituximab.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01324",
      "source": "DB00073",
      "target": "DB01324",
      "description": "Polythiazide may increase the hypotensive activities of Rituximab.",
      "name": "Polythiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00457",
      "source": "DB00073",
      "target": "DB00457",
      "description": "Prazosin may increase the hypotensive activities of Rituximab.",
      "name": "Prazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00571",
      "source": "DB00073",
      "target": "DB00571",
      "description": "Propranolol may increase the hypotensive activities of Rituximab.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00881",
      "source": "DB00073",
      "target": "DB00881",
      "description": "Quinapril may increase the hypotensive activities of Rituximab.",
      "name": "Quinapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB10283",
      "source": "DB00073",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB10283",
      "source": "DB00073",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Rituximab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00178",
      "source": "DB00073",
      "target": "DB00178",
      "description": "Ramipril may increase the hypotensive activities of Rituximab.",
      "name": "Ramipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00212",
      "source": "DB00073",
      "target": "DB00212",
      "description": "Remikiren may increase the hypotensive activities of Rituximab.",
      "name": "Remikiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01180",
      "source": "DB00073",
      "target": "DB01180",
      "description": "Rescinnamine may increase the hypotensive activities of Rituximab.",
      "name": "Rescinnamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00206",
      "source": "DB00073",
      "target": "DB00206",
      "description": "Reserpine may increase the hypotensive activities of Rituximab.",
      "name": "Reserpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08931",
      "source": "DB00073",
      "target": "DB08931",
      "description": "Riociguat may increase the hypotensive activities of Rituximab.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01656",
      "source": "DB00073",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Rituximab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01347",
      "source": "DB00073",
      "target": "DB01347",
      "description": "Saprisartan may increase the hypotensive activities of Rituximab.",
      "name": "Saprisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB11362",
      "source": "DB00073",
      "target": "DB11362",
      "description": "Selexipag may increase the hypotensive activities of Rituximab.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06688",
      "source": "DB00073",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06268",
      "source": "DB00073",
      "target": "DB06268",
      "description": "Sitaxentan may increase the hypotensive activities of Rituximab.",
      "name": "Sitaxentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01348",
      "source": "DB00073",
      "target": "DB01348",
      "description": "Spirapril may increase the hypotensive activities of Rituximab.",
      "name": "Spirapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00864",
      "source": "DB00073",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rituximab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00966",
      "source": "DB00073",
      "target": "DB00966",
      "description": "Telmisartan may increase the hypotensive activities of Rituximab.",
      "name": "Telmisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08836",
      "source": "DB00073",
      "target": "DB08836",
      "description": "Temocapril may increase the hypotensive activities of Rituximab.",
      "name": "Temocapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB02638",
      "source": "DB00073",
      "target": "DB02638",
      "description": "Terlipressin may increase the hypotensive activities of Rituximab.",
      "name": "Terlipressin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09070",
      "source": "DB00073",
      "target": "DB09070",
      "description": "Tibolone may increase the hypotensive activities of Rituximab.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB04831",
      "source": "DB00073",
      "target": "DB04831",
      "description": "Ticrynafen may increase the hypotensive activities of Rituximab.",
      "name": "Ticrynafen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00373",
      "source": "DB00073",
      "target": "DB00373",
      "description": "Timolol may increase the hypotensive activities of Rituximab.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB08895",
      "source": "DB00073",
      "target": "DB08895",
      "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00797",
      "source": "DB00073",
      "target": "DB00797",
      "description": "Tolazoline may increase the hypotensive activities of Rituximab.",
      "name": "Tolazoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00214",
      "source": "DB00073",
      "target": "DB00214",
      "description": "Torasemide may increase the hypotensive activities of Rituximab.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00519",
      "source": "DB00073",
      "target": "DB00519",
      "description": "Trandolapril may increase the hypotensive activities of Rituximab.",
      "name": "Trandolapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00072",
      "source": "DB00073",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rituximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00287",
      "source": "DB00073",
      "target": "DB00287",
      "description": "Travoprost may increase the hypotensive activities of Rituximab.",
      "name": "Travoprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00374",
      "source": "DB00073",
      "target": "DB00374",
      "description": "Treprostinil may increase the hypotensive activities of Rituximab.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01021",
      "source": "DB00073",
      "target": "DB01021",
      "description": "Trichlormethiazide may increase the hypotensive activities of Rituximab.",
      "name": "Trichlormethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB09206",
      "source": "DB00073",
      "target": "DB09206",
      "description": "Trimazosin may increase the hypotensive activities of Rituximab.",
      "name": "Trimazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB01116",
      "source": "DB00073",
      "target": "DB01116",
      "description": "Trimethaphan may increase the hypotensive activities of Rituximab.",
      "name": "Trimethaphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06826",
      "source": "DB00073",
      "target": "DB06826",
      "description": "Unoprostone may increase the hypotensive activities of Rituximab.",
      "name": "Unoprostone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00177",
      "source": "DB00073",
      "target": "DB00177",
      "description": "Valsartan may increase the hypotensive activities of Rituximab.",
      "name": "Valsartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB06694",
      "source": "DB00073",
      "target": "DB06694",
      "description": "Xylometazoline may increase the hypotensive activities of Rituximab.",
      "name": "Xylometazoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03509",
      "source": "DB00072",
      "target": "DB03509",
      "description": "Trastuzumab may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.",
      "name": "2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02342",
      "source": "DB00072",
      "target": "DB02342",
      "description": "Trastuzumab may increase the cardiotoxic activities of 2-Methoxyestradiol.",
      "name": "2-Methoxyestradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02806",
      "source": "DB00072",
      "target": "DB02806",
      "description": "Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.",
      "name": "2-Methoxyethanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03073",
      "source": "DB00072",
      "target": "DB03073",
      "description": "Trastuzumab may increase the cardiotoxic activities of 3-Methoxybenzamide.",
      "name": "3-Methoxybenzamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03946",
      "source": "DB00072",
      "target": "DB03946",
      "description": "Trastuzumab may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.",
      "name": "3,4-Dihydroxybenzoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03625",
      "source": "DB00072",
      "target": "DB03625",
      "description": "Trastuzumab may increase the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.",
      "name": "5,10-Dideazatetrahydrofolic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01933",
      "source": "DB00072",
      "target": "DB01933",
      "description": "Trastuzumab may increase the cardiotoxic activities of 7-Hydroxystaurosporine.",
      "name": "7-Hydroxystaurosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01667",
      "source": "DB00072",
      "target": "DB01667",
      "description": "Trastuzumab may increase the cardiotoxic activities of 8-azaguanine.",
      "name": "8-azaguanine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08843",
      "source": "DB00072",
      "target": "DB08843",
      "description": "Trastuzumab may increase the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.",
      "name": "9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01281",
      "source": "DB00072",
      "target": "DB01281",
      "description": "Trastuzumab may increase the neutropenic activities of Abatacept.",
      "name": "Abatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06662",
      "source": "DB00072",
      "target": "DB06662",
      "description": "Trastuzumab may increase the neutropenic activities of abetimus.",
      "name": "abetimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05812",
      "source": "DB00072",
      "target": "DB05812",
      "description": "Trastuzumab may increase the cardiotoxic activities of Abiraterone.",
      "name": "Abiraterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05901",
      "source": "DB00072",
      "target": "DB05901",
      "description": "Trastuzumab may increase the neutropenic activities of ABR-215757.",
      "name": "ABR-215757"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05764",
      "source": "DB00072",
      "target": "DB05764",
      "description": "Trastuzumab may increase the cardiotoxic activities of ABT-263.",
      "name": "ABT-263"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00511",
      "source": "DB00072",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11617",
      "source": "DB00072",
      "target": "DB11617",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aclarubicin.",
      "name": "Aclarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00051",
      "source": "DB00072",
      "target": "DB00051",
      "description": "Trastuzumab may increase the neutropenic activities of Adalimumab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00718",
      "source": "DB00072",
      "target": "DB00718",
      "description": "Trastuzumab may increase the neutropenic activities of Adefovir Dipivoxil.",
      "name": "Adefovir Dipivoxil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08916",
      "source": "DB00072",
      "target": "DB08916",
      "description": "Trastuzumab may increase the cardiotoxic activities of Afatinib.",
      "name": "Afatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04956",
      "source": "DB00072",
      "target": "DB04956",
      "description": "Trastuzumab may increase the neutropenic activities of Afelimomab.",
      "name": "Afelimomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04468",
      "source": "DB00072",
      "target": "DB04468",
      "description": "Trastuzumab may increase the cardiotoxic activities of Afimoxifene.",
      "name": "Afimoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08885",
      "source": "DB00072",
      "target": "DB08885",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aflibercept.",
      "name": "Aflibercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09335",
      "source": "DB00072",
      "target": "DB09335",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alatrofloxacin.",
      "name": "Alatrofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00518",
      "source": "DB00072",
      "target": "DB00518",
      "description": "Trastuzumab may increase the cardiotoxic activities of Albendazole.",
      "name": "Albendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00041",
      "source": "DB00072",
      "target": "DB00041",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00092",
      "source": "DB00072",
      "target": "DB00092",
      "description": "Trastuzumab may increase the neutropenic activities of Alefacept.",
      "name": "Alefacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00087",
      "source": "DB00072",
      "target": "DB00087",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Alemtuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06224",
      "source": "DB00072",
      "target": "DB06224",
      "description": "Trastuzumab may increase the neutropenic activities of alicaforsen.",
      "name": "alicaforsen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00523",
      "source": "DB00072",
      "target": "DB00523",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alitretinoin.",
      "name": "Alitretinoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03856",
      "source": "DB00072",
      "target": "DB03856",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alpha-Difluoromethylornithine.",
      "name": "Alpha-Difluoromethylornithine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00488",
      "source": "DB00072",
      "target": "DB00488",
      "description": "Trastuzumab may increase the cardiotoxic activities of Altretamine.",
      "name": "Altretamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00357",
      "source": "DB00072",
      "target": "DB00357",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aminoglutethimide.",
      "name": "Aminoglutethimide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00855",
      "source": "DB00072",
      "target": "DB00855",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aminolevulinic acid.",
      "name": "Aminolevulinic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05022",
      "source": "DB00072",
      "target": "DB05022",
      "description": "Trastuzumab may increase the cardiotoxic activities of Amonafide.",
      "name": "Amonafide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06263",
      "source": "DB00072",
      "target": "DB06263",
      "description": "Trastuzumab may increase the cardiotoxic activities of Amrubicin.",
      "name": "Amrubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00276",
      "source": "DB00072",
      "target": "DB00276",
      "description": "Trastuzumab may increase the cardiotoxic activities of Amsacrine.",
      "name": "Amsacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00261",
      "source": "DB00072",
      "target": "DB00261",
      "description": "Trastuzumab may increase the cardiotoxic activities of Anagrelide.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00026",
      "source": "DB00072",
      "target": "DB00026",
      "description": "Trastuzumab may increase the neutropenic activities of Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01217",
      "source": "DB00072",
      "target": "DB01217",
      "description": "Trastuzumab may increase the cardiotoxic activities of Anastrozole.",
      "name": "Anastrozole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06420",
      "source": "DB00072",
      "target": "DB06420",
      "description": "Trastuzumab may increase the cardiotoxic activities of annamycin.",
      "name": "annamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00098",
      "source": "DB00072",
      "target": "DB00098",
      "description": "Trastuzumab may increase the neutropenic activities of Anti-thymocyte Globulin (Rabbit).",
      "name": "Anti-thymocyte Globulin (Rabbit)"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05697",
      "source": "DB00072",
      "target": "DB05697",
      "description": "Trastuzumab may increase the cardiotoxic activities of AP 12009.",
      "name": "AP 12009"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06300",
      "source": "DB00072",
      "target": "DB06300",
      "description": "Trastuzumab may increase the cardiotoxic activities of AP24534.",
      "name": "AP24534"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05676",
      "source": "DB00072",
      "target": "DB05676",
      "description": "Trastuzumab may increase the neutropenic activities of Apremilast.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01169",
      "source": "DB00072",
      "target": "DB01169",
      "description": "Trastuzumab may increase the cardiotoxic activities of Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06235",
      "source": "DB00072",
      "target": "DB06235",
      "description": "Trastuzumab may increase the cardiotoxic activities of ASA404.",
      "name": "ASA404"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00023",
      "source": "DB00072",
      "target": "DB00023",
      "description": "Trastuzumab may increase the cardiotoxic activities of Asparaginase.",
      "name": "Asparaginase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05707",
      "source": "DB00072",
      "target": "DB05707",
      "description": "Trastuzumab may increase the cardiotoxic activities of AT-101.",
      "name": "AT-101"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06626",
      "source": "DB00072",
      "target": "DB06626",
      "description": "Trastuzumab may increase the cardiotoxic activities of Axitinib.",
      "name": "Axitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00928",
      "source": "DB00072",
      "target": "DB00928",
      "description": "Trastuzumab may increase the cardiotoxic activities of Azacitidine.",
      "name": "Azacitidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00993",
      "source": "DB00072",
      "target": "DB00993",
      "description": "Trastuzumab may increase the cardiotoxic activities of Azathioprine.",
      "name": "Azathioprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04849",
      "source": "DB00072",
      "target": "DB04849",
      "description": "Trastuzumab may increase the cardiotoxic activities of AZD2171.",
      "name": "AZD2171"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00548",
      "source": "DB00072",
      "target": "DB00548",
      "description": "Trastuzumab may increase the cardiotoxic activities of Azelaic Acid.",
      "name": "Azelaic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00074",
      "source": "DB00072",
      "target": "DB00074",
      "description": "Trastuzumab may increase the neutropenic activities of Basiliximab.",
      "name": "Basiliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03880",
      "source": "DB00072",
      "target": "DB03880",
      "description": "Trastuzumab may increase the cardiotoxic activities of Batimastat.",
      "name": "Batimastat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06681",
      "source": "DB00072",
      "target": "DB06681",
      "description": "Trastuzumab may increase the neutropenic activities of Belatacept.",
      "name": "Belatacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08879",
      "source": "DB00072",
      "target": "DB08879",
      "description": "The risk or severity of adverse effects can be increased when Trastuzumab is combined with Belimumab.",
      "name": "Belimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05015",
      "source": "DB00072",
      "target": "DB05015",
      "description": "Trastuzumab may increase the cardiotoxic activities of Belinostat.",
      "name": "Belinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06769",
      "source": "DB00072",
      "target": "DB06769",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bendamustine.",
      "name": "Bendamustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06771",
      "source": "DB00072",
      "target": "DB06771",
      "description": "Trastuzumab may increase the cardiotoxic activities of Besifloxacin.",
      "name": "Besifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00443",
      "source": "DB00072",
      "target": "DB00443",
      "description": "Trastuzumab may increase the neutropenic activities of Betamethasone.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00112",
      "source": "DB00072",
      "target": "DB00112",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bevacizumab.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00307",
      "source": "DB00072",
      "target": "DB00307",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bexarotene.",
      "name": "Bexarotene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01128",
      "source": "DB00072",
      "target": "DB01128",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bicalutamide.",
      "name": "Bicalutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00290",
      "source": "DB00072",
      "target": "DB00290",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bleomycin.",
      "name": "Bleomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09052",
      "source": "DB00072",
      "target": "DB09052",
      "description": "Trastuzumab may increase the cardiotoxic activities of Blinatumomab.",
      "name": "Blinatumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00188",
      "source": "DB00072",
      "target": "DB00188",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bortezomib.",
      "name": "Bortezomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06616",
      "source": "DB00072",
      "target": "DB06616",
      "description": "Trastuzumab may increase the cardiotoxic activities of Bosutinib.",
      "name": "Bosutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08870",
      "source": "DB00072",
      "target": "DB08870",
      "description": "Trastuzumab may increase the cardiotoxic activities of Brentuximab vedotin.",
      "name": "Brentuximab vedotin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05459",
      "source": "DB00072",
      "target": "DB05459",
      "description": "Trastuzumab may increase the neutropenic activities of Briakinumab.",
      "name": "Briakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05975",
      "source": "DB00072",
      "target": "DB05975",
      "description": "Trastuzumab may increase the cardiotoxic activities of BSI-201.",
      "name": "BSI-201"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01222",
      "source": "DB00072",
      "target": "DB01222",
      "description": "Trastuzumab may increase the neutropenic activities of Budesonide.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01008",
      "source": "DB00072",
      "target": "DB01008",
      "description": "Trastuzumab may increase the cardiotoxic activities of Busulfan.",
      "name": "Busulfan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06404",
      "source": "DB00072",
      "target": "DB06404",
      "description": "Trastuzumab may increase the neutropenic activities of C1 Esterase Inhibitor (Human).",
      "name": "C1 Esterase Inhibitor (Human)"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06772",
      "source": "DB00072",
      "target": "DB06772",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cabazitaxel.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00248",
      "source": "DB00072",
      "target": "DB00248",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cabergoline.",
      "name": "Cabergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08875",
      "source": "DB00072",
      "target": "DB08875",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cabozantinib.",
      "name": "Cabozantinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02300",
      "source": "DB00072",
      "target": "DB02300",
      "description": "Trastuzumab may increase the cardiotoxic activities of Calcipotriol.",
      "name": "Calcipotriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04690",
      "source": "DB00072",
      "target": "DB04690",
      "description": "Trastuzumab may increase the cardiotoxic activities of Camptothecin.",
      "name": "Camptothecin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06168",
      "source": "DB00072",
      "target": "DB06168",
      "description": "Trastuzumab may increase the neutropenic activities of Canakinumab.",
      "name": "Canakinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01101",
      "source": "DB00072",
      "target": "DB01101",
      "description": "Trastuzumab may increase the cardiotoxic activities of Capecitabine.",
      "name": "Capecitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00958",
      "source": "DB00072",
      "target": "DB00958",
      "description": "Trastuzumab may increase the cardiotoxic activities of Carboplatin.",
      "name": "Carboplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08889",
      "source": "DB00072",
      "target": "DB08889",
      "description": "Trastuzumab may increase the cardiotoxic activities of Carfilzomib.",
      "name": "Carfilzomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09010",
      "source": "DB00072",
      "target": "DB09010",
      "description": "Trastuzumab may increase the cardiotoxic activities of Carmofur.",
      "name": "Carmofur"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00262",
      "source": "DB00072",
      "target": "DB00262",
      "description": "Trastuzumab may increase the cardiotoxic activities of Carmustine.",
      "name": "Carmustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01816",
      "source": "DB00072",
      "target": "DB01816",
      "description": "Trastuzumab may increase the neutropenic activities of Castanospermine.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06607",
      "source": "DB00072",
      "target": "DB06607",
      "description": "Trastuzumab may increase the cardiotoxic activities of Catumaxomab.",
      "name": "Catumaxomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04253",
      "source": "DB00072",
      "target": "DB04253",
      "description": "Trastuzumab may increase the cardiotoxic activities of CB1954.",
      "name": "CB1954"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00482",
      "source": "DB00072",
      "target": "DB00482",
      "description": "Trastuzumab may increase the cardiotoxic activities of Celecoxib.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09063",
      "source": "DB00072",
      "target": "DB09063",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08904",
      "source": "DB00072",
      "target": "DB08904",
      "description": "Trastuzumab may increase the neutropenic activities of Certolizumab pegol.",
      "name": "Certolizumab pegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00002",
      "source": "DB00072",
      "target": "DB00002",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cetuximab.",
      "name": "Cetuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00291",
      "source": "DB00072",
      "target": "DB00291",
      "description": "Trastuzumab may increase the cardiotoxic activities of Chlorambucil.",
      "name": "Chlorambucil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00269",
      "source": "DB00072",
      "target": "DB00269",
      "description": "Trastuzumab may increase the cardiotoxic activities of Chlorotrianisene.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00827",
      "source": "DB00072",
      "target": "DB00827",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cinoxacin.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00537",
      "source": "DB00072",
      "target": "DB00537",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ciprofloxacin.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00515",
      "source": "DB00072",
      "target": "DB00515",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cisplatin.",
      "name": "Cisplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00242",
      "source": "DB00072",
      "target": "DB00242",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cladribine.",
      "name": "Cladribine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00631",
      "source": "DB00072",
      "target": "DB00631",
      "description": "Trastuzumab may increase the cardiotoxic activities of Clofarabine.",
      "name": "Clofarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06189",
      "source": "DB00072",
      "target": "DB06189",
      "description": "Trastuzumab may increase the cardiotoxic activities of clorarabine.",
      "name": "clorarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01394",
      "source": "DB00072",
      "target": "DB01394",
      "description": "Trastuzumab may increase the cardiotoxic activities of Colchicine.",
      "name": "Colchicine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01285",
      "source": "DB00072",
      "target": "DB01285",
      "description": "Trastuzumab may increase the neutropenic activities of Corticotropin.",
      "name": "Corticotropin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01380",
      "source": "DB00072",
      "target": "DB01380",
      "description": "Trastuzumab may increase the neutropenic activities of Cortisone acetate.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08865",
      "source": "DB00072",
      "target": "DB08865",
      "description": "Trastuzumab may increase the cardiotoxic activities of Crizotinib.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00531",
      "source": "DB00072",
      "target": "DB00531",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00091",
      "source": "DB00072",
      "target": "DB00091",
      "description": "Trastuzumab may increase the neutropenic activities of Cyclosporine.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04839",
      "source": "DB00072",
      "target": "DB04839",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cyproterone acetate.",
      "name": "Cyproterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00987",
      "source": "DB00072",
      "target": "DB00987",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cytarabine.",
      "name": "Cytarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08912",
      "source": "DB00072",
      "target": "DB08912",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dabrafenib.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00851",
      "source": "DB00072",
      "target": "DB00851",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dacarbazine.",
      "name": "Dacarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00111",
      "source": "DB00072",
      "target": "DB00111",
      "description": "Trastuzumab may increase the neutropenic activities of Daclizumab.",
      "name": "Daclizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00970",
      "source": "DB00072",
      "target": "DB00970",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dactinomycin.",
      "name": "Dactinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09331",
      "source": "DB00072",
      "target": "DB09331",
      "description": "Trastuzumab may increase the cardiotoxic activities of Daratumumab.",
      "name": "Daratumumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01254",
      "source": "DB00072",
      "target": "DB01254",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dasatinib.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00694",
      "source": "DB00072",
      "target": "DB00694",
      "description": "Trastuzumab may increase the cardiotoxic activities of Daunorubicin.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01262",
      "source": "DB00072",
      "target": "DB01262",
      "description": "Trastuzumab may increase the cardiotoxic activities of Decitabine.",
      "name": "Decitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00004",
      "source": "DB00072",
      "target": "DB00004",
      "description": "Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Denileukin diftitox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01078",
      "source": "DB00072",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Trastuzumab.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01234",
      "source": "DB00072",
      "target": "DB01234",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00380",
      "source": "DB00072",
      "target": "DB00380",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dexrazoxane.",
      "name": "Dexrazoxane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09123",
      "source": "DB00072",
      "target": "DB09123",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00255",
      "source": "DB00072",
      "target": "DB00255",
      "description": "Trastuzumab may increase the cardiotoxic activities of Diethylstilbestrol.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01396",
      "source": "DB00072",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Trastuzumab.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00390",
      "source": "DB00072",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Trastuzumab.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08908",
      "source": "DB00072",
      "target": "DB08908",
      "description": "Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.",
      "name": "Dimethyl fumarate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09077",
      "source": "DB00072",
      "target": "DB09077",
      "description": "Trastuzumab may increase the cardiotoxic activities of Dinutuximab.",
      "name": "Dinutuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01248",
      "source": "DB00072",
      "target": "DB01248",
      "description": "Trastuzumab may increase the cardiotoxic activities of Docetaxel.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00997",
      "source": "DB00072",
      "target": "DB00997",
      "description": "Trastuzumab may increase the cardiotoxic activities of Doxorubicin.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05265",
      "source": "DB00072",
      "target": "DB05265",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ecabet.",
      "name": "Ecabet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01257",
      "source": "DB00072",
      "target": "DB01257",
      "description": "Trastuzumab may increase the neutropenic activities of Eculizumab.",
      "name": "Eculizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00095",
      "source": "DB00072",
      "target": "DB00095",
      "description": "Trastuzumab may increase the neutropenic activities of Efalizumab.",
      "name": "Efalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06459",
      "source": "DB00072",
      "target": "DB06459",
      "description": "Trastuzumab may increase the cardiotoxic activities of efaproxiral.",
      "name": "efaproxiral"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06243",
      "source": "DB00072",
      "target": "DB06243",
      "description": "Trastuzumab may increase the cardiotoxic activities of Eflornithine.",
      "name": "Eflornithine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04907",
      "source": "DB00072",
      "target": "DB04907",
      "description": "Trastuzumab may increase the cardiotoxic activities of EG009.",
      "name": "EG009"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05129",
      "source": "DB00072",
      "target": "DB05129",
      "description": "Trastuzumab may increase the cardiotoxic activities of Elsamitrucin.",
      "name": "Elsamitrucin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06423",
      "source": "DB00072",
      "target": "DB06423",
      "description": "Trastuzumab may increase the cardiotoxic activities of Endostatin.",
      "name": "Endostatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00467",
      "source": "DB00072",
      "target": "DB00467",
      "description": "Trastuzumab may increase the cardiotoxic activities of Enoxacin.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11404",
      "source": "DB00072",
      "target": "DB11404",
      "description": "Trastuzumab may increase the cardiotoxic activities of Enrofloxacin.",
      "name": "Enrofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00445",
      "source": "DB00072",
      "target": "DB00445",
      "description": "Trastuzumab may increase the cardiotoxic activities of Epirubicin.",
      "name": "Epirubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03010",
      "source": "DB00072",
      "target": "DB03010",
      "description": "Trastuzumab may increase the cardiotoxic activities of Epothilone B.",
      "name": "Epothilone B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08871",
      "source": "DB00072",
      "target": "DB08871",
      "description": "Trastuzumab may increase the cardiotoxic activities of Eribulin.",
      "name": "Eribulin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00530",
      "source": "DB00072",
      "target": "DB00530",
      "description": "Trastuzumab may increase the cardiotoxic activities of Erlotinib.",
      "name": "Erlotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01196",
      "source": "DB00072",
      "target": "DB01196",
      "description": "Trastuzumab may increase the cardiotoxic activities of Estramustine.",
      "name": "Estramustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00005",
      "source": "DB00072",
      "target": "DB00005",
      "description": "Trastuzumab may increase the neutropenic activities of Etanercept.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00965",
      "source": "DB00072",
      "target": "DB00965",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ethiodized oil.",
      "name": "Ethiodized oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04827",
      "source": "DB00072",
      "target": "DB04827",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ethyl carbamate.",
      "name": "Ethyl carbamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00773",
      "source": "DB00072",
      "target": "DB00773",
      "description": "Trastuzumab may increase the cardiotoxic activities of Etoposide.",
      "name": "Etoposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01590",
      "source": "DB00072",
      "target": "DB01590",
      "description": "Trastuzumab may increase the cardiotoxic activities of Everolimus.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00990",
      "source": "DB00072",
      "target": "DB00990",
      "description": "Trastuzumab may increase the cardiotoxic activities of Exemestane.",
      "name": "Exemestane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06246",
      "source": "DB00072",
      "target": "DB06246",
      "description": "Trastuzumab may increase the cardiotoxic activities of exisulind.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05076",
      "source": "DB00072",
      "target": "DB05076",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fenretinide.",
      "name": "Fenretinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08868",
      "source": "DB00072",
      "target": "DB08868",
      "description": "Trastuzumab may increase the neutropenic activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03496",
      "source": "DB00072",
      "target": "DB03496",
      "description": "Trastuzumab may increase the cardiotoxic activities of Flavopiridol.",
      "name": "Flavopiridol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04576",
      "source": "DB00072",
      "target": "DB04576",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fleroxacin.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00322",
      "source": "DB00072",
      "target": "DB00322",
      "description": "Trastuzumab may increase the cardiotoxic activities of Floxuridine.",
      "name": "Floxuridine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01073",
      "source": "DB00072",
      "target": "DB01073",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fludarabine.",
      "name": "Fludarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00687",
      "source": "DB00072",
      "target": "DB00687",
      "description": "Trastuzumab may increase the neutropenic activities of Fludrocortisone.",
      "name": "Fludrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08972",
      "source": "DB00072",
      "target": "DB08972",
      "description": "Trastuzumab may increase the cardiotoxic activities of Flumequine.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00544",
      "source": "DB00072",
      "target": "DB00544",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fluorouracil.",
      "name": "Fluorouracil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00499",
      "source": "DB00072",
      "target": "DB00499",
      "description": "Trastuzumab may increase the cardiotoxic activities of Flutamide.",
      "name": "Flutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08905",
      "source": "DB00072",
      "target": "DB08905",
      "description": "Trastuzumab may increase the cardiotoxic activities of Formestane.",
      "name": "Formestane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02281",
      "source": "DB00072",
      "target": "DB02281",
      "description": "Trastuzumab may increase the cardiotoxic activities of Formycin.",
      "name": "Formycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04106",
      "source": "DB00072",
      "target": "DB04106",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fotemustine.",
      "name": "Fotemustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00947",
      "source": "DB00072",
      "target": "DB00947",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fulvestrant.",
      "name": "Fulvestrant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02640",
      "source": "DB00072",
      "target": "DB02640",
      "description": "Trastuzumab may increase the cardiotoxic activities of Fumagillin.",
      "name": "Fumagillin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05260",
      "source": "DB00072",
      "target": "DB05260",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gallium nitrate.",
      "name": "Gallium nitrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06160",
      "source": "DB00072",
      "target": "DB06160",
      "description": "Trastuzumab may increase the cardiotoxic activities of Garenoxacin.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01044",
      "source": "DB00072",
      "target": "DB01044",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gatifloxacin.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00317",
      "source": "DB00072",
      "target": "DB00317",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gefitinib.",
      "name": "Gefitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02424",
      "source": "DB00072",
      "target": "DB02424",
      "description": "Trastuzumab may increase the cardiotoxic activities of Geldanamycin.",
      "name": "Geldanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00441",
      "source": "DB00072",
      "target": "DB00441",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemcitabine.",
      "name": "Gemcitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01155",
      "source": "DB00072",
      "target": "DB01155",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemifloxacin.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00056",
      "source": "DB00072",
      "target": "DB00056",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Gemtuzumab ozogamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01645",
      "source": "DB00072",
      "target": "DB01645",
      "description": "Trastuzumab may increase the cardiotoxic activities of Genistein.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06748",
      "source": "DB00072",
      "target": "DB06748",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ginsenoside C.",
      "name": "Ginsenoside C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05259",
      "source": "DB00072",
      "target": "DB05259",
      "description": "Trastuzumab may increase the neutropenic activities of Glatiramer Acetate.",
      "name": "Glatiramer Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00222",
      "source": "DB00072",
      "target": "DB00222",
      "description": "Trastuzumab may increase the neutropenic activities of Glimepiride.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06674",
      "source": "DB00072",
      "target": "DB06674",
      "description": "Trastuzumab may increase the neutropenic activities of Golimumab.",
      "name": "Golimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00014",
      "source": "DB00072",
      "target": "DB00014",
      "description": "Trastuzumab may increase the cardiotoxic activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00365",
      "source": "DB00072",
      "target": "DB00365",
      "description": "Trastuzumab may increase the cardiotoxic activities of Grepafloxacin.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02109",
      "source": "DB00072",
      "target": "DB02109",
      "description": "Trastuzumab may increase the cardiotoxic activities of Hadacidin.",
      "name": "Hadacidin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04866",
      "source": "DB00072",
      "target": "DB04866",
      "description": "Trastuzumab may increase the cardiotoxic activities of Halofuginone.",
      "name": "Halofuginone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB07931",
      "source": "DB00072",
      "target": "DB07931",
      "description": "Trastuzumab may increase the cardiotoxic activities of Hexestrol.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00741",
      "source": "DB00072",
      "target": "DB00741",
      "description": "Trastuzumab may increase the neutropenic activities of Hydrocortisone.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06789",
      "source": "DB00072",
      "target": "DB06789",
      "description": "Trastuzumab may increase the cardiotoxic activities of Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01005",
      "source": "DB00072",
      "target": "DB01005",
      "description": "Trastuzumab may increase the cardiotoxic activities of Hydroxyurea.",
      "name": "Hydroxyurea"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00078",
      "source": "DB00072",
      "target": "DB00078",
      "description": "Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09053",
      "source": "DB00072",
      "target": "DB09053",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ibrutinib.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06196",
      "source": "DB00072",
      "target": "DB06196",
      "description": "Trastuzumab may increase the neutropenic activities of Icatibant.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01177",
      "source": "DB00072",
      "target": "DB01177",
      "description": "Trastuzumab may increase the cardiotoxic activities of Idarubicin.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09054",
      "source": "DB00072",
      "target": "DB09054",
      "description": "Trastuzumab may increase the cardiotoxic activities of Idelalisib.",
      "name": "Idelalisib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01181",
      "source": "DB00072",
      "target": "DB01181",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ifosfamide.",
      "name": "Ifosfamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00619",
      "source": "DB00072",
      "target": "DB00619",
      "description": "Trastuzumab may increase the cardiotoxic activities of Imatinib.",
      "name": "Imatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00724",
      "source": "DB00072",
      "target": "DB00724",
      "description": "Trastuzumab may increase the cardiotoxic activities of Imiquimod.",
      "name": "Imiquimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00065",
      "source": "DB00072",
      "target": "DB00065",
      "description": "Trastuzumab may increase the neutropenic activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00060",
      "source": "DB00072",
      "target": "DB00060",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Interferon beta-1a"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00068",
      "source": "DB00072",
      "target": "DB00068",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Interferon beta-1b"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06704",
      "source": "DB00072",
      "target": "DB06704",
      "description": "Trastuzumab may increase the cardiotoxic activities of Iobenguane.",
      "name": "Iobenguane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06186",
      "source": "DB00072",
      "target": "DB06186",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ipilimumab.",
      "name": "Ipilimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00762",
      "source": "DB00072",
      "target": "DB00762",
      "description": "Trastuzumab may increase the cardiotoxic activities of Irinotecan.",
      "name": "Irinotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04845",
      "source": "DB00072",
      "target": "DB04845",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ixabepilone.",
      "name": "Ixabepilone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09570",
      "source": "DB00072",
      "target": "DB09570",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ixazomib.",
      "name": "Ixazomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05903",
      "source": "DB00072",
      "target": "DB05903",
      "description": "Trastuzumab may increase the cardiotoxic activities of KOS-1584.",
      "name": "KOS-1584"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05540",
      "source": "DB00072",
      "target": "DB05540",
      "description": "Trastuzumab may increase the cardiotoxic activities of L-alanosine.",
      "name": "L-alanosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00120",
      "source": "DB00072",
      "target": "DB00120",
      "description": "Trastuzumab may increase the neutropenic activities of L-Phenylalanine.",
      "name": "L-Phenylalanine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06791",
      "source": "DB00072",
      "target": "DB06791",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01259",
      "source": "DB00072",
      "target": "DB01259",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lapatinib.",
      "name": "Lapatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01097",
      "source": "DB00072",
      "target": "DB01097",
      "description": "Trastuzumab may increase the cardiotoxic activities of Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00480",
      "source": "DB00072",
      "target": "DB00480",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lenalidomide.",
      "name": "Lenalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09078",
      "source": "DB00072",
      "target": "DB09078",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lenvatinib.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01006",
      "source": "DB00072",
      "target": "DB01006",
      "description": "Trastuzumab may increase the cardiotoxic activities of Letrozole.",
      "name": "Letrozole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00007",
      "source": "DB00072",
      "target": "DB00007",
      "description": "Trastuzumab may increase the cardiotoxic activities of Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01137",
      "source": "DB00072",
      "target": "DB01137",
      "description": "Trastuzumab may increase the cardiotoxic activities of Levofloxacin.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00978",
      "source": "DB00072",
      "target": "DB00978",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lomefloxacin.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01206",
      "source": "DB00072",
      "target": "DB01206",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lomustine.",
      "name": "Lomustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06266",
      "source": "DB00072",
      "target": "DB06266",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lonidamine.",
      "name": "Lonidamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11231",
      "source": "DB00072",
      "target": "DB11231",
      "description": "Trastuzumab may increase the cardiotoxic activities of Lycopene.",
      "name": "Lycopene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11526",
      "source": "DB00072",
      "target": "DB11526",
      "description": "Trastuzumab may increase the cardiotoxic activities of Masitinib.",
      "name": "Masitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00179",
      "source": "DB00072",
      "target": "DB00179",
      "description": "Trastuzumab may increase the cardiotoxic activities of Masoprocol.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06272",
      "source": "DB00072",
      "target": "DB06272",
      "description": "Trastuzumab may increase the cardiotoxic activities of Maxacalcitol.",
      "name": "Maxacalcitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06132",
      "source": "DB00072",
      "target": "DB06132",
      "description": "Trastuzumab may increase the cardiotoxic activities of MDX-1106.",
      "name": "MDX-1106"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00643",
      "source": "DB00072",
      "target": "DB00643",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mebendazole.",
      "name": "Mebendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00888",
      "source": "DB00072",
      "target": "DB00888",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mechlorethamine.",
      "name": "Mechlorethamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09124",
      "source": "DB00072",
      "target": "DB09124",
      "description": "Trastuzumab may increase the cardiotoxic activities of Medrogestone.",
      "name": "Medrogestone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00603",
      "source": "DB00072",
      "target": "DB00603",
      "description": "Trastuzumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00351",
      "source": "DB00072",
      "target": "DB00351",
      "description": "Trastuzumab may increase the cardiotoxic activities of Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01042",
      "source": "DB00072",
      "target": "DB01042",
      "description": "Trastuzumab may increase the cardiotoxic activities of Melphalan.",
      "name": "Melphalan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06612",
      "source": "DB00072",
      "target": "DB06612",
      "description": "Trastuzumab may increase the neutropenic activities of Mepolizumab.",
      "name": "Mepolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09516",
      "source": "DB00072",
      "target": "DB09516",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mequinol.",
      "name": "Mequinol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01033",
      "source": "DB00072",
      "target": "DB01033",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mercaptopurine.",
      "name": "Mercaptopurine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00563",
      "source": "DB00072",
      "target": "DB00563",
      "description": "Trastuzumab may increase the cardiotoxic activities of Methotrexate.",
      "name": "Methotrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00992",
      "source": "DB00072",
      "target": "DB00992",
      "description": "Trastuzumab may increase the cardiotoxic activities of Methyl aminolevulinate.",
      "name": "Methyl aminolevulinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00959",
      "source": "DB00072",
      "target": "DB00959",
      "description": "Trastuzumab may increase the cardiotoxic activities of Methylprednisolone.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06710",
      "source": "DB00072",
      "target": "DB06710",
      "description": "Trastuzumab may increase the cardiotoxic activities of Methyltestosterone.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05786",
      "source": "DB00072",
      "target": "DB05786",
      "description": "Trastuzumab may increase the cardiotoxic activities of MGI-114.",
      "name": "MGI-114"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06595",
      "source": "DB00072",
      "target": "DB06595",
      "description": "Trastuzumab may increase the cardiotoxic activities of Midostaurin.",
      "name": "Midostaurin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09031",
      "source": "DB00072",
      "target": "DB09031",
      "description": "Trastuzumab may increase the cardiotoxic activities of Miltefosine.",
      "name": "Miltefosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00305",
      "source": "DB00072",
      "target": "DB00305",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mitomycin.",
      "name": "Mitomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00648",
      "source": "DB00072",
      "target": "DB00648",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mitotane.",
      "name": "Mitotane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01204",
      "source": "DB00072",
      "target": "DB01204",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mitoxantrone.",
      "name": "Mitoxantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06517",
      "source": "DB00072",
      "target": "DB06517",
      "description": "Trastuzumab may increase the cardiotoxic activities of MLN576.",
      "name": "MLN576"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05428",
      "source": "DB00072",
      "target": "DB05428",
      "description": "Trastuzumab may increase the cardiotoxic activities of motexafin gadolinium.",
      "name": "motexafin gadolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00218",
      "source": "DB00072",
      "target": "DB00218",
      "description": "Trastuzumab may increase the cardiotoxic activities of Moxifloxacin.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00075",
      "source": "DB00072",
      "target": "DB00075",
      "description": "Trastuzumab may increase the neutropenic activities of Muromonab.",
      "name": "Muromonab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00688",
      "source": "DB00072",
      "target": "DB00688",
      "description": "Trastuzumab may increase the neutropenic activities of Mycophenolate mofetil.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01024",
      "source": "DB00072",
      "target": "DB01024",
      "description": "Trastuzumab may increase the cardiotoxic activities of Mycophenolic acid.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00779",
      "source": "DB00072",
      "target": "DB00779",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nalidixic Acid.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00108",
      "source": "DB00072",
      "target": "DB00108",
      "description": "Trastuzumab may increase the neutropenic activities of Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09559",
      "source": "DB00072",
      "target": "DB09559",
      "description": "Trastuzumab may increase the cardiotoxic activities of Necitumumab.",
      "name": "Necitumumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01280",
      "source": "DB00072",
      "target": "DB01280",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nelarabine.",
      "name": "Nelarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09239",
      "source": "DB00072",
      "target": "DB09239",
      "description": "Trastuzumab may increase the cardiotoxic activities of Niguldipine.",
      "name": "Niguldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04868",
      "source": "DB00072",
      "target": "DB04868",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00665",
      "source": "DB00072",
      "target": "DB00665",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nilutamide.",
      "name": "Nilutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09079",
      "source": "DB00072",
      "target": "DB09079",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nintedanib.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09035",
      "source": "DB00072",
      "target": "DB09035",
      "description": "Trastuzumab may increase the cardiotoxic activities of Nivolumab.",
      "name": "Nivolumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08313",
      "source": "DB00072",
      "target": "DB08313",
      "description": "Trastuzumab may increase the cardiotoxic activities of nocodazole.",
      "name": "nocodazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01059",
      "source": "DB00072",
      "target": "DB01059",
      "description": "Trastuzumab may increase the cardiotoxic activities of Norfloxacin.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08935",
      "source": "DB00072",
      "target": "DB08935",
      "description": "Trastuzumab may increase the cardiotoxic activities of Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00104",
      "source": "DB00072",
      "target": "DB00104",
      "description": "Trastuzumab may increase the cardiotoxic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06650",
      "source": "DB00072",
      "target": "DB06650",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ofatumumab.",
      "name": "Ofatumumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01165",
      "source": "DB00072",
      "target": "DB01165",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ofloxacin.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09074",
      "source": "DB00072",
      "target": "DB09074",
      "description": "Trastuzumab may increase the cardiotoxic activities of Olaparib.",
      "name": "Olaparib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04865",
      "source": "DB00072",
      "target": "DB04865",
      "description": "Trastuzumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00038",
      "source": "DB00072",
      "target": "DB00038",
      "description": "Trastuzumab may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Oprelvekin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09330",
      "source": "DB00072",
      "target": "DB09330",
      "description": "Trastuzumab may increase the cardiotoxic activities of Osimertinib.",
      "name": "Osimertinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01092",
      "source": "DB00072",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Trastuzumab.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00526",
      "source": "DB00072",
      "target": "DB00526",
      "description": "Trastuzumab may increase the cardiotoxic activities of Oxaliplatin.",
      "name": "Oxaliplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01229",
      "source": "DB00072",
      "target": "DB01229",
      "description": "Trastuzumab may increase the cardiotoxic activities of Paclitaxel.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01229",
      "source": "DB00072",
      "target": "DB01229",
      "description": "The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09073",
      "source": "DB00072",
      "target": "DB09073",
      "description": "Trastuzumab may increase the cardiotoxic activities of Palbociclib.",
      "name": "Palbociclib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05668",
      "source": "DB00072",
      "target": "DB05668",
      "description": "Trastuzumab may increase the cardiotoxic activities of Palifosfamide.",
      "name": "Palifosfamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00282",
      "source": "DB00072",
      "target": "DB00282",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pamidronate.",
      "name": "Pamidronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01269",
      "source": "DB00072",
      "target": "DB01269",
      "description": "Trastuzumab may increase the cardiotoxic activities of Panitumumab.",
      "name": "Panitumumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06603",
      "source": "DB00072",
      "target": "DB06603",
      "description": "Trastuzumab may increase the cardiotoxic activities of Panobinostat.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05940",
      "source": "DB00072",
      "target": "DB05940",
      "description": "Trastuzumab may increase the cardiotoxic activities of PARP inhibitor.",
      "name": "PARP inhibitor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06589",
      "source": "DB00072",
      "target": "DB06589",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pazopanib.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00487",
      "source": "DB00072",
      "target": "DB00487",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pefloxacin.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00059",
      "source": "DB00072",
      "target": "DB00059",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Pegaspargase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09037",
      "source": "DB00072",
      "target": "DB09037",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pembrolizumab.",
      "name": "Pembrolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00642",
      "source": "DB00072",
      "target": "DB00642",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pemetrexed.",
      "name": "Pemetrexed"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00552",
      "source": "DB00072",
      "target": "DB00552",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pentostatin.",
      "name": "Pentostatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06366",
      "source": "DB00072",
      "target": "DB06366",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pertuzumab.",
      "name": "Pertuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09269",
      "source": "DB00072",
      "target": "DB09269",
      "description": "Trastuzumab may increase the cardiotoxic activities of Phenylacetic acid.",
      "name": "Phenylacetic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00337",
      "source": "DB00072",
      "target": "DB00337",
      "description": "Trastuzumab may increase the neutropenic activities of Pimecrolimus.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00236",
      "source": "DB00072",
      "target": "DB00236",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pipobroman.",
      "name": "Pipobroman"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11616",
      "source": "DB00072",
      "target": "DB11616",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pirarubicin.",
      "name": "Pirarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04951",
      "source": "DB00072",
      "target": "DB04951",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pirfenidone.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09244",
      "source": "DB00072",
      "target": "DB09244",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pirlindole.",
      "name": "Pirlindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06193",
      "source": "DB00072",
      "target": "DB06193",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pixantrone.",
      "name": "Pixantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06163",
      "source": "DB00072",
      "target": "DB06163",
      "description": "Trastuzumab may increase the cardiotoxic activities of Plevitrexed.",
      "name": "Plevitrexed"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06810",
      "source": "DB00072",
      "target": "DB06810",
      "description": "Trastuzumab may increase the cardiotoxic activities of Plicamycin.",
      "name": "Plicamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01179",
      "source": "DB00072",
      "target": "DB01179",
      "description": "Trastuzumab may increase the cardiotoxic activities of Podofilox.",
      "name": "Podofilox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09094",
      "source": "DB00072",
      "target": "DB09094",
      "description": "Trastuzumab may increase the cardiotoxic activities of Podophyllin.",
      "name": "Podophyllin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05384",
      "source": "DB00072",
      "target": "DB05384",
      "description": "Trastuzumab may increase the cardiotoxic activities of polyacrylic acid.",
      "name": "polyacrylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08910",
      "source": "DB00072",
      "target": "DB08910",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pomalidomide.",
      "name": "Pomalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08901",
      "source": "DB00072",
      "target": "DB08901",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ponatinib.",
      "name": "Ponatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00707",
      "source": "DB00072",
      "target": "DB00707",
      "description": "Trastuzumab may increase the cardiotoxic activities of Porfimer.",
      "name": "Porfimer"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06478",
      "source": "DB00072",
      "target": "DB06478",
      "description": "Trastuzumab may increase the cardiotoxic activities of porfiromycin.",
      "name": "porfiromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06813",
      "source": "DB00072",
      "target": "DB06813",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pralatrexate.",
      "name": "Pralatrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00860",
      "source": "DB00072",
      "target": "DB00860",
      "description": "Trastuzumab may increase the cardiotoxic activities of Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00635",
      "source": "DB00072",
      "target": "DB00635",
      "description": "Trastuzumab may increase the cardiotoxic activities of Prednisone.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01168",
      "source": "DB00072",
      "target": "DB01168",
      "description": "Trastuzumab may increase the cardiotoxic activities of Procarbazine.",
      "name": "Procarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04440",
      "source": "DB00072",
      "target": "DB04440",
      "description": "Trastuzumab may increase the cardiotoxic activities of Purine Riboside.",
      "name": "Purine Riboside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08437",
      "source": "DB00072",
      "target": "DB08437",
      "description": "Trastuzumab may increase the cardiotoxic activities of Puromycin.",
      "name": "Puromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01103",
      "source": "DB00072",
      "target": "DB01103",
      "description": "Trastuzumab may increase the cardiotoxic activities of Quinacrine.",
      "name": "Quinacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB10283",
      "source": "DB00072",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Trastuzumab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08913",
      "source": "DB00072",
      "target": "DB08913",
      "description": "Trastuzumab may increase the cardiotoxic activities of Radium Ra 223 Dichloride.",
      "name": "Radium Ra 223 Dichloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00293",
      "source": "DB00072",
      "target": "DB00293",
      "description": "Trastuzumab may increase the cardiotoxic activities of Raltitrexed.",
      "name": "Raltitrexed"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05578",
      "source": "DB00072",
      "target": "DB05578",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ramucirumab.",
      "name": "Ramucirumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01270",
      "source": "DB00072",
      "target": "DB01270",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ranibizumab.",
      "name": "Ranibizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04950",
      "source": "DB00072",
      "target": "DB04950",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ranpirnase.",
      "name": "Ranpirnase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08896",
      "source": "DB00072",
      "target": "DB08896",
      "description": "Trastuzumab may increase the cardiotoxic activities of Regorafenib.",
      "name": "Regorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02709",
      "source": "DB00072",
      "target": "DB02709",
      "description": "Trastuzumab may increase the cardiotoxic activities of Resveratrol.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03825",
      "source": "DB00072",
      "target": "DB03825",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rhodamine 6G.",
      "name": "Rhodamine 6G"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06372",
      "source": "DB00072",
      "target": "DB06372",
      "description": "Trastuzumab may increase the neutropenic activities of Rilonacept.",
      "name": "Rilonacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00073",
      "source": "DB00072",
      "target": "DB00073",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06176",
      "source": "DB00072",
      "target": "DB06176",
      "description": "Trastuzumab may increase the cardiotoxic activities of Romidepsin.",
      "name": "Romidepsin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05332",
      "source": "DB00072",
      "target": "DB05332",
      "description": "Trastuzumab may increase the cardiotoxic activities of Romiplostim.",
      "name": "Romiplostim"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11366",
      "source": "DB00072",
      "target": "DB11366",
      "description": "Trastuzumab may increase the cardiotoxic activities of Roquinimex.",
      "name": "Roquinimex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06159",
      "source": "DB00072",
      "target": "DB06159",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rubitecan.",
      "name": "Rubitecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08877",
      "source": "DB00072",
      "target": "DB08877",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ruxolitinib.",
      "name": "Ruxolitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04996",
      "source": "DB00072",
      "target": "DB04996",
      "description": "Trastuzumab may increase the cardiotoxic activities of Satraplatin.",
      "name": "Satraplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09029",
      "source": "DB00072",
      "target": "DB09029",
      "description": "Trastuzumab may increase the neutropenic activities of Secukinumab.",
      "name": "Secukinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06195",
      "source": "DB00072",
      "target": "DB06195",
      "description": "Trastuzumab may increase the cardiotoxic activities of Seliciclib.",
      "name": "Seliciclib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06436",
      "source": "DB00072",
      "target": "DB06436",
      "description": "Trastuzumab may increase the cardiotoxic activities of Semaxanib.",
      "name": "Semaxanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04258",
      "source": "DB00072",
      "target": "DB04258",
      "description": "Trastuzumab may increase the cardiotoxic activities of Seocalcitol.",
      "name": "Seocalcitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09036",
      "source": "DB00072",
      "target": "DB09036",
      "description": "Trastuzumab may increase the cardiotoxic activities of Siltuximab.",
      "name": "Siltuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00877",
      "source": "DB00072",
      "target": "DB00877",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sirolimus.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06819",
      "source": "DB00072",
      "target": "DB06819",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sodium phenylbutyrate.",
      "name": "Sodium phenylbutyrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09143",
      "source": "DB00072",
      "target": "DB09143",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sonidegib.",
      "name": "Sonidegib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00398",
      "source": "DB00072",
      "target": "DB00398",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sorafenib.",
      "name": "Sorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01208",
      "source": "DB00072",
      "target": "DB01208",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sparfloxacin.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03459",
      "source": "DB00072",
      "target": "DB03459",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sparfosic acid.",
      "name": "Sparfosic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04222",
      "source": "DB00072",
      "target": "DB04222",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sparsomycin.",
      "name": "Sparsomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06461",
      "source": "DB00072",
      "target": "DB06461",
      "description": "Trastuzumab may increase the cardiotoxic activities of squalamine.",
      "name": "squalamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05073",
      "source": "DB00072",
      "target": "DB05073",
      "description": "Trastuzumab may increase the cardiotoxic activities of SRT501.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01423",
      "source": "DB00072",
      "target": "DB01423",
      "description": "Trastuzumab may increase the neutropenic activities of Stepronin.",
      "name": "Stepronin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00428",
      "source": "DB00072",
      "target": "DB00428",
      "description": "Trastuzumab may increase the cardiotoxic activities of Streptozocin.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00605",
      "source": "DB00072",
      "target": "DB00605",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sulindac.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01268",
      "source": "DB00072",
      "target": "DB01268",
      "description": "Trastuzumab may increase the cardiotoxic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04786",
      "source": "DB00072",
      "target": "DB04786",
      "description": "Trastuzumab may increase the cardiotoxic activities of Suramin.",
      "name": "Suramin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02034",
      "source": "DB00072",
      "target": "DB02034",
      "description": "Trastuzumab may increase the cardiotoxic activities of Swainsonine.",
      "name": "Swainsonine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00864",
      "source": "DB00072",
      "target": "DB00864",
      "description": "Trastuzumab may increase the neutropenic activities of Tacrolimus.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00675",
      "source": "DB00072",
      "target": "DB00675",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tamoxifen.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09256",
      "source": "DB00072",
      "target": "DB09256",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tegafur.",
      "name": "Tegafur"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01405",
      "source": "DB00072",
      "target": "DB01405",
      "description": "Trastuzumab may increase the cardiotoxic activities of Temafloxacin.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00853",
      "source": "DB00072",
      "target": "DB00853",
      "description": "Trastuzumab may increase the cardiotoxic activities of Temozolomide.",
      "name": "Temozolomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06287",
      "source": "DB00072",
      "target": "DB06287",
      "description": "Trastuzumab may increase the cardiotoxic activities of Temsirolimus.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00444",
      "source": "DB00072",
      "target": "DB00444",
      "description": "Trastuzumab may increase the cardiotoxic activities of Teniposide.",
      "name": "Teniposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11466",
      "source": "DB00072",
      "target": "DB11466",
      "description": "Trastuzumab may increase the neutropenic activities of Tepoxalin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08880",
      "source": "DB00072",
      "target": "DB08880",
      "description": "Trastuzumab may increase the neutropenic activities of Teriflunomide.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00894",
      "source": "DB00072",
      "target": "DB00894",
      "description": "Trastuzumab may increase the cardiotoxic activities of Testolactone.",
      "name": "Testolactone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05088",
      "source": "DB00072",
      "target": "DB05088",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tetrathiomolybdate.",
      "name": "Tetrathiomolybdate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06433",
      "source": "DB00072",
      "target": "DB06433",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tezacitabine.",
      "name": "Tezacitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01041",
      "source": "DB00072",
      "target": "DB01041",
      "description": "Trastuzumab may increase the cardiotoxic activities of Thalidomide.",
      "name": "Thalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04572",
      "source": "DB00072",
      "target": "DB04572",
      "description": "Trastuzumab may increase the cardiotoxic activities of Thiotepa.",
      "name": "Thiotepa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04900",
      "source": "DB00072",
      "target": "DB04900",
      "description": "Trastuzumab may increase the cardiotoxic activities of Thymalfasin.",
      "name": "Thymalfasin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09070",
      "source": "DB00072",
      "target": "DB09070",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tibolone.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00352",
      "source": "DB00072",
      "target": "DB00352",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tioguanine.",
      "name": "Tioguanine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04960",
      "source": "DB00072",
      "target": "DB04960",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tipifarnib.",
      "name": "Tipifarnib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04858",
      "source": "DB00072",
      "target": "DB04858",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tirapazamine.",
      "name": "Tirapazamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06273",
      "source": "DB00072",
      "target": "DB06273",
      "description": "Trastuzumab may increase the neutropenic activities of Tocilizumab.",
      "name": "Tocilizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08895",
      "source": "DB00072",
      "target": "DB08895",
      "description": "Trastuzumab may increase the neutropenic activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01030",
      "source": "DB00072",
      "target": "DB01030",
      "description": "Trastuzumab may increase the cardiotoxic activities of Topotecan.",
      "name": "Topotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00539",
      "source": "DB00072",
      "target": "DB00539",
      "description": "Trastuzumab may increase the cardiotoxic activities of Toremifene.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00081",
      "source": "DB00072",
      "target": "DB00081",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00081",
      "source": "DB00072",
      "target": "DB00081",
      "description": "Trastuzumab may increase the neutropenic activities of Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05109",
      "source": "DB00072",
      "target": "DB05109",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trabectedin.",
      "name": "Trabectedin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08911",
      "source": "DB00072",
      "target": "DB08911",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trametinib.",
      "name": "Trametinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05773",
      "source": "DB00072",
      "target": "DB05773",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trastuzumab emtansine.",
      "name": "Trastuzumab emtansine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00755",
      "source": "DB00072",
      "target": "DB00755",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tretinoin.",
      "name": "Tretinoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00620",
      "source": "DB00072",
      "target": "DB00620",
      "description": "Trastuzumab may increase the neutropenic activities of Triamcinolone.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00432",
      "source": "DB00072",
      "target": "DB00432",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trifluridine.",
      "name": "Trifluridine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01108",
      "source": "DB00072",
      "target": "DB01108",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trilostane.",
      "name": "Trilostane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB01157",
      "source": "DB00072",
      "target": "DB01157",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trimetrexate.",
      "name": "Trimetrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB06825",
      "source": "DB00072",
      "target": "DB06825",
      "description": "Trastuzumab may increase the cardiotoxic activities of Triptorelin.",
      "name": "Triptorelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00685",
      "source": "DB00072",
      "target": "DB00685",
      "description": "Trastuzumab may increase the cardiotoxic activities of Trovafloxacin.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04961",
      "source": "DB00072",
      "target": "DB04961",
      "description": "Trastuzumab may increase the cardiotoxic activities of Troxacitabine.",
      "name": "Troxacitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02877",
      "source": "DB00072",
      "target": "DB02877",
      "description": "Trastuzumab may increase the cardiotoxic activities of TTNPB.",
      "name": "TTNPB"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03172",
      "source": "DB00072",
      "target": "DB03172",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tubercidin.",
      "name": "Tubercidin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB03424",
      "source": "DB00072",
      "target": "DB03424",
      "description": "Trastuzumab may increase the cardiotoxic activities of Ubenimex.",
      "name": "Ubenimex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00791",
      "source": "DB00072",
      "target": "DB00791",
      "description": "Trastuzumab may increase the cardiotoxic activities of Uracil mustard.",
      "name": "Uracil mustard"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05679",
      "source": "DB00072",
      "target": "DB05679",
      "description": "Trastuzumab may increase the neutropenic activities of Ustekinumab.",
      "name": "Ustekinumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00385",
      "source": "DB00072",
      "target": "DB00385",
      "description": "Trastuzumab may increase the cardiotoxic activities of Valrubicin.",
      "name": "Valrubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB05294",
      "source": "DB00072",
      "target": "DB05294",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vandetanib.",
      "name": "Vandetanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB04894",
      "source": "DB00072",
      "target": "DB04894",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vapreotide.",
      "name": "Vapreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09033",
      "source": "DB00072",
      "target": "DB09033",
      "description": "Trastuzumab may increase the neutropenic activities of Vedolizumab.",
      "name": "Vedolizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB07232",
      "source": "DB00072",
      "target": "DB07232",
      "description": "Trastuzumab may increase the cardiotoxic activities of Veliparib.",
      "name": "Veliparib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08881",
      "source": "DB00072",
      "target": "DB08881",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vemurafenib.",
      "name": "Vemurafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00460",
      "source": "DB00072",
      "target": "DB00460",
      "description": "Trastuzumab may increase the cardiotoxic activities of Verteporfin.",
      "name": "Verteporfin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB09082",
      "source": "DB00072",
      "target": "DB09082",
      "description": "Trastuzumab may increase the neutropenic activities of Vilanterol.",
      "name": "Vilanterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00570",
      "source": "DB00072",
      "target": "DB00570",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vinblastine.",
      "name": "Vinblastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00541",
      "source": "DB00072",
      "target": "DB00541",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vincristine.",
      "name": "Vincristine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00309",
      "source": "DB00072",
      "target": "DB00309",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vindesine.",
      "name": "Vindesine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00361",
      "source": "DB00072",
      "target": "DB00361",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vinorelbine.",
      "name": "Vinorelbine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB08828",
      "source": "DB00072",
      "target": "DB08828",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vismodegib.",
      "name": "Vismodegib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00162",
      "source": "DB00072",
      "target": "DB00162",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vitamin A.",
      "name": "Vitamin A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB02546",
      "source": "DB00072",
      "target": "DB02546",
      "description": "Trastuzumab may increase the cardiotoxic activities of Vorinostat.",
      "name": "Vorinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB11618",
      "source": "DB00072",
      "target": "DB11618",
      "description": "Trastuzumab may increase the cardiotoxic activities of Zorubicin.",
      "name": "Zorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB12768",
      "source": "DB00074",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Basiliximab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB06643",
      "source": "DB00074",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB08868",
      "source": "DB00074",
      "target": "DB08868",
      "description": "Basiliximab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB01097",
      "source": "DB00074",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB00108",
      "source": "DB00074",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB00337",
      "source": "DB00074",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB10283",
      "source": "DB00074",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB10283",
      "source": "DB00074",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Basiliximab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB01656",
      "source": "DB00074",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Basiliximab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB06688",
      "source": "DB00074",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB00864",
      "source": "DB00074",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basiliximab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB08895",
      "source": "DB00074",
      "target": "DB08895",
      "description": "Basiliximab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB00072",
      "source": "DB00074",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Basiliximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB01076",
      "source": "DB00080",
      "target": "DB01076",
      "description": "The risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB12768",
      "source": "DB00080",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Daptomycin.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB00439",
      "source": "DB00080",
      "target": "DB00439",
      "description": "The risk or severity of adverse effects can be increased when Cerivastatin is combined with Daptomycin.",
      "name": "Cerivastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB09270",
      "source": "DB00080",
      "target": "DB09270",
      "description": "The risk or severity of adverse effects can be increased when Coenzyme Q10 is combined with Daptomycin.",
      "name": "Coenzyme Q10"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB01095",
      "source": "DB00080",
      "target": "DB01095",
      "description": "The risk or severity of adverse effects can be increased when Fluvastatin is combined with Daptomycin.",
      "name": "Fluvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB00227",
      "source": "DB00080",
      "target": "DB00227",
      "description": "The risk or severity of adverse effects can be increased when Lovastatin is combined with Daptomycin.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB06693",
      "source": "DB00080",
      "target": "DB06693",
      "description": "The risk or severity of adverse effects can be increased when Mevastatin is combined with Daptomycin.",
      "name": "Mevastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB09268",
      "source": "DB00080",
      "target": "DB09268",
      "description": "The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Daptomycin.",
      "name": "Picosulfuric acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB08860",
      "source": "DB00080",
      "target": "DB08860",
      "description": "The risk or severity of adverse effects can be increased when Pitavastatin is combined with Daptomycin.",
      "name": "Pitavastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB00175",
      "source": "DB00080",
      "target": "DB00175",
      "description": "The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.",
      "name": "Pravastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB01098",
      "source": "DB00080",
      "target": "DB01098",
      "description": "The risk or severity of adverse effects can be increased when Rosuvastatin is combined with Daptomycin.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00080-DB00641",
      "source": "DB00080",
      "target": "DB00641",
      "description": "The risk or severity of adverse effects can be increased when Simvastatin is combined with Daptomycin.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00054",
      "source": "DB00078",
      "target": "DB00054",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01418",
      "source": "DB00078",
      "target": "DB01418",
      "description": "The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00945",
      "source": "DB00078",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00770",
      "source": "DB00078",
      "target": "DB00770",
      "description": "The risk or severity of adverse effects can be increased when Alprostadil is combined with Ibritumomab tiuxetan.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00261",
      "source": "DB00078",
      "target": "DB00261",
      "description": "The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05099",
      "source": "DB00078",
      "target": "DB05099",
      "description": "The risk or severity of adverse effects can be increased when Ancrod is combined with Ibritumomab tiuxetan.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11598",
      "source": "DB00078",
      "target": "DB11598",
      "description": "The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06605",
      "source": "DB00078",
      "target": "DB06605",
      "description": "The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00407",
      "source": "DB00078",
      "target": "DB00407",
      "description": "The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00278",
      "source": "DB00078",
      "target": "DB00278",
      "description": "The risk or severity of adverse effects can be increased when Argatroban is combined with Ibritumomab tiuxetan.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00972",
      "source": "DB00078",
      "target": "DB00972",
      "description": "The risk or severity of adverse effects can be increased when Azelastine is combined with Ibritumomab tiuxetan.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB12768",
      "source": "DB00078",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Ibritumomab tiuxetan.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00102",
      "source": "DB00078",
      "target": "DB00102",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05229",
      "source": "DB00078",
      "target": "DB05229",
      "description": "The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00006",
      "source": "DB00078",
      "target": "DB00006",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06441",
      "source": "DB00078",
      "target": "DB06441",
      "description": "The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09261",
      "source": "DB00078",
      "target": "DB09261",
      "description": "The risk or severity of adverse effects can be increased when Certoparin is combined with Ibritumomab tiuxetan.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01166",
      "source": "DB00078",
      "target": "DB01166",
      "description": "The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04272",
      "source": "DB00078",
      "target": "DB04272",
      "description": "The risk or severity of adverse effects can be increased when Citric Acid is combined with Ibritumomab tiuxetan.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00758",
      "source": "DB00078",
      "target": "DB00758",
      "description": "The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00363",
      "source": "DB00078",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06695",
      "source": "DB00078",
      "target": "DB06695",
      "description": "The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06779",
      "source": "DB00078",
      "target": "DB06779",
      "description": "The risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06754",
      "source": "DB00078",
      "target": "DB06754",
      "description": "The risk or severity of adverse effects can be increased when Danaparoid is combined with Ibritumomab tiuxetan.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04932",
      "source": "DB00078",
      "target": "DB04932",
      "description": "The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06643",
      "source": "DB00078",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11095",
      "source": "DB00078",
      "target": "DB11095",
      "description": "The risk or severity of adverse effects can be increased when Desirudin is combined with Ibritumomab tiuxetan.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09255",
      "source": "DB00078",
      "target": "DB09255",
      "description": "The risk or severity of adverse effects can be increased when Dextran is combined with Ibritumomab tiuxetan.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11122",
      "source": "DB00078",
      "target": "DB11122",
      "description": "The risk or severity of adverse effects can be increased when Dextran 40 is combined with Ibritumomab tiuxetan.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11076",
      "source": "DB00078",
      "target": "DB11076",
      "description": "The risk or severity of adverse effects can be increased when Dextran 70 is combined with Ibritumomab tiuxetan.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11241",
      "source": "DB00078",
      "target": "DB11241",
      "description": "The risk or severity of adverse effects can be increased when Dextran 75 is combined with Ibritumomab tiuxetan.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00266",
      "source": "DB00078",
      "target": "DB00266",
      "description": "The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00975",
      "source": "DB00078",
      "target": "DB00975",
      "description": "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00974",
      "source": "DB00078",
      "target": "DB00974",
      "description": "The risk or severity of adverse effects can be increased when Edetic Acid is combined with Ibritumomab tiuxetan.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09075",
      "source": "DB00078",
      "target": "DB09075",
      "description": "The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01225",
      "source": "DB00078",
      "target": "DB01225",
      "description": "The risk or severity of adverse effects can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00751",
      "source": "DB00078",
      "target": "DB00751",
      "description": "The risk or severity of adverse effects can be increased when Epinastine is combined with Ibritumomab tiuxetan.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06392",
      "source": "DB00078",
      "target": "DB06392",
      "description": "The risk or severity of adverse effects can be increased when eplivanserine is combined with Ibritumomab tiuxetan.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01240",
      "source": "DB00078",
      "target": "DB01240",
      "description": "The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00063",
      "source": "DB00078",
      "target": "DB00063",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08794",
      "source": "DB00078",
      "target": "DB08794",
      "description": "The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08868",
      "source": "DB00078",
      "target": "DB08868",
      "description": "Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00569",
      "source": "DB00078",
      "target": "DB00569",
      "description": "The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Ibritumomab tiuxetan.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01109",
      "source": "DB00078",
      "target": "DB01109",
      "description": "The risk or severity of adverse effects can be increased when Heparin is combined with Ibritumomab tiuxetan.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB02351",
      "source": "DB00078",
      "target": "DB02351",
      "description": "The risk or severity of adverse effects can be increased when Hirulog is combined with Ibritumomab tiuxetan.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05266",
      "source": "DB00078",
      "target": "DB05266",
      "description": "The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08887",
      "source": "DB00078",
      "target": "DB08887",
      "description": "The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06406",
      "source": "DB00078",
      "target": "DB06406",
      "description": "The risk or severity of adverse effects can be increased when idraparinux is combined with Ibritumomab tiuxetan.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08954",
      "source": "DB00078",
      "target": "DB08954",
      "description": "The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ibritumomab tiuxetan.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01088",
      "source": "DB00078",
      "target": "DB01088",
      "description": "The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01097",
      "source": "DB00078",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00001",
      "source": "DB00078",
      "target": "DB00001",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04817",
      "source": "DB00078",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Ibritumomab tiuxetan.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00235",
      "source": "DB00078",
      "target": "DB00235",
      "description": "The risk or severity of adverse effects can be increased when Milrinone is combined with Ibritumomab tiuxetan.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08813",
      "source": "DB00078",
      "target": "DB08813",
      "description": "The risk or severity of adverse effects can be increased when Nadroparin is combined with Ibritumomab tiuxetan.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00108",
      "source": "DB00078",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05822",
      "source": "DB00078",
      "target": "DB05822",
      "description": "The risk or severity of adverse effects can be increased when NCX 4016 is combined with Ibritumomab tiuxetan.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04743",
      "source": "DB00078",
      "target": "DB04743",
      "description": "The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06635",
      "source": "DB00078",
      "target": "DB06635",
      "description": "The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00686",
      "source": "DB00078",
      "target": "DB00686",
      "description": "The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibritumomab tiuxetan.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00806",
      "source": "DB00078",
      "target": "DB00806",
      "description": "The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00498",
      "source": "DB00078",
      "target": "DB00498",
      "description": "The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00946",
      "source": "DB00078",
      "target": "DB00946",
      "description": "The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00337",
      "source": "DB00078",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06209",
      "source": "DB00078",
      "target": "DB06209",
      "description": "The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11312",
      "source": "DB00078",
      "target": "DB11312",
      "description": "The risk or severity of adverse effects can be increased when Protein C is combined with Ibritumomab tiuxetan.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB11268",
      "source": "DB00078",
      "target": "DB11268",
      "description": "The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Ibritumomab tiuxetan.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB10283",
      "source": "DB00078",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB10283",
      "source": "DB00078",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Ibritumomab tiuxetan.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB02709",
      "source": "DB00078",
      "target": "DB02709",
      "description": "The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09259",
      "source": "DB00078",
      "target": "DB09259",
      "description": "The risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01207",
      "source": "DB00078",
      "target": "DB01207",
      "description": "The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06228",
      "source": "DB00078",
      "target": "DB06228",
      "description": "The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01656",
      "source": "DB00078",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05692",
      "source": "DB00078",
      "target": "DB05692",
      "description": "The risk or severity of adverse effects can be increased when SCH-530348 is combined with Ibritumomab tiuxetan.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB01236",
      "source": "DB00078",
      "target": "DB01236",
      "description": "The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06688",
      "source": "DB00078",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB05073",
      "source": "DB00078",
      "target": "DB05073",
      "description": "The risk or severity of adverse effects can be increased when SRT501 is combined with Ibritumomab tiuxetan.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB06271",
      "source": "DB00078",
      "target": "DB06271",
      "description": "The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00864",
      "source": "DB00078",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibritumomab tiuxetan.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04905",
      "source": "DB00078",
      "target": "DB04905",
      "description": "The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00208",
      "source": "DB00078",
      "target": "DB00208",
      "description": "The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00775",
      "source": "DB00078",
      "target": "DB00775",
      "description": "The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08895",
      "source": "DB00078",
      "target": "DB08895",
      "description": "Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB07615",
      "source": "DB00078",
      "target": "DB07615",
      "description": "The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09283",
      "source": "DB00078",
      "target": "DB09283",
      "description": "The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00072",
      "source": "DB00078",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB08814",
      "source": "DB00078",
      "target": "DB08814",
      "description": "The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB09030",
      "source": "DB00078",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00682",
      "source": "DB00078",
      "target": "DB00682",
      "description": "The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB04898",
      "source": "DB00078",
      "target": "DB04898",
      "description": "The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00054",
      "source": "DB00081",
      "target": "DB00054",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01418",
      "source": "DB00081",
      "target": "DB01418",
      "description": "The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Tositumomab.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00511",
      "source": "DB00081",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Tositumomab.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00945",
      "source": "DB00081",
      "target": "DB00945",
      "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00770",
      "source": "DB00081",
      "target": "DB00770",
      "description": "The risk or severity of adverse effects can be increased when Alprostadil is combined with Tositumomab.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00261",
      "source": "DB00081",
      "target": "DB00261",
      "description": "The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05099",
      "source": "DB00081",
      "target": "DB05099",
      "description": "The risk or severity of adverse effects can be increased when Ancrod is combined with Tositumomab.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11598",
      "source": "DB00081",
      "target": "DB11598",
      "description": "The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Tositumomab.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06605",
      "source": "DB00081",
      "target": "DB06605",
      "description": "The risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00407",
      "source": "DB00081",
      "target": "DB00407",
      "description": "The risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00278",
      "source": "DB00081",
      "target": "DB00278",
      "description": "The risk or severity of adverse effects can be increased when Argatroban is combined with Tositumomab.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00972",
      "source": "DB00081",
      "target": "DB00972",
      "description": "The risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB12768",
      "source": "DB00081",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Tositumomab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00102",
      "source": "DB00081",
      "target": "DB00102",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05229",
      "source": "DB00081",
      "target": "DB05229",
      "description": "The risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00112",
      "source": "DB00081",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Tositumomab.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00006",
      "source": "DB00081",
      "target": "DB00006",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06772",
      "source": "DB00081",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06441",
      "source": "DB00081",
      "target": "DB06441",
      "description": "The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09261",
      "source": "DB00081",
      "target": "DB09261",
      "description": "The risk or severity of adverse effects can be increased when Certoparin is combined with Tositumomab.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01166",
      "source": "DB00081",
      "target": "DB01166",
      "description": "The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04272",
      "source": "DB00081",
      "target": "DB04272",
      "description": "The risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00758",
      "source": "DB00081",
      "target": "DB00758",
      "description": "The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00363",
      "source": "DB00081",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00531",
      "source": "DB00081",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Tositumomab.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06695",
      "source": "DB00081",
      "target": "DB06695",
      "description": "The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06779",
      "source": "DB00081",
      "target": "DB06779",
      "description": "The risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06754",
      "source": "DB00081",
      "target": "DB06754",
      "description": "The risk or severity of adverse effects can be increased when Danaparoid is combined with Tositumomab.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04932",
      "source": "DB00081",
      "target": "DB04932",
      "description": "The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06643",
      "source": "DB00081",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11095",
      "source": "DB00081",
      "target": "DB11095",
      "description": "The risk or severity of adverse effects can be increased when Desirudin is combined with Tositumomab.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01078",
      "source": "DB00081",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Tositumomab.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09255",
      "source": "DB00081",
      "target": "DB09255",
      "description": "The risk or severity of adverse effects can be increased when Dextran is combined with Tositumomab.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11122",
      "source": "DB00081",
      "target": "DB11122",
      "description": "The risk or severity of adverse effects can be increased when Dextran 40 is combined with Tositumomab.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11076",
      "source": "DB00081",
      "target": "DB11076",
      "description": "The risk or severity of adverse effects can be increased when Dextran 70 is combined with Tositumomab.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11241",
      "source": "DB00081",
      "target": "DB11241",
      "description": "The risk or severity of adverse effects can be increased when Dextran 75 is combined with Tositumomab.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00266",
      "source": "DB00081",
      "target": "DB00266",
      "description": "The risk or severity of adverse effects can be increased when Dicoumarol is combined with Tositumomab.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01396",
      "source": "DB00081",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Tositumomab.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00390",
      "source": "DB00081",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Tositumomab.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00975",
      "source": "DB00081",
      "target": "DB00975",
      "description": "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01248",
      "source": "DB00081",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00974",
      "source": "DB00081",
      "target": "DB00974",
      "description": "The risk or severity of adverse effects can be increased when Edetic Acid is combined with Tositumomab.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09075",
      "source": "DB00081",
      "target": "DB09075",
      "description": "The risk or severity of adverse effects can be increased when Edoxaban is combined with Tositumomab.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01225",
      "source": "DB00081",
      "target": "DB01225",
      "description": "The risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00751",
      "source": "DB00081",
      "target": "DB00751",
      "description": "The risk or severity of adverse effects can be increased when Epinastine is combined with Tositumomab.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06392",
      "source": "DB00081",
      "target": "DB06392",
      "description": "The risk or severity of adverse effects can be increased when eplivanserine is combined with Tositumomab.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01240",
      "source": "DB00081",
      "target": "DB01240",
      "description": "The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00063",
      "source": "DB00081",
      "target": "DB00063",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08794",
      "source": "DB00081",
      "target": "DB08794",
      "description": "The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Tositumomab.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08868",
      "source": "DB00081",
      "target": "DB08868",
      "description": "Tositumomab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00569",
      "source": "DB00081",
      "target": "DB00569",
      "description": "The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Tositumomab.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01109",
      "source": "DB00081",
      "target": "DB01109",
      "description": "The risk or severity of adverse effects can be increased when Heparin is combined with Tositumomab.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB02351",
      "source": "DB00081",
      "target": "DB02351",
      "description": "The risk or severity of adverse effects can be increased when Hirulog is combined with Tositumomab.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05266",
      "source": "DB00081",
      "target": "DB05266",
      "description": "The risk or severity of adverse effects can be increased when Ibudilast is combined with Tositumomab.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08887",
      "source": "DB00081",
      "target": "DB08887",
      "description": "The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06406",
      "source": "DB00081",
      "target": "DB06406",
      "description": "The risk or severity of adverse effects can be increased when idraparinux is combined with Tositumomab.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08954",
      "source": "DB00081",
      "target": "DB08954",
      "description": "The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tositumomab.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01088",
      "source": "DB00081",
      "target": "DB01088",
      "description": "The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01097",
      "source": "DB00081",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00001",
      "source": "DB00081",
      "target": "DB00001",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04817",
      "source": "DB00081",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Tositumomab.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00235",
      "source": "DB00081",
      "target": "DB00235",
      "description": "The risk or severity of adverse effects can be increased when Milrinone is combined with Tositumomab.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08813",
      "source": "DB00081",
      "target": "DB08813",
      "description": "The risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00108",
      "source": "DB00081",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05822",
      "source": "DB00081",
      "target": "DB05822",
      "description": "The risk or severity of adverse effects can be increased when NCX 4016 is combined with Tositumomab.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04743",
      "source": "DB00081",
      "target": "DB04743",
      "description": "The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06635",
      "source": "DB00081",
      "target": "DB06635",
      "description": "The risk or severity of adverse effects can be increased when Otamixaban is combined with Tositumomab.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01092",
      "source": "DB00081",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Tositumomab.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01229",
      "source": "DB00081",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00686",
      "source": "DB00081",
      "target": "DB00686",
      "description": "The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00806",
      "source": "DB00081",
      "target": "DB00806",
      "description": "The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00498",
      "source": "DB00081",
      "target": "DB00498",
      "description": "The risk or severity of adverse effects can be increased when Phenindione is combined with Tositumomab.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00946",
      "source": "DB00081",
      "target": "DB00946",
      "description": "The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Tositumomab.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00337",
      "source": "DB00081",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06209",
      "source": "DB00081",
      "target": "DB06209",
      "description": "The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11312",
      "source": "DB00081",
      "target": "DB11312",
      "description": "The risk or severity of adverse effects can be increased when Protein C is combined with Tositumomab.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB11268",
      "source": "DB00081",
      "target": "DB11268",
      "description": "The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Tositumomab.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB10283",
      "source": "DB00081",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB10283",
      "source": "DB00081",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Tositumomab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB02709",
      "source": "DB00081",
      "target": "DB02709",
      "description": "The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09259",
      "source": "DB00081",
      "target": "DB09259",
      "description": "The risk or severity of adverse effects can be increased when Reviparin is combined with Tositumomab.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01207",
      "source": "DB00081",
      "target": "DB01207",
      "description": "The risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06228",
      "source": "DB00081",
      "target": "DB06228",
      "description": "The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01656",
      "source": "DB00081",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Tositumomab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05692",
      "source": "DB00081",
      "target": "DB05692",
      "description": "The risk or severity of adverse effects can be increased when SCH-530348 is combined with Tositumomab.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB01236",
      "source": "DB00081",
      "target": "DB01236",
      "description": "The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06688",
      "source": "DB00081",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB05073",
      "source": "DB00081",
      "target": "DB05073",
      "description": "The risk or severity of adverse effects can be increased when SRT501 is combined with Tositumomab.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB06271",
      "source": "DB00081",
      "target": "DB06271",
      "description": "The risk or severity of adverse effects can be increased when Sulodexide is combined with Tositumomab.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00864",
      "source": "DB00081",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tositumomab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04905",
      "source": "DB00081",
      "target": "DB04905",
      "description": "The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00208",
      "source": "DB00081",
      "target": "DB00208",
      "description": "The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00775",
      "source": "DB00081",
      "target": "DB00775",
      "description": "The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08895",
      "source": "DB00081",
      "target": "DB08895",
      "description": "Tositumomab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB07615",
      "source": "DB00081",
      "target": "DB07615",
      "description": "The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09283",
      "source": "DB00081",
      "target": "DB09283",
      "description": "The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00072",
      "source": "DB00081",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tositumomab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00072",
      "source": "DB00081",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Tositumomab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB08814",
      "source": "DB00081",
      "target": "DB08814",
      "description": "The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB09030",
      "source": "DB00081",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00682",
      "source": "DB00081",
      "target": "DB00682",
      "description": "The risk or severity of adverse effects can be increased when Warfarin is combined with Tositumomab.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB04898",
      "source": "DB00081",
      "target": "DB04898",
      "description": "The risk or severity of adverse effects can be increased when Ximelagatran is combined with Tositumomab.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11617",
      "source": "DB00083",
      "target": "DB11617",
      "description": "Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Aclarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB08897",
      "source": "DB00083",
      "target": "DB08897",
      "description": "Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Aclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00479",
      "source": "DB00083",
      "target": "DB00479",
      "description": "Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Amikacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00517",
      "source": "DB00083",
      "target": "DB00517",
      "description": "Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Anisotropine Methylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00732",
      "source": "DB00083",
      "target": "DB00732",
      "description": "Atracurium besylate may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Atracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00572",
      "source": "DB00083",
      "target": "DB00572",
      "description": "Atropine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Atropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB09023",
      "source": "DB00083",
      "target": "DB09023",
      "description": "Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Benactyzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00245",
      "source": "DB00083",
      "target": "DB00245",
      "description": "Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Benzatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00810",
      "source": "DB00083",
      "target": "DB00810",
      "description": "Biperiden may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Biperiden"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00042",
      "source": "DB00083",
      "target": "DB00042",
      "description": "Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.",
      "name": "Botulinum Toxin Type B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB09007",
      "source": "DB00083",
      "target": "DB09007",
      "description": "Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Chlorphenoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00565",
      "source": "DB00083",
      "target": "DB00565",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium besylate.",
      "name": "Cisatracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00979",
      "source": "DB00083",
      "target": "DB00979",
      "description": "Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Cyclopentolate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00496",
      "source": "DB00083",
      "target": "DB00496",
      "description": "Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00694",
      "source": "DB00083",
      "target": "DB00694",
      "description": "Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01245",
      "source": "DB00083",
      "target": "DB01245",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.",
      "name": "Decamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00967",
      "source": "DB00083",
      "target": "DB00967",
      "description": "Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB08997",
      "source": "DB00083",
      "target": "DB08997",
      "description": "Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Dexetimide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00804",
      "source": "DB00083",
      "target": "DB00804",
      "description": "Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Dicyclomine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11512",
      "source": "DB00083",
      "target": "DB11512",
      "description": "Dihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Dihydrostreptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB02852",
      "source": "DB00083",
      "target": "DB02852",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.",
      "name": "Domoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01135",
      "source": "DB00083",
      "target": "DB01135",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.",
      "name": "Doxacurium chloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00997",
      "source": "DB00083",
      "target": "DB00997",
      "description": "Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00445",
      "source": "DB00083",
      "target": "DB00445",
      "description": "Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Epirubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00392",
      "source": "DB00083",
      "target": "DB00392",
      "description": "Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Ethopropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB06702",
      "source": "DB00083",
      "target": "DB06702",
      "description": "Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00452",
      "source": "DB00083",
      "target": "DB00452",
      "description": "Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Framycetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00483",
      "source": "DB00083",
      "target": "DB00483",
      "description": "Gallamine Triethiodide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Gallamine Triethiodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00798",
      "source": "DB00083",
      "target": "DB00798",
      "description": "Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Gentamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00986",
      "source": "DB00083",
      "target": "DB00986",
      "description": "Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Glycopyrronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB08960",
      "source": "DB00083",
      "target": "DB08960",
      "description": "Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Hexamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11181",
      "source": "DB00083",
      "target": "DB11181",
      "description": "Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Homatropine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11520",
      "source": "DB00083",
      "target": "DB11520",
      "description": "Hygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Hygromycin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00424",
      "source": "DB00083",
      "target": "DB00424",
      "description": "Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Hyoscyamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01177",
      "source": "DB00083",
      "target": "DB01177",
      "description": "Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00332",
      "source": "DB00083",
      "target": "DB00332",
      "description": "Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01172",
      "source": "DB00083",
      "target": "DB01172",
      "description": "Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Kanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00657",
      "source": "DB00083",
      "target": "DB00657",
      "description": "Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Mecamylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00940",
      "source": "DB00083",
      "target": "DB00940",
      "description": "Methantheline may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Methantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00340",
      "source": "DB00083",
      "target": "DB00340",
      "description": "Metixene may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Metixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01336",
      "source": "DB00083",
      "target": "DB01336",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine.",
      "name": "Metocurine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00416",
      "source": "DB00083",
      "target": "DB00416",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.",
      "name": "Metocurine Iodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01578",
      "source": "DB00083",
      "target": "DB01578",
      "description": "Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Metrizamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01226",
      "source": "DB00083",
      "target": "DB01226",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.",
      "name": "Mivacurium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11535",
      "source": "DB00083",
      "target": "DB11535",
      "description": "N-butylscopolammonium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "N-butylscopolammonium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00994",
      "source": "DB00083",
      "target": "DB00994",
      "description": "Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Neomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00955",
      "source": "DB00083",
      "target": "DB00955",
      "description": "Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Netilmicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB06583",
      "source": "DB00083",
      "target": "DB06583",
      "description": "NVA237 may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "NVA237"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01173",
      "source": "DB00083",
      "target": "DB01173",
      "description": "Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Orphenadrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01062",
      "source": "DB00083",
      "target": "DB01062",
      "description": "Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Oxybutynin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00219",
      "source": "DB00083",
      "target": "DB00219",
      "description": "Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Oxyphenonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01337",
      "source": "DB00083",
      "target": "DB01337",
      "description": "Pancuronium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Pancuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01421",
      "source": "DB00083",
      "target": "DB01421",
      "description": "Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Paromomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01090",
      "source": "DB00083",
      "target": "DB01090",
      "description": "Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Pentolinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01338",
      "source": "DB00083",
      "target": "DB01338",
      "description": "Pipecuronium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Pipecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00670",
      "source": "DB00083",
      "target": "DB00670",
      "description": "Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Pirenzepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB06810",
      "source": "DB00083",
      "target": "DB06810",
      "description": "Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Plicamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00387",
      "source": "DB00083",
      "target": "DB00387",
      "description": "Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Procyclidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00782",
      "source": "DB00083",
      "target": "DB00782",
      "description": "Propantheline may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Propantheline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB08437",
      "source": "DB00083",
      "target": "DB08437",
      "description": "Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Puromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB11156",
      "source": "DB00083",
      "target": "DB11156",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pyrantel.",
      "name": "Pyrantel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00908",
      "source": "DB00083",
      "target": "DB00908",
      "description": "Quinidine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB04834",
      "source": "DB00083",
      "target": "DB04834",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.",
      "name": "Rapacuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB03615",
      "source": "DB00083",
      "target": "DB03615",
      "description": "Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Ribostamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00728",
      "source": "DB00083",
      "target": "DB00728",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rocuronium.",
      "name": "Rocuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00747",
      "source": "DB00083",
      "target": "DB00747",
      "description": "Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Scopolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB09300",
      "source": "DB00083",
      "target": "DB09300",
      "description": "Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Scopolamine butylbromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01591",
      "source": "DB00083",
      "target": "DB01591",
      "description": "Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00919",
      "source": "DB00083",
      "target": "DB00919",
      "description": "Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Spectinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01082",
      "source": "DB00083",
      "target": "DB01082",
      "description": "Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Streptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00428",
      "source": "DB00083",
      "target": "DB00428",
      "description": "Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00202",
      "source": "DB00083",
      "target": "DB00202",
      "description": "Botulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.",
      "name": "Succinylcholine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01409",
      "source": "DB00083",
      "target": "DB01409",
      "description": "Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00684",
      "source": "DB00083",
      "target": "DB00684",
      "description": "Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.",
      "name": "Tobramycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01036",
      "source": "DB00083",
      "target": "DB01036",
      "description": "Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00376",
      "source": "DB00083",
      "target": "DB00376",
      "description": "Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Trihexyphenidyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01116",
      "source": "DB00083",
      "target": "DB01116",
      "description": "Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Trimethaphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00809",
      "source": "DB00083",
      "target": "DB00809",
      "description": "Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Tropicamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00209",
      "source": "DB00083",
      "target": "DB00209",
      "description": "Trospium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Trospium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01199",
      "source": "DB00083",
      "target": "DB01199",
      "description": "Tubocurarine may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Tubocurarine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB09076",
      "source": "DB00083",
      "target": "DB09076",
      "description": "Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB01339",
      "source": "DB00083",
      "target": "DB01339",
      "description": "Vecuronium may increase the anticholinergic activities of Botulinum Toxin Type A.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00284",
      "source": "DB00082",
      "target": "DB00284",
      "description": "Pegvisomant may increase the hypoglycemic activities of Acarbose.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB09043",
      "source": "DB00082",
      "target": "DB09043",
      "description": "Pegvisomant may increase the hypoglycemic activities of Albiglutide.",
      "name": "Albiglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00802",
      "source": "DB00082",
      "target": "DB00802",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.",
      "name": "Alfentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06203",
      "source": "DB00082",
      "target": "DB06203",
      "description": "Pegvisomant may increase the hypoglycemic activities of Alogliptin.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01555",
      "source": "DB00082",
      "target": "DB01555",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphacetylmethadol.",
      "name": "Alphacetylmethadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01238",
      "source": "DB00082",
      "target": "DB01238",
      "description": "The serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01459",
      "source": "DB00082",
      "target": "DB01459",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.",
      "name": "Bezitramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01200",
      "source": "DB00082",
      "target": "DB01200",
      "description": "Pegvisomant may increase the hypoglycemic activities of Bromocriptine.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00921",
      "source": "DB00082",
      "target": "DB00921",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.",
      "name": "Buprenorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00611",
      "source": "DB00082",
      "target": "DB00611",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.",
      "name": "Butorphanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB08907",
      "source": "DB00082",
      "target": "DB08907",
      "description": "Pegvisomant may increase the hypoglycemic activities of Canagliflozin.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01535",
      "source": "DB00082",
      "target": "DB01535",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil.",
      "name": "Carfentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00672",
      "source": "DB00082",
      "target": "DB00672",
      "description": "Pegvisomant may increase the hypoglycemic activities of Chlorpropamide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01166",
      "source": "DB00082",
      "target": "DB01166",
      "description": "The serum concentration of Cilostazol can be increased when it is combined with Pegvisomant.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00318",
      "source": "DB00082",
      "target": "DB00318",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.",
      "name": "Codeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06292",
      "source": "DB00082",
      "target": "DB06292",
      "description": "Pegvisomant may increase the hypoglycemic activities of Dapagliflozin.",
      "name": "Dapagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01529",
      "source": "DB00082",
      "target": "DB01529",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.",
      "name": "Dextromoramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00647",
      "source": "DB00082",
      "target": "DB00647",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.",
      "name": "Dextropropoxyphene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01209",
      "source": "DB00082",
      "target": "DB01209",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.",
      "name": "Dezocine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01551",
      "source": "DB00082",
      "target": "DB01551",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.",
      "name": "Dihydrocodeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01450",
      "source": "DB00082",
      "target": "DB01450",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.",
      "name": "Dihydroetorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01565",
      "source": "DB00082",
      "target": "DB01565",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.",
      "name": "Dihydromorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01081",
      "source": "DB00082",
      "target": "DB01081",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.",
      "name": "Diphenoxylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00280",
      "source": "DB00082",
      "target": "DB00280",
      "description": "Pegvisomant may increase the hypoglycemic activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB08861",
      "source": "DB00082",
      "target": "DB08861",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.",
      "name": "DPDPE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB09045",
      "source": "DB00082",
      "target": "DB09045",
      "description": "Pegvisomant may increase the hypoglycemic activities of Dulaglutide.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB09038",
      "source": "DB00082",
      "target": "DB09038",
      "description": "Pegvisomant may increase the hypoglycemic activities of Empagliflozin.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01466",
      "source": "DB00082",
      "target": "DB01466",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.",
      "name": "Ethylmorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01497",
      "source": "DB00082",
      "target": "DB01497",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.",
      "name": "Etorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01276",
      "source": "DB00082",
      "target": "DB01276",
      "description": "Pegvisomant may increase the hypoglycemic activities of Exenatide.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00813",
      "source": "DB00082",
      "target": "DB00813",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.",
      "name": "Fentanyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01120",
      "source": "DB00082",
      "target": "DB01120",
      "description": "Pegvisomant may increase the hypoglycemic activities of Gliclazide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00222",
      "source": "DB00082",
      "target": "DB00222",
      "description": "Pegvisomant may increase the hypoglycemic activities of Glimepiride.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01067",
      "source": "DB00082",
      "target": "DB01067",
      "description": "Pegvisomant may increase the hypoglycemic activities of Glipizide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01016",
      "source": "DB00082",
      "target": "DB01016",
      "description": "Pegvisomant may increase the hypoglycemic activities of Glyburide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01452",
      "source": "DB00082",
      "target": "DB01452",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Heroin.",
      "name": "Heroin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00956",
      "source": "DB00082",
      "target": "DB00956",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.",
      "name": "Hydrocodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00327",
      "source": "DB00082",
      "target": "DB00327",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.",
      "name": "Hydromorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01306",
      "source": "DB00082",
      "target": "DB01306",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Aspart.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01307",
      "source": "DB00082",
      "target": "DB01307",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Detemir.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00047",
      "source": "DB00082",
      "target": "DB00047",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01309",
      "source": "DB00082",
      "target": "DB01309",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Glulisine.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00030",
      "source": "DB00082",
      "target": "DB00030",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00046",
      "source": "DB00082",
      "target": "DB00046",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06738",
      "source": "DB00082",
      "target": "DB06738",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.",
      "name": "Ketobemidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06791",
      "source": "DB00082",
      "target": "DB06791",
      "description": "Pegvisomant may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01227",
      "source": "DB00082",
      "target": "DB01227",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levomethadyl Acetate.",
      "name": "Levomethadyl Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00854",
      "source": "DB00082",
      "target": "DB00854",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.",
      "name": "Levorphanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06655",
      "source": "DB00082",
      "target": "DB06655",
      "description": "Pegvisomant may increase the hypoglycemic activities of Liraglutide.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB09174",
      "source": "DB00082",
      "target": "DB09174",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Lofentanil.",
      "name": "Lofentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01277",
      "source": "DB00082",
      "target": "DB01277",
      "description": "Pegvisomant may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00331",
      "source": "DB00082",
      "target": "DB00331",
      "description": "Pegvisomant may increase the hypoglycemic activities of Metformin.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00333",
      "source": "DB00082",
      "target": "DB00333",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01433",
      "source": "DB00082",
      "target": "DB01433",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl Acetate.",
      "name": "Methadyl Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00834",
      "source": "DB00082",
      "target": "DB00834",
      "description": "Pegvisomant may increase the hypoglycemic activities of Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00491",
      "source": "DB00082",
      "target": "DB00491",
      "description": "Pegvisomant may increase the hypoglycemic activities of Miglitol.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00295",
      "source": "DB00082",
      "target": "DB00295",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.",
      "name": "Morphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00844",
      "source": "DB00082",
      "target": "DB00844",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.",
      "name": "Nalbuphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00731",
      "source": "DB00082",
      "target": "DB00731",
      "description": "Pegvisomant may increase the hypoglycemic activities of Nateglinide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB11609",
      "source": "DB00082",
      "target": "DB11609",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.",
      "name": "Normethadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00104",
      "source": "DB00082",
      "target": "DB00104",
      "description": "Pegvisomant may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB11130",
      "source": "DB00082",
      "target": "DB11130",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.",
      "name": "Opium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00497",
      "source": "DB00082",
      "target": "DB00497",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.",
      "name": "Oxycodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01192",
      "source": "DB00082",
      "target": "DB01192",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.",
      "name": "Oxymorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06663",
      "source": "DB00082",
      "target": "DB06663",
      "description": "Pegvisomant may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB09208",
      "source": "DB00082",
      "target": "DB09208",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegloticase.",
      "name": "Pegloticase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00738",
      "source": "DB00082",
      "target": "DB00738",
      "description": "Pegvisomant may increase the hypoglycemic activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00652",
      "source": "DB00082",
      "target": "DB00652",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.",
      "name": "Pentazocine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00454",
      "source": "DB00082",
      "target": "DB00454",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pethidine.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01132",
      "source": "DB00082",
      "target": "DB01132",
      "description": "Pegvisomant may increase the hypoglycemic activities of Pioglitazone.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01278",
      "source": "DB00082",
      "target": "DB01278",
      "description": "Pegvisomant may increase the hypoglycemic activities of Pramlintide.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00468",
      "source": "DB00082",
      "target": "DB00468",
      "description": "Pegvisomant may increase the hypoglycemic activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00899",
      "source": "DB00082",
      "target": "DB00899",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.",
      "name": "Remifentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00912",
      "source": "DB00082",
      "target": "DB00912",
      "description": "Pegvisomant may increase the hypoglycemic activities of Repaglinide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00412",
      "source": "DB00082",
      "target": "DB00412",
      "description": "Pegvisomant may increase the hypoglycemic activities of Rosiglitazone.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06335",
      "source": "DB00082",
      "target": "DB06335",
      "description": "Pegvisomant may increase the hypoglycemic activities of Saxagliptin.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01261",
      "source": "DB00082",
      "target": "DB01261",
      "description": "Pegvisomant may increase the hypoglycemic activities of Sitagliptin.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00708",
      "source": "DB00082",
      "target": "DB00708",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.",
      "name": "Sufentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00359",
      "source": "DB00082",
      "target": "DB00359",
      "description": "Pegvisomant may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01015",
      "source": "DB00082",
      "target": "DB01015",
      "description": "Pegvisomant may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00263",
      "source": "DB00082",
      "target": "DB00263",
      "description": "Pegvisomant may increase the hypoglycemic activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01268",
      "source": "DB00082",
      "target": "DB01268",
      "description": "Pegvisomant may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB06204",
      "source": "DB00082",
      "target": "DB06204",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.",
      "name": "Tapentadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00839",
      "source": "DB00082",
      "target": "DB00839",
      "description": "Pegvisomant may increase the hypoglycemic activities of Tolazamide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB01124",
      "source": "DB00082",
      "target": "DB01124",
      "description": "Pegvisomant may increase the hypoglycemic activities of Tolbutamide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00193",
      "source": "DB00082",
      "target": "DB00193",
      "description": "The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.",
      "name": "Tramadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00054",
      "source": "DB00086",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Streptokinase.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01418",
      "source": "DB00086",
      "target": "DB01418",
      "description": "Streptokinase may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00945",
      "source": "DB00086",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Streptokinase.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00770",
      "source": "DB00086",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Streptokinase.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00233",
      "source": "DB00086",
      "target": "DB00233",
      "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Streptokinase.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00261",
      "source": "DB00086",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Streptokinase.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05099",
      "source": "DB00086",
      "target": "DB05099",
      "description": "Streptokinase may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11598",
      "source": "DB00086",
      "target": "DB11598",
      "description": "Streptokinase may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06605",
      "source": "DB00086",
      "target": "DB06605",
      "description": "Streptokinase may increase the anticoagulant activities of Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06692",
      "source": "DB00086",
      "target": "DB06692",
      "description": "The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00407",
      "source": "DB00086",
      "target": "DB00407",
      "description": "Streptokinase may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00278",
      "source": "DB00086",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Streptokinase.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00972",
      "source": "DB00086",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Streptokinase.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00102",
      "source": "DB00086",
      "target": "DB00102",
      "description": "Streptokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05229",
      "source": "DB00086",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Streptokinase.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00006",
      "source": "DB00086",
      "target": "DB00006",
      "description": "Streptokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06441",
      "source": "DB00086",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Streptokinase.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09261",
      "source": "DB00086",
      "target": "DB09261",
      "description": "Streptokinase may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01166",
      "source": "DB00086",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Streptokinase.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB04272",
      "source": "DB00086",
      "target": "DB04272",
      "description": "Streptokinase may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00758",
      "source": "DB00086",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Streptokinase.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06695",
      "source": "DB00086",
      "target": "DB06695",
      "description": "Streptokinase may increase the anticoagulant activities of Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06779",
      "source": "DB00086",
      "target": "DB06779",
      "description": "Streptokinase may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06754",
      "source": "DB00086",
      "target": "DB06754",
      "description": "Streptokinase may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB04932",
      "source": "DB00086",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Streptokinase.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11095",
      "source": "DB00086",
      "target": "DB11095",
      "description": "Streptokinase may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09255",
      "source": "DB00086",
      "target": "DB09255",
      "description": "Streptokinase may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11122",
      "source": "DB00086",
      "target": "DB11122",
      "description": "Streptokinase may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11076",
      "source": "DB00086",
      "target": "DB11076",
      "description": "Streptokinase may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11241",
      "source": "DB00086",
      "target": "DB11241",
      "description": "Streptokinase may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00266",
      "source": "DB00086",
      "target": "DB00266",
      "description": "Streptokinase may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00861",
      "source": "DB00086",
      "target": "DB00861",
      "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Streptokinase.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00975",
      "source": "DB00086",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Streptokinase.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00974",
      "source": "DB00086",
      "target": "DB00974",
      "description": "Streptokinase may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09075",
      "source": "DB00086",
      "target": "DB09075",
      "description": "Streptokinase may increase the anticoagulant activities of Edoxaban.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01225",
      "source": "DB00086",
      "target": "DB01225",
      "description": "Streptokinase may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00751",
      "source": "DB00086",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Streptokinase.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06392",
      "source": "DB00086",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Streptokinase.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01240",
      "source": "DB00086",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Streptokinase.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00063",
      "source": "DB00086",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Streptokinase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB08794",
      "source": "DB00086",
      "target": "DB08794",
      "description": "Streptokinase may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00569",
      "source": "DB00086",
      "target": "DB00569",
      "description": "Streptokinase may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01109",
      "source": "DB00086",
      "target": "DB01109",
      "description": "Streptokinase may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB02351",
      "source": "DB00086",
      "target": "DB02351",
      "description": "Streptokinase may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05266",
      "source": "DB00086",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Streptokinase.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB08887",
      "source": "DB00086",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Streptokinase.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06406",
      "source": "DB00086",
      "target": "DB06406",
      "description": "Streptokinase may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB08954",
      "source": "DB00086",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Streptokinase.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01088",
      "source": "DB00086",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Streptokinase.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00001",
      "source": "DB00086",
      "target": "DB00001",
      "description": "Streptokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09211",
      "source": "DB00086",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Streptokinase.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00244",
      "source": "DB00086",
      "target": "DB00244",
      "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Streptokinase.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00235",
      "source": "DB00086",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Streptokinase.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB08813",
      "source": "DB00086",
      "target": "DB08813",
      "description": "Streptokinase may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05822",
      "source": "DB00086",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Streptokinase.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB04743",
      "source": "DB00086",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Streptokinase.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06635",
      "source": "DB00086",
      "target": "DB06635",
      "description": "Streptokinase may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00686",
      "source": "DB00086",
      "target": "DB00686",
      "description": "Streptokinase may increase the anticoagulant activities of Pentosan Polysulfate.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00806",
      "source": "DB00086",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Streptokinase.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00498",
      "source": "DB00086",
      "target": "DB00498",
      "description": "Streptokinase may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00946",
      "source": "DB00086",
      "target": "DB00946",
      "description": "Streptokinase may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06209",
      "source": "DB00086",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Streptokinase.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11312",
      "source": "DB00086",
      "target": "DB11312",
      "description": "Streptokinase may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB11268",
      "source": "DB00086",
      "target": "DB11268",
      "description": "Streptokinase may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB02709",
      "source": "DB00086",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Streptokinase.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09259",
      "source": "DB00086",
      "target": "DB09259",
      "description": "Streptokinase may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01207",
      "source": "DB00086",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Streptokinase.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06228",
      "source": "DB00086",
      "target": "DB06228",
      "description": "Streptokinase may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00936",
      "source": "DB00086",
      "target": "DB00936",
      "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Streptokinase.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05692",
      "source": "DB00086",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Streptokinase.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB01236",
      "source": "DB00086",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Streptokinase.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB05073",
      "source": "DB00086",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Streptokinase.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB06271",
      "source": "DB00086",
      "target": "DB06271",
      "description": "Streptokinase may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB04905",
      "source": "DB00086",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Streptokinase.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00208",
      "source": "DB00086",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Streptokinase.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00775",
      "source": "DB00086",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Streptokinase.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB07615",
      "source": "DB00086",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Streptokinase.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09283",
      "source": "DB00086",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Streptokinase.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00374",
      "source": "DB00086",
      "target": "DB00374",
      "description": "The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB08814",
      "source": "DB00086",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Streptokinase.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB09030",
      "source": "DB00086",
      "target": "DB09030",
      "description": "Vorapaxar may increase the anticoagulant activities of Streptokinase.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00682",
      "source": "DB00086",
      "target": "DB00682",
      "description": "Streptokinase may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB04898",
      "source": "DB00086",
      "target": "DB04898",
      "description": "Streptokinase may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00511",
      "source": "DB00087",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Alemtuzumab.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB12768",
      "source": "DB00087",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Alemtuzumab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00112",
      "source": "DB00087",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB06772",
      "source": "DB00087",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alemtuzumab.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00363",
      "source": "DB00087",
      "target": "DB00363",
      "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00531",
      "source": "DB00087",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB06643",
      "source": "DB00087",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01078",
      "source": "DB00087",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Alemtuzumab.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01396",
      "source": "DB00087",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Alemtuzumab.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00390",
      "source": "DB00087",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Alemtuzumab.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01248",
      "source": "DB00087",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB08868",
      "source": "DB00087",
      "target": "DB08868",
      "description": "Alemtuzumab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01097",
      "source": "DB00087",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB04817",
      "source": "DB00087",
      "target": "DB04817",
      "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Alemtuzumab.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00108",
      "source": "DB00087",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01092",
      "source": "DB00087",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Alemtuzumab.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01229",
      "source": "DB00087",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Alemtuzumab.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00337",
      "source": "DB00087",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB10283",
      "source": "DB00087",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB10283",
      "source": "DB00087",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Alemtuzumab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB01656",
      "source": "DB00087",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Alemtuzumab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB06688",
      "source": "DB00087",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00864",
      "source": "DB00087",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alemtuzumab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB08895",
      "source": "DB00087",
      "target": "DB08895",
      "description": "Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00072",
      "source": "DB00087",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB12768",
      "source": "DB00092",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Alefacept.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB06643",
      "source": "DB00092",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB08868",
      "source": "DB00092",
      "target": "DB08868",
      "description": "Alefacept may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB01097",
      "source": "DB00092",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB00108",
      "source": "DB00092",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB00337",
      "source": "DB00092",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB10283",
      "source": "DB00092",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Alefacept is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB10283",
      "source": "DB00092",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Alefacept.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB01656",
      "source": "DB00092",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Alefacept.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB06688",
      "source": "DB00092",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB00864",
      "source": "DB00092",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alefacept.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB08895",
      "source": "DB00092",
      "target": "DB08895",
      "description": "Alefacept may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB00072",
      "source": "DB00092",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Alefacept.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB12768",
      "source": "DB00095",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Efalizumab.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB06643",
      "source": "DB00095",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB08868",
      "source": "DB00095",
      "target": "DB08868",
      "description": "Efalizumab may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB01097",
      "source": "DB00095",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB00108",
      "source": "DB00095",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB00337",
      "source": "DB00095",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB10283",
      "source": "DB00095",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB10283",
      "source": "DB00095",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Efalizumab.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB01656",
      "source": "DB00095",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Efalizumab.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB06688",
      "source": "DB00095",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB00864",
      "source": "DB00095",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Efalizumab.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB08895",
      "source": "DB00095",
      "target": "DB08895",
      "description": "Efalizumab may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB00072",
      "source": "DB00095",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Efalizumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02365",
      "source": "DB00091",
      "target": "DB02365",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.",
      "name": "1,10-Phenanthroline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04744",
      "source": "DB00091",
      "target": "DB04744",
      "description": "The metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.",
      "name": "2-HYDROXY-1,4-NAPHTHOQUINONE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11496",
      "source": "DB00091",
      "target": "DB11496",
      "description": "The metabolism of Cyclosporine can be decreased when combined with 2-mercaptobenzothiazole.",
      "name": "2-mercaptobenzothiazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04459",
      "source": "DB00091",
      "target": "DB04459",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.",
      "name": "3,4-Dichloroisocoumarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB07347",
      "source": "DB00091",
      "target": "DB07347",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.",
      "name": "4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05812",
      "source": "DB00091",
      "target": "DB05812",
      "description": "The metabolism of Abiraterone can be decreased when combined with Cyclosporine.",
      "name": "Abiraterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01193",
      "source": "DB00091",
      "target": "DB01193",
      "description": "The serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06736",
      "source": "DB00091",
      "target": "DB06736",
      "description": "Aceclofenac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06736",
      "source": "DB00091",
      "target": "DB06736",
      "description": "The metabolism of Aceclofenac can be decreased when combined with Cyclosporine.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01418",
      "source": "DB00091",
      "target": "DB01418",
      "description": "The metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00316",
      "source": "DB00091",
      "target": "DB00316",
      "description": "The metabolism of Acetaminophen can be decreased when combined with Cyclosporine.",
      "name": "Acetaminophen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00819",
      "source": "DB00091",
      "target": "DB00819",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.",
      "name": "Acetazolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00945",
      "source": "DB00091",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00945",
      "source": "DB00091",
      "target": "DB00945",
      "description": "The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Cyclosporine.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11617",
      "source": "DB00091",
      "target": "DB11617",
      "description": "Aclarubicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Aclarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00051",
      "source": "DB00091",
      "target": "DB00051",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00210",
      "source": "DB00091",
      "target": "DB00210",
      "description": "Adapalene may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00546",
      "source": "DB00091",
      "target": "DB00546",
      "description": "The metabolism of Adinazolam can be decreased when combined with Cyclosporine.",
      "name": "Adinazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08916",
      "source": "DB00091",
      "target": "DB08916",
      "description": "The serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.",
      "name": "Afatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00518",
      "source": "DB00091",
      "target": "DB00518",
      "description": "The metabolism of Albendazole can be decreased when combined with Cyclosporine.",
      "name": "Albendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00240",
      "source": "DB00091",
      "target": "DB00240",
      "description": "The metabolism of Alclometasone can be decreased when combined with Cyclosporine.",
      "name": "Alclometasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04630",
      "source": "DB00091",
      "target": "DB04630",
      "description": "The serum concentration of Aldosterone can be decreased when it is combined with Cyclosporine.",
      "name": "Aldosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11363",
      "source": "DB00091",
      "target": "DB11363",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alectinib.",
      "name": "Alectinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00802",
      "source": "DB00091",
      "target": "DB00802",
      "description": "The metabolism of Alfentanil can be decreased when combined with Cyclosporine.",
      "name": "Alfentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00346",
      "source": "DB00091",
      "target": "DB00346",
      "description": "The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.",
      "name": "Alfuzosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09026",
      "source": "DB00091",
      "target": "DB09026",
      "description": "The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.",
      "name": "Aliskiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09026",
      "source": "DB00091",
      "target": "DB09026",
      "description": "The metabolism of Aliskiren can be decreased when combined with Cyclosporine.",
      "name": "Aliskiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00523",
      "source": "DB00091",
      "target": "DB00523",
      "description": "The serum concentration of Alitretinoin can be decreased when it is combined with Cyclosporine.",
      "name": "Alitretinoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01431",
      "source": "DB00091",
      "target": "DB01431",
      "description": "The metabolism of Allylestrenol can be decreased when combined with Cyclosporine.",
      "name": "Allylestrenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00918",
      "source": "DB00091",
      "target": "DB00918",
      "description": "The metabolism of Almotriptan can be decreased when combined with Cyclosporine.",
      "name": "Almotriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06203",
      "source": "DB00091",
      "target": "DB06203",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06203",
      "source": "DB00091",
      "target": "DB06203",
      "description": "The metabolism of Alogliptin can be decreased when combined with Cyclosporine.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00969",
      "source": "DB00091",
      "target": "DB00969",
      "description": "The metabolism of Alosetron can be decreased when combined with Cyclosporine.",
      "name": "Alosetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00058",
      "source": "DB00091",
      "target": "DB00058",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Alpha-1-proteinase inhibitor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00404",
      "source": "DB00091",
      "target": "DB00404",
      "description": "The metabolism of Alprazolam can be decreased when combined with Cyclosporine.",
      "name": "Alprazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00915",
      "source": "DB00091",
      "target": "DB00915",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Amantadine.",
      "name": "Amantadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06403",
      "source": "DB00091",
      "target": "DB06403",
      "description": "The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.",
      "name": "Ambrisentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06403",
      "source": "DB00091",
      "target": "DB06403",
      "description": "The metabolism of Ambrisentan can be decreased when combined with Cyclosporine.",
      "name": "Ambrisentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06742",
      "source": "DB00091",
      "target": "DB06742",
      "description": "The metabolism of Ambroxol can be decreased when combined with Cyclosporine.",
      "name": "Ambroxol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00479",
      "source": "DB00091",
      "target": "DB00479",
      "description": "Amikacin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Amikacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00594",
      "source": "DB00091",
      "target": "DB00594",
      "description": "Amiloride may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Amiloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00345",
      "source": "DB00091",
      "target": "DB00345",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Aminohippuric acid.",
      "name": "Aminohippuric acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01424",
      "source": "DB00091",
      "target": "DB01424",
      "description": "The metabolism of Aminophenazone can be decreased when combined with Cyclosporine.",
      "name": "Aminophenazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01223",
      "source": "DB00091",
      "target": "DB01223",
      "description": "The metabolism of Aminophylline can be decreased when combined with Cyclosporine.",
      "name": "Aminophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01118",
      "source": "DB00091",
      "target": "DB01118",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Amiodarone.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00321",
      "source": "DB00091",
      "target": "DB00321",
      "description": "The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.",
      "name": "Amitriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00381",
      "source": "DB00091",
      "target": "DB00381",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Amlodipine.",
      "name": "Amlodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01351",
      "source": "DB00091",
      "target": "DB01351",
      "description": "The metabolism of Cyclosporine can be increased when combined with Amobarbital.",
      "name": "Amobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00613",
      "source": "DB00091",
      "target": "DB00613",
      "description": "The serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine.",
      "name": "Amodiaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09056",
      "source": "DB00091",
      "target": "DB09056",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Amorolfine.",
      "name": "Amorolfine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00681",
      "source": "DB00091",
      "target": "DB00681",
      "description": "The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cyclosporine.",
      "name": "Amphotericin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00681",
      "source": "DB00091",
      "target": "DB00681",
      "description": "Amphotericin B may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Amphotericin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00701",
      "source": "DB00091",
      "target": "DB00701",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Amprenavir.",
      "name": "Amprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00701",
      "source": "DB00091",
      "target": "DB00701",
      "description": "The metabolism of Amprenavir can be decreased when combined with Cyclosporine.",
      "name": "Amprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01427",
      "source": "DB00091",
      "target": "DB01427",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone.",
      "name": "Amrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00276",
      "source": "DB00091",
      "target": "DB00276",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Amsacrine.",
      "name": "Amsacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05058",
      "source": "DB00091",
      "target": "DB05058",
      "description": "The metabolism of Cyclosporine can be decreased when combined with AN2690.",
      "name": "AN2690"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00362",
      "source": "DB00091",
      "target": "DB00362",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Anidulafungin.",
      "name": "Anidulafungin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01435",
      "source": "DB00091",
      "target": "DB01435",
      "description": "Antipyrine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01435",
      "source": "DB00091",
      "target": "DB01435",
      "description": "The metabolism of Antipyrine can be decreased when combined with Cyclosporine.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11598",
      "source": "DB00091",
      "target": "DB11598",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06605",
      "source": "DB00091",
      "target": "DB06605",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Apixaban.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05676",
      "source": "DB00091",
      "target": "DB05676",
      "description": "Apremilast may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05676",
      "source": "DB00091",
      "target": "DB05676",
      "description": "The metabolism of Apremilast can be decreased when combined with Cyclosporine.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00673",
      "source": "DB00091",
      "target": "DB00673",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.",
      "name": "Aprepitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06692",
      "source": "DB00091",
      "target": "DB06692",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.",
      "name": "Aprotinin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04557",
      "source": "DB00091",
      "target": "DB04557",
      "description": "The metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine.",
      "name": "Arachidonic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01274",
      "source": "DB00091",
      "target": "DB01274",
      "description": "The metabolism of Arformoterol can be decreased when combined with Cyclosporine.",
      "name": "Arformoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00278",
      "source": "DB00091",
      "target": "DB00278",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Argatroban.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00278",
      "source": "DB00091",
      "target": "DB00278",
      "description": "The metabolism of Argatroban can be decreased when combined with Cyclosporine.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01238",
      "source": "DB00091",
      "target": "DB01238",
      "description": "The serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.",
      "name": "Aripiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06413",
      "source": "DB00091",
      "target": "DB06413",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.",
      "name": "Armodafinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01169",
      "source": "DB00091",
      "target": "DB01169",
      "description": "The serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06697",
      "source": "DB00091",
      "target": "DB06697",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Artemether.",
      "name": "Artemether"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06216",
      "source": "DB00091",
      "target": "DB06216",
      "description": "The metabolism of Asenapine can be decreased when combined with Cyclosporine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00637",
      "source": "DB00091",
      "target": "DB00637",
      "description": "The metabolism of Astemizole can be decreased when combined with Cyclosporine.",
      "name": "Astemizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11586",
      "source": "DB00091",
      "target": "DB11586",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Asunaprevir.",
      "name": "Asunaprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01072",
      "source": "DB00091",
      "target": "DB01072",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01072",
      "source": "DB00091",
      "target": "DB01072",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Atazanavir.",
      "name": "Atazanavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00335",
      "source": "DB00091",
      "target": "DB00335",
      "description": "The serum concentration of Atenolol can be decreased when it is combined with Cyclosporine.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00289",
      "source": "DB00091",
      "target": "DB00289",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Atomoxetine.",
      "name": "Atomoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01076",
      "source": "DB00091",
      "target": "DB01076",
      "description": "The serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01076",
      "source": "DB00091",
      "target": "DB01076",
      "description": "The metabolism of Atorvastatin can be decreased when combined with Cyclosporine.",
      "name": "Atorvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00732",
      "source": "DB00091",
      "target": "DB00732",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Atracurium besylate.",
      "name": "Atracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06237",
      "source": "DB00091",
      "target": "DB06237",
      "description": "The serum concentration of Avanafil can be increased when it is combined with Cyclosporine.",
      "name": "Avanafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06626",
      "source": "DB00091",
      "target": "DB06626",
      "description": "The metabolism of Axitinib can be decreased when combined with Cyclosporine.",
      "name": "Axitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB07402",
      "source": "DB00091",
      "target": "DB07402",
      "description": "Azapropazone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00972",
      "source": "DB00091",
      "target": "DB00972",
      "description": "Azelastine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00972",
      "source": "DB00091",
      "target": "DB00972",
      "description": "The metabolism of Azelastine can be decreased when combined with Cyclosporine.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09230",
      "source": "DB00091",
      "target": "DB09230",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.",
      "name": "Azelnidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08822",
      "source": "DB00091",
      "target": "DB08822",
      "description": "Azilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Azilsartan medoxomil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04957",
      "source": "DB00091",
      "target": "DB04957",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Azimilide.",
      "name": "Azimilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00207",
      "source": "DB00091",
      "target": "DB00207",
      "description": "The metabolism of Azithromycin can be decreased when combined with Cyclosporine.",
      "name": "Azithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06733",
      "source": "DB00091",
      "target": "DB06733",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Bafilomycin A1.",
      "name": "Bafilomycin A1"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01014",
      "source": "DB00091",
      "target": "DB01014",
      "description": "Balsalazide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04975",
      "source": "DB00091",
      "target": "DB04975",
      "description": "The metabolism of Banoxantrone can be decreased when combined with Cyclosporine.",
      "name": "Banoxantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01483",
      "source": "DB00091",
      "target": "DB01483",
      "description": "The metabolism of Cyclosporine can be increased when combined with Barbital.",
      "name": "Barbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09227",
      "source": "DB00091",
      "target": "DB09227",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Barnidipine.",
      "name": "Barnidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03880",
      "source": "DB00091",
      "target": "DB03880",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Batimastat.",
      "name": "Batimastat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB12768",
      "source": "DB00091",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Cyclosporine.",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08903",
      "source": "DB00091",
      "target": "DB08903",
      "description": "The metabolism of Bedaquiline can be decreased when combined with Cyclosporine.",
      "name": "Bedaquiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00542",
      "source": "DB00091",
      "target": "DB00542",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Benazepril.",
      "name": "Benazepril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09231",
      "source": "DB00091",
      "target": "DB09231",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.",
      "name": "Benidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04812",
      "source": "DB00091",
      "target": "DB04812",
      "description": "Benoxaprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03127",
      "source": "DB00091",
      "target": "DB03127",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.",
      "name": "Benzamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01086",
      "source": "DB00091",
      "target": "DB01086",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Benzocaine.",
      "name": "Benzocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03793",
      "source": "DB00091",
      "target": "DB03793",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Benzoic Acid.",
      "name": "Benzoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00865",
      "source": "DB00091",
      "target": "DB00865",
      "description": "The metabolism of Benzphetamine can be decreased when combined with Cyclosporine.",
      "name": "Benzphetamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06770",
      "source": "DB00091",
      "target": "DB06770",
      "description": "The metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.",
      "name": "Benzyl alcohol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01244",
      "source": "DB00091",
      "target": "DB01244",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.",
      "name": "Bepridil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00443",
      "source": "DB00091",
      "target": "DB00443",
      "description": "The serum concentration of Betamethasone can be decreased when it is combined with Cyclosporine.",
      "name": "Betamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00307",
      "source": "DB00091",
      "target": "DB00307",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Bexarotene.",
      "name": "Bexarotene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01393",
      "source": "DB00091",
      "target": "DB01393",
      "description": "Cyclosporine may increase the nephrotoxic activities of Bezafibrate.",
      "name": "Bezafibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01393",
      "source": "DB00091",
      "target": "DB01393",
      "description": "The metabolism of Bezafibrate can be decreased when combined with Cyclosporine.",
      "name": "Bezafibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01128",
      "source": "DB00091",
      "target": "DB01128",
      "description": "The metabolism of Bicalutamide can be decreased when combined with Cyclosporine.",
      "name": "Bicalutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04794",
      "source": "DB00091",
      "target": "DB04794",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Bifonazole.",
      "name": "Bifonazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00810",
      "source": "DB00091",
      "target": "DB00810",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Biperiden.",
      "name": "Biperiden"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00612",
      "source": "DB00091",
      "target": "DB00612",
      "description": "The metabolism of Bisoprolol can be decreased when combined with Cyclosporine.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00006",
      "source": "DB00091",
      "target": "DB00006",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08873",
      "source": "DB00091",
      "target": "DB08873",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Boceprevir.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08873",
      "source": "DB00091",
      "target": "DB08873",
      "description": "The serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.",
      "name": "Boceprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00188",
      "source": "DB00091",
      "target": "DB00188",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Bortezomib.",
      "name": "Bortezomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00559",
      "source": "DB00091",
      "target": "DB00559",
      "description": "The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.",
      "name": "Bosentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06616",
      "source": "DB00091",
      "target": "DB06616",
      "description": "The serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.",
      "name": "Bosutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08870",
      "source": "DB00091",
      "target": "DB08870",
      "description": "The serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclosporine.",
      "name": "Brentuximab vedotin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09128",
      "source": "DB00091",
      "target": "DB09128",
      "description": "The serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.",
      "name": "Brexpiprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01194",
      "source": "DB00091",
      "target": "DB01194",
      "description": "The metabolism of Brinzolamide can be decreased when combined with Cyclosporine.",
      "name": "Brinzolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01558",
      "source": "DB00091",
      "target": "DB01558",
      "description": "The metabolism of Bromazepam can be decreased when combined with Cyclosporine.",
      "name": "Bromazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00963",
      "source": "DB00091",
      "target": "DB00963",
      "description": "Bromfenac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01200",
      "source": "DB00091",
      "target": "DB01200",
      "description": "The metabolism of Bromocriptine can be decreased when combined with Cyclosporine.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01200",
      "source": "DB00091",
      "target": "DB01200",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00835",
      "source": "DB00091",
      "target": "DB00835",
      "description": "The metabolism of Brompheniramine can be decreased when combined with Cyclosporine.",
      "name": "Brompheniramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01222",
      "source": "DB00091",
      "target": "DB01222",
      "description": "The serum concentration of Budesonide can be increased when it is combined with Cyclosporine.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01222",
      "source": "DB00091",
      "target": "DB01222",
      "description": "The metabolism of Budesonide can be decreased when combined with Cyclosporine.",
      "name": "Budesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00887",
      "source": "DB00091",
      "target": "DB00887",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.",
      "name": "Bumetanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00297",
      "source": "DB00091",
      "target": "DB00297",
      "description": "The metabolism of Bupivacaine can be decreased when combined with Cyclosporine.",
      "name": "Bupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00921",
      "source": "DB00091",
      "target": "DB00921",
      "description": "The metabolism of Buprenorphine can be decreased when combined with Cyclosporine.",
      "name": "Buprenorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01156",
      "source": "DB00091",
      "target": "DB01156",
      "description": "The metabolism of Bupropion can be decreased when combined with Cyclosporine.",
      "name": "Bupropion"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00490",
      "source": "DB00091",
      "target": "DB00490",
      "description": "The metabolism of Buspirone can be decreased when combined with Cyclosporine.",
      "name": "Buspirone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01008",
      "source": "DB00091",
      "target": "DB01008",
      "description": "The serum concentration of Busulfan can be increased when it is combined with Cyclosporine.",
      "name": "Busulfan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01091",
      "source": "DB00091",
      "target": "DB01091",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Butenafine.",
      "name": "Butenafine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00639",
      "source": "DB00091",
      "target": "DB00639",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Butoconazole.",
      "name": "Butoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06772",
      "source": "DB00091",
      "target": "DB06772",
      "description": "The metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00248",
      "source": "DB00091",
      "target": "DB00248",
      "description": "The metabolism of Cabergoline can be decreased when combined with Cyclosporine.",
      "name": "Cabergoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08875",
      "source": "DB00091",
      "target": "DB08875",
      "description": "The metabolism of Cabozantinib can be decreased when combined with Cyclosporine.",
      "name": "Cabozantinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00201",
      "source": "DB00091",
      "target": "DB00201",
      "description": "The metabolism of Caffeine can be decreased when combined with Cyclosporine.",
      "name": "Caffeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00136",
      "source": "DB00091",
      "target": "DB00136",
      "description": "The metabolism of Calcitriol can be decreased when combined with Cyclosporine.",
      "name": "Calcitriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04690",
      "source": "DB00091",
      "target": "DB04690",
      "description": "The serum concentration of Camptothecin can be decreased when it is combined with Cyclosporine.",
      "name": "Camptothecin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08907",
      "source": "DB00091",
      "target": "DB08907",
      "description": "The metabolism of Canagliflozin can be decreased when combined with Cyclosporine.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00796",
      "source": "DB00091",
      "target": "DB00796",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Candesartan.",
      "name": "Candesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00796",
      "source": "DB00091",
      "target": "DB00796",
      "description": "Candesartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Candesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01152",
      "source": "DB00091",
      "target": "DB01152",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Candicidin.",
      "name": "Candicidin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00616",
      "source": "DB00091",
      "target": "DB00616",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.",
      "name": "Candoxatril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11623",
      "source": "DB00091",
      "target": "DB11623",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Candoxatrilat.",
      "name": "Candoxatrilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01197",
      "source": "DB00091",
      "target": "DB01197",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Captopril.",
      "name": "Captopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00564",
      "source": "DB00091",
      "target": "DB00564",
      "description": "The metabolism of Cyclosporine can be increased when combined with Carbamazepine.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00564",
      "source": "DB00091",
      "target": "DB00564",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.",
      "name": "Carbamazepine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00748",
      "source": "DB00091",
      "target": "DB00748",
      "description": "The metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.",
      "name": "Carbinoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08889",
      "source": "DB00091",
      "target": "DB08889",
      "description": "The serum concentration of Carfilzomib can be decreased when it is combined with Cyclosporine.",
      "name": "Carfilzomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06016",
      "source": "DB00091",
      "target": "DB06016",
      "description": "The metabolism of Cariprazine can be decreased when combined with Cyclosporine.",
      "name": "Cariprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00821",
      "source": "DB00091",
      "target": "DB00821",
      "description": "Carprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01136",
      "source": "DB00091",
      "target": "DB01136",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00520",
      "source": "DB00091",
      "target": "DB00520",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.",
      "name": "Caspofungin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00520",
      "source": "DB00091",
      "target": "DB00520",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Caspofungin.",
      "name": "Caspofungin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01816",
      "source": "DB00091",
      "target": "DB01816",
      "description": "Castanospermine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00482",
      "source": "DB00091",
      "target": "DB00482",
      "description": "Celecoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00482",
      "source": "DB00091",
      "target": "DB00482",
      "description": "The metabolism of Celecoxib can be decreased when combined with Cyclosporine.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04846",
      "source": "DB00091",
      "target": "DB04846",
      "description": "The metabolism of Celiprolol can be decreased when combined with Cyclosporine.",
      "name": "Celiprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00567",
      "source": "DB00091",
      "target": "DB00567",
      "description": "The metabolism of Cephalexin can be decreased when combined with Cyclosporine.",
      "name": "Cephalexin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09063",
      "source": "DB00091",
      "target": "DB09063",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00439",
      "source": "DB00091",
      "target": "DB00439",
      "description": "The metabolism of Cerivastatin can be decreased when combined with Cyclosporine.",
      "name": "Cerivastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01034",
      "source": "DB00091",
      "target": "DB01034",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Cerulenin.",
      "name": "Cerulenin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00185",
      "source": "DB00091",
      "target": "DB00185",
      "description": "The metabolism of Cevimeline can be decreased when combined with Cyclosporine.",
      "name": "Cevimeline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06777",
      "source": "DB00091",
      "target": "DB06777",
      "description": "The metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.",
      "name": "Chenodeoxycholic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00446",
      "source": "DB00091",
      "target": "DB00446",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.",
      "name": "Chloramphenicol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00475",
      "source": "DB00091",
      "target": "DB00475",
      "description": "The metabolism of Chlordiazepoxide can be decreased when combined with Cyclosporine.",
      "name": "Chlordiazepoxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00608",
      "source": "DB00091",
      "target": "DB00608",
      "description": "Chloroquine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00608",
      "source": "DB00091",
      "target": "DB00608",
      "description": "The metabolism of Chloroquine can be decreased when combined with Cyclosporine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01243",
      "source": "DB00091",
      "target": "DB01243",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Chloroxine.",
      "name": "Chloroxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01114",
      "source": "DB00091",
      "target": "DB01114",
      "description": "The metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.",
      "name": "Chlorphenamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00477",
      "source": "DB00091",
      "target": "DB00477",
      "description": "The metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00672",
      "source": "DB00091",
      "target": "DB00672",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Chlorpropamide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01239",
      "source": "DB00091",
      "target": "DB01239",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Chlorprothixene.",
      "name": "Chlorprothixene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00356",
      "source": "DB00091",
      "target": "DB00356",
      "description": "The metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.",
      "name": "Chlorzoxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00169",
      "source": "DB00091",
      "target": "DB00169",
      "description": "The metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.",
      "name": "Cholecalciferol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04540",
      "source": "DB00091",
      "target": "DB04540",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.",
      "name": "Cholesterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02659",
      "source": "DB00091",
      "target": "DB02659",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Cholic Acid.",
      "name": "Cholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01683",
      "source": "DB00091",
      "target": "DB01683",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Chymostatin.",
      "name": "Chymostatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01410",
      "source": "DB00091",
      "target": "DB01410",
      "description": "The metabolism of Ciclesonide can be decreased when combined with Cyclosporine.",
      "name": "Ciclesonide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01188",
      "source": "DB00091",
      "target": "DB01188",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Ciclopirox.",
      "name": "Ciclopirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01597",
      "source": "DB00091",
      "target": "DB01597",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Cilastatin.",
      "name": "Cilastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01340",
      "source": "DB00091",
      "target": "DB01340",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.",
      "name": "Cilazapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09232",
      "source": "DB00091",
      "target": "DB09232",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.",
      "name": "Cilnidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01166",
      "source": "DB00091",
      "target": "DB01166",
      "description": "The serum concentration of Cilostazol can be increased when it is combined with Cyclosporine.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00501",
      "source": "DB00091",
      "target": "DB00501",
      "description": "The serum concentration of Cimetidine can be decreased when it is combined with Cyclosporine.",
      "name": "Cimetidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01012",
      "source": "DB00091",
      "target": "DB01012",
      "description": "The metabolism of Cinacalcet can be decreased when combined with Cyclosporine.",
      "name": "Cinacalcet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00568",
      "source": "DB00091",
      "target": "DB00568",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cinnarizine.",
      "name": "Cinnarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09064",
      "source": "DB00091",
      "target": "DB09064",
      "description": "Cyclosporine may increase the nephrotoxic activities of Ciprofibrate.",
      "name": "Ciprofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00537",
      "source": "DB00091",
      "target": "DB00537",
      "description": "The serum concentration of Ciprofloxacin can be decreased when it is combined with Cyclosporine.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00604",
      "source": "DB00091",
      "target": "DB00604",
      "description": "The serum concentration of Cisapride can be increased when it is combined with Cyclosporine.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00565",
      "source": "DB00091",
      "target": "DB00565",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Cisatracurium besylate.",
      "name": "Cisatracurium besylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00515",
      "source": "DB00091",
      "target": "DB00515",
      "description": "The serum concentration of Cisplatin can be decreased when it is combined with Cyclosporine.",
      "name": "Cisplatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00215",
      "source": "DB00091",
      "target": "DB00215",
      "description": "The metabolism of Citalopram can be decreased when combined with Cyclosporine.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01211",
      "source": "DB00091",
      "target": "DB01211",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00283",
      "source": "DB00091",
      "target": "DB00283",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Clemastine.",
      "name": "Clemastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01190",
      "source": "DB00091",
      "target": "DB01190",
      "description": "The metabolism of Clindamycin can be decreased when combined with Cyclosporine.",
      "name": "Clindamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00349",
      "source": "DB00091",
      "target": "DB00349",
      "description": "The metabolism of Clobazam can be decreased when combined with Cyclosporine.",
      "name": "Clobazam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00845",
      "source": "DB00091",
      "target": "DB00845",
      "description": "The metabolism of Clofazimine can be decreased when combined with Cyclosporine.",
      "name": "Clofazimine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00636",
      "source": "DB00091",
      "target": "DB00636",
      "description": "Cyclosporine may increase the nephrotoxic activities of Clofibrate.",
      "name": "Clofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00636",
      "source": "DB00091",
      "target": "DB00636",
      "description": "The metabolism of Clofibrate can be decreased when combined with Cyclosporine.",
      "name": "Clofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06470",
      "source": "DB00091",
      "target": "DB06470",
      "description": "The metabolism of clomethiazole can be decreased when combined with Cyclosporine.",
      "name": "clomethiazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00882",
      "source": "DB00091",
      "target": "DB00882",
      "description": "The serum concentration of Clomifene can be decreased when it is combined with Cyclosporine.",
      "name": "Clomifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01242",
      "source": "DB00091",
      "target": "DB01242",
      "description": "The metabolism of Clomipramine can be decreased when combined with Cyclosporine.",
      "name": "Clomipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01068",
      "source": "DB00091",
      "target": "DB01068",
      "description": "The metabolism of Clonazepam can be decreased when combined with Cyclosporine.",
      "name": "Clonazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00575",
      "source": "DB00091",
      "target": "DB00575",
      "description": "The metabolism of Clonidine can be decreased when combined with Cyclosporine.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09218",
      "source": "DB00091",
      "target": "DB09218",
      "description": "Clonixin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00758",
      "source": "DB00091",
      "target": "DB00758",
      "description": "The metabolism of Clopidogrel can be decreased when combined with Cyclosporine.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00628",
      "source": "DB00091",
      "target": "DB00628",
      "description": "The metabolism of Clorazepate can be decreased when combined with Cyclosporine.",
      "name": "Clorazepate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01559",
      "source": "DB00091",
      "target": "DB01559",
      "description": "The metabolism of Clotiazepam can be decreased when combined with Cyclosporine.",
      "name": "Clotiazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00257",
      "source": "DB00091",
      "target": "DB00257",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Clotrimazole.",
      "name": "Clotrimazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00363",
      "source": "DB00091",
      "target": "DB00363",
      "description": "The metabolism of Clozapine can be decreased when combined with Cyclosporine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09065",
      "source": "DB00091",
      "target": "DB09065",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Cobicistat.",
      "name": "Cobicistat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05239",
      "source": "DB00091",
      "target": "DB05239",
      "description": "The serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.",
      "name": "Cobimetinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00907",
      "source": "DB00091",
      "target": "DB00907",
      "description": "The metabolism of Cocaine can be decreased when combined with Cyclosporine.",
      "name": "Cocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00318",
      "source": "DB00091",
      "target": "DB00318",
      "description": "The metabolism of Codeine can be decreased when combined with Cyclosporine.",
      "name": "Codeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01394",
      "source": "DB00091",
      "target": "DB01394",
      "description": "The serum concentration of Colchicine can be increased when it is combined with Cyclosporine.",
      "name": "Colchicine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00930",
      "source": "DB00091",
      "target": "DB00930",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.",
      "name": "Colesevelam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02587",
      "source": "DB00091",
      "target": "DB02587",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Colforsin.",
      "name": "Colforsin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00872",
      "source": "DB00091",
      "target": "DB00872",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.",
      "name": "Conivaptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00286",
      "source": "DB00091",
      "target": "DB00286",
      "description": "The metabolism of Conjugated Equine Estrogens can be decreased when combined with Cyclosporine.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01380",
      "source": "DB00091",
      "target": "DB01380",
      "description": "The metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.",
      "name": "Cortisone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08865",
      "source": "DB00091",
      "target": "DB08865",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08865",
      "source": "DB00091",
      "target": "DB08865",
      "description": "The metabolism of Crizotinib can be decreased when combined with Cyclosporine.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00924",
      "source": "DB00091",
      "target": "DB00924",
      "description": "The metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.",
      "name": "Cyclobenzaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00531",
      "source": "DB00091",
      "target": "DB00531",
      "description": "The metabolism of Cyclophosphamide can be decreased when combined with Cyclosporine.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00531",
      "source": "DB00091",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the immunosuppressive activities of Cyclosporine.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00987",
      "source": "DB00091",
      "target": "DB00987",
      "description": "The metabolism of Cytarabine can be decreased when combined with Cyclosporine.",
      "name": "Cytarabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08921",
      "source": "DB00091",
      "target": "DB08921",
      "description": "D-Limonene may increase the nephrotoxic activities of Cyclosporine.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06695",
      "source": "DB00091",
      "target": "DB06695",
      "description": "The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06695",
      "source": "DB00091",
      "target": "DB06695",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08912",
      "source": "DB00091",
      "target": "DB08912",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.",
      "name": "Dabrafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09102",
      "source": "DB00091",
      "target": "DB09102",
      "description": "The metabolism of Daclatasvir can be decreased when combined with Cyclosporine.",
      "name": "Daclatasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00970",
      "source": "DB00091",
      "target": "DB00970",
      "description": "The serum concentration of Dactinomycin can be decreased when it is combined with Cyclosporine.",
      "name": "Dactinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01219",
      "source": "DB00091",
      "target": "DB01219",
      "description": "The metabolism of Dantrolene can be decreased when combined with Cyclosporine.",
      "name": "Dantrolene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06292",
      "source": "DB00091",
      "target": "DB06292",
      "description": "The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.",
      "name": "Dapagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04884",
      "source": "DB00091",
      "target": "DB04884",
      "description": "The serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00250",
      "source": "DB00091",
      "target": "DB00250",
      "description": "The metabolism of Dapsone can be decreased when combined with Cyclosporine.",
      "name": "Dapsone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00496",
      "source": "DB00091",
      "target": "DB00496",
      "description": "The metabolism of Darifenacin can be decreased when combined with Cyclosporine.",
      "name": "Darifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09234",
      "source": "DB00091",
      "target": "DB09234",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.",
      "name": "Darodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01264",
      "source": "DB00091",
      "target": "DB01264",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.",
      "name": "Darunavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01264",
      "source": "DB00091",
      "target": "DB01264",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Darunavir.",
      "name": "Darunavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09183",
      "source": "DB00091",
      "target": "DB09183",
      "description": "The metabolism of Dasabuvir can be decreased when combined with Cyclosporine.",
      "name": "Dasabuvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01254",
      "source": "DB00091",
      "target": "DB01254",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00694",
      "source": "DB00091",
      "target": "DB00694",
      "description": "Daunorubicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00694",
      "source": "DB00091",
      "target": "DB00694",
      "description": "The metabolism of Daunorubicin can be decreased when combined with Cyclosporine.",
      "name": "Daunorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04840",
      "source": "DB00091",
      "target": "DB04840",
      "description": "The serum concentration of Debrisoquin can be decreased when it is combined with Cyclosporine.",
      "name": "Debrisoquin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01245",
      "source": "DB00091",
      "target": "DB01245",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Decamethonium.",
      "name": "Decamethonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03600",
      "source": "DB00091",
      "target": "DB03600",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Decanoic Acid.",
      "name": "Decanoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01609",
      "source": "DB00091",
      "target": "DB01609",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01708",
      "source": "DB00091",
      "target": "DB01708",
      "description": "The metabolism of Dehydroepiandrosterone can be decreased when combined with Cyclosporine.",
      "name": "Dehydroepiandrosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00705",
      "source": "DB00091",
      "target": "DB00705",
      "description": "The metabolism of Delavirdine can be decreased when combined with Cyclosporine.",
      "name": "Delavirdine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06643",
      "source": "DB00091",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01151",
      "source": "DB00091",
      "target": "DB01151",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Desipramine.",
      "name": "Desipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00967",
      "source": "DB00091",
      "target": "DB00967",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Desloratadine.",
      "name": "Desloratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06700",
      "source": "DB00091",
      "target": "DB06700",
      "description": "The metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01234",
      "source": "DB00091",
      "target": "DB01234",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.",
      "name": "Dexamethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00514",
      "source": "DB00091",
      "target": "DB00514",
      "description": "The metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.",
      "name": "Dextromethorphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00647",
      "source": "DB00091",
      "target": "DB00647",
      "description": "The metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.",
      "name": "Dextropropoxyphene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00829",
      "source": "DB00091",
      "target": "DB00829",
      "description": "The metabolism of Diazepam can be decreased when combined with Cyclosporine.",
      "name": "Diazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00586",
      "source": "DB00091",
      "target": "DB00586",
      "description": "Diclofenac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00586",
      "source": "DB00091",
      "target": "DB00586",
      "description": "The metabolism of Diclofenac can be decreased when combined with Cyclosporine.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00266",
      "source": "DB00091",
      "target": "DB00266",
      "description": "The metabolism of Dicoumarol can be decreased when combined with Cyclosporine.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00900",
      "source": "DB00091",
      "target": "DB00900",
      "description": "Didanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.",
      "name": "Didanosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00255",
      "source": "DB00091",
      "target": "DB00255",
      "description": "The serum concentration of Diethylstilbestrol can be decreased when it is combined with Cyclosporine.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00861",
      "source": "DB00091",
      "target": "DB00861",
      "description": "Diflunisal may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01396",
      "source": "DB00091",
      "target": "DB01396",
      "description": "The metabolism of Digitoxin can be decreased when combined with Cyclosporine.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00390",
      "source": "DB00091",
      "target": "DB00390",
      "description": "The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00390",
      "source": "DB00091",
      "target": "DB00390",
      "description": "The metabolism of Digoxin can be decreased when combined with Cyclosporine.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01551",
      "source": "DB00091",
      "target": "DB01551",
      "description": "The metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.",
      "name": "Dihydrocodeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00320",
      "source": "DB00091",
      "target": "DB00320",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.",
      "name": "Dihydroergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11512",
      "source": "DB00091",
      "target": "DB11512",
      "description": "Dihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Dihydrostreptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02901",
      "source": "DB00091",
      "target": "DB02901",
      "description": "Dihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02901",
      "source": "DB00091",
      "target": "DB02901",
      "description": "The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cyclosporine.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00343",
      "source": "DB00091",
      "target": "DB00343",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Diltiazem.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01075",
      "source": "DB00091",
      "target": "DB01075",
      "description": "The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.",
      "name": "Diphenhydramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00975",
      "source": "DB00091",
      "target": "DB00975",
      "description": "The serum concentration of Dipyridamole can be decreased when it is combined with Cyclosporine.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00280",
      "source": "DB00091",
      "target": "DB00280",
      "description": "The metabolism of Disopyramide can be decreased when combined with Cyclosporine.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00822",
      "source": "DB00091",
      "target": "DB00822",
      "description": "The metabolism of Disulfiram can be decreased when combined with Cyclosporine.",
      "name": "Disulfiram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01248",
      "source": "DB00091",
      "target": "DB01248",
      "description": "The metabolism of Docetaxel can be decreased when combined with Cyclosporine.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00204",
      "source": "DB00091",
      "target": "DB00204",
      "description": "The metabolism of Dofetilide can be decreased when combined with Cyclosporine.",
      "name": "Dofetilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00757",
      "source": "DB00091",
      "target": "DB00757",
      "description": "The metabolism of Dolasetron can be decreased when combined with Cyclosporine.",
      "name": "Dolasetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02852",
      "source": "DB00091",
      "target": "DB02852",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Domoic Acid.",
      "name": "Domoic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01184",
      "source": "DB00091",
      "target": "DB01184",
      "description": "The serum concentration of Domperidone can be increased when it is combined with Cyclosporine.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00843",
      "source": "DB00091",
      "target": "DB00843",
      "description": "The metabolism of Donepezil can be decreased when combined with Cyclosporine.",
      "name": "Donepezil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00988",
      "source": "DB00091",
      "target": "DB00988",
      "description": "The metabolism of Dopamine can be decreased when combined with Cyclosporine.",
      "name": "Dopamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00869",
      "source": "DB00091",
      "target": "DB00869",
      "description": "The metabolism of Dorzolamide can be decreased when combined with Cyclosporine.",
      "name": "Dorzolamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06446",
      "source": "DB00091",
      "target": "DB06446",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.",
      "name": "Dotarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01135",
      "source": "DB00091",
      "target": "DB01135",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Doxacurium chloride.",
      "name": "Doxacurium chloride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00590",
      "source": "DB00091",
      "target": "DB00590",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.",
      "name": "Doxazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01142",
      "source": "DB00091",
      "target": "DB01142",
      "description": "The metabolism of Doxepin can be decreased when combined with Cyclosporine.",
      "name": "Doxepin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00997",
      "source": "DB00091",
      "target": "DB00997",
      "description": "The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00997",
      "source": "DB00091",
      "target": "DB00997",
      "description": "Doxorubicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00997",
      "source": "DB00091",
      "target": "DB00997",
      "description": "The metabolism of Doxorubicin can be decreased when combined with Cyclosporine.",
      "name": "Doxorubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00254",
      "source": "DB00091",
      "target": "DB00254",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Doxycycline.",
      "name": "Doxycycline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00470",
      "source": "DB00091",
      "target": "DB00470",
      "description": "The serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.",
      "name": "Dronabinol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04855",
      "source": "DB00091",
      "target": "DB04855",
      "description": "The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04855",
      "source": "DB00091",
      "target": "DB04855",
      "description": "The metabolism of Dronedarone can be decreased when combined with Cyclosporine.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09215",
      "source": "DB00091",
      "target": "DB09215",
      "description": "Droxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01126",
      "source": "DB00091",
      "target": "DB01126",
      "description": "The metabolism of Dutasteride can be decreased when combined with Cyclosporine.",
      "name": "Dutasteride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05265",
      "source": "DB00091",
      "target": "DB05265",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ecabet.",
      "name": "Ecabet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01127",
      "source": "DB00091",
      "target": "DB01127",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Econazole.",
      "name": "Econazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09075",
      "source": "DB00091",
      "target": "DB09075",
      "description": "The serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00625",
      "source": "DB00091",
      "target": "DB00625",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.",
      "name": "Efavirenz"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09040",
      "source": "DB00091",
      "target": "DB09040",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Efinaconazole.",
      "name": "Efinaconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09235",
      "source": "DB00091",
      "target": "DB09235",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.",
      "name": "Efonidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05161",
      "source": "DB00091",
      "target": "DB05161",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Elafin.",
      "name": "Elafin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11574",
      "source": "DB00091",
      "target": "DB11574",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Elbasvir.",
      "name": "Elbasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00216",
      "source": "DB00091",
      "target": "DB00216",
      "description": "The serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.",
      "name": "Eletriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09039",
      "source": "DB00091",
      "target": "DB09039",
      "description": "The serum concentration of Eliglustat can be increased when it is combined with Cyclosporine.",
      "name": "Eliglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09272",
      "source": "DB00091",
      "target": "DB09272",
      "description": "The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.",
      "name": "Eluxadoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09101",
      "source": "DB00091",
      "target": "DB09101",
      "description": "The metabolism of Elvitegravir can be decreased when combined with Cyclosporine.",
      "name": "Elvitegravir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00584",
      "source": "DB00091",
      "target": "DB00584",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Enalapril.",
      "name": "Enalapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00584",
      "source": "DB00091",
      "target": "DB00584",
      "description": "The metabolism of Enalapril can be decreased when combined with Cyclosporine.",
      "name": "Enalapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09477",
      "source": "DB00091",
      "target": "DB09477",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.",
      "name": "Enalaprilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03395",
      "source": "DB00091",
      "target": "DB03395",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.",
      "name": "Enalkiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08899",
      "source": "DB00091",
      "target": "DB08899",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.",
      "name": "Enzalutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08992",
      "source": "DB00091",
      "target": "DB08992",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Eperisone.",
      "name": "Eperisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00751",
      "source": "DB00091",
      "target": "DB00751",
      "description": "The metabolism of Epinastine can be decreased when combined with Cyclosporine.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08991",
      "source": "DB00091",
      "target": "DB08991",
      "description": "Epirizole may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00445",
      "source": "DB00091",
      "target": "DB00445",
      "description": "Epirubicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Epirubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00700",
      "source": "DB00091",
      "target": "DB00700",
      "description": "Eplerenone may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Eplerenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00700",
      "source": "DB00091",
      "target": "DB00700",
      "description": "The serum concentration of Eplerenone can be increased when it is combined with Cyclosporine.",
      "name": "Eplerenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01240",
      "source": "DB00091",
      "target": "DB01240",
      "description": "The metabolism of Epoprostenol can be decreased when combined with Cyclosporine.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00876",
      "source": "DB00091",
      "target": "DB00876",
      "description": "Eprosartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Eprosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00153",
      "source": "DB00091",
      "target": "DB00153",
      "description": "The metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.",
      "name": "Ergocalciferol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01049",
      "source": "DB00091",
      "target": "DB01049",
      "description": "The metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.",
      "name": "Ergoloid mesylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01253",
      "source": "DB00091",
      "target": "DB01253",
      "description": "The metabolism of Ergonovine can be decreased when combined with Cyclosporine.",
      "name": "Ergonovine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00696",
      "source": "DB00091",
      "target": "DB00696",
      "description": "The metabolism of Ergotamine can be decreased when combined with Cyclosporine.",
      "name": "Ergotamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00530",
      "source": "DB00091",
      "target": "DB00530",
      "description": "The metabolism of Erlotinib can be decreased when combined with Cyclosporine.",
      "name": "Erlotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00199",
      "source": "DB00091",
      "target": "DB00199",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Erythromycin.",
      "name": "Erythromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01175",
      "source": "DB00091",
      "target": "DB01175",
      "description": "The metabolism of Escitalopram can be decreased when combined with Cyclosporine.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09119",
      "source": "DB00091",
      "target": "DB09119",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Eslicarbazepine acetate.",
      "name": "Eslicarbazepine acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00736",
      "source": "DB00091",
      "target": "DB00736",
      "description": "The metabolism of Esomeprazole can be decreased when combined with Cyclosporine.",
      "name": "Esomeprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01215",
      "source": "DB00091",
      "target": "DB01215",
      "description": "The metabolism of Estazolam can be decreased when combined with Cyclosporine.",
      "name": "Estazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00783",
      "source": "DB00091",
      "target": "DB00783",
      "description": "The metabolism of Estradiol can be decreased when combined with Cyclosporine.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08866",
      "source": "DB00091",
      "target": "DB08866",
      "description": "The metabolism of Estradiol valerate/Dienogest can be decreased when combined with Cyclosporine.",
      "name": "Estradiol valerate/Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01196",
      "source": "DB00091",
      "target": "DB01196",
      "description": "The metabolism of Estramustine can be decreased when combined with Cyclosporine.",
      "name": "Estramustine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04573",
      "source": "DB00091",
      "target": "DB04573",
      "description": "The serum concentration of Estriol can be decreased when it is combined with Cyclosporine.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00655",
      "source": "DB00091",
      "target": "DB00655",
      "description": "The metabolism of Estrone can be decreased when combined with Cyclosporine.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04574",
      "source": "DB00091",
      "target": "DB04574",
      "description": "The metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.",
      "name": "Estrone sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00402",
      "source": "DB00091",
      "target": "DB00402",
      "description": "The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.",
      "name": "Eszopiclone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00903",
      "source": "DB00091",
      "target": "DB00903",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.",
      "name": "Etacrynic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00005",
      "source": "DB00091",
      "target": "DB00005",
      "description": "Etanercept may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00898",
      "source": "DB00091",
      "target": "DB00898",
      "description": "The metabolism of Ethanol can be decreased when combined with Cyclosporine.",
      "name": "Ethanol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00977",
      "source": "DB00091",
      "target": "DB00977",
      "description": "The metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00593",
      "source": "DB00091",
      "target": "DB00593",
      "description": "The metabolism of Ethosuximide can be decreased when combined with Cyclosporine.",
      "name": "Ethosuximide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01466",
      "source": "DB00091",
      "target": "DB01466",
      "description": "The metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.",
      "name": "Ethylmorphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00749",
      "source": "DB00091",
      "target": "DB00749",
      "description": "Etodolac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00749",
      "source": "DB00091",
      "target": "DB00749",
      "description": "The metabolism of Etodolac can be decreased when combined with Cyclosporine.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08984",
      "source": "DB00091",
      "target": "DB08984",
      "description": "Etofenamate may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08983",
      "source": "DB00091",
      "target": "DB08983",
      "description": "Cyclosporine may increase the nephrotoxic activities of Etofibrate.",
      "name": "Etofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00294",
      "source": "DB00091",
      "target": "DB00294",
      "description": "The metabolism of Etonogestrel can be decreased when combined with Cyclosporine.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00773",
      "source": "DB00091",
      "target": "DB00773",
      "description": "The metabolism of Etoposide can be decreased when combined with Cyclosporine.",
      "name": "Etoposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01628",
      "source": "DB00091",
      "target": "DB01628",
      "description": "Etoricoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01628",
      "source": "DB00091",
      "target": "DB01628",
      "description": "The metabolism of Etoricoxib can be decreased when combined with Cyclosporine.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06414",
      "source": "DB00091",
      "target": "DB06414",
      "description": "The serum concentration of Etravirine can be increased when it is combined with Cyclosporine.",
      "name": "Etravirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11358",
      "source": "DB00091",
      "target": "DB11358",
      "description": "Evening primrose oil may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01590",
      "source": "DB00091",
      "target": "DB01590",
      "description": "The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.",
      "name": "Everolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00990",
      "source": "DB00091",
      "target": "DB00990",
      "description": "The metabolism of Exemestane can be decreased when combined with Cyclosporine.",
      "name": "Exemestane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06246",
      "source": "DB00091",
      "target": "DB06246",
      "description": "exisulind may increase the nephrotoxic activities of Cyclosporine.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00973",
      "source": "DB00091",
      "target": "DB00973",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.",
      "name": "Ezetimibe"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00973",
      "source": "DB00091",
      "target": "DB00973",
      "description": "The serum concentration of Ezetimibe can be decreased when it is combined with Cyclosporine.",
      "name": "Ezetimibe"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00426",
      "source": "DB00091",
      "target": "DB00426",
      "description": "The metabolism of Famciclovir can be decreased when combined with Cyclosporine.",
      "name": "Famciclovir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00949",
      "source": "DB00091",
      "target": "DB00949",
      "description": "The metabolism of Felbamate can be decreased when combined with Cyclosporine.",
      "name": "Felbamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01023",
      "source": "DB00091",
      "target": "DB01023",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Felodipine.",
      "name": "Felodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08981",
      "source": "DB00091",
      "target": "DB08981",
      "description": "Fenbufen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08980",
      "source": "DB00091",
      "target": "DB08980",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.",
      "name": "Fendiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01039",
      "source": "DB00091",
      "target": "DB01039",
      "description": "Cyclosporine may increase the nephrotoxic activities of Fenofibrate.",
      "name": "Fenofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01039",
      "source": "DB00091",
      "target": "DB01039",
      "description": "The metabolism of Fenofibrate can be decreased when combined with Cyclosporine.",
      "name": "Fenofibrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00573",
      "source": "DB00091",
      "target": "DB00573",
      "description": "Fenoprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00813",
      "source": "DB00091",
      "target": "DB00813",
      "description": "The serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.",
      "name": "Fentanyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06702",
      "source": "DB00091",
      "target": "DB06702",
      "description": "The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.",
      "name": "Fesoterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00950",
      "source": "DB00091",
      "target": "DB00950",
      "description": "The serum concentration of Fexofenadine can be decreased when it is combined with Cyclosporine.",
      "name": "Fexofenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08874",
      "source": "DB00091",
      "target": "DB08874",
      "description": "The serum concentration of Fidaxomicin can be decreased when it is combined with Cyclosporine.",
      "name": "Fidaxomicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09279",
      "source": "DB00091",
      "target": "DB09279",
      "description": "The serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.",
      "name": "Fimasartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01216",
      "source": "DB00091",
      "target": "DB01216",
      "description": "The metabolism of Finasteride can be decreased when combined with Cyclosporine.",
      "name": "Finasteride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08868",
      "source": "DB00091",
      "target": "DB08868",
      "description": "Cyclosporine may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04908",
      "source": "DB00091",
      "target": "DB04908",
      "description": "The serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.",
      "name": "Flibanserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08976",
      "source": "DB00091",
      "target": "DB08976",
      "description": "Floctafenine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00196",
      "source": "DB00091",
      "target": "DB00196",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.",
      "name": "Fluconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00196",
      "source": "DB00091",
      "target": "DB00196",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Fluconazole.",
      "name": "Fluconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01099",
      "source": "DB00091",
      "target": "DB01099",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Flucytosine.",
      "name": "Flucytosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04841",
      "source": "DB00091",
      "target": "DB04841",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunarizine.",
      "name": "Flunarizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00180",
      "source": "DB00091",
      "target": "DB00180",
      "description": "The metabolism of Flunisolide can be decreased when combined with Cyclosporine.",
      "name": "Flunisolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01544",
      "source": "DB00091",
      "target": "DB01544",
      "description": "The metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.",
      "name": "Flunitrazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11518",
      "source": "DB00091",
      "target": "DB11518",
      "description": "Flunixin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00324",
      "source": "DB00091",
      "target": "DB00324",
      "description": "The metabolism of Fluorometholone can be decreased when combined with Cyclosporine.",
      "name": "Fluorometholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00472",
      "source": "DB00091",
      "target": "DB00472",
      "description": "The metabolism of Fluoxetine can be decreased when combined with Cyclosporine.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01185",
      "source": "DB00091",
      "target": "DB01185",
      "description": "Fluoxymesterone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Fluoxymesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00875",
      "source": "DB00091",
      "target": "DB00875",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Flupentixol.",
      "name": "Flupentixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00623",
      "source": "DB00091",
      "target": "DB00623",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fluphenazine.",
      "name": "Fluphenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00690",
      "source": "DB00091",
      "target": "DB00690",
      "description": "The metabolism of Flurazepam can be decreased when combined with Cyclosporine.",
      "name": "Flurazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00712",
      "source": "DB00091",
      "target": "DB00712",
      "description": "Flurbiprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00712",
      "source": "DB00091",
      "target": "DB00712",
      "description": "The metabolism of Flurbiprofen can be decreased when combined with Cyclosporine.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00499",
      "source": "DB00091",
      "target": "DB00499",
      "description": "The metabolism of Flutamide can be decreased when combined with Cyclosporine.",
      "name": "Flutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08906",
      "source": "DB00091",
      "target": "DB08906",
      "description": "The metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.",
      "name": "Fluticasone furoate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00588",
      "source": "DB00091",
      "target": "DB00588",
      "description": "The metabolism of Fluticasone Propionate can be decreased when combined with Cyclosporine.",
      "name": "Fluticasone Propionate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01095",
      "source": "DB00091",
      "target": "DB01095",
      "description": "The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.",
      "name": "Fluvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01095",
      "source": "DB00091",
      "target": "DB01095",
      "description": "The metabolism of Fluvastatin can be decreased when combined with Cyclosporine.",
      "name": "Fluvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00176",
      "source": "DB00091",
      "target": "DB00176",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01342",
      "source": "DB00091",
      "target": "DB01342",
      "description": "Forasartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Forasartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00983",
      "source": "DB00091",
      "target": "DB00983",
      "description": "The metabolism of Formoterol can be decreased when combined with Cyclosporine.",
      "name": "Formoterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01319",
      "source": "DB00091",
      "target": "DB01319",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fosamprenavir.",
      "name": "Fosamprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01319",
      "source": "DB00091",
      "target": "DB01319",
      "description": "The metabolism of Fosamprenavir can be decreased when combined with Cyclosporine.",
      "name": "Fosamprenavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06717",
      "source": "DB00091",
      "target": "DB06717",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.",
      "name": "Fosaprepitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00529",
      "source": "DB00091",
      "target": "DB00529",
      "description": "Foscarnet may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Foscarnet"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00492",
      "source": "DB00091",
      "target": "DB00492",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.",
      "name": "Fosinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01320",
      "source": "DB00091",
      "target": "DB01320",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.",
      "name": "Fosphenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00452",
      "source": "DB00091",
      "target": "DB00452",
      "description": "Framycetin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Framycetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00947",
      "source": "DB00091",
      "target": "DB00947",
      "description": "The metabolism of Fulvestrant can be decreased when combined with Cyclosporine.",
      "name": "Fulvestrant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00695",
      "source": "DB00091",
      "target": "DB00695",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.",
      "name": "Furosemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02703",
      "source": "DB00091",
      "target": "DB02703",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.",
      "name": "Fusidic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00996",
      "source": "DB00091",
      "target": "DB00996",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.",
      "name": "Gabapentin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00674",
      "source": "DB00091",
      "target": "DB00674",
      "description": "The metabolism of Galantamine can be decreased when combined with Cyclosporine.",
      "name": "Galantamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00483",
      "source": "DB00091",
      "target": "DB00483",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Gallamine Triethiodide.",
      "name": "Gallamine Triethiodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06741",
      "source": "DB00091",
      "target": "DB06741",
      "description": "The metabolism of Gavestinel can be decreased when combined with Cyclosporine.",
      "name": "Gavestinel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00317",
      "source": "DB00091",
      "target": "DB00317",
      "description": "The metabolism of Gefitinib can be decreased when combined with Cyclosporine.",
      "name": "Gefitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02424",
      "source": "DB00091",
      "target": "DB02424",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Geldanamycin.",
      "name": "Geldanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00441",
      "source": "DB00091",
      "target": "DB00441",
      "description": "The serum concentration of Gemcitabine can be decreased when it is combined with Cyclosporine.",
      "name": "Gemcitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01241",
      "source": "DB00091",
      "target": "DB01241",
      "description": "Cyclosporine may increase the nephrotoxic activities of Gemfibrozil.",
      "name": "Gemfibrozil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01241",
      "source": "DB00091",
      "target": "DB01241",
      "description": "The metabolism of Gemfibrozil can be decreased when combined with Cyclosporine.",
      "name": "Gemfibrozil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01645",
      "source": "DB00091",
      "target": "DB01645",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Genistein.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00798",
      "source": "DB00091",
      "target": "DB00798",
      "description": "Gentamicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Gentamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01120",
      "source": "DB00091",
      "target": "DB01120",
      "description": "The metabolism of Gliclazide can be decreased when combined with Cyclosporine.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00222",
      "source": "DB00091",
      "target": "DB00222",
      "description": "The metabolism of Glimepiride can be decreased when combined with Cyclosporine.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01067",
      "source": "DB00091",
      "target": "DB01067",
      "description": "The metabolism of Glipizide can be decreased when combined with Cyclosporine.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01016",
      "source": "DB00091",
      "target": "DB01016",
      "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01016",
      "source": "DB00091",
      "target": "DB01016",
      "description": "The metabolism of Glyburide can be decreased when combined with Cyclosporine.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04077",
      "source": "DB00091",
      "target": "DB04077",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Glycerol.",
      "name": "Glycerol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04539",
      "source": "DB00091",
      "target": "DB04539",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Glyphosate.",
      "name": "Glyphosate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02255",
      "source": "DB00091",
      "target": "DB02255",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with GM6001.",
      "name": "GM6001"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00027",
      "source": "DB00091",
      "target": "DB00027",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.",
      "name": "Gramicidin D"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00889",
      "source": "DB00091",
      "target": "DB00889",
      "description": "The metabolism of Granisetron can be decreased when combined with Cyclosporine.",
      "name": "Granisetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11575",
      "source": "DB00091",
      "target": "DB11575",
      "description": "The serum concentration of Grazoprevir can be decreased when it is combined with Cyclosporine.",
      "name": "Grazoprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00365",
      "source": "DB00091",
      "target": "DB00365",
      "description": "The metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00400",
      "source": "DB00091",
      "target": "DB00400",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.",
      "name": "Griseofulvin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01018",
      "source": "DB00091",
      "target": "DB01018",
      "description": "The metabolism of Guanfacine can be decreased when combined with Cyclosporine.",
      "name": "Guanfacine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01218",
      "source": "DB00091",
      "target": "DB01218",
      "description": "The serum concentration of Halofantrine can be increased when it is combined with Cyclosporine.",
      "name": "Halofantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00502",
      "source": "DB00091",
      "target": "DB00502",
      "description": "The metabolism of Haloperidol can be decreased when combined with Cyclosporine.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00793",
      "source": "DB00091",
      "target": "DB00793",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Haloprogin.",
      "name": "Haloprogin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01159",
      "source": "DB00091",
      "target": "DB01159",
      "description": "The metabolism of Halothane can be decreased when combined with Cyclosporine.",
      "name": "Halothane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08958",
      "source": "DB00091",
      "target": "DB08958",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Hexetidine.",
      "name": "Hexetidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01355",
      "source": "DB00091",
      "target": "DB01355",
      "description": "The metabolism of Cyclosporine can be increased when combined with Hexobarbital.",
      "name": "Hexobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02351",
      "source": "DB00091",
      "target": "DB02351",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00667",
      "source": "DB00091",
      "target": "DB00667",
      "description": "The metabolism of Histamine Phosphate can be decreased when combined with Cyclosporine.",
      "name": "Histamine Phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05767",
      "source": "DB00091",
      "target": "DB05767",
      "description": "HMPL-004 may increase the nephrotoxic activities of Cyclosporine.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00956",
      "source": "DB00091",
      "target": "DB00956",
      "description": "The serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.",
      "name": "Hydrocodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00741",
      "source": "DB00091",
      "target": "DB00741",
      "description": "The metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.",
      "name": "Hydrocortisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00327",
      "source": "DB00091",
      "target": "DB00327",
      "description": "The metabolism of Hydromorphone can be decreased when combined with Cyclosporine.",
      "name": "Hydromorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06789",
      "source": "DB00091",
      "target": "DB06789",
      "description": "The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11520",
      "source": "DB00091",
      "target": "DB11520",
      "description": "Hygromycin B may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Hygromycin B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09053",
      "source": "DB00091",
      "target": "DB09053",
      "description": "The serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01050",
      "source": "DB00091",
      "target": "DB01050",
      "description": "Ibuprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01050",
      "source": "DB00091",
      "target": "DB01050",
      "description": "The serum concentration of Ibuprofen can be decreased when it is combined with Cyclosporine.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08955",
      "source": "DB00091",
      "target": "DB08955",
      "description": "Ibuproxam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06196",
      "source": "DB00091",
      "target": "DB06196",
      "description": "Icatibant may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01177",
      "source": "DB00091",
      "target": "DB01177",
      "description": "Idarubicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01177",
      "source": "DB00091",
      "target": "DB01177",
      "description": "The metabolism of Idarubicin can be decreased when combined with Cyclosporine.",
      "name": "Idarubicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09054",
      "source": "DB00091",
      "target": "DB09054",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Idelalisib.",
      "name": "Idelalisib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06406",
      "source": "DB00091",
      "target": "DB06406",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01181",
      "source": "DB00091",
      "target": "DB01181",
      "description": "The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.",
      "name": "Ifosfamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04946",
      "source": "DB00091",
      "target": "DB04946",
      "description": "The metabolism of Iloperidone can be decreased when combined with Cyclosporine.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00619",
      "source": "DB00091",
      "target": "DB00619",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.",
      "name": "Imatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01598",
      "source": "DB00091",
      "target": "DB01598",
      "description": "Cyclosporine may increase the neurotoxic activities of Imipenem.",
      "name": "Imipenem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00458",
      "source": "DB00091",
      "target": "DB00458",
      "description": "The metabolism of Imipramine can be decreased when combined with Cyclosporine.",
      "name": "Imipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00724",
      "source": "DB00091",
      "target": "DB00724",
      "description": "The metabolism of Imiquimod can be decreased when combined with Cyclosporine.",
      "name": "Imiquimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05039",
      "source": "DB00091",
      "target": "DB05039",
      "description": "The metabolism of Indacaterol can be decreased when combined with Cyclosporine.",
      "name": "Indacaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00808",
      "source": "DB00091",
      "target": "DB00808",
      "description": "The metabolism of Indapamide can be decreased when combined with Cyclosporine.",
      "name": "Indapamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00224",
      "source": "DB00091",
      "target": "DB00224",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Indinavir.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00224",
      "source": "DB00091",
      "target": "DB00224",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Indinavir.",
      "name": "Indinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06370",
      "source": "DB00091",
      "target": "DB06370",
      "description": "The metabolism of indisulam can be decreased when combined with Cyclosporine.",
      "name": "indisulam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00328",
      "source": "DB00091",
      "target": "DB00328",
      "description": "Indomethacin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00328",
      "source": "DB00091",
      "target": "DB00328",
      "description": "The serum concentration of Indomethacin can be decreased when it is combined with Cyclosporine.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08951",
      "source": "DB00091",
      "target": "DB08951",
      "description": "Indoprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00332",
      "source": "DB00091",
      "target": "DB00332",
      "description": "The metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.",
      "name": "Ipratropium bromide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01029",
      "source": "DB00091",
      "target": "DB01029",
      "description": "The metabolism of Irbesartan can be decreased when combined with Cyclosporine.",
      "name": "Irbesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01029",
      "source": "DB00091",
      "target": "DB01029",
      "description": "Irbesartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Irbesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00762",
      "source": "DB00091",
      "target": "DB00762",
      "description": "The metabolism of Irinotecan can be decreased when combined with Cyclosporine.",
      "name": "Irinotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06636",
      "source": "DB00091",
      "target": "DB06636",
      "description": "The metabolism of Isavuconazonium can be decreased when combined with Cyclosporine.",
      "name": "Isavuconazonium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08943",
      "source": "DB00091",
      "target": "DB08943",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Isoconazole.",
      "name": "Isoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00677",
      "source": "DB00091",
      "target": "DB00677",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.",
      "name": "Isoflurophate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00883",
      "source": "DB00091",
      "target": "DB00883",
      "description": "The metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.",
      "name": "Isosorbide Dinitrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01020",
      "source": "DB00091",
      "target": "DB01020",
      "description": "The metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.",
      "name": "Isosorbide Mononitrate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08942",
      "source": "DB00091",
      "target": "DB08942",
      "description": "Isoxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00270",
      "source": "DB00091",
      "target": "DB00270",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Isradipine.",
      "name": "Isradipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01167",
      "source": "DB00091",
      "target": "DB01167",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Itraconazole.",
      "name": "Itraconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09083",
      "source": "DB00091",
      "target": "DB09083",
      "description": "The serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.",
      "name": "Ivabradine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08820",
      "source": "DB00091",
      "target": "DB08820",
      "description": "The serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.",
      "name": "Ivacaftor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00602",
      "source": "DB00091",
      "target": "DB00602",
      "description": "The metabolism of Ivermectin can be decreased when combined with Cyclosporine.",
      "name": "Ivermectin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04845",
      "source": "DB00091",
      "target": "DB04845",
      "description": "The metabolism of Ixabepilone can be decreased when combined with Cyclosporine.",
      "name": "Ixabepilone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09570",
      "source": "DB00091",
      "target": "DB09570",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.",
      "name": "Ixazomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09570",
      "source": "DB00091",
      "target": "DB09570",
      "description": "The metabolism of Ixazomib can be decreased when combined with Cyclosporine.",
      "name": "Ixazomib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01172",
      "source": "DB00091",
      "target": "DB01172",
      "description": "Kanamycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Kanamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08940",
      "source": "DB00091",
      "target": "DB08940",
      "description": "Kebuzone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01221",
      "source": "DB00091",
      "target": "DB01221",
      "description": "The metabolism of Ketamine can be decreased when combined with Cyclosporine.",
      "name": "Ketamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01587",
      "source": "DB00091",
      "target": "DB01587",
      "description": "The metabolism of Ketazolam can be decreased when combined with Cyclosporine.",
      "name": "Ketazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06738",
      "source": "DB00091",
      "target": "DB06738",
      "description": "The metabolism of Ketobemidone can be decreased when combined with Cyclosporine.",
      "name": "Ketobemidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01026",
      "source": "DB00091",
      "target": "DB01026",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Ketoconazole.",
      "name": "Ketoconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01009",
      "source": "DB00091",
      "target": "DB01009",
      "description": "Ketoprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01009",
      "source": "DB00091",
      "target": "DB01009",
      "description": "The metabolism of Ketoprofen can be decreased when combined with Cyclosporine.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00465",
      "source": "DB00091",
      "target": "DB00465",
      "description": "Ketorolac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09236",
      "source": "DB00091",
      "target": "DB09236",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.",
      "name": "Lacidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00709",
      "source": "DB00091",
      "target": "DB00709",
      "description": "The serum concentration of Lamivudine can be decreased when it is combined with Cyclosporine.",
      "name": "Lamivudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00555",
      "source": "DB00091",
      "target": "DB00555",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lamotrigine.",
      "name": "Lamotrigine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06791",
      "source": "DB00091",
      "target": "DB06791",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00448",
      "source": "DB00091",
      "target": "DB00448",
      "description": "The metabolism of Lansoprazole can be decreased when combined with Cyclosporine.",
      "name": "Lansoprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01259",
      "source": "DB00091",
      "target": "DB01259",
      "description": "The metabolism of Lapatinib can be decreased when combined with Cyclosporine.",
      "name": "Lapatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06685",
      "source": "DB00091",
      "target": "DB06685",
      "description": "The metabolism of Laquinimod can be decreased when combined with Cyclosporine.",
      "name": "Laquinimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09027",
      "source": "DB00091",
      "target": "DB09027",
      "description": "The serum concentration of Ledipasvir can be decreased when it is combined with Cyclosporine.",
      "name": "Ledipasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01097",
      "source": "DB00091",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01097",
      "source": "DB00091",
      "target": "DB01097",
      "description": "Leflunomide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00480",
      "source": "DB00091",
      "target": "DB00480",
      "description": "The serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.",
      "name": "Lenalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09078",
      "source": "DB00091",
      "target": "DB09078",
      "description": "The metabolism of Lenvatinib can be decreased when combined with Cyclosporine.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00001",
      "source": "DB00091",
      "target": "DB00001",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00528",
      "source": "DB00091",
      "target": "DB00528",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.",
      "name": "Lercanidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00528",
      "source": "DB00091",
      "target": "DB00528",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lercanidipine.",
      "name": "Lercanidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11560",
      "source": "DB00091",
      "target": "DB11560",
      "description": "The metabolism of Lesinurad can be decreased when combined with Cyclosporine.",
      "name": "Lesinurad"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01006",
      "source": "DB00091",
      "target": "DB01006",
      "description": "The metabolism of Letrozole can be decreased when combined with Cyclosporine.",
      "name": "Letrozole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01202",
      "source": "DB00091",
      "target": "DB01202",
      "description": "The serum concentration of Levetiracetam can be decreased when it is combined with Cyclosporine.",
      "name": "Levetiracetam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01002",
      "source": "DB00091",
      "target": "DB01002",
      "description": "The metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.",
      "name": "Levobupivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06282",
      "source": "DB00091",
      "target": "DB06282",
      "description": "The metabolism of Levocetirizine can be decreased when combined with Cyclosporine.",
      "name": "Levocetirizine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01137",
      "source": "DB00091",
      "target": "DB01137",
      "description": "The serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01227",
      "source": "DB00091",
      "target": "DB01227",
      "description": "The metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.",
      "name": "Levomethadyl Acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08918",
      "source": "DB00091",
      "target": "DB08918",
      "description": "The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00367",
      "source": "DB00091",
      "target": "DB00367",
      "description": "The metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00451",
      "source": "DB00091",
      "target": "DB00451",
      "description": "The metabolism of Levothyroxine can be decreased when combined with Cyclosporine.",
      "name": "Levothyroxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04725",
      "source": "DB00091",
      "target": "DB04725",
      "description": "The metabolism of Licofelone can be decreased when combined with Cyclosporine.",
      "name": "Licofelone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00281",
      "source": "DB00091",
      "target": "DB00281",
      "description": "The metabolism of Lidocaine can be decreased when combined with Cyclosporine.",
      "name": "Lidocaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08882",
      "source": "DB00091",
      "target": "DB08882",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08882",
      "source": "DB00091",
      "target": "DB08882",
      "description": "The serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00279",
      "source": "DB00091",
      "target": "DB00279",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Liothyronine.",
      "name": "Liothyronine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01583",
      "source": "DB00091",
      "target": "DB01583",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Liotrix.",
      "name": "Liotrix"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00722",
      "source": "DB00091",
      "target": "DB00722",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.",
      "name": "Lisinopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00589",
      "source": "DB00091",
      "target": "DB00589",
      "description": "The metabolism of Lisuride can be decreased when combined with Cyclosporine.",
      "name": "Lisuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08827",
      "source": "DB00091",
      "target": "DB08827",
      "description": "The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.",
      "name": "Lomitapide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00836",
      "source": "DB00091",
      "target": "DB00836",
      "description": "The metabolism of Loperamide can be decreased when combined with Cyclosporine.",
      "name": "Loperamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01601",
      "source": "DB00091",
      "target": "DB01601",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01601",
      "source": "DB00091",
      "target": "DB01601",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00455",
      "source": "DB00091",
      "target": "DB00455",
      "description": "The metabolism of Loratadine can be decreased when combined with Cyclosporine.",
      "name": "Loratadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04871",
      "source": "DB00091",
      "target": "DB04871",
      "description": "The metabolism of Lorcaserin can be decreased when combined with Cyclosporine.",
      "name": "Lorcaserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06725",
      "source": "DB00091",
      "target": "DB06725",
      "description": "Lornoxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06725",
      "source": "DB00091",
      "target": "DB06725",
      "description": "The metabolism of Lornoxicam can be decreased when combined with Cyclosporine.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00678",
      "source": "DB00091",
      "target": "DB00678",
      "description": "The metabolism of Losartan can be decreased when combined with Cyclosporine.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00678",
      "source": "DB00091",
      "target": "DB00678",
      "description": "Losartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Losartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00227",
      "source": "DB00091",
      "target": "DB00227",
      "description": "The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00227",
      "source": "DB00091",
      "target": "DB00227",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Lovastatin.",
      "name": "Lovastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09212",
      "source": "DB00091",
      "target": "DB09212",
      "description": "Loxoprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08933",
      "source": "DB00091",
      "target": "DB08933",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.",
      "name": "Luliconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09280",
      "source": "DB00091",
      "target": "DB09280",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.",
      "name": "Lumacaftor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06708",
      "source": "DB00091",
      "target": "DB06708",
      "description": "The metabolism of Lumefantrine can be decreased when combined with Cyclosporine.",
      "name": "Lumefantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01283",
      "source": "DB00091",
      "target": "DB01283",
      "description": "Lumiracoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01283",
      "source": "DB00091",
      "target": "DB01283",
      "description": "The metabolism of Lumiracoxib can be decreased when combined with Cyclosporine.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08815",
      "source": "DB00091",
      "target": "DB08815",
      "description": "The serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.",
      "name": "Lurasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08932",
      "source": "DB00091",
      "target": "DB08932",
      "description": "The metabolism of Macitentan can be decreased when combined with Cyclosporine.",
      "name": "Macitentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01397",
      "source": "DB00091",
      "target": "DB01397",
      "description": "Magnesium salicylate may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00653",
      "source": "DB00091",
      "target": "DB00653",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.",
      "name": "Magnesium Sulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09238",
      "source": "DB00091",
      "target": "DB09238",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Manidipine.",
      "name": "Manidipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00742",
      "source": "DB00091",
      "target": "DB00742",
      "description": "The serum concentration of Mannitol can be decreased when it is combined with Cyclosporine.",
      "name": "Mannitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00934",
      "source": "DB00091",
      "target": "DB00934",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Maprotiline.",
      "name": "Maprotiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04835",
      "source": "DB00091",
      "target": "DB04835",
      "description": "The metabolism of Maraviroc can be decreased when combined with Cyclosporine.",
      "name": "Maraviroc"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00179",
      "source": "DB00091",
      "target": "DB00179",
      "description": "Masoprocol may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00643",
      "source": "DB00091",
      "target": "DB00643",
      "description": "The metabolism of Mebendazole can be decreased when combined with Cyclosporine.",
      "name": "Mebendazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00939",
      "source": "DB00091",
      "target": "DB00939",
      "description": "Meclofenamic acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00603",
      "source": "DB00091",
      "target": "DB00603",
      "description": "The metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00784",
      "source": "DB00091",
      "target": "DB00784",
      "description": "Mefenamic acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00784",
      "source": "DB00091",
      "target": "DB00784",
      "description": "The metabolism of Mefenamic acid can be decreased when combined with Cyclosporine.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00358",
      "source": "DB00091",
      "target": "DB00358",
      "description": "The metabolism of Mefloquine can be decreased when combined with Cyclosporine.",
      "name": "Mefloquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00351",
      "source": "DB00091",
      "target": "DB00351",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01065",
      "source": "DB00091",
      "target": "DB01065",
      "description": "The metabolism of Melatonin can be decreased when combined with Cyclosporine.",
      "name": "Melatonin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00814",
      "source": "DB00091",
      "target": "DB00814",
      "description": "Meloxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00814",
      "source": "DB00091",
      "target": "DB00814",
      "description": "The metabolism of Meloxicam can be decreased when combined with Cyclosporine.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01042",
      "source": "DB00091",
      "target": "DB01042",
      "description": "Melphalan may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Melphalan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00532",
      "source": "DB00091",
      "target": "DB00532",
      "description": "The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.",
      "name": "Mephenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00371",
      "source": "DB00091",
      "target": "DB00371",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.",
      "name": "Meprobamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00244",
      "source": "DB00091",
      "target": "DB00244",
      "description": "Mesalazine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01357",
      "source": "DB00091",
      "target": "DB01357",
      "description": "The metabolism of Mestranol can be decreased when combined with Cyclosporine.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04817",
      "source": "DB00091",
      "target": "DB04817",
      "description": "Metamizole may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00333",
      "source": "DB00091",
      "target": "DB00333",
      "description": "The metabolism of Methadone can be decreased when combined with Cyclosporine.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04833",
      "source": "DB00091",
      "target": "DB04833",
      "description": "The metabolism of Methaqualone can be decreased when combined with Cyclosporine.",
      "name": "Methaqualone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00474",
      "source": "DB00091",
      "target": "DB00474",
      "description": "The metabolism of Cyclosporine can be increased when combined with Methohexital.",
      "name": "Methohexital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00563",
      "source": "DB00091",
      "target": "DB00563",
      "description": "The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.",
      "name": "Methotrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00563",
      "source": "DB00091",
      "target": "DB00563",
      "description": "The serum concentration of Methotrexate can be decreased when it is combined with Cyclosporine.",
      "name": "Methotrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00553",
      "source": "DB00091",
      "target": "DB00553",
      "description": "The metabolism of Methoxsalen can be decreased when combined with Cyclosporine.",
      "name": "Methoxsalen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01028",
      "source": "DB00091",
      "target": "DB01028",
      "description": "The metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.",
      "name": "Methoxyflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00849",
      "source": "DB00091",
      "target": "DB00849",
      "description": "The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.",
      "name": "Methylphenobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00959",
      "source": "DB00091",
      "target": "DB00959",
      "description": "The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00959",
      "source": "DB00091",
      "target": "DB00959",
      "description": "The metabolism of Methylprednisolone can be decreased when combined with Cyclosporine.",
      "name": "Methylprednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06710",
      "source": "DB00091",
      "target": "DB06710",
      "description": "Methyltestosterone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06710",
      "source": "DB00091",
      "target": "DB06710",
      "description": "The metabolism of Methyltestosterone can be decreased when combined with Cyclosporine.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01233",
      "source": "DB00091",
      "target": "DB01233",
      "description": "Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.",
      "name": "Metoclopramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01336",
      "source": "DB00091",
      "target": "DB01336",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Metocurine.",
      "name": "Metocurine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00416",
      "source": "DB00091",
      "target": "DB00416",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Metocurine Iodide.",
      "name": "Metocurine Iodide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00264",
      "source": "DB00091",
      "target": "DB00264",
      "description": "The serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09046",
      "source": "DB00091",
      "target": "DB09046",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.",
      "name": "Metreleptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01578",
      "source": "DB00091",
      "target": "DB01578",
      "description": "Metrizamide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Metrizamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00916",
      "source": "DB00091",
      "target": "DB00916",
      "description": "The metabolism of Metronidazole can be decreased when combined with Cyclosporine.",
      "name": "Metronidazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06693",
      "source": "DB00091",
      "target": "DB06693",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Mevastatin.",
      "name": "Mevastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00379",
      "source": "DB00091",
      "target": "DB00379",
      "description": "The metabolism of Mexiletine can be decreased when combined with Cyclosporine.",
      "name": "Mexiletine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06148",
      "source": "DB00091",
      "target": "DB06148",
      "description": "The metabolism of Mianserin can be decreased when combined with Cyclosporine.",
      "name": "Mianserin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01388",
      "source": "DB00091",
      "target": "DB01388",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mibefradil.",
      "name": "Mibefradil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01141",
      "source": "DB00091",
      "target": "DB01141",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Micafungin.",
      "name": "Micafungin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01110",
      "source": "DB00091",
      "target": "DB01110",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Miconazole.",
      "name": "Miconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00683",
      "source": "DB00091",
      "target": "DB00683",
      "description": "The metabolism of Midazolam can be decreased when combined with Cyclosporine.",
      "name": "Midazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00834",
      "source": "DB00091",
      "target": "DB00834",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09031",
      "source": "DB00091",
      "target": "DB09031",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Miltefosine.",
      "name": "Miltefosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00350",
      "source": "DB00091",
      "target": "DB00350",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.",
      "name": "Minoxidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08893",
      "source": "DB00091",
      "target": "DB08893",
      "description": "The metabolism of Mirabegron can be decreased when combined with Cyclosporine.",
      "name": "Mirabegron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00370",
      "source": "DB00091",
      "target": "DB00370",
      "description": "The metabolism of Mirtazapine can be decreased when combined with Cyclosporine.",
      "name": "Mirtazapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00305",
      "source": "DB00091",
      "target": "DB00305",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Mitomycin.",
      "name": "Mitomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00648",
      "source": "DB00091",
      "target": "DB00648",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.",
      "name": "Mitotane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01204",
      "source": "DB00091",
      "target": "DB01204",
      "description": "The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.",
      "name": "Mitoxantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01204",
      "source": "DB00091",
      "target": "DB01204",
      "description": "The serum concentration of Mitoxantrone can be decreased when it is combined with Cyclosporine.",
      "name": "Mitoxantrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01226",
      "source": "DB00091",
      "target": "DB01226",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Mivacurium.",
      "name": "Mivacurium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01171",
      "source": "DB00091",
      "target": "DB01171",
      "description": "The metabolism of Moclobemide can be decreased when combined with Cyclosporine.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00745",
      "source": "DB00091",
      "target": "DB00745",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.",
      "name": "Modafinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00691",
      "source": "DB00091",
      "target": "DB00691",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Moexipril.",
      "name": "Moexipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11430",
      "source": "DB00091",
      "target": "DB11430",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Monensin.",
      "name": "Monensin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00471",
      "source": "DB00091",
      "target": "DB00471",
      "description": "The metabolism of Montelukast can be decreased when combined with Cyclosporine.",
      "name": "Montelukast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00295",
      "source": "DB00091",
      "target": "DB00295",
      "description": "The metabolism of Morphine can be decreased when combined with Cyclosporine.",
      "name": "Morphine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00688",
      "source": "DB00091",
      "target": "DB00688",
      "description": "Mycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00688",
      "source": "DB00091",
      "target": "DB00688",
      "description": "The metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01024",
      "source": "DB00091",
      "target": "DB01024",
      "description": "The serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04741",
      "source": "DB00091",
      "target": "DB04741",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Myxothiazol.",
      "name": "Myxothiazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02855",
      "source": "DB00091",
      "target": "DB02855",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.",
      "name": "N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00461",
      "source": "DB00091",
      "target": "DB00461",
      "description": "Nabumetone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01203",
      "source": "DB00091",
      "target": "DB01203",
      "description": "The serum concentration of Nadolol can be decreased when it is combined with Cyclosporine.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00607",
      "source": "DB00091",
      "target": "DB00607",
      "description": "The metabolism of Cyclosporine can be increased when combined with Nafcillin.",
      "name": "Nafcillin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00607",
      "source": "DB00091",
      "target": "DB00607",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Nafcillin.",
      "name": "Nafcillin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00735",
      "source": "DB00091",
      "target": "DB00735",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Naftifine.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09049",
      "source": "DB00091",
      "target": "DB09049",
      "description": "The serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.",
      "name": "Naloxegol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01183",
      "source": "DB00091",
      "target": "DB01183",
      "description": "The metabolism of Naloxone can be decreased when combined with Cyclosporine.",
      "name": "Naloxone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00704",
      "source": "DB00091",
      "target": "DB00704",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Naltrexone.",
      "name": "Naltrexone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00788",
      "source": "DB00091",
      "target": "DB00788",
      "description": "Naproxen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00788",
      "source": "DB00091",
      "target": "DB00788",
      "description": "The metabolism of Naproxen can be decreased when combined with Cyclosporine.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03467",
      "source": "DB00091",
      "target": "DB03467",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Naringenin.",
      "name": "Naringenin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00108",
      "source": "DB00091",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00826",
      "source": "DB00091",
      "target": "DB00826",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Natamycin.",
      "name": "Natamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00731",
      "source": "DB00091",
      "target": "DB00731",
      "description": "The metabolism of Nateglinide can be decreased when combined with Cyclosporine.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05822",
      "source": "DB00091",
      "target": "DB05822",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with NCX 4016.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01149",
      "source": "DB00091",
      "target": "DB01149",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Nefazodone.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00220",
      "source": "DB00091",
      "target": "DB00220",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00220",
      "source": "DB00091",
      "target": "DB00220",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.",
      "name": "Nelfinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00994",
      "source": "DB00091",
      "target": "DB00994",
      "description": "Neomycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Neomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01400",
      "source": "DB00091",
      "target": "DB01400",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Neostigmine.",
      "name": "Neostigmine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06802",
      "source": "DB00091",
      "target": "DB06802",
      "description": "Nepafenac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00955",
      "source": "DB00091",
      "target": "DB00955",
      "description": "Netilmicin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Netilmicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09048",
      "source": "DB00091",
      "target": "DB09048",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Netupitant.",
      "name": "Netupitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00238",
      "source": "DB00091",
      "target": "DB00238",
      "description": "The metabolism of Cyclosporine can be increased when combined with Nevirapine.",
      "name": "Nevirapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00622",
      "source": "DB00091",
      "target": "DB00622",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nicardipine.",
      "name": "Nicardipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06803",
      "source": "DB00091",
      "target": "DB06803",
      "description": "The metabolism of Niclosamide can be decreased when combined with Cyclosporine.",
      "name": "Niclosamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00184",
      "source": "DB00091",
      "target": "DB00184",
      "description": "The metabolism of Nicotine can be decreased when combined with Cyclosporine.",
      "name": "Nicotine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01115",
      "source": "DB00091",
      "target": "DB01115",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nifedipine.",
      "name": "Nifedipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04552",
      "source": "DB00091",
      "target": "DB04552",
      "description": "Niflumic Acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09239",
      "source": "DB00091",
      "target": "DB09239",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.",
      "name": "Niguldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04868",
      "source": "DB00091",
      "target": "DB04868",
      "description": "The metabolism of Nilotinib can be decreased when combined with Cyclosporine.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09240",
      "source": "DB00091",
      "target": "DB09240",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Niludipine.",
      "name": "Niludipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06712",
      "source": "DB00091",
      "target": "DB06712",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilvadipine.",
      "name": "Nilvadipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04743",
      "source": "DB00091",
      "target": "DB04743",
      "description": "Nimesulide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04743",
      "source": "DB00091",
      "target": "DB04743",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nimesulide.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00393",
      "source": "DB00091",
      "target": "DB00393",
      "description": "The serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.",
      "name": "Nimodipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09079",
      "source": "DB00091",
      "target": "DB09079",
      "description": "The serum concentration of Nintedanib can be increased when it is combined with Cyclosporine.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00401",
      "source": "DB00091",
      "target": "DB00401",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nisoldipine.",
      "name": "Nisoldipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01595",
      "source": "DB00091",
      "target": "DB01595",
      "description": "The metabolism of Nitrazepam can be decreased when combined with Cyclosporine.",
      "name": "Nitrazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01054",
      "source": "DB00091",
      "target": "DB01054",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.",
      "name": "Nitrendipine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01422",
      "source": "DB00091",
      "target": "DB01422",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Nitroxoline.",
      "name": "Nitroxoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00585",
      "source": "DB00091",
      "target": "DB00585",
      "description": "The serum concentration of Nizatidine can be decreased when it is combined with Cyclosporine.",
      "name": "Nizatidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00717",
      "source": "DB00091",
      "target": "DB00717",
      "description": "The metabolism of Norethisterone can be decreased when combined with Cyclosporine.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01059",
      "source": "DB00091",
      "target": "DB01059",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09389",
      "source": "DB00091",
      "target": "DB09389",
      "description": "The metabolism of Norgestrel can be decreased when combined with Cyclosporine.",
      "name": "Norgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00540",
      "source": "DB00091",
      "target": "DB00540",
      "description": "The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.",
      "name": "Nortriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00646",
      "source": "DB00091",
      "target": "DB00646",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Nystatin.",
      "name": "Nystatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00104",
      "source": "DB00091",
      "target": "DB00104",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00334",
      "source": "DB00091",
      "target": "DB00334",
      "description": "The serum concentration of Olanzapine can be decreased when it is combined with Cyclosporine.",
      "name": "Olanzapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09074",
      "source": "DB00091",
      "target": "DB09074",
      "description": "The serum concentration of Olaparib can be increased when it is combined with Cyclosporine.",
      "name": "Olaparib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00275",
      "source": "DB00091",
      "target": "DB00275",
      "description": "Olmesartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Olmesartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09080",
      "source": "DB00091",
      "target": "DB09080",
      "description": "The metabolism of Olodaterol can be decreased when combined with Cyclosporine.",
      "name": "Olodaterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00768",
      "source": "DB00091",
      "target": "DB00768",
      "description": "Olopatadine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00768",
      "source": "DB00091",
      "target": "DB00768",
      "description": "The metabolism of Olopatadine can be decreased when combined with Cyclosporine.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01250",
      "source": "DB00091",
      "target": "DB01250",
      "description": "Olsalazine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00886",
      "source": "DB00091",
      "target": "DB00886",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Omapatrilat.",
      "name": "Omapatrilat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09296",
      "source": "DB00091",
      "target": "DB09296",
      "description": "The serum concentration of Ombitasvir can be decreased when it is combined with Cyclosporine.",
      "name": "Ombitasvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00338",
      "source": "DB00091",
      "target": "DB00338",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.",
      "name": "Omeprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00338",
      "source": "DB00091",
      "target": "DB00338",
      "description": "The metabolism of Omeprazole can be decreased when combined with Cyclosporine.",
      "name": "Omeprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00904",
      "source": "DB00091",
      "target": "DB00904",
      "description": "The metabolism of Ondansetron can be decreased when combined with Cyclosporine.",
      "name": "Ondansetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11444",
      "source": "DB00091",
      "target": "DB11444",
      "description": "Orgotein may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01083",
      "source": "DB00091",
      "target": "DB01083",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Orlistat.",
      "name": "Orlistat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01173",
      "source": "DB00091",
      "target": "DB01173",
      "description": "The metabolism of Orphenadrine can be decreased when combined with Cyclosporine.",
      "name": "Orphenadrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09330",
      "source": "DB00091",
      "target": "DB09330",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Osimertinib.",
      "name": "Osimertinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04938",
      "source": "DB00091",
      "target": "DB04938",
      "description": "The metabolism of Ospemifene can be decreased when combined with Cyclosporine.",
      "name": "Ospemifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06635",
      "source": "DB00091",
      "target": "DB06635",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00621",
      "source": "DB00091",
      "target": "DB00621",
      "description": "Oxandrolone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Oxandrolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00991",
      "source": "DB00091",
      "target": "DB00991",
      "description": "Oxaprozin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00991",
      "source": "DB00091",
      "target": "DB00991",
      "description": "The metabolism of Oxaprozin can be decreased when combined with Cyclosporine.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00842",
      "source": "DB00091",
      "target": "DB00842",
      "description": "The metabolism of Oxazepam can be decreased when combined with Cyclosporine.",
      "name": "Oxazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00239",
      "source": "DB00091",
      "target": "DB00239",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Oxiconazole.",
      "name": "Oxiconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01062",
      "source": "DB00091",
      "target": "DB01062",
      "description": "The metabolism of Oxybutynin can be decreased when combined with Cyclosporine.",
      "name": "Oxybutynin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00497",
      "source": "DB00091",
      "target": "DB00497",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.",
      "name": "Oxycodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06412",
      "source": "DB00091",
      "target": "DB06412",
      "description": "Oxymetholone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Oxymetholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01192",
      "source": "DB00091",
      "target": "DB01192",
      "description": "The metabolism of Oxymorphone can be decreased when combined with Cyclosporine.",
      "name": "Oxymorphone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03585",
      "source": "DB00091",
      "target": "DB03585",
      "description": "Oxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04417",
      "source": "DB00091",
      "target": "DB04417",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with P-Nitrophenol.",
      "name": "P-Nitrophenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01229",
      "source": "DB00091",
      "target": "DB01229",
      "description": "The metabolism of Paclitaxel can be decreased when combined with Cyclosporine.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06532",
      "source": "DB00091",
      "target": "DB06532",
      "description": "The metabolism of Cyclosporine can be decreased when combined with pafuramidine.",
      "name": "pafuramidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09073",
      "source": "DB00091",
      "target": "DB09073",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.",
      "name": "Palbociclib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03796",
      "source": "DB00091",
      "target": "DB03796",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Palmitic Acid.",
      "name": "Palmitic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00377",
      "source": "DB00091",
      "target": "DB00377",
      "description": "The metabolism of Palonosetron can be decreased when combined with Cyclosporine.",
      "name": "Palonosetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01337",
      "source": "DB00091",
      "target": "DB01337",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Pancuronium.",
      "name": "Pancuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06603",
      "source": "DB00091",
      "target": "DB06603",
      "description": "The metabolism of Panobinostat can be decreased when combined with Cyclosporine.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00213",
      "source": "DB00091",
      "target": "DB00213",
      "description": "The metabolism of Pantoprazole can be decreased when combined with Cyclosporine.",
      "name": "Pantoprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00617",
      "source": "DB00091",
      "target": "DB00617",
      "description": "The metabolism of Paramethadione can be decreased when combined with Cyclosporine.",
      "name": "Paramethadione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01384",
      "source": "DB00091",
      "target": "DB01384",
      "description": "The metabolism of Paramethasone can be decreased when combined with Cyclosporine.",
      "name": "Paramethasone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08439",
      "source": "DB00091",
      "target": "DB08439",
      "description": "Parecoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08439",
      "source": "DB00091",
      "target": "DB08439",
      "description": "The metabolism of Parecoxib can be decreased when combined with Cyclosporine.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00910",
      "source": "DB00091",
      "target": "DB00910",
      "description": "The metabolism of Paricalcitol can be decreased when combined with Cyclosporine.",
      "name": "Paricalcitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09297",
      "source": "DB00091",
      "target": "DB09297",
      "description": "The metabolism of Paritaprevir can be decreased when combined with Cyclosporine.",
      "name": "Paritaprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01421",
      "source": "DB00091",
      "target": "DB01421",
      "description": "Paromomycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Paromomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00715",
      "source": "DB00091",
      "target": "DB00715",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Paroxetine.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06663",
      "source": "DB00091",
      "target": "DB06663",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06589",
      "source": "DB00091",
      "target": "DB06589",
      "description": "The serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00738",
      "source": "DB00091",
      "target": "DB00738",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00312",
      "source": "DB00091",
      "target": "DB00312",
      "description": "The metabolism of Cyclosporine can be increased when combined with Pentobarbital.",
      "name": "Pentobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08883",
      "source": "DB00091",
      "target": "DB08883",
      "description": "The metabolism of Perampanel can be decreased when combined with Cyclosporine.",
      "name": "Perampanel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01186",
      "source": "DB00091",
      "target": "DB01186",
      "description": "The metabolism of Pergolide can be decreased when combined with Cyclosporine.",
      "name": "Pergolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01074",
      "source": "DB00091",
      "target": "DB01074",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Perhexiline.",
      "name": "Perhexiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00790",
      "source": "DB00091",
      "target": "DB00790",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Perindopril.",
      "name": "Perindopril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04930",
      "source": "DB00091",
      "target": "DB04930",
      "description": "The metabolism of Permethrin can be decreased when combined with Cyclosporine.",
      "name": "Permethrin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00850",
      "source": "DB00091",
      "target": "DB00850",
      "description": "The metabolism of Perphenazine can be decreased when combined with Cyclosporine.",
      "name": "Perphenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00454",
      "source": "DB00091",
      "target": "DB00454",
      "description": "The metabolism of Pethidine can be decreased when combined with Cyclosporine.",
      "name": "Pethidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03783",
      "source": "DB00091",
      "target": "DB03783",
      "description": "The metabolism of Phenacetin can be decreased when combined with Cyclosporine.",
      "name": "Phenacetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01174",
      "source": "DB00091",
      "target": "DB01174",
      "description": "The metabolism of Cyclosporine can be increased when combined with Phenobarbital.",
      "name": "Phenobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00925",
      "source": "DB00091",
      "target": "DB00925",
      "description": "The metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.",
      "name": "Phenoxybenzamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00946",
      "source": "DB00091",
      "target": "DB00946",
      "description": "The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00812",
      "source": "DB00091",
      "target": "DB00812",
      "description": "Phenylbutazone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00812",
      "source": "DB00091",
      "target": "DB00812",
      "description": "The metabolism of Phenylbutazone can be decreased when combined with Cyclosporine.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00252",
      "source": "DB00091",
      "target": "DB00252",
      "description": "The metabolism of Cyclosporine can be increased when combined with Phenytoin.",
      "name": "Phenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00252",
      "source": "DB00091",
      "target": "DB00252",
      "description": "The serum concentration of Phenytoin can be increased when it is combined with Cyclosporine.",
      "name": "Phenytoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02557",
      "source": "DB00091",
      "target": "DB02557",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Phosphoramidon.",
      "name": "Phosphoramidon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01085",
      "source": "DB00091",
      "target": "DB01085",
      "description": "The metabolism of Pilocarpine can be decreased when combined with Cyclosporine.",
      "name": "Pilocarpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00337",
      "source": "DB00091",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00337",
      "source": "DB00091",
      "target": "DB00337",
      "description": "Pimecrolimus may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01100",
      "source": "DB00091",
      "target": "DB01100",
      "description": "The serum concentration of Pimozide can be increased when it is combined with Cyclosporine.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06762",
      "source": "DB00091",
      "target": "DB06762",
      "description": "The metabolism of Pinacidil can be decreased when combined with Cyclosporine.",
      "name": "Pinacidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09090",
      "source": "DB00091",
      "target": "DB09090",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pinaverium.",
      "name": "Pinaverium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01132",
      "source": "DB00091",
      "target": "DB01132",
      "description": "The metabolism of Pioglitazone can be decreased when combined with Cyclosporine.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01338",
      "source": "DB00091",
      "target": "DB01338",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Pipecuronium.",
      "name": "Pipecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01621",
      "source": "DB00091",
      "target": "DB01621",
      "description": "The metabolism of Pipotiazine can be decreased when combined with Cyclosporine.",
      "name": "Pipotiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02925",
      "source": "DB00091",
      "target": "DB02925",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.",
      "name": "Piretanide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04951",
      "source": "DB00091",
      "target": "DB04951",
      "description": "Pirfenidone may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00554",
      "source": "DB00091",
      "target": "DB00554",
      "description": "Piroxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00554",
      "source": "DB00091",
      "target": "DB00554",
      "description": "The metabolism of Piroxicam can be decreased when combined with Cyclosporine.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08860",
      "source": "DB00091",
      "target": "DB08860",
      "description": "The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.",
      "name": "Pitavastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08860",
      "source": "DB00091",
      "target": "DB08860",
      "description": "The serum concentration of Pitavastatin can be decreased when it is combined with Cyclosporine.",
      "name": "Pitavastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02261",
      "source": "DB00091",
      "target": "DB02261",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Platelet Activating Factor.",
      "name": "Platelet Activating Factor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06810",
      "source": "DB00091",
      "target": "DB06810",
      "description": "Plicamycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Plicamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01179",
      "source": "DB00091",
      "target": "DB01179",
      "description": "The metabolism of Podofilox can be decreased when combined with Cyclosporine.",
      "name": "Podofilox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08910",
      "source": "DB00091",
      "target": "DB08910",
      "description": "The metabolism of Pomalidomide can be decreased when combined with Cyclosporine.",
      "name": "Pomalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08901",
      "source": "DB00091",
      "target": "DB08901",
      "description": "The metabolism of Ponatinib can be decreased when combined with Cyclosporine.",
      "name": "Ponatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01263",
      "source": "DB00091",
      "target": "DB01263",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Posaconazole.",
      "name": "Posaconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06209",
      "source": "DB00091",
      "target": "DB06209",
      "description": "The metabolism of Prasugrel can be decreased when combined with Cyclosporine.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00175",
      "source": "DB00091",
      "target": "DB00175",
      "description": "The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.",
      "name": "Pravastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00175",
      "source": "DB00091",
      "target": "DB00175",
      "description": "The metabolism of Pravastatin can be decreased when combined with Cyclosporine.",
      "name": "Pravastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01588",
      "source": "DB00091",
      "target": "DB01588",
      "description": "The metabolism of Prazepam can be decreased when combined with Cyclosporine.",
      "name": "Prazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01058",
      "source": "DB00091",
      "target": "DB01058",
      "description": "The metabolism of Praziquantel can be decreased when combined with Cyclosporine.",
      "name": "Praziquantel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00457",
      "source": "DB00091",
      "target": "DB00457",
      "description": "The serum concentration of Prazosin can be decreased when it is combined with Cyclosporine.",
      "name": "Prazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00860",
      "source": "DB00091",
      "target": "DB00860",
      "description": "The metabolism of Prednisolone can be decreased when combined with Cyclosporine.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00860",
      "source": "DB00091",
      "target": "DB00860",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.",
      "name": "Prednisolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00635",
      "source": "DB00091",
      "target": "DB00635",
      "description": "The serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00635",
      "source": "DB00091",
      "target": "DB00635",
      "description": "The metabolism of Prednisone can be decreased when combined with Cyclosporine.",
      "name": "Prednisone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00230",
      "source": "DB00091",
      "target": "DB00230",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.",
      "name": "Pregabalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04825",
      "source": "DB00091",
      "target": "DB04825",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.",
      "name": "Prenylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01087",
      "source": "DB00091",
      "target": "DB01087",
      "description": "The metabolism of Primaquine can be decreased when combined with Cyclosporine.",
      "name": "Primaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00794",
      "source": "DB00091",
      "target": "DB00794",
      "description": "The metabolism of Cyclosporine can be increased when combined with Primidone.",
      "name": "Primidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05100",
      "source": "DB00091",
      "target": "DB05100",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Prinomastat.",
      "name": "Prinomastat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01032",
      "source": "DB00091",
      "target": "DB01032",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Probenecid.",
      "name": "Probenecid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00433",
      "source": "DB00091",
      "target": "DB00433",
      "description": "The metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.",
      "name": "Prochlorperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00396",
      "source": "DB00091",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01131",
      "source": "DB00091",
      "target": "DB01131",
      "description": "The metabolism of Proguanil can be decreased when combined with Cyclosporine.",
      "name": "Proguanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00420",
      "source": "DB00091",
      "target": "DB00420",
      "description": "The metabolism of Promazine can be decreased when combined with Cyclosporine.",
      "name": "Promazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01069",
      "source": "DB00091",
      "target": "DB01069",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Promethazine.",
      "name": "Promethazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09288",
      "source": "DB00091",
      "target": "DB09288",
      "description": "Propacetamol may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01182",
      "source": "DB00091",
      "target": "DB01182",
      "description": "The serum concentration of Propafenone can be increased when it is combined with Cyclosporine.",
      "name": "Propafenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00818",
      "source": "DB00091",
      "target": "DB00818",
      "description": "The metabolism of Propofol can be decreased when combined with Cyclosporine.",
      "name": "Propofol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00571",
      "source": "DB00091",
      "target": "DB00571",
      "description": "The metabolism of Propranolol can be decreased when combined with Cyclosporine.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00344",
      "source": "DB00091",
      "target": "DB00344",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.",
      "name": "Protriptyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06480",
      "source": "DB00091",
      "target": "DB06480",
      "description": "The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.",
      "name": "Prucalopride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05173",
      "source": "DB00091",
      "target": "DB05173",
      "description": "PTC299 may increase the nephrotoxic activities of Cyclosporine.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08437",
      "source": "DB00091",
      "target": "DB08437",
      "description": "Puromycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Puromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11156",
      "source": "DB00091",
      "target": "DB11156",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Pyrantel.",
      "name": "Pyrantel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00339",
      "source": "DB00091",
      "target": "DB00339",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.",
      "name": "Pyrazinamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00339",
      "source": "DB00091",
      "target": "DB00339",
      "description": "The metabolism of Pyrazinamide can be decreased when combined with Cyclosporine.",
      "name": "Pyrazinamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01589",
      "source": "DB00091",
      "target": "DB01589",
      "description": "The metabolism of Quazepam can be decreased when combined with Cyclosporine.",
      "name": "Quazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04216",
      "source": "DB00091",
      "target": "DB04216",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Quercetin.",
      "name": "Quercetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01224",
      "source": "DB00091",
      "target": "DB01224",
      "description": "The metabolism of Quetiapine can be decreased when combined with Cyclosporine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01103",
      "source": "DB00091",
      "target": "DB01103",
      "description": "The metabolism of Quinacrine can be decreased when combined with Cyclosporine.",
      "name": "Quinacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00881",
      "source": "DB00091",
      "target": "DB00881",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Quinapril.",
      "name": "Quinapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00908",
      "source": "DB00091",
      "target": "DB00908",
      "description": "The metabolism of Quinidine can be decreased when combined with Cyclosporine.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00468",
      "source": "DB00091",
      "target": "DB00468",
      "description": "The metabolism of Quinine can be decreased when combined with Cyclosporine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01369",
      "source": "DB00091",
      "target": "DB01369",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.",
      "name": "Quinupristin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01129",
      "source": "DB00091",
      "target": "DB01129",
      "description": "The metabolism of Rabeprazole can be decreased when combined with Cyclosporine.",
      "name": "Rabeprazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB10283",
      "source": "DB00091",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB10283",
      "source": "DB00091",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cyclosporine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03758",
      "source": "DB00091",
      "target": "DB03758",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Radicicol.",
      "name": "Radicicol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00481",
      "source": "DB00091",
      "target": "DB00481",
      "description": "The metabolism of Raloxifene can be decreased when combined with Cyclosporine.",
      "name": "Raloxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00980",
      "source": "DB00091",
      "target": "DB00980",
      "description": "The metabolism of Ramelteon can be decreased when combined with Cyclosporine.",
      "name": "Ramelteon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00178",
      "source": "DB00091",
      "target": "DB00178",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ramipril.",
      "name": "Ramipril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00863",
      "source": "DB00091",
      "target": "DB00863",
      "description": "The serum concentration of Ranitidine can be decreased when it is combined with Cyclosporine.",
      "name": "Ranitidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00243",
      "source": "DB00091",
      "target": "DB00243",
      "description": "The metabolism of Ranolazine can be decreased when combined with Cyclosporine.",
      "name": "Ranolazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04834",
      "source": "DB00091",
      "target": "DB04834",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Rapacuronium.",
      "name": "Rapacuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00234",
      "source": "DB00091",
      "target": "DB00234",
      "description": "The metabolism of Reboxetine can be decreased when combined with Cyclosporine.",
      "name": "Reboxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08896",
      "source": "DB00091",
      "target": "DB08896",
      "description": "The metabolism of Regorafenib can be decreased when combined with Cyclosporine.",
      "name": "Regorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00212",
      "source": "DB00091",
      "target": "DB00212",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Remikiren.",
      "name": "Remikiren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00912",
      "source": "DB00091",
      "target": "DB00912",
      "description": "The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00912",
      "source": "DB00091",
      "target": "DB00912",
      "description": "The metabolism of Repaglinide can be decreased when combined with Cyclosporine.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00206",
      "source": "DB00091",
      "target": "DB00206",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Reserpine.",
      "name": "Reserpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02709",
      "source": "DB00091",
      "target": "DB02709",
      "description": "Resveratrol may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01256",
      "source": "DB00091",
      "target": "DB01256",
      "description": "The metabolism of Retapamulin can be decreased when combined with Cyclosporine.",
      "name": "Retapamulin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03615",
      "source": "DB00091",
      "target": "DB03615",
      "description": "Ribostamycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Ribostamycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00615",
      "source": "DB00091",
      "target": "DB00615",
      "description": "The metabolism of Cyclosporine can be increased when combined with Rifabutin.",
      "name": "Rifabutin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01045",
      "source": "DB00091",
      "target": "DB01045",
      "description": "The metabolism of Cyclosporine can be increased when combined with Rifampicin.",
      "name": "Rifampicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01201",
      "source": "DB00091",
      "target": "DB01201",
      "description": "The metabolism of Cyclosporine can be increased when combined with Rifapentine.",
      "name": "Rifapentine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01220",
      "source": "DB00091",
      "target": "DB01220",
      "description": "The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.",
      "name": "Rifaximin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08864",
      "source": "DB00091",
      "target": "DB08864",
      "description": "The metabolism of Rilpivirine can be decreased when combined with Cyclosporine.",
      "name": "Rilpivirine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06155",
      "source": "DB00091",
      "target": "DB06155",
      "description": "The metabolism of Rimonabant can be decreased when combined with Cyclosporine.",
      "name": "Rimonabant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08931",
      "source": "DB00091",
      "target": "DB08931",
      "description": "The metabolism of Riociguat can be decreased when combined with Cyclosporine.",
      "name": "Riociguat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00884",
      "source": "DB00091",
      "target": "DB00884",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.",
      "name": "Risedronate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00734",
      "source": "DB00091",
      "target": "DB00734",
      "description": "The metabolism of Risperidone can be decreased when combined with Cyclosporine.",
      "name": "Risperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00503",
      "source": "DB00091",
      "target": "DB00503",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00503",
      "source": "DB00091",
      "target": "DB00503",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Ritonavir.",
      "name": "Ritonavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06228",
      "source": "DB00091",
      "target": "DB06228",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06228",
      "source": "DB00091",
      "target": "DB06228",
      "description": "The metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00728",
      "source": "DB00091",
      "target": "DB00728",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Rocuronium.",
      "name": "Rocuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00533",
      "source": "DB00091",
      "target": "DB00533",
      "description": "Rofecoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00533",
      "source": "DB00091",
      "target": "DB00533",
      "description": "The metabolism of Rofecoxib can be decreased when combined with Cyclosporine.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01656",
      "source": "DB00091",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Cyclosporine.",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09291",
      "source": "DB00091",
      "target": "DB09291",
      "description": "The metabolism of Rolapitant can be decreased when combined with Cyclosporine.",
      "name": "Rolapitant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06176",
      "source": "DB00091",
      "target": "DB06176",
      "description": "The metabolism of Romidepsin can be decreased when combined with Cyclosporine.",
      "name": "Romidepsin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00268",
      "source": "DB00091",
      "target": "DB00268",
      "description": "The metabolism of Ropinirole can be decreased when combined with Cyclosporine.",
      "name": "Ropinirole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00296",
      "source": "DB00091",
      "target": "DB00296",
      "description": "The metabolism of Ropivacaine can be decreased when combined with Cyclosporine.",
      "name": "Ropivacaine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00412",
      "source": "DB00091",
      "target": "DB00412",
      "description": "The metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01098",
      "source": "DB00091",
      "target": "DB01098",
      "description": "The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01098",
      "source": "DB00091",
      "target": "DB01098",
      "description": "The metabolism of Rosuvastatin can be decreased when combined with Cyclosporine.",
      "name": "Rosuvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05271",
      "source": "DB00091",
      "target": "DB05271",
      "description": "The metabolism of Rotigotine can be decreased when combined with Cyclosporine.",
      "name": "Rotigotine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00778",
      "source": "DB00091",
      "target": "DB00778",
      "description": "The metabolism of Roxithromycin can be decreased when combined with Cyclosporine.",
      "name": "Roxithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08877",
      "source": "DB00091",
      "target": "DB08877",
      "description": "The metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.",
      "name": "Ruxolitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09292",
      "source": "DB00091",
      "target": "DB09292",
      "description": "Sacubitril may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Sacubitril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08797",
      "source": "DB00091",
      "target": "DB08797",
      "description": "Salicylamide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03819",
      "source": "DB00091",
      "target": "DB03819",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.",
      "name": "Salicylhydroxamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00936",
      "source": "DB00091",
      "target": "DB00936",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Salicylic acid.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00936",
      "source": "DB00091",
      "target": "DB00936",
      "description": "The serum concentration of Salicylic acid can be decreased when it is combined with Cyclosporine.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00938",
      "source": "DB00091",
      "target": "DB00938",
      "description": "The serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.",
      "name": "Salmeterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01399",
      "source": "DB00091",
      "target": "DB01399",
      "description": "Salsalate may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01347",
      "source": "DB00091",
      "target": "DB01347",
      "description": "Saprisartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Saprisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01232",
      "source": "DB00091",
      "target": "DB01232",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01232",
      "source": "DB00091",
      "target": "DB01232",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06763",
      "source": "DB00091",
      "target": "DB06763",
      "description": "Saralasin may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Saralasin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06335",
      "source": "DB00091",
      "target": "DB06335",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Saxagliptin.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00747",
      "source": "DB00091",
      "target": "DB00747",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Scopolamine.",
      "name": "Scopolamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00418",
      "source": "DB00091",
      "target": "DB00418",
      "description": "The metabolism of Cyclosporine can be increased when combined with Secobarbital.",
      "name": "Secobarbital"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01037",
      "source": "DB00091",
      "target": "DB01037",
      "description": "The metabolism of Selegiline can be decreased when combined with Cyclosporine.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11362",
      "source": "DB00091",
      "target": "DB11362",
      "description": "The metabolism of Selexipag can be decreased when combined with Cyclosporine.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06739",
      "source": "DB00091",
      "target": "DB06739",
      "description": "Seratrodast may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06739",
      "source": "DB00091",
      "target": "DB06739",
      "description": "The metabolism of Seratrodast can be decreased when combined with Cyclosporine.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01153",
      "source": "DB00091",
      "target": "DB01153",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Sertaconazole.",
      "name": "Sertaconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06144",
      "source": "DB00091",
      "target": "DB06144",
      "description": "The metabolism of Sertindole can be decreased when combined with Cyclosporine.",
      "name": "Sertindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01104",
      "source": "DB00091",
      "target": "DB01104",
      "description": "The metabolism of Sertraline can be decreased when combined with Cyclosporine.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00658",
      "source": "DB00091",
      "target": "DB00658",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.",
      "name": "Sevelamer"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01236",
      "source": "DB00091",
      "target": "DB01236",
      "description": "The metabolism of Sevoflurane can be decreased when combined with Cyclosporine.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01105",
      "source": "DB00091",
      "target": "DB01105",
      "description": "The metabolism of Sibutramine can be decreased when combined with Cyclosporine.",
      "name": "Sibutramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00203",
      "source": "DB00091",
      "target": "DB00203",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Sildenafil.",
      "name": "Sildenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06207",
      "source": "DB00091",
      "target": "DB06207",
      "description": "The serum concentration of Silodosin can be increased when it is combined with Cyclosporine.",
      "name": "Silodosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09036",
      "source": "DB00091",
      "target": "DB09036",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.",
      "name": "Siltuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06290",
      "source": "DB00091",
      "target": "DB06290",
      "description": "The serum concentration of Simeprevir can be increased when it is combined with Cyclosporine.",
      "name": "Simeprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00641",
      "source": "DB00091",
      "target": "DB00641",
      "description": "The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00641",
      "source": "DB00091",
      "target": "DB00641",
      "description": "The metabolism of Simvastatin can be decreased when combined with Cyclosporine.",
      "name": "Simvastatin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01910",
      "source": "DB00091",
      "target": "DB01910",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Sinefungin.",
      "name": "Sinefungin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06688",
      "source": "DB00091",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00877",
      "source": "DB00091",
      "target": "DB00877",
      "description": "The risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00877",
      "source": "DB00091",
      "target": "DB00877",
      "description": "The metabolism of Sirolimus can be decreased when combined with Cyclosporine.",
      "name": "Sirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01261",
      "source": "DB00091",
      "target": "DB01261",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01261",
      "source": "DB00091",
      "target": "DB01261",
      "description": "The metabolism of Sitagliptin can be decreased when combined with Cyclosporine.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06268",
      "source": "DB00091",
      "target": "DB06268",
      "description": "The serum concentration of Sitaxentan can be increased when it is combined with Cyclosporine.",
      "name": "Sitaxentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06268",
      "source": "DB00091",
      "target": "DB06268",
      "description": "The metabolism of Sitaxentan can be decreased when combined with Cyclosporine.",
      "name": "Sitaxentan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08934",
      "source": "DB00091",
      "target": "DB08934",
      "description": "The serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.",
      "name": "Sofosbuvir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01591",
      "source": "DB00091",
      "target": "DB01591",
      "description": "The metabolism of Solifenacin can be decreased when combined with Cyclosporine.",
      "name": "Solifenacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09143",
      "source": "DB00091",
      "target": "DB09143",
      "description": "The serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.",
      "name": "Sonidegib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00398",
      "source": "DB00091",
      "target": "DB00398",
      "description": "The metabolism of Sorafenib can be decreased when combined with Cyclosporine.",
      "name": "Sorafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01208",
      "source": "DB00091",
      "target": "DB01208",
      "description": "The serum concentration of Sparfloxacin can be decreased when it is combined with Cyclosporine.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00919",
      "source": "DB00091",
      "target": "DB00919",
      "description": "Spectinomycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Spectinomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03203",
      "source": "DB00091",
      "target": "DB03203",
      "description": "The serum concentration of Sphingosine can be decreased when it is combined with Cyclosporine.",
      "name": "Sphingosine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06145",
      "source": "DB00091",
      "target": "DB06145",
      "description": "The metabolism of Spiramycin can be decreased when combined with Cyclosporine.",
      "name": "Spiramycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01348",
      "source": "DB00091",
      "target": "DB01348",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Spirapril.",
      "name": "Spirapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00421",
      "source": "DB00091",
      "target": "DB00421",
      "description": "Spironolactone may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Spironolactone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00421",
      "source": "DB00091",
      "target": "DB00421",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Spironolactone.",
      "name": "Spironolactone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05073",
      "source": "DB00091",
      "target": "DB05073",
      "description": "SRT501 may increase the nephrotoxic activities of Cyclosporine.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01323",
      "source": "DB00091",
      "target": "DB01323",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with St. John&#39;s Wort.",
      "name": "St. John's Wort"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06718",
      "source": "DB00091",
      "target": "DB06718",
      "description": "Stanozolol may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Stanozolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02010",
      "source": "DB00091",
      "target": "DB02010",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Staurosporine.",
      "name": "Staurosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09118",
      "source": "DB00091",
      "target": "DB09118",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.",
      "name": "Stiripentol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01082",
      "source": "DB00091",
      "target": "DB01082",
      "description": "Streptomycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Streptomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00428",
      "source": "DB00091",
      "target": "DB00428",
      "description": "Streptozocin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00428",
      "source": "DB00091",
      "target": "DB00428",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Streptozocin.",
      "name": "Streptozocin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00202",
      "source": "DB00091",
      "target": "DB00202",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Succinylcholine.",
      "name": "Succinylcholine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00364",
      "source": "DB00091",
      "target": "DB00364",
      "description": "Sucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.",
      "name": "Sucralfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00708",
      "source": "DB00091",
      "target": "DB00708",
      "description": "The metabolism of Sufentanil can be decreased when combined with Cyclosporine.",
      "name": "Sufentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06820",
      "source": "DB00091",
      "target": "DB06820",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Sulconazole.",
      "name": "Sulconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00359",
      "source": "DB00091",
      "target": "DB00359",
      "description": "The metabolism of Sulfadiazine can be decreased when combined with Cyclosporine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00359",
      "source": "DB00091",
      "target": "DB00359",
      "description": "Sulfadiazine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01015",
      "source": "DB00091",
      "target": "DB01015",
      "description": "The metabolism of Sulfamethoxazole can be decreased when combined with Cyclosporine.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01015",
      "source": "DB00091",
      "target": "DB01015",
      "description": "Sulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08798",
      "source": "DB00091",
      "target": "DB08798",
      "description": "The metabolism of Sulfamoxole can be decreased when combined with Cyclosporine.",
      "name": "Sulfamoxole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00795",
      "source": "DB00091",
      "target": "DB00795",
      "description": "Sulfasalazine may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01138",
      "source": "DB00091",
      "target": "DB01138",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.",
      "name": "Sulfinpyrazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01138",
      "source": "DB00091",
      "target": "DB01138",
      "description": "The metabolism of Sulfinpyrazone can be decreased when combined with Cyclosporine.",
      "name": "Sulfinpyrazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00263",
      "source": "DB00091",
      "target": "DB00263",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00263",
      "source": "DB00091",
      "target": "DB00263",
      "description": "Sulfisoxazole may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00605",
      "source": "DB00091",
      "target": "DB00605",
      "description": "Sulindac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00669",
      "source": "DB00091",
      "target": "DB00669",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Sumatriptan.",
      "name": "Sumatriptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01268",
      "source": "DB00091",
      "target": "DB01268",
      "description": "The metabolism of Sunitinib can be decreased when combined with Cyclosporine.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00870",
      "source": "DB00091",
      "target": "DB00870",
      "description": "Suprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00870",
      "source": "DB00091",
      "target": "DB00870",
      "description": "The metabolism of Suprofen can be decreased when combined with Cyclosporine.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09034",
      "source": "DB00091",
      "target": "DB09034",
      "description": "The serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.",
      "name": "Suvorexant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09317",
      "source": "DB00091",
      "target": "DB09317",
      "description": "The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09318",
      "source": "DB00091",
      "target": "DB09318",
      "description": "The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00382",
      "source": "DB00091",
      "target": "DB00382",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Tacrine.",
      "name": "Tacrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00864",
      "source": "DB00091",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclosporine.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00864",
      "source": "DB00091",
      "target": "DB00864",
      "description": "Tacrolimus may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00864",
      "source": "DB00091",
      "target": "DB00864",
      "description": "The metabolism of Tacrolimus can be decreased when combined with Cyclosporine.",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00820",
      "source": "DB00091",
      "target": "DB00820",
      "description": "The metabolism of Tadalafil can be decreased when combined with Cyclosporine.",
      "name": "Tadalafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00675",
      "source": "DB00091",
      "target": "DB00675",
      "description": "The metabolism of Tamoxifen can be decreased when combined with Cyclosporine.",
      "name": "Tamoxifen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00706",
      "source": "DB00091",
      "target": "DB00706",
      "description": "The metabolism of Tamsulosin can be decreased when combined with Cyclosporine.",
      "name": "Tamsulosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06204",
      "source": "DB00091",
      "target": "DB06204",
      "description": "The metabolism of Tapentadol can be decreased when combined with Cyclosporine.",
      "name": "Tapentadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01349",
      "source": "DB00091",
      "target": "DB01349",
      "description": "The metabolism of Tasosartan can be decreased when combined with Cyclosporine.",
      "name": "Tasosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01349",
      "source": "DB00091",
      "target": "DB01349",
      "description": "Tasosartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Tasosartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08833",
      "source": "DB00091",
      "target": "DB08833",
      "description": "The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.",
      "name": "Taurochenodeoxycholic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04348",
      "source": "DB00091",
      "target": "DB04348",
      "description": "The serum concentration of Taurocholic Acid can be decreased when it is combined with Cyclosporine.",
      "name": "Taurocholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09041",
      "source": "DB00091",
      "target": "DB09041",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Tavaborole.",
      "name": "Tavaborole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09161",
      "source": "DB00091",
      "target": "DB09161",
      "description": "The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Cyclosporine.",
      "name": "Technetium Tc-99m sestamibi"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05521",
      "source": "DB00091",
      "target": "DB05521",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.",
      "name": "Telaprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05521",
      "source": "DB00091",
      "target": "DB05521",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Telaprevir.",
      "name": "Telaprevir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00976",
      "source": "DB00091",
      "target": "DB00976",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Telithromycin.",
      "name": "Telithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00966",
      "source": "DB00091",
      "target": "DB00966",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Telmisartan.",
      "name": "Telmisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00966",
      "source": "DB00091",
      "target": "DB00966",
      "description": "Telmisartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Telmisartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00231",
      "source": "DB00091",
      "target": "DB00231",
      "description": "The metabolism of Temazepam can be decreased when combined with Cyclosporine.",
      "name": "Temazepam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08836",
      "source": "DB00091",
      "target": "DB08836",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Temocapril.",
      "name": "Temocapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06287",
      "source": "DB00091",
      "target": "DB06287",
      "description": "The risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06287",
      "source": "DB00091",
      "target": "DB06287",
      "description": "The metabolism of Temsirolimus can be decreased when combined with Cyclosporine.",
      "name": "Temsirolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00444",
      "source": "DB00091",
      "target": "DB00444",
      "description": "The metabolism of Teniposide can be decreased when combined with Cyclosporine.",
      "name": "Teniposide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00469",
      "source": "DB00091",
      "target": "DB00469",
      "description": "Tenoxicam may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00469",
      "source": "DB00091",
      "target": "DB00469",
      "description": "The metabolism of Tenoxicam can be decreased when combined with Cyclosporine.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11466",
      "source": "DB00091",
      "target": "DB11466",
      "description": "Tepoxalin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01162",
      "source": "DB00091",
      "target": "DB01162",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Terazosin.",
      "name": "Terazosin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00857",
      "source": "DB00091",
      "target": "DB00857",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Terbinafine.",
      "name": "Terbinafine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00251",
      "source": "DB00091",
      "target": "DB00251",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Terconazole.",
      "name": "Terconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00342",
      "source": "DB00091",
      "target": "DB00342",
      "description": "The metabolism of Terfenadine can be decreased when combined with Cyclosporine.",
      "name": "Terfenadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08880",
      "source": "DB00091",
      "target": "DB08880",
      "description": "Teriflunomide may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04905",
      "source": "DB00091",
      "target": "DB04905",
      "description": "The metabolism of Tesmilifene can be decreased when combined with Cyclosporine.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00624",
      "source": "DB00091",
      "target": "DB00624",
      "description": "Testosterone may increase the hepatotoxic activities of Cyclosporine.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00624",
      "source": "DB00091",
      "target": "DB00624",
      "description": "The metabolism of Testosterone can be decreased when combined with Cyclosporine.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00759",
      "source": "DB00091",
      "target": "DB00759",
      "description": "The metabolism of Tetracycline can be decreased when combined with Cyclosporine.",
      "name": "Tetracycline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01041",
      "source": "DB00091",
      "target": "DB01041",
      "description": "The metabolism of Thalidomide can be decreased when combined with Cyclosporine.",
      "name": "Thalidomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00277",
      "source": "DB00091",
      "target": "DB00277",
      "description": "The metabolism of Theophylline can be decreased when combined with Cyclosporine.",
      "name": "Theophylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01154",
      "source": "DB00091",
      "target": "DB01154",
      "description": "The metabolism of Cyclosporine can be increased when combined with Thiamylal.",
      "name": "Thiamylal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00599",
      "source": "DB00091",
      "target": "DB00599",
      "description": "The metabolism of Cyclosporine can be increased when combined with Thiopental.",
      "name": "Thiopental"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00679",
      "source": "DB00091",
      "target": "DB00679",
      "description": "The serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.",
      "name": "Thioridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08626",
      "source": "DB00091",
      "target": "DB08626",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Thiorphan.",
      "name": "Thiorphan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04572",
      "source": "DB00091",
      "target": "DB04572",
      "description": "The metabolism of Thiotepa can be decreased when combined with Cyclosporine.",
      "name": "Thiotepa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB02513",
      "source": "DB00091",
      "target": "DB02513",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Thymol.",
      "name": "Thymol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00906",
      "source": "DB00091",
      "target": "DB00906",
      "description": "The metabolism of Tiagabine can be decreased when combined with Cyclosporine.",
      "name": "Tiagabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01600",
      "source": "DB00091",
      "target": "DB01600",
      "description": "Tiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08816",
      "source": "DB00091",
      "target": "DB08816",
      "description": "The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08816",
      "source": "DB00091",
      "target": "DB08816",
      "description": "The metabolism of Ticagrelor can be decreased when combined with Cyclosporine.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00208",
      "source": "DB00091",
      "target": "DB00208",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Ticlopidine.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00373",
      "source": "DB00091",
      "target": "DB00373",
      "description": "The serum concentration of Timolol can be decreased when it is combined with Cyclosporine.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00911",
      "source": "DB00091",
      "target": "DB00911",
      "description": "The metabolism of Tinidazole can be decreased when combined with Cyclosporine.",
      "name": "Tinidazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01007",
      "source": "DB00091",
      "target": "DB01007",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Tioconazole.",
      "name": "Tioconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01409",
      "source": "DB00091",
      "target": "DB01409",
      "description": "The metabolism of Tiotropium can be decreased when combined with Cyclosporine.",
      "name": "Tiotropium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00932",
      "source": "DB00091",
      "target": "DB00932",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00932",
      "source": "DB00091",
      "target": "DB00932",
      "description": "The metabolism of Tipranavir can be decreased when combined with Cyclosporine.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00684",
      "source": "DB00091",
      "target": "DB00684",
      "description": "Tobramycin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tobramycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06273",
      "source": "DB00091",
      "target": "DB06273",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.",
      "name": "Tocilizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08895",
      "source": "DB00091",
      "target": "DB08895",
      "description": "Cyclosporine may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01124",
      "source": "DB00091",
      "target": "DB01124",
      "description": "The metabolism of Tolbutamide can be decreased when combined with Cyclosporine.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09216",
      "source": "DB00091",
      "target": "DB09216",
      "description": "Tolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09216",
      "source": "DB00091",
      "target": "DB09216",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tolfenamic Acid.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00500",
      "source": "DB00091",
      "target": "DB00500",
      "description": "Tolmetin may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00525",
      "source": "DB00091",
      "target": "DB00525",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Tolnaftate.",
      "name": "Tolnaftate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01036",
      "source": "DB00091",
      "target": "DB01036",
      "description": "The metabolism of Tolterodine can be decreased when combined with Cyclosporine.",
      "name": "Tolterodine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06212",
      "source": "DB00091",
      "target": "DB06212",
      "description": "The serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.",
      "name": "Tolvaptan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01030",
      "source": "DB00091",
      "target": "DB01030",
      "description": "The serum concentration of Topotecan can be increased when it is combined with Cyclosporine.",
      "name": "Topotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00214",
      "source": "DB00091",
      "target": "DB00214",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00214",
      "source": "DB00091",
      "target": "DB00214",
      "description": "The metabolism of Torasemide can be decreased when combined with Cyclosporine.",
      "name": "Torasemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00539",
      "source": "DB00091",
      "target": "DB00539",
      "description": "The metabolism of Toremifene can be decreased when combined with Cyclosporine.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05109",
      "source": "DB00091",
      "target": "DB05109",
      "description": "The serum concentration of Trabectedin can be increased when it is combined with Cyclosporine.",
      "name": "Trabectedin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00193",
      "source": "DB00091",
      "target": "DB00193",
      "description": "The metabolism of Tramadol can be decreased when combined with Cyclosporine.",
      "name": "Tramadol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00519",
      "source": "DB00091",
      "target": "DB00519",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.",
      "name": "Trandolapril"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB07615",
      "source": "DB00091",
      "target": "DB07615",
      "description": "Tranilast may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB07615",
      "source": "DB00091",
      "target": "DB07615",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tranilast.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00072",
      "source": "DB00091",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Cyclosporine.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05773",
      "source": "DB00091",
      "target": "DB05773",
      "description": "The metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine.",
      "name": "Trastuzumab emtansine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00656",
      "source": "DB00091",
      "target": "DB00656",
      "description": "The metabolism of Trazodone can be decreased when combined with Cyclosporine.",
      "name": "Trazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00374",
      "source": "DB00091",
      "target": "DB00374",
      "description": "The metabolism of Treprostinil can be decreased when combined with Cyclosporine.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00755",
      "source": "DB00091",
      "target": "DB00755",
      "description": "The metabolism of Tretinoin can be decreased when combined with Cyclosporine.",
      "name": "Tretinoin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00620",
      "source": "DB00091",
      "target": "DB00620",
      "description": "The metabolism of Triamcinolone can be decreased when combined with Cyclosporine.",
      "name": "Triamcinolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00384",
      "source": "DB00091",
      "target": "DB00384",
      "description": "Triamterene may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Triamterene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00897",
      "source": "DB00091",
      "target": "DB00897",
      "description": "The metabolism of Triazolam can be decreased when combined with Cyclosporine.",
      "name": "Triazolam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00831",
      "source": "DB00091",
      "target": "DB00831",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Trifluoperazine.",
      "name": "Trifluoperazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00508",
      "source": "DB00091",
      "target": "DB00508",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Triflupromazine.",
      "name": "Triflupromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00347",
      "source": "DB00091",
      "target": "DB00347",
      "description": "The metabolism of Trimethadione can be decreased when combined with Cyclosporine.",
      "name": "Trimethadione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00440",
      "source": "DB00091",
      "target": "DB00440",
      "description": "The metabolism of Trimethoprim can be decreased when combined with Cyclosporine.",
      "name": "Trimethoprim"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01157",
      "source": "DB00091",
      "target": "DB01157",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Trimetrexate.",
      "name": "Trimetrexate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00726",
      "source": "DB00091",
      "target": "DB00726",
      "description": "The metabolism of Trimipramine can be decreased when combined with Cyclosporine.",
      "name": "Trimipramine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01401",
      "source": "DB00091",
      "target": "DB01401",
      "description": "Trisalicylate-choline may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00197",
      "source": "DB00091",
      "target": "DB00197",
      "description": "The metabolism of Troglitazone can be decreased when combined with Cyclosporine.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01361",
      "source": "DB00091",
      "target": "DB01361",
      "description": "The metabolism of Troleandomycin can be decreased when combined with Cyclosporine.",
      "name": "Troleandomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01199",
      "source": "DB00091",
      "target": "DB01199",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Tubocurarine.",
      "name": "Tubocurarine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03424",
      "source": "DB00091",
      "target": "DB03424",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ubenimex.",
      "name": "Ubenimex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06267",
      "source": "DB00091",
      "target": "DB06267",
      "description": "The metabolism of Udenafil can be decreased when combined with Cyclosporine.",
      "name": "Udenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08867",
      "source": "DB00091",
      "target": "DB08867",
      "description": "The serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.",
      "name": "Ulipristal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09076",
      "source": "DB00091",
      "target": "DB09076",
      "description": "The serum concentration of Umeclidinium can be decreased when it is combined with Cyclosporine.",
      "name": "Umeclidinium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00580",
      "source": "DB00091",
      "target": "DB00580",
      "description": "Valdecoxib may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00580",
      "source": "DB00091",
      "target": "DB00580",
      "description": "The metabolism of Valdecoxib can be decreased when combined with Cyclosporine.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00313",
      "source": "DB00091",
      "target": "DB00313",
      "description": "The metabolism of Valproic Acid can be decreased when combined with Cyclosporine.",
      "name": "Valproic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00177",
      "source": "DB00091",
      "target": "DB00177",
      "description": "The metabolism of Valsartan can be decreased when combined with Cyclosporine.",
      "name": "Valsartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00177",
      "source": "DB00091",
      "target": "DB00177",
      "description": "Valsartan may increase the hyperkalemic activities of Cyclosporine.",
      "name": "Valsartan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB05294",
      "source": "DB00091",
      "target": "DB05294",
      "description": "The metabolism of Vandetanib can be decreased when combined with Cyclosporine.",
      "name": "Vandetanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB03701",
      "source": "DB00091",
      "target": "DB03701",
      "description": "The metabolism of Vanoxerine can be decreased when combined with Cyclosporine.",
      "name": "Vanoxerine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00862",
      "source": "DB00091",
      "target": "DB00862",
      "description": "The metabolism of Vardenafil can be decreased when combined with Cyclosporine.",
      "name": "Vardenafil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01339",
      "source": "DB00091",
      "target": "DB01339",
      "description": "Cyclosporine may increase the neuromuscular blocking activities of Vecuronium.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01339",
      "source": "DB00091",
      "target": "DB01339",
      "description": "The serum concentration of Vecuronium can be decreased when it is combined with Cyclosporine.",
      "name": "Vecuronium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08881",
      "source": "DB00091",
      "target": "DB08881",
      "description": "The metabolism of Vemurafenib can be decreased when combined with Cyclosporine.",
      "name": "Vemurafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB11581",
      "source": "DB00091",
      "target": "DB11581",
      "description": "The metabolism of Venetoclax can be decreased when combined with Cyclosporine.",
      "name": "Venetoclax"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00285",
      "source": "DB00091",
      "target": "DB00285",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00661",
      "source": "DB00091",
      "target": "DB00661",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Verapamil.",
      "name": "Verapamil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06652",
      "source": "DB00091",
      "target": "DB06652",
      "description": "The metabolism of Vicriviroc can be decreased when combined with Cyclosporine.",
      "name": "Vicriviroc"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09082",
      "source": "DB00091",
      "target": "DB09082",
      "description": "The metabolism of Vilanterol can be decreased when combined with Cyclosporine.",
      "name": "Vilanterol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06684",
      "source": "DB00091",
      "target": "DB06684",
      "description": "The serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.",
      "name": "Vilazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04876",
      "source": "DB00091",
      "target": "DB04876",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00570",
      "source": "DB00091",
      "target": "DB00570",
      "description": "The metabolism of Vinblastine can be decreased when combined with Cyclosporine.",
      "name": "Vinblastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00541",
      "source": "DB00091",
      "target": "DB00541",
      "description": "The serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.",
      "name": "Vincristine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00541",
      "source": "DB00091",
      "target": "DB00541",
      "description": "The metabolism of Vincristine can be decreased when combined with Cyclosporine.",
      "name": "Vincristine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00309",
      "source": "DB00091",
      "target": "DB00309",
      "description": "The serum concentration of Vindesine can be increased when it is combined with Cyclosporine.",
      "name": "Vindesine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00361",
      "source": "DB00091",
      "target": "DB00361",
      "description": "The metabolism of Vinorelbine can be decreased when combined with Cyclosporine.",
      "name": "Vinorelbine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB08828",
      "source": "DB00091",
      "target": "DB08828",
      "description": "The metabolism of Vismodegib can be decreased when combined with Cyclosporine.",
      "name": "Vismodegib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00126",
      "source": "DB00091",
      "target": "DB00126",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin C.",
      "name": "Vitamin C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00163",
      "source": "DB00091",
      "target": "DB00163",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00582",
      "source": "DB00091",
      "target": "DB00582",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Voriconazole.",
      "name": "Voriconazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB09068",
      "source": "DB00091",
      "target": "DB09068",
      "description": "The metabolism of Vortioxetine can be decreased when combined with Cyclosporine.",
      "name": "Vortioxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00682",
      "source": "DB00091",
      "target": "DB00682",
      "description": "The metabolism of Warfarin can be decreased when combined with Cyclosporine.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04898",
      "source": "DB00091",
      "target": "DB04898",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04898",
      "source": "DB00091",
      "target": "DB04898",
      "description": "The metabolism of Ximelagatran can be decreased when combined with Cyclosporine.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06694",
      "source": "DB00091",
      "target": "DB06694",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.",
      "name": "Xylometazoline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01392",
      "source": "DB00091",
      "target": "DB01392",
      "description": "The metabolism of Yohimbine can be decreased when combined with Cyclosporine.",
      "name": "Yohimbine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00549",
      "source": "DB00091",
      "target": "DB00549",
      "description": "The metabolism of Zafirlukast can be decreased when combined with Cyclosporine.",
      "name": "Zafirlukast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00943",
      "source": "DB00091",
      "target": "DB00943",
      "description": "The metabolism of Zalcitabine can be decreased when combined with Cyclosporine.",
      "name": "Zalcitabine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00962",
      "source": "DB00091",
      "target": "DB00962",
      "description": "The metabolism of Zaleplon can be decreased when combined with Cyclosporine.",
      "name": "Zaleplon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06737",
      "source": "DB00091",
      "target": "DB06737",
      "description": "Zaltoprofen may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06737",
      "source": "DB00091",
      "target": "DB06737",
      "description": "The metabolism of Zaltoprofen can be decreased when combined with Cyclosporine.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB06283",
      "source": "DB00091",
      "target": "DB06283",
      "description": "The risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.",
      "name": "Ziconotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00495",
      "source": "DB00091",
      "target": "DB00495",
      "description": "The metabolism of Zidovudine can be decreased when combined with Cyclosporine.",
      "name": "Zidovudine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00744",
      "source": "DB00091",
      "target": "DB00744",
      "description": "Zileuton may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00744",
      "source": "DB00091",
      "target": "DB00744",
      "description": "The metabolism of Zileuton can be decreased when combined with Cyclosporine.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04832",
      "source": "DB00091",
      "target": "DB04832",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Zimelidine.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00246",
      "source": "DB00091",
      "target": "DB00246",
      "description": "The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00425",
      "source": "DB00091",
      "target": "DB00425",
      "description": "The serum concentration of Zolpidem can be increased when it is combined with Cyclosporine.",
      "name": "Zolpidem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04828",
      "source": "DB00091",
      "target": "DB04828",
      "description": "Zomepirac may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB04828",
      "source": "DB00091",
      "target": "DB04828",
      "description": "The metabolism of Zomepirac can be decreased when combined with Cyclosporine.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00909",
      "source": "DB00091",
      "target": "DB00909",
      "description": "The metabolism of Zonisamide can be decreased when combined with Cyclosporine.",
      "name": "Zonisamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01198",
      "source": "DB00091",
      "target": "DB01198",
      "description": "The serum concentration of Zopiclone can be increased when it is combined with Cyclosporine.",
      "name": "Zopiclone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB01624",
      "source": "DB00091",
      "target": "DB01624",
      "description": "The serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.",
      "name": "Zuclopenthixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB12768",
      "source": "DB00098",
      "target": "DB12768",
      "description": "The therapeutic efficacy of Bcg can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).",
      "name": "Bcg"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB06643",
      "source": "DB00098",
      "target": "DB06643",
      "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Anti-thymocyte Globulin (Rabbit).",
      "name": "Denosumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB08868",
      "source": "DB00098",
      "target": "DB08868",
      "description": "Anti-thymocyte Globulin (Rabbit) may increase the immunosuppressive activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB01097",
      "source": "DB00098",
      "target": "DB01097",
      "description": "The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Leflunomide.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB00108",
      "source": "DB00098",
      "target": "DB00108",
      "description": "The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Natalizumab.",
      "name": "Natalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB00337",
      "source": "DB00098",
      "target": "DB00337",
      "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anti-thymocyte Globulin (Rabbit).",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB10283",
      "source": "DB00098",
      "target": "DB10283",
      "description": "The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Rabies vaccine.",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB10283",
      "source": "DB00098",
      "target": "DB10283",
      "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).",
      "name": "Rabies vaccine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB01656",
      "source": "DB00098",
      "target": "DB01656",
      "description": "Roflumilast may increase the immunosuppressive activities of Anti-thymocyte Globulin (Rabbit).",
      "name": "Roflumilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB06688",
      "source": "DB00098",
      "target": "DB06688",
      "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).",
      "name": "Sipuleucel-T"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB00864",
      "source": "DB00098",
      "target": "DB00864",
      "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anti-thymocyte Globulin (Rabbit).",
      "name": "Tacrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB08895",
      "source": "DB00098",
      "target": "DB08895",
      "description": "Anti-thymocyte Globulin (Rabbit) may increase the immunosuppressive activities of Tofacitinib.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB00072",
      "source": "DB00098",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Anti-thymocyte Globulin (Rabbit).",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00099-DB00290",
      "source": "DB00099",
      "target": "DB00290",
      "description": "The risk or severity of adverse effects can be increased when Filgrastim is combined with Bleomycin.",
      "name": "Bleomycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00099-DB00531",
      "source": "DB00099",
      "target": "DB00531",
      "description": "The risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00099-DB01030",
      "source": "DB00099",
      "target": "DB01030",
      "description": "The risk or severity of adverse effects can be increased when Filgrastim is combined with Topotecan.",
      "name": "Topotecan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00100-DB00513",
      "source": "DB00100",
      "target": "DB00513",
      "description": "The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Coagulation Factor IX (Recombinant).",
      "name": "Aminocaproic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00103-DB01118",
      "source": "DB00103",
      "target": "DB01118",
      "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00103-DB00608",
      "source": "DB00103",
      "target": "DB00608",
      "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00103-DB00798",
      "source": "DB00103",
      "target": "DB00798",
      "description": "The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.",
      "name": "Gentamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00054",
      "source": "DB00102",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Becaplermin.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06736",
      "source": "DB00102",
      "target": "DB06736",
      "description": "Aceclofenac may increase the anticoagulant activities of Becaplermin.",
      "name": "Aceclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01418",
      "source": "DB00102",
      "target": "DB01418",
      "description": "Becaplermin may increase the anticoagulant activities of Acenocoumarol.",
      "name": "Acenocoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00945",
      "source": "DB00102",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00210",
      "source": "DB00102",
      "target": "DB00210",
      "description": "Adapalene may increase the anticoagulant activities of Becaplermin.",
      "name": "Adapalene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01431",
      "source": "DB00102",
      "target": "DB01431",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Allylestrenol.",
      "name": "Allylestrenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00770",
      "source": "DB00102",
      "target": "DB00770",
      "description": "Alprostadil may increase the anticoagulant activities of Becaplermin.",
      "name": "Alprostadil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00009",
      "source": "DB00102",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11372",
      "source": "DB00102",
      "target": "DB11372",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Altrenogest.",
      "name": "Altrenogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06081",
      "source": "DB00102",
      "target": "DB06081",
      "description": "ALX-0081 may increase the anticoagulant activities of Becaplermin.",
      "name": "ALX-0081"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00233",
      "source": "DB00102",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00261",
      "source": "DB00102",
      "target": "DB00261",
      "description": "Anagrelide may increase the anticoagulant activities of Becaplermin.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05099",
      "source": "DB00102",
      "target": "DB05099",
      "description": "Becaplermin may increase the anticoagulant activities of Ancrod.",
      "name": "Ancrod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00029",
      "source": "DB00102",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01435",
      "source": "DB00102",
      "target": "DB01435",
      "description": "Antipyrine may increase the anticoagulant activities of Becaplermin.",
      "name": "Antipyrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11598",
      "source": "DB00102",
      "target": "DB11598",
      "description": "Becaplermin may increase the anticoagulant activities of Antithrombin III human.",
      "name": "Antithrombin III human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06605",
      "source": "DB00102",
      "target": "DB06605",
      "description": "Apixaban may increase the anticoagulant activities of Becaplermin.",
      "name": "Apixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05676",
      "source": "DB00102",
      "target": "DB05676",
      "description": "Apremilast may increase the anticoagulant activities of Becaplermin.",
      "name": "Apremilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00407",
      "source": "DB00102",
      "target": "DB00407",
      "description": "Becaplermin may increase the anticoagulant activities of Ardeparin.",
      "name": "Ardeparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00278",
      "source": "DB00102",
      "target": "DB00278",
      "description": "Argatroban may increase the anticoagulant activities of Becaplermin.",
      "name": "Argatroban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06543",
      "source": "DB00102",
      "target": "DB06543",
      "description": "Astaxanthin may increase the anticoagulant activities of Becaplermin.",
      "name": "Astaxanthin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB07402",
      "source": "DB00102",
      "target": "DB07402",
      "description": "Azapropazone may increase the anticoagulant activities of Becaplermin.",
      "name": "Azapropazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00972",
      "source": "DB00102",
      "target": "DB00972",
      "description": "Azelastine may increase the anticoagulant activities of Becaplermin.",
      "name": "Azelastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01014",
      "source": "DB00102",
      "target": "DB01014",
      "description": "Balsalazide may increase the anticoagulant activities of Becaplermin.",
      "name": "Balsalazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09005",
      "source": "DB00102",
      "target": "DB09005",
      "description": "Batroxobin may increase the anticoagulant activities of Becaplermin.",
      "name": "Batroxobin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06401",
      "source": "DB00102",
      "target": "DB06401",
      "description": "Bazedoxifene may decrease the anticoagulant activities of Becaplermin.",
      "name": "Bazedoxifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09258",
      "source": "DB00102",
      "target": "DB09258",
      "description": "Bemiparin may increase the anticoagulant activities of Becaplermin.",
      "name": "Bemiparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04812",
      "source": "DB00102",
      "target": "DB04812",
      "description": "Benoxaprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Benoxaprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05229",
      "source": "DB00102",
      "target": "DB05229",
      "description": "Beraprost may increase the anticoagulant activities of Becaplermin.",
      "name": "Beraprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00006",
      "source": "DB00102",
      "target": "DB00006",
      "description": "Bivalirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00963",
      "source": "DB00102",
      "target": "DB00963",
      "description": "Bromfenac may increase the anticoagulant activities of Becaplermin.",
      "name": "Bromfenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06441",
      "source": "DB00102",
      "target": "DB06441",
      "description": "Cangrelor may increase the anticoagulant activities of Becaplermin.",
      "name": "Cangrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00821",
      "source": "DB00102",
      "target": "DB00821",
      "description": "Carprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Carprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01816",
      "source": "DB00102",
      "target": "DB01816",
      "description": "Castanospermine may increase the anticoagulant activities of Becaplermin.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00482",
      "source": "DB00102",
      "target": "DB00482",
      "description": "Celecoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Celecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09261",
      "source": "DB00102",
      "target": "DB09261",
      "description": "Becaplermin may increase the anticoagulant activities of Certoparin.",
      "name": "Certoparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00608",
      "source": "DB00102",
      "target": "DB00608",
      "description": "Chloroquine may increase the anticoagulant activities of Becaplermin.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00269",
      "source": "DB00102",
      "target": "DB00269",
      "description": "Chlorotrianisene may decrease the anticoagulant activities of Becaplermin.",
      "name": "Chlorotrianisene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01166",
      "source": "DB00102",
      "target": "DB01166",
      "description": "Cilostazol may increase the anticoagulant activities of Becaplermin.",
      "name": "Cilostazol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04272",
      "source": "DB00102",
      "target": "DB04272",
      "description": "Becaplermin may increase the anticoagulant activities of Citric Acid.",
      "name": "Citric Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09218",
      "source": "DB00102",
      "target": "DB09218",
      "description": "Clonixin may increase the anticoagulant activities of Becaplermin.",
      "name": "Clonixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00758",
      "source": "DB00102",
      "target": "DB00758",
      "description": "Clopidogrel may increase the anticoagulant activities of Becaplermin.",
      "name": "Clopidogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11249",
      "source": "DB00102",
      "target": "DB11249",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Collagenase.",
      "name": "Collagenase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00286",
      "source": "DB00102",
      "target": "DB00286",
      "description": "Conjugated Equine Estrogens may decrease the anticoagulant activities of Becaplermin.",
      "name": "Conjugated Equine Estrogens"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08921",
      "source": "DB00102",
      "target": "DB08921",
      "description": "D-Limonene may increase the anticoagulant activities of Becaplermin.",
      "name": "D-Limonene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06695",
      "source": "DB00102",
      "target": "DB06695",
      "description": "Dabigatran etexilate may increase the anticoagulant activities of Becaplermin.",
      "name": "Dabigatran etexilate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06779",
      "source": "DB00102",
      "target": "DB06779",
      "description": "Becaplermin may increase the anticoagulant activities of Dalteparin.",
      "name": "Dalteparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06754",
      "source": "DB00102",
      "target": "DB06754",
      "description": "Becaplermin may increase the anticoagulant activities of Danaparoid.",
      "name": "Danaparoid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01254",
      "source": "DB00102",
      "target": "DB01254",
      "description": "Dasatinib may increase the anticoagulant activities of Becaplermin.",
      "name": "Dasatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01609",
      "source": "DB00102",
      "target": "DB01609",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Deferasirox.",
      "name": "Deferasirox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04932",
      "source": "DB00102",
      "target": "DB04932",
      "description": "Defibrotide may increase the anticoagulant activities of Becaplermin.",
      "name": "Defibrotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB03619",
      "source": "DB00102",
      "target": "DB03619",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Deoxycholic Acid.",
      "name": "Deoxycholic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11095",
      "source": "DB00102",
      "target": "DB11095",
      "description": "Becaplermin may increase the anticoagulant activities of Desirudin.",
      "name": "Desirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04925",
      "source": "DB00102",
      "target": "DB04925",
      "description": "Desmoteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Desmoteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00304",
      "source": "DB00102",
      "target": "DB00304",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Desogestrel.",
      "name": "Desogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09255",
      "source": "DB00102",
      "target": "DB09255",
      "description": "Becaplermin may increase the anticoagulant activities of Dextran.",
      "name": "Dextran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11122",
      "source": "DB00102",
      "target": "DB11122",
      "description": "Becaplermin may increase the anticoagulant activities of Dextran 40.",
      "name": "Dextran 40"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11076",
      "source": "DB00102",
      "target": "DB11076",
      "description": "Becaplermin may increase the anticoagulant activities of Dextran 70.",
      "name": "Dextran 70"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11241",
      "source": "DB00102",
      "target": "DB11241",
      "description": "Becaplermin may increase the anticoagulant activities of Dextran 75.",
      "name": "Dextran 75"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00586",
      "source": "DB00102",
      "target": "DB00586",
      "description": "Diclofenac may increase the anticoagulant activities of Becaplermin.",
      "name": "Diclofenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00266",
      "source": "DB00102",
      "target": "DB00266",
      "description": "Becaplermin may increase the anticoagulant activities of Dicoumarol.",
      "name": "Dicoumarol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00890",
      "source": "DB00102",
      "target": "DB00890",
      "description": "Dienestrol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Dienestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09123",
      "source": "DB00102",
      "target": "DB09123",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Dienogest.",
      "name": "Dienogest"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00255",
      "source": "DB00102",
      "target": "DB00255",
      "description": "Diethylstilbestrol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Diethylstilbestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00861",
      "source": "DB00102",
      "target": "DB00861",
      "description": "Diflunisal may increase the anticoagulant activities of Becaplermin.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00975",
      "source": "DB00102",
      "target": "DB00975",
      "description": "Dipyridamole may increase the anticoagulant activities of Becaplermin.",
      "name": "Dipyridamole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08994",
      "source": "DB00102",
      "target": "DB08994",
      "description": "Ditazole may increase the anticoagulant activities of Becaplermin.",
      "name": "Ditazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01395",
      "source": "DB00102",
      "target": "DB01395",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Drospirenone.",
      "name": "Drospirenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00055",
      "source": "DB00102",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09215",
      "source": "DB00102",
      "target": "DB09215",
      "description": "Droxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Droxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00378",
      "source": "DB00102",
      "target": "DB00378",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Dydrogesterone.",
      "name": "Dydrogesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00974",
      "source": "DB00102",
      "target": "DB00974",
      "description": "Becaplermin may increase the anticoagulant activities of Edetic Acid.",
      "name": "Edetic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09075",
      "source": "DB00102",
      "target": "DB09075",
      "description": "Edoxaban may increase the anticoagulant activities of Becaplermin.",
      "name": "Edoxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01225",
      "source": "DB00102",
      "target": "DB01225",
      "description": "Becaplermin may increase the anticoagulant activities of Enoxaparin.",
      "name": "Enoxaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00751",
      "source": "DB00102",
      "target": "DB00751",
      "description": "Epinastine may increase the anticoagulant activities of Becaplermin.",
      "name": "Epinastine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08991",
      "source": "DB00102",
      "target": "DB08991",
      "description": "Epirizole may increase the anticoagulant activities of Becaplermin.",
      "name": "Epirizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06392",
      "source": "DB00102",
      "target": "DB06392",
      "description": "eplivanserine may increase the anticoagulant activities of Becaplermin.",
      "name": "eplivanserine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01240",
      "source": "DB00102",
      "target": "DB01240",
      "description": "Epoprostenol may increase the anticoagulant activities of Becaplermin.",
      "name": "Epoprostenol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00063",
      "source": "DB00102",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Becaplermin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00783",
      "source": "DB00102",
      "target": "DB00783",
      "description": "Estradiol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04573",
      "source": "DB00102",
      "target": "DB04573",
      "description": "Estriol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Estriol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00655",
      "source": "DB00102",
      "target": "DB00655",
      "description": "Estrone may decrease the anticoagulant activities of Becaplermin.",
      "name": "Estrone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00005",
      "source": "DB00102",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Becaplermin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00977",
      "source": "DB00102",
      "target": "DB00977",
      "description": "Ethinyl Estradiol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Ethinyl Estradiol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08794",
      "source": "DB00102",
      "target": "DB08794",
      "description": "Becaplermin may increase the anticoagulant activities of Ethyl biscoumacetate.",
      "name": "Ethyl biscoumacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00823",
      "source": "DB00102",
      "target": "DB00823",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Ethynodiol diacetate.",
      "name": "Ethynodiol diacetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00749",
      "source": "DB00102",
      "target": "DB00749",
      "description": "Etodolac may increase the anticoagulant activities of Becaplermin.",
      "name": "Etodolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08984",
      "source": "DB00102",
      "target": "DB08984",
      "description": "Etofenamate may increase the anticoagulant activities of Becaplermin.",
      "name": "Etofenamate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00294",
      "source": "DB00102",
      "target": "DB00294",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Etonogestrel.",
      "name": "Etonogestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01628",
      "source": "DB00102",
      "target": "DB01628",
      "description": "Etoricoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Etoricoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11358",
      "source": "DB00102",
      "target": "DB11358",
      "description": "Evening primrose oil may increase the anticoagulant activities of Becaplermin.",
      "name": "Evening primrose oil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06246",
      "source": "DB00102",
      "target": "DB06246",
      "description": "exisulind may increase the anticoagulant activities of Becaplermin.",
      "name": "exisulind"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08981",
      "source": "DB00102",
      "target": "DB08981",
      "description": "Fenbufen may increase the anticoagulant activities of Becaplermin.",
      "name": "Fenbufen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00573",
      "source": "DB00102",
      "target": "DB00573",
      "description": "Fenoprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Fenoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08977",
      "source": "DB00102",
      "target": "DB08977",
      "description": "Fibrinolysin may increase the anticoagulant activities of Becaplermin.",
      "name": "Fibrinolysin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08976",
      "source": "DB00102",
      "target": "DB08976",
      "description": "Floctafenine may increase the anticoagulant activities of Becaplermin.",
      "name": "Floctafenine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11518",
      "source": "DB00102",
      "target": "DB11518",
      "description": "Flunixin may increase the anticoagulant activities of Becaplermin.",
      "name": "Flunixin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00712",
      "source": "DB00102",
      "target": "DB00712",
      "description": "Flurbiprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Flurbiprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00569",
      "source": "DB00102",
      "target": "DB00569",
      "description": "Becaplermin may increase the anticoagulant activities of Fondaparinux sodium.",
      "name": "Fondaparinux sodium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01645",
      "source": "DB00102",
      "target": "DB01645",
      "description": "Genistein may decrease the anticoagulant activities of Becaplermin.",
      "name": "Genistein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06730",
      "source": "DB00102",
      "target": "DB06730",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Gestodene.",
      "name": "Gestodene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11619",
      "source": "DB00102",
      "target": "DB11619",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Gestrinone.",
      "name": "Gestrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB03404",
      "source": "DB00102",
      "target": "DB03404",
      "description": "Hemin may increase the anticoagulant activities of Becaplermin.",
      "name": "Hemin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01109",
      "source": "DB00102",
      "target": "DB01109",
      "description": "Becaplermin may increase the anticoagulant activities of Heparin.",
      "name": "Heparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB07931",
      "source": "DB00102",
      "target": "DB07931",
      "description": "Hexestrol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Hexestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB02351",
      "source": "DB00102",
      "target": "DB02351",
      "description": "Becaplermin may increase the anticoagulant activities of Hirulog.",
      "name": "Hirulog"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05767",
      "source": "DB00102",
      "target": "DB05767",
      "description": "HMPL-004 may increase the anticoagulant activities of Becaplermin.",
      "name": "HMPL-004"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06789",
      "source": "DB00102",
      "target": "DB06789",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Hydroxyprogesterone caproate.",
      "name": "Hydroxyprogesterone caproate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00078",
      "source": "DB00102",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09053",
      "source": "DB00102",
      "target": "DB09053",
      "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Becaplermin.",
      "name": "Ibrutinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05266",
      "source": "DB00102",
      "target": "DB05266",
      "description": "Ibudilast may increase the anticoagulant activities of Becaplermin.",
      "name": "Ibudilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01050",
      "source": "DB00102",
      "target": "DB01050",
      "description": "Ibuprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Ibuprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08955",
      "source": "DB00102",
      "target": "DB08955",
      "description": "Ibuproxam may increase the anticoagulant activities of Becaplermin.",
      "name": "Ibuproxam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06196",
      "source": "DB00102",
      "target": "DB06196",
      "description": "Icatibant may increase the anticoagulant activities of Becaplermin.",
      "name": "Icatibant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08887",
      "source": "DB00102",
      "target": "DB08887",
      "description": "Icosapent ethyl may increase the anticoagulant activities of Becaplermin.",
      "name": "Icosapent ethyl"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06406",
      "source": "DB00102",
      "target": "DB06406",
      "description": "Becaplermin may increase the anticoagulant activities of idraparinux.",
      "name": "idraparinux"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08954",
      "source": "DB00102",
      "target": "DB08954",
      "description": "Ifenprodil may increase the anticoagulant activities of Becaplermin.",
      "name": "Ifenprodil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01088",
      "source": "DB00102",
      "target": "DB01088",
      "description": "Iloprost may increase the anticoagulant activities of Becaplermin.",
      "name": "Iloprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00328",
      "source": "DB00102",
      "target": "DB00328",
      "description": "Indomethacin may increase the anticoagulant activities of Becaplermin.",
      "name": "Indomethacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08951",
      "source": "DB00102",
      "target": "DB08951",
      "description": "Indoprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Indoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08942",
      "source": "DB00102",
      "target": "DB08942",
      "description": "Isoxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Isoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08940",
      "source": "DB00102",
      "target": "DB08940",
      "description": "Kebuzone may increase the anticoagulant activities of Becaplermin.",
      "name": "Kebuzone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01009",
      "source": "DB00102",
      "target": "DB01009",
      "description": "Ketoprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Ketoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00465",
      "source": "DB00102",
      "target": "DB00465",
      "description": "Ketorolac may increase the anticoagulant activities of Becaplermin.",
      "name": "Ketorolac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01097",
      "source": "DB00102",
      "target": "DB01097",
      "description": "Leflunomide may increase the anticoagulant activities of Becaplermin.",
      "name": "Leflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00001",
      "source": "DB00102",
      "target": "DB00001",
      "description": "Lepirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00367",
      "source": "DB00102",
      "target": "DB00367",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Levonorgestrel.",
      "name": "Levonorgestrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09211",
      "source": "DB00102",
      "target": "DB09211",
      "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Becaplermin.",
      "name": "Limaprost"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06725",
      "source": "DB00102",
      "target": "DB06725",
      "description": "Lornoxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Lornoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09212",
      "source": "DB00102",
      "target": "DB09212",
      "description": "Loxoprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Loxoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01283",
      "source": "DB00102",
      "target": "DB01283",
      "description": "Lumiracoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Lumiracoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01397",
      "source": "DB00102",
      "target": "DB01397",
      "description": "Magnesium salicylate may increase the anticoagulant activities of Becaplermin.",
      "name": "Magnesium salicylate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00179",
      "source": "DB00102",
      "target": "DB00179",
      "description": "Masoprocol may increase the anticoagulant activities of Becaplermin.",
      "name": "Masoprocol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00939",
      "source": "DB00102",
      "target": "DB00939",
      "description": "Meclofenamic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Meclofenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09124",
      "source": "DB00102",
      "target": "DB09124",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Medrogestone.",
      "name": "Medrogestone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00603",
      "source": "DB00102",
      "target": "DB00603",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Medroxyprogesterone acetate.",
      "name": "Medroxyprogesterone acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00784",
      "source": "DB00102",
      "target": "DB00784",
      "description": "Mefenamic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Mefenamic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00351",
      "source": "DB00102",
      "target": "DB00351",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Megestrol acetate.",
      "name": "Megestrol acetate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00814",
      "source": "DB00102",
      "target": "DB00814",
      "description": "Meloxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Meloxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00244",
      "source": "DB00102",
      "target": "DB00244",
      "description": "Mesalazine may increase the anticoagulant activities of Becaplermin.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01357",
      "source": "DB00102",
      "target": "DB01357",
      "description": "Mestranol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Mestranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04817",
      "source": "DB00102",
      "target": "DB04817",
      "description": "Metamizole may increase the anticoagulant activities of Becaplermin.",
      "name": "Metamizole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00235",
      "source": "DB00102",
      "target": "DB00235",
      "description": "Milrinone may increase the anticoagulant activities of Becaplermin.",
      "name": "Milrinone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00688",
      "source": "DB00102",
      "target": "DB00688",
      "description": "Mycophenolate mofetil may increase the anticoagulant activities of Becaplermin.",
      "name": "Mycophenolate mofetil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01024",
      "source": "DB00102",
      "target": "DB01024",
      "description": "Mycophenolic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Mycophenolic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00461",
      "source": "DB00102",
      "target": "DB00461",
      "description": "Nabumetone may increase the anticoagulant activities of Becaplermin.",
      "name": "Nabumetone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08813",
      "source": "DB00102",
      "target": "DB08813",
      "description": "Becaplermin may increase the anticoagulant activities of Nadroparin.",
      "name": "Nadroparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00735",
      "source": "DB00102",
      "target": "DB00735",
      "description": "Naftifine may increase the anticoagulant activities of Becaplermin.",
      "name": "Naftifine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00788",
      "source": "DB00102",
      "target": "DB00788",
      "description": "Naproxen may increase the anticoagulant activities of Becaplermin.",
      "name": "Naproxen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05822",
      "source": "DB00102",
      "target": "DB05822",
      "description": "NCX 4016 may increase the anticoagulant activities of Becaplermin.",
      "name": "NCX 4016"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06802",
      "source": "DB00102",
      "target": "DB06802",
      "description": "Nepafenac may increase the anticoagulant activities of Becaplermin.",
      "name": "Nepafenac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04552",
      "source": "DB00102",
      "target": "DB04552",
      "description": "Niflumic Acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Niflumic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04743",
      "source": "DB00102",
      "target": "DB04743",
      "description": "Nimesulide may increase the anticoagulant activities of Becaplermin.",
      "name": "Nimesulide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09079",
      "source": "DB00102",
      "target": "DB09079",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Nintedanib.",
      "name": "Nintedanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00717",
      "source": "DB00102",
      "target": "DB00717",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Norethisterone.",
      "name": "Norethisterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08935",
      "source": "DB00102",
      "target": "DB08935",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Obinutuzumab.",
      "name": "Obinutuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00768",
      "source": "DB00102",
      "target": "DB00768",
      "description": "Olopatadine may increase the anticoagulant activities of Becaplermin.",
      "name": "Olopatadine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01250",
      "source": "DB00102",
      "target": "DB01250",
      "description": "Olsalazine may increase the anticoagulant activities of Becaplermin.",
      "name": "Olsalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04865",
      "source": "DB00102",
      "target": "DB04865",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Omacetaxine mepesuccinate.",
      "name": "Omacetaxine mepesuccinate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11133",
      "source": "DB00102",
      "target": "DB11133",
      "description": "Omega-3 fatty acids may increase the anticoagulant activities of Becaplermin.",
      "name": "Omega-3 fatty acids"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11444",
      "source": "DB00102",
      "target": "DB11444",
      "description": "Orgotein may increase the anticoagulant activities of Becaplermin.",
      "name": "Orgotein"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06635",
      "source": "DB00102",
      "target": "DB06635",
      "description": "Becaplermin may increase the anticoagulant activities of Otamixaban.",
      "name": "Otamixaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00991",
      "source": "DB00102",
      "target": "DB00991",
      "description": "Oxaprozin may increase the anticoagulant activities of Becaplermin.",
      "name": "Oxaprozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB03585",
      "source": "DB00102",
      "target": "DB03585",
      "description": "Oxyphenbutazone may increase the anticoagulant activities of Becaplermin.",
      "name": "Oxyphenbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08439",
      "source": "DB00102",
      "target": "DB08439",
      "description": "Parecoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Parecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09260",
      "source": "DB00102",
      "target": "DB09260",
      "description": "Parnaparin may increase the anticoagulant activities of Becaplermin.",
      "name": "Parnaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00686",
      "source": "DB00102",
      "target": "DB00686",
      "description": "Pentosan Polysulfate may increase the anticoagulant activities of Becaplermin.",
      "name": "Pentosan Polysulfate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00806",
      "source": "DB00102",
      "target": "DB00806",
      "description": "Pentoxifylline may increase the anticoagulant activities of Becaplermin.",
      "name": "Pentoxifylline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00498",
      "source": "DB00102",
      "target": "DB00498",
      "description": "Becaplermin may increase the anticoagulant activities of Phenindione.",
      "name": "Phenindione"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00946",
      "source": "DB00102",
      "target": "DB00946",
      "description": "Becaplermin may increase the anticoagulant activities of Phenprocoumon.",
      "name": "Phenprocoumon"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00812",
      "source": "DB00102",
      "target": "DB00812",
      "description": "Phenylbutazone may increase the anticoagulant activities of Becaplermin.",
      "name": "Phenylbutazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00337",
      "source": "DB00102",
      "target": "DB00337",
      "description": "Pimecrolimus may increase the anticoagulant activities of Becaplermin.",
      "name": "Pimecrolimus"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04951",
      "source": "DB00102",
      "target": "DB04951",
      "description": "Pirfenidone may increase the anticoagulant activities of Becaplermin.",
      "name": "Pirfenidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00554",
      "source": "DB00102",
      "target": "DB00554",
      "description": "Piroxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Piroxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05254",
      "source": "DB00102",
      "target": "DB05254",
      "description": "Plasmin may increase the anticoagulant activities of Becaplermin.",
      "name": "Plasmin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09369",
      "source": "DB00102",
      "target": "DB09369",
      "description": "Polyestradiol phosphate may decrease the anticoagulant activities of Becaplermin.",
      "name": "Polyestradiol phosphate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06209",
      "source": "DB00102",
      "target": "DB06209",
      "description": "Prasugrel may increase the anticoagulant activities of Becaplermin.",
      "name": "Prasugrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00396",
      "source": "DB00102",
      "target": "DB00396",
      "description": "The therapeutic efficacy of Becaplermin can be decreased when used in combination with Progesterone.",
      "name": "Progesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09288",
      "source": "DB00102",
      "target": "DB09288",
      "description": "Propacetamol may increase the anticoagulant activities of Becaplermin.",
      "name": "Propacetamol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11312",
      "source": "DB00102",
      "target": "DB11312",
      "description": "Becaplermin may increase the anticoagulant activities of Protein C.",
      "name": "Protein C"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11268",
      "source": "DB00102",
      "target": "DB11268",
      "description": "Becaplermin may increase the anticoagulant activities of Protocatechualdehyde.",
      "name": "Protocatechualdehyde"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05173",
      "source": "DB00102",
      "target": "DB05173",
      "description": "PTC299 may increase the anticoagulant activities of Becaplermin.",
      "name": "PTC299"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04575",
      "source": "DB00102",
      "target": "DB04575",
      "description": "Quinestrol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Quinestrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB02709",
      "source": "DB00102",
      "target": "DB02709",
      "description": "Resveratrol may increase the anticoagulant activities of Becaplermin.",
      "name": "Resveratrol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00015",
      "source": "DB00102",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09259",
      "source": "DB00102",
      "target": "DB09259",
      "description": "Becaplermin may increase the anticoagulant activities of Reviparin.",
      "name": "Reviparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01207",
      "source": "DB00102",
      "target": "DB01207",
      "description": "Ridogrel may increase the anticoagulant activities of Becaplermin.",
      "name": "Ridogrel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06228",
      "source": "DB00102",
      "target": "DB06228",
      "description": "Becaplermin may increase the anticoagulant activities of Rivaroxaban.",
      "name": "Rivaroxaban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00533",
      "source": "DB00102",
      "target": "DB00533",
      "description": "Rofecoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Rofecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00412",
      "source": "DB00102",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the anticoagulant activities of Becaplermin.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08797",
      "source": "DB00102",
      "target": "DB08797",
      "description": "Salicylamide may increase the anticoagulant activities of Becaplermin.",
      "name": "Salicylamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00936",
      "source": "DB00102",
      "target": "DB00936",
      "description": "Salicylic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01399",
      "source": "DB00102",
      "target": "DB01399",
      "description": "Salsalate may increase the anticoagulant activities of Becaplermin.",
      "name": "Salsalate"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05692",
      "source": "DB00102",
      "target": "DB05692",
      "description": "SCH-530348 may increase the anticoagulant activities of Becaplermin.",
      "name": "SCH-530348"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11362",
      "source": "DB00102",
      "target": "DB11362",
      "description": "Selexipag may increase the anticoagulant activities of Becaplermin.",
      "name": "Selexipag"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06739",
      "source": "DB00102",
      "target": "DB06739",
      "description": "Seratrodast may increase the anticoagulant activities of Becaplermin.",
      "name": "Seratrodast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01236",
      "source": "DB00102",
      "target": "DB01236",
      "description": "Sevoflurane may increase the anticoagulant activities of Becaplermin.",
      "name": "Sevoflurane"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB05073",
      "source": "DB00102",
      "target": "DB05073",
      "description": "SRT501 may increase the anticoagulant activities of Becaplermin.",
      "name": "SRT501"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00086",
      "source": "DB00102",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06206",
      "source": "DB00102",
      "target": "DB06206",
      "description": "Sugammadex may increase the anticoagulant activities of Becaplermin.",
      "name": "Sugammadex"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00795",
      "source": "DB00102",
      "target": "DB00795",
      "description": "Sulfasalazine may increase the anticoagulant activities of Becaplermin.",
      "name": "Sulfasalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00605",
      "source": "DB00102",
      "target": "DB00605",
      "description": "Sulindac may increase the anticoagulant activities of Becaplermin.",
      "name": "Sulindac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06271",
      "source": "DB00102",
      "target": "DB06271",
      "description": "Becaplermin may increase the anticoagulant activities of Sulodexide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00870",
      "source": "DB00102",
      "target": "DB00870",
      "description": "Suprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Suprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09317",
      "source": "DB00102",
      "target": "DB09317",
      "description": "Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Becaplermin.",
      "name": "Synthetic Conjugated Estrogens, A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09318",
      "source": "DB00102",
      "target": "DB09318",
      "description": "Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Becaplermin.",
      "name": "Synthetic Conjugated Estrogens, B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00031",
      "source": "DB00102",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00469",
      "source": "DB00102",
      "target": "DB00469",
      "description": "Tenoxicam may increase the anticoagulant activities of Becaplermin.",
      "name": "Tenoxicam"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11466",
      "source": "DB00102",
      "target": "DB11466",
      "description": "Tepoxalin may increase the anticoagulant activities of Becaplermin.",
      "name": "Tepoxalin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08880",
      "source": "DB00102",
      "target": "DB08880",
      "description": "Teriflunomide may increase the anticoagulant activities of Becaplermin.",
      "name": "Teriflunomide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04905",
      "source": "DB00102",
      "target": "DB04905",
      "description": "Tesmilifene may increase the anticoagulant activities of Becaplermin.",
      "name": "Tesmilifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01600",
      "source": "DB00102",
      "target": "DB01600",
      "description": "Tiaprofenic acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Tiaprofenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09070",
      "source": "DB00102",
      "target": "DB09070",
      "description": "Tibolone may increase the anticoagulant activities of Becaplermin.",
      "name": "Tibolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08816",
      "source": "DB00102",
      "target": "DB08816",
      "description": "Ticagrelor may increase the anticoagulant activities of Becaplermin.",
      "name": "Ticagrelor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00208",
      "source": "DB00102",
      "target": "DB00208",
      "description": "Ticlopidine may increase the anticoagulant activities of Becaplermin.",
      "name": "Ticlopidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06822",
      "source": "DB00102",
      "target": "DB06822",
      "description": "Tinzaparin may increase the anticoagulant activities of Becaplermin.",
      "name": "Tinzaparin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00932",
      "source": "DB00102",
      "target": "DB00932",
      "description": "Tipranavir may increase the anticoagulant activities of Becaplermin.",
      "name": "Tipranavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00775",
      "source": "DB00102",
      "target": "DB00775",
      "description": "Tirofiban may increase the anticoagulant activities of Becaplermin.",
      "name": "Tirofiban"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09216",
      "source": "DB00102",
      "target": "DB09216",
      "description": "Tolfenamic Acid may increase the anticoagulant activities of Becaplermin.",
      "name": "Tolfenamic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00500",
      "source": "DB00102",
      "target": "DB00500",
      "description": "Tolmetin may increase the anticoagulant activities of Becaplermin.",
      "name": "Tolmetin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00081",
      "source": "DB00102",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB07615",
      "source": "DB00102",
      "target": "DB07615",
      "description": "Tranilast may increase the anticoagulant activities of Becaplermin.",
      "name": "Tranilast"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09283",
      "source": "DB00102",
      "target": "DB09283",
      "description": "Trapidil may increase the anticoagulant activities of Becaplermin.",
      "name": "Trapidil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00374",
      "source": "DB00102",
      "target": "DB00374",
      "description": "Treprostinil may increase the anticoagulant activities of Becaplermin.",
      "name": "Treprostinil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB08814",
      "source": "DB00102",
      "target": "DB08814",
      "description": "Triflusal may increase the anticoagulant activities of Becaplermin.",
      "name": "Triflusal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB01401",
      "source": "DB00102",
      "target": "DB01401",
      "description": "Trisalicylate-choline may increase the anticoagulant activities of Becaplermin.",
      "name": "Trisalicylate-choline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00013",
      "source": "DB00102",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00580",
      "source": "DB00102",
      "target": "DB00580",
      "description": "Valdecoxib may increase the anticoagulant activities of Becaplermin.",
      "name": "Valdecoxib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00163",
      "source": "DB00102",
      "target": "DB00163",
      "description": "Vitamin E may increase the anticoagulant activities of Becaplermin.",
      "name": "Vitamin E"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB09030",
      "source": "DB00102",
      "target": "DB09030",
      "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Becaplermin.",
      "name": "Vorapaxar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00682",
      "source": "DB00102",
      "target": "DB00682",
      "description": "Becaplermin may increase the anticoagulant activities of Warfarin.",
      "name": "Warfarin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04898",
      "source": "DB00102",
      "target": "DB04898",
      "description": "Becaplermin may increase the anticoagulant activities of Ximelagatran.",
      "name": "Ximelagatran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB06737",
      "source": "DB00102",
      "target": "DB06737",
      "description": "Zaltoprofen may increase the anticoagulant activities of Becaplermin.",
      "name": "Zaltoprofen"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB11478",
      "source": "DB00102",
      "target": "DB11478",
      "description": "Zeranol may decrease the anticoagulant activities of Becaplermin.",
      "name": "Zeranol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00744",
      "source": "DB00102",
      "target": "DB00744",
      "description": "Zileuton may increase the anticoagulant activities of Becaplermin.",
      "name": "Zileuton"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB04828",
      "source": "DB00102",
      "target": "DB04828",
      "description": "Zomepirac may increase the anticoagulant activities of Becaplermin.",
      "name": "Zomepirac"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08550",
      "source": "DB00104",
      "target": "DB08550",
      "description": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Octreotide.",
      "name": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00284",
      "source": "DB00104",
      "target": "DB00284",
      "description": "Acarbose may increase the hypoglycemic activities of Octreotide.",
      "name": "Acarbose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01193",
      "source": "DB00104",
      "target": "DB01193",
      "description": "Octreotide may increase the bradycardic activities of Acebutolol.",
      "name": "Acebutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00414",
      "source": "DB00104",
      "target": "DB00414",
      "description": "Acetohexamide may increase the hypoglycemic activities of Octreotide.",
      "name": "Acetohexamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00511",
      "source": "DB00104",
      "target": "DB00511",
      "description": "Acetyldigitoxin may decrease the cardiotoxic activities of Octreotide.",
      "name": "Acetyldigitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00945",
      "source": "DB00104",
      "target": "DB00945",
      "description": "Acetylsalicylic acid may increase the hypoglycemic activities of Octreotide.",
      "name": "Acetylsalicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01700",
      "source": "DB00104",
      "target": "DB01700",
      "description": "Aicar may increase the hypoglycemic activities of Octreotide.",
      "name": "Aicar"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06203",
      "source": "DB00104",
      "target": "DB06203",
      "description": "Alogliptin may increase the hypoglycemic activities of Octreotide.",
      "name": "Alogliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00233",
      "source": "DB00104",
      "target": "DB00233",
      "description": "Aminosalicylic Acid may increase the hypoglycemic activities of Octreotide.",
      "name": "Aminosalicylic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01118",
      "source": "DB00104",
      "target": "DB01118",
      "description": "Octreotide may increase the QTc-prolonging activities of Amiodarone.",
      "name": "Amiodarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00261",
      "source": "DB00104",
      "target": "DB00261",
      "description": "Octreotide may increase the QTc-prolonging activities of Anagrelide.",
      "name": "Anagrelide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01169",
      "source": "DB00104",
      "target": "DB01169",
      "description": "Octreotide may increase the QTc-prolonging activities of Arsenic trioxide.",
      "name": "Arsenic trioxide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06697",
      "source": "DB00104",
      "target": "DB06697",
      "description": "Octreotide may increase the QTc-prolonging activities of Artemether.",
      "name": "Artemether"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06216",
      "source": "DB00104",
      "target": "DB06216",
      "description": "Octreotide may increase the QTc-prolonging activities of Asenapine.",
      "name": "Asenapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00335",
      "source": "DB00104",
      "target": "DB00335",
      "description": "Octreotide may increase the bradycardic activities of Atenolol.",
      "name": "Atenolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00207",
      "source": "DB00104",
      "target": "DB00207",
      "description": "Octreotide may increase the QTc-prolonging activities of Azithromycin.",
      "name": "Azithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08903",
      "source": "DB00104",
      "target": "DB08903",
      "description": "Octreotide may increase the QTc-prolonging activities of Bedaquiline.",
      "name": "Bedaquiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00436",
      "source": "DB00104",
      "target": "DB00436",
      "description": "Octreotide may increase the bradycardic activities of Bendroflumethiazide.",
      "name": "Bendroflumethiazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09246",
      "source": "DB00104",
      "target": "DB09246",
      "description": "Benmoxin may increase the hypoglycemic activities of Octreotide.",
      "name": "Benmoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06761",
      "source": "DB00104",
      "target": "DB06761",
      "description": "Octreotide may increase the bradycardic activities of Beractant.",
      "name": "Beractant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00195",
      "source": "DB00104",
      "target": "DB00195",
      "description": "Octreotide may increase the bradycardic activities of Betaxolol.",
      "name": "Betaxolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00112",
      "source": "DB00104",
      "target": "DB00112",
      "description": "Bevacizumab may increase the cardiotoxic activities of Octreotide.",
      "name": "Bevacizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00612",
      "source": "DB00104",
      "target": "DB00612",
      "description": "Octreotide may increase the bradycardic activities of Bisoprolol.",
      "name": "Bisoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01158",
      "source": "DB00104",
      "target": "DB01158",
      "description": "Bretylium may increase the bradycardic activities of Octreotide.",
      "name": "Bretylium"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01200",
      "source": "DB00104",
      "target": "DB01200",
      "description": "The serum concentration of Bromocriptine can be increased when it is combined with Octreotide.",
      "name": "Bromocriptine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04830",
      "source": "DB00104",
      "target": "DB04830",
      "description": "Buformin may increase the hypoglycemic activities of Octreotide.",
      "name": "Buformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06772",
      "source": "DB00104",
      "target": "DB06772",
      "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.",
      "name": "Cabazitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06415",
      "source": "DB00104",
      "target": "DB06415",
      "description": "Octreotide may increase the bradycardic activities of Calfactant.",
      "name": "Calfactant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08907",
      "source": "DB00104",
      "target": "DB08907",
      "description": "Canagliflozin may increase the hypoglycemic activities of Octreotide.",
      "name": "Canagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09254",
      "source": "DB00104",
      "target": "DB09254",
      "description": "Caroxazone may increase the hypoglycemic activities of Octreotide.",
      "name": "Caroxazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00521",
      "source": "DB00104",
      "target": "DB00521",
      "description": "Octreotide may increase the bradycardic activities of Carteolol.",
      "name": "Carteolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01136",
      "source": "DB00104",
      "target": "DB01136",
      "description": "Octreotide may increase the bradycardic activities of Carvedilol.",
      "name": "Carvedilol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01816",
      "source": "DB00104",
      "target": "DB01816",
      "description": "Castanospermine may increase the hypoglycemic activities of Octreotide.",
      "name": "Castanospermine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09063",
      "source": "DB00104",
      "target": "DB09063",
      "description": "Octreotide may increase the bradycardic activities of Ceritinib.",
      "name": "Ceritinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00608",
      "source": "DB00104",
      "target": "DB00608",
      "description": "Octreotide may increase the QTc-prolonging activities of Chloroquine.",
      "name": "Chloroquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00477",
      "source": "DB00104",
      "target": "DB00477",
      "description": "Octreotide may increase the QTc-prolonging activities of Chlorpromazine.",
      "name": "Chlorpromazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00672",
      "source": "DB00104",
      "target": "DB00672",
      "description": "Chlorpropamide may increase the hypoglycemic activities of Octreotide.",
      "name": "Chlorpropamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09201",
      "source": "DB00104",
      "target": "DB09201",
      "description": "Ciglitazone may increase the hypoglycemic activities of Octreotide.",
      "name": "Ciglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00827",
      "source": "DB00104",
      "target": "DB00827",
      "description": "Cinoxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Cinoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00537",
      "source": "DB00104",
      "target": "DB00537",
      "description": "Octreotide may increase the QTc-prolonging activities of Ciprofloxacin.",
      "name": "Ciprofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00604",
      "source": "DB00104",
      "target": "DB00604",
      "description": "Octreotide may increase the QTc-prolonging activities of Cisapride.",
      "name": "Cisapride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00215",
      "source": "DB00104",
      "target": "DB00215",
      "description": "Octreotide may increase the QTc-prolonging activities of Citalopram.",
      "name": "Citalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01211",
      "source": "DB00104",
      "target": "DB01211",
      "description": "Octreotide may increase the QTc-prolonging activities of Clarithromycin.",
      "name": "Clarithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00575",
      "source": "DB00104",
      "target": "DB00575",
      "description": "Octreotide may increase the bradycardic activities of Clonidine.",
      "name": "Clonidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00363",
      "source": "DB00104",
      "target": "DB00363",
      "description": "Octreotide may increase the QTc-prolonging activities of Clozapine.",
      "name": "Clozapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00318",
      "source": "DB00104",
      "target": "DB00318",
      "description": "The metabolism of Codeine can be decreased when combined with Octreotide.",
      "name": "Codeine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08865",
      "source": "DB00104",
      "target": "DB08865",
      "description": "Octreotide may increase the QTc-prolonging activities of Crizotinib.",
      "name": "Crizotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00531",
      "source": "DB00104",
      "target": "DB00531",
      "description": "Cyclophosphamide may increase the cardiotoxic activities of Octreotide.",
      "name": "Cyclophosphamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00091",
      "source": "DB00104",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04884",
      "source": "DB00104",
      "target": "DB04884",
      "description": "Dapoxetine may increase the hypoglycemic activities of Octreotide.",
      "name": "Dapoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01078",
      "source": "DB00104",
      "target": "DB01078",
      "description": "Deslanoside may decrease the cardiotoxic activities of Octreotide.",
      "name": "Deslanoside"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06700",
      "source": "DB00104",
      "target": "DB06700",
      "description": "Desvenlafaxine may increase the hypoglycemic activities of Octreotide.",
      "name": "Desvenlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00633",
      "source": "DB00104",
      "target": "DB00633",
      "description": "Octreotide may increase the bradycardic activities of Dexmedetomidine.",
      "name": "Dexmedetomidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00861",
      "source": "DB00104",
      "target": "DB00861",
      "description": "Diflunisal may increase the hypoglycemic activities of Octreotide.",
      "name": "Diflunisal"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01396",
      "source": "DB00104",
      "target": "DB01396",
      "description": "Digitoxin may decrease the cardiotoxic activities of Octreotide.",
      "name": "Digitoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00390",
      "source": "DB00104",
      "target": "DB00390",
      "description": "Digoxin may decrease the cardiotoxic activities of Octreotide.",
      "name": "Digoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB02901",
      "source": "DB00104",
      "target": "DB02901",
      "description": "Dihydrotestosterone may increase the hypoglycemic activities of Octreotide.",
      "name": "Dihydrotestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00343",
      "source": "DB00104",
      "target": "DB00343",
      "description": "Octreotide may increase the bradycardic activities of Diltiazem.",
      "name": "Diltiazem"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00280",
      "source": "DB00104",
      "target": "DB00280",
      "description": "Octreotide may increase the QTc-prolonging activities of Disopyramide.",
      "name": "Disopyramide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01248",
      "source": "DB00104",
      "target": "DB01248",
      "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.",
      "name": "Docetaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00204",
      "source": "DB00104",
      "target": "DB00204",
      "description": "Octreotide may increase the QTc-prolonging activities of Dofetilide.",
      "name": "Dofetilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00757",
      "source": "DB00104",
      "target": "DB00757",
      "description": "Octreotide may increase the QTc-prolonging activities of Dolasetron.",
      "name": "Dolasetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01184",
      "source": "DB00104",
      "target": "DB01184",
      "description": "Octreotide may increase the QTc-prolonging activities of Domperidone.",
      "name": "Domperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00843",
      "source": "DB00104",
      "target": "DB00843",
      "description": "Octreotide may increase the bradycardic activities of Donepezil.",
      "name": "Donepezil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04855",
      "source": "DB00104",
      "target": "DB04855",
      "description": "Octreotide may increase the QTc-prolonging activities of Dronedarone.",
      "name": "Dronedarone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00450",
      "source": "DB00104",
      "target": "DB00450",
      "description": "Octreotide may increase the QTc-prolonging activities of Droperidol.",
      "name": "Droperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09045",
      "source": "DB00104",
      "target": "DB09045",
      "description": "Dulaglutide may increase the hypoglycemic activities of Octreotide.",
      "name": "Dulaglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00476",
      "source": "DB00104",
      "target": "DB00476",
      "description": "Duloxetine may increase the hypoglycemic activities of Octreotide.",
      "name": "Duloxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09039",
      "source": "DB00104",
      "target": "DB09039",
      "description": "Octreotide may increase the QTc-prolonging activities of Eliglustat.",
      "name": "Eliglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09038",
      "source": "DB00104",
      "target": "DB09038",
      "description": "Empagliflozin may increase the hypoglycemic activities of Octreotide.",
      "name": "Empagliflozin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00467",
      "source": "DB00104",
      "target": "DB00467",
      "description": "Enoxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Enoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00199",
      "source": "DB00104",
      "target": "DB00199",
      "description": "Octreotide may increase the QTc-prolonging activities of Erythromycin.",
      "name": "Erythromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01175",
      "source": "DB00104",
      "target": "DB01175",
      "description": "Octreotide may increase the QTc-prolonging activities of Escitalopram.",
      "name": "Escitalopram"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00187",
      "source": "DB00104",
      "target": "DB00187",
      "description": "Octreotide may increase the bradycardic activities of Esmolol.",
      "name": "Esmolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09194",
      "source": "DB00104",
      "target": "DB09194",
      "description": "Etoperidone may increase the hypoglycemic activities of Octreotide.",
      "name": "Etoperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01276",
      "source": "DB00104",
      "target": "DB01276",
      "description": "Exenatide may increase the hypoglycemic activities of Octreotide.",
      "name": "Exenatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08868",
      "source": "DB00104",
      "target": "DB08868",
      "description": "Octreotide may increase the bradycardic activities of Fingolimod.",
      "name": "Fingolimod"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01195",
      "source": "DB00104",
      "target": "DB01195",
      "description": "Octreotide may increase the QTc-prolonging activities of Flecainide.",
      "name": "Flecainide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04576",
      "source": "DB00104",
      "target": "DB04576",
      "description": "Fleroxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Fleroxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08972",
      "source": "DB00104",
      "target": "DB08972",
      "description": "Flumequine may increase the hypoglycemic activities of Octreotide.",
      "name": "Flumequine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00472",
      "source": "DB00104",
      "target": "DB00472",
      "description": "Octreotide may increase the QTc-prolonging activities of Fluoxetine.",
      "name": "Fluoxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01185",
      "source": "DB00104",
      "target": "DB01185",
      "description": "Fluoxymesterone may increase the hypoglycemic activities of Octreotide.",
      "name": "Fluoxymesterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00875",
      "source": "DB00104",
      "target": "DB00875",
      "description": "Octreotide may increase the QTc-prolonging activities of Flupentixol.",
      "name": "Flupentixol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00176",
      "source": "DB00104",
      "target": "DB00176",
      "description": "Fluvoxamine may increase the hypoglycemic activities of Octreotide.",
      "name": "Fluvoxamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00614",
      "source": "DB00104",
      "target": "DB00614",
      "description": "Furazolidone may increase the hypoglycemic activities of Octreotide.",
      "name": "Furazolidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00743",
      "source": "DB00104",
      "target": "DB00743",
      "description": "Octreotide may increase the QTc-prolonging activities of Gadobenic acid.",
      "name": "Gadobenic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00674",
      "source": "DB00104",
      "target": "DB00674",
      "description": "Octreotide may increase the bradycardic activities of Galantamine.",
      "name": "Galantamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06160",
      "source": "DB00104",
      "target": "DB06160",
      "description": "Garenoxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Garenoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01044",
      "source": "DB00104",
      "target": "DB01044",
      "description": "Gatifloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Gatifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01155",
      "source": "DB00104",
      "target": "DB01155",
      "description": "Octreotide may increase the QTc-prolonging activities of Gemifloxacin.",
      "name": "Gemifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08962",
      "source": "DB00104",
      "target": "DB08962",
      "description": "Glibornuride may increase the hypoglycemic activities of Octreotide.",
      "name": "Glibornuride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01120",
      "source": "DB00104",
      "target": "DB01120",
      "description": "Gliclazide may increase the hypoglycemic activities of Octreotide.",
      "name": "Gliclazide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00222",
      "source": "DB00104",
      "target": "DB00222",
      "description": "Glimepiride may increase the hypoglycemic activities of Octreotide.",
      "name": "Glimepiride"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01067",
      "source": "DB00104",
      "target": "DB01067",
      "description": "Glipizide may increase the hypoglycemic activities of Octreotide.",
      "name": "Glipizide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01251",
      "source": "DB00104",
      "target": "DB01251",
      "description": "Gliquidone may increase the hypoglycemic activities of Octreotide.",
      "name": "Gliquidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01016",
      "source": "DB00104",
      "target": "DB01016",
      "description": "Glyburide may increase the hypoglycemic activities of Octreotide.",
      "name": "Glyburide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00014",
      "source": "DB00104",
      "target": "DB00014",
      "description": "Octreotide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00889",
      "source": "DB00104",
      "target": "DB00889",
      "description": "Octreotide may increase the QTc-prolonging activities of Granisetron.",
      "name": "Granisetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00365",
      "source": "DB00104",
      "target": "DB00365",
      "description": "Grepafloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Grepafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01018",
      "source": "DB00104",
      "target": "DB01018",
      "description": "Octreotide may increase the bradycardic activities of Guanfacine.",
      "name": "Guanfacine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00502",
      "source": "DB00104",
      "target": "DB00502",
      "description": "Octreotide may increase the QTc-prolonging activities of Haloperidol.",
      "name": "Haloperidol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09243",
      "source": "DB00104",
      "target": "DB09243",
      "description": "Hydracarbazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Hydracarbazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00308",
      "source": "DB00104",
      "target": "DB00308",
      "description": "Octreotide may increase the QTc-prolonging activities of Ibutilide.",
      "name": "Ibutilide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04946",
      "source": "DB00104",
      "target": "DB04946",
      "description": "Octreotide may increase the QTc-prolonging activities of Iloperidone.",
      "name": "Iloperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08953",
      "source": "DB00104",
      "target": "DB08953",
      "description": "Indalpine may increase the hypoglycemic activities of Octreotide.",
      "name": "Indalpine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01306",
      "source": "DB00104",
      "target": "DB01306",
      "description": "Insulin Aspart may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Aspart"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01307",
      "source": "DB00104",
      "target": "DB01307",
      "description": "Insulin Detemir may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Detemir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00047",
      "source": "DB00104",
      "target": "DB00047",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01309",
      "source": "DB00104",
      "target": "DB01309",
      "description": "Insulin Glulisine may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Glulisine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00030",
      "source": "DB00104",
      "target": "DB00030",
      "description": "Insulin Human may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00046",
      "source": "DB00104",
      "target": "DB00046",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00071",
      "source": "DB00104",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09247",
      "source": "DB00104",
      "target": "DB09247",
      "description": "Iproclozide may increase the hypoglycemic activities of Octreotide.",
      "name": "Iproclozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04818",
      "source": "DB00104",
      "target": "DB04818",
      "description": "Iproniazid may increase the hypoglycemic activities of Octreotide.",
      "name": "Iproniazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01247",
      "source": "DB00104",
      "target": "DB01247",
      "description": "Isocarboxazid may increase the hypoglycemic activities of Octreotide.",
      "name": "Isocarboxazid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09083",
      "source": "DB00104",
      "target": "DB09083",
      "description": "Octreotide may increase the bradycardic activities of Ivabradine.",
      "name": "Ivabradine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00598",
      "source": "DB00104",
      "target": "DB00598",
      "description": "Octreotide may increase the bradycardic activities of Labetalol.",
      "name": "Labetalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06218",
      "source": "DB00104",
      "target": "DB06218",
      "description": "Octreotide may increase the atrioventricular blocking (AV block) activities of Lacosamide.",
      "name": "Lacosamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06791",
      "source": "DB00104",
      "target": "DB06791",
      "description": "Octreotide may increase the hypoglycemic activities of Lanreotide.",
      "name": "Lanreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09078",
      "source": "DB00104",
      "target": "DB09078",
      "description": "Octreotide may increase the QTc-prolonging activities of Lenvatinib.",
      "name": "Lenvatinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00007",
      "source": "DB00104",
      "target": "DB00007",
      "description": "Octreotide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01210",
      "source": "DB00104",
      "target": "DB01210",
      "description": "Octreotide may increase the bradycardic activities of Levobunolol.",
      "name": "Levobunolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01137",
      "source": "DB00104",
      "target": "DB01137",
      "description": "Octreotide may increase the QTc-prolonging activities of Levofloxacin.",
      "name": "Levofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08918",
      "source": "DB00104",
      "target": "DB08918",
      "description": "Levomilnacipran may increase the hypoglycemic activities of Octreotide.",
      "name": "Levomilnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08882",
      "source": "DB00104",
      "target": "DB08882",
      "description": "Linagliptin may increase the hypoglycemic activities of Octreotide.",
      "name": "Linagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06655",
      "source": "DB00104",
      "target": "DB06655",
      "description": "Liraglutide may increase the hypoglycemic activities of Octreotide.",
      "name": "Liraglutide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00978",
      "source": "DB00104",
      "target": "DB00978",
      "description": "Lomefloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Lomefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01601",
      "source": "DB00104",
      "target": "DB01601",
      "description": "Octreotide may increase the QTc-prolonging activities of Lopinavir.",
      "name": "Lopinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04897",
      "source": "DB00104",
      "target": "DB04897",
      "description": "Octreotide may increase the bradycardic activities of Lucinactant.",
      "name": "Lucinactant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06708",
      "source": "DB00104",
      "target": "DB06708",
      "description": "Octreotide may increase the QTc-prolonging activities of Lumefantrine.",
      "name": "Lumefantrine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09248",
      "source": "DB00104",
      "target": "DB09248",
      "description": "Mebanazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Mebanazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01277",
      "source": "DB00104",
      "target": "DB01277",
      "description": "Octreotide may increase the hypoglycemic activities of Mecasermin.",
      "name": "Mecasermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00244",
      "source": "DB00104",
      "target": "DB00244",
      "description": "Mesalazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Mesalazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00331",
      "source": "DB00104",
      "target": "DB00331",
      "description": "Metformin may increase the hypoglycemic activities of Octreotide.",
      "name": "Metformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00333",
      "source": "DB00104",
      "target": "DB00333",
      "description": "Octreotide may increase the QTc-prolonging activities of Methadone.",
      "name": "Methadone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00968",
      "source": "DB00104",
      "target": "DB00968",
      "description": "Octreotide may increase the bradycardic activities of Methyldopa.",
      "name": "Methyldopa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09241",
      "source": "DB00104",
      "target": "DB09241",
      "description": "Methylene blue may increase the hypoglycemic activities of Octreotide.",
      "name": "Methylene blue"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06710",
      "source": "DB00104",
      "target": "DB06710",
      "description": "Methyltestosterone may increase the hypoglycemic activities of Octreotide.",
      "name": "Methyltestosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01214",
      "source": "DB00104",
      "target": "DB01214",
      "description": "Octreotide may increase the bradycardic activities of Metipranolol.",
      "name": "Metipranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00264",
      "source": "DB00104",
      "target": "DB00264",
      "description": "Octreotide may increase the bradycardic activities of Metoprolol.",
      "name": "Metoprolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00834",
      "source": "DB00104",
      "target": "DB00834",
      "description": "Mifepristone may increase the QTc-prolonging activities of Octreotide.",
      "name": "Mifepristone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00491",
      "source": "DB00104",
      "target": "DB00491",
      "description": "Miglitol may increase the hypoglycemic activities of Octreotide.",
      "name": "Miglitol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00419",
      "source": "DB00104",
      "target": "DB00419",
      "description": "Miglustat may increase the hypoglycemic activities of Octreotide.",
      "name": "Miglustat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04896",
      "source": "DB00104",
      "target": "DB04896",
      "description": "Milnacipran may increase the hypoglycemic activities of Octreotide.",
      "name": "Milnacipran"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00805",
      "source": "DB00104",
      "target": "DB00805",
      "description": "Minaprine may increase the hypoglycemic activities of Octreotide.",
      "name": "Minaprine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01252",
      "source": "DB00104",
      "target": "DB01252",
      "description": "Mitiglinide may increase the hypoglycemic activities of Octreotide.",
      "name": "Mitiglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01171",
      "source": "DB00104",
      "target": "DB01171",
      "description": "Moclobemide may increase the hypoglycemic activities of Octreotide.",
      "name": "Moclobemide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00218",
      "source": "DB00104",
      "target": "DB00218",
      "description": "Octreotide may increase the QTc-prolonging activities of Moxifloxacin.",
      "name": "Moxifloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01203",
      "source": "DB00104",
      "target": "DB01203",
      "description": "Octreotide may increase the bradycardic activities of Nadolol.",
      "name": "Nadolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00779",
      "source": "DB00104",
      "target": "DB00779",
      "description": "Nalidixic Acid may increase the hypoglycemic activities of Octreotide.",
      "name": "Nalidixic Acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00731",
      "source": "DB00104",
      "target": "DB00731",
      "description": "Nateglinide may increase the hypoglycemic activities of Octreotide.",
      "name": "Nateglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04861",
      "source": "DB00104",
      "target": "DB04861",
      "description": "Octreotide may increase the bradycardic activities of Nebivolol.",
      "name": "Nebivolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01149",
      "source": "DB00104",
      "target": "DB01149",
      "description": "Nefazodone may increase the hypoglycemic activities of Octreotide.",
      "name": "Nefazodone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06600",
      "source": "DB00104",
      "target": "DB06600",
      "description": "Nemonoxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Nemonoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04820",
      "source": "DB00104",
      "target": "DB04820",
      "description": "Nialamide may increase the hypoglycemic activities of Octreotide.",
      "name": "Nialamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04868",
      "source": "DB00104",
      "target": "DB04868",
      "description": "Octreotide may increase the QTc-prolonging activities of Nilotinib.",
      "name": "Nilotinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01059",
      "source": "DB00104",
      "target": "DB01059",
      "description": "Norfloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Norfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09249",
      "source": "DB00104",
      "target": "DB09249",
      "description": "Octamoxin may increase the hypoglycemic activities of Octreotide.",
      "name": "Octamoxin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01165",
      "source": "DB00104",
      "target": "DB01165",
      "description": "Octreotide may increase the QTc-prolonging activities of Ofloxacin.",
      "name": "Ofloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00904",
      "source": "DB00104",
      "target": "DB00904",
      "description": "Octreotide may increase the QTc-prolonging activities of Ondansetron.",
      "name": "Ondansetron"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01092",
      "source": "DB00104",
      "target": "DB01092",
      "description": "Ouabain may decrease the cardiotoxic activities of Octreotide.",
      "name": "Ouabain"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00621",
      "source": "DB00104",
      "target": "DB00621",
      "description": "Oxandrolone may increase the hypoglycemic activities of Octreotide.",
      "name": "Oxandrolone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06412",
      "source": "DB00104",
      "target": "DB06412",
      "description": "Oxymetholone may increase the hypoglycemic activities of Octreotide.",
      "name": "Oxymetholone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01229",
      "source": "DB00104",
      "target": "DB01229",
      "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.",
      "name": "Paclitaxel"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01267",
      "source": "DB00104",
      "target": "DB01267",
      "description": "Octreotide may increase the QTc-prolonging activities of Paliperidone.",
      "name": "Paliperidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06603",
      "source": "DB00104",
      "target": "DB06603",
      "description": "Octreotide may increase the QTc-prolonging activities of Panobinostat.",
      "name": "Panobinostat"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01626",
      "source": "DB00104",
      "target": "DB01626",
      "description": "Pargyline may increase the hypoglycemic activities of Octreotide.",
      "name": "Pargyline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00715",
      "source": "DB00104",
      "target": "DB00715",
      "description": "Paroxetine may increase the hypoglycemic activities of Octreotide.",
      "name": "Paroxetine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06663",
      "source": "DB00104",
      "target": "DB06663",
      "description": "Octreotide may increase the hypoglycemic activities of Pasireotide.",
      "name": "Pasireotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06589",
      "source": "DB00104",
      "target": "DB06589",
      "description": "Octreotide may increase the QTc-prolonging activities of Pazopanib.",
      "name": "Pazopanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00487",
      "source": "DB00104",
      "target": "DB00487",
      "description": "Pefloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Pefloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00082",
      "source": "DB00104",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Octreotide.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01359",
      "source": "DB00104",
      "target": "DB01359",
      "description": "Octreotide may increase the bradycardic activities of Penbutolol.",
      "name": "Penbutolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00738",
      "source": "DB00104",
      "target": "DB00738",
      "description": "Octreotide may increase the QTc-prolonging activities of Pentamidine.",
      "name": "Pentamidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00556",
      "source": "DB00104",
      "target": "DB00556",
      "description": "Octreotide may increase the QTc-prolonging activities of Perflutren.",
      "name": "Perflutren"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00780",
      "source": "DB00104",
      "target": "DB00780",
      "description": "Phenelzine may increase the hypoglycemic activities of Octreotide.",
      "name": "Phenelzine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00914",
      "source": "DB00104",
      "target": "DB00914",
      "description": "Phenformin may increase the hypoglycemic activities of Octreotide.",
      "name": "Phenformin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09250",
      "source": "DB00104",
      "target": "DB09250",
      "description": "Pheniprazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Pheniprazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09251",
      "source": "DB00104",
      "target": "DB09251",
      "description": "Phenoxypropazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Phenoxypropazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01100",
      "source": "DB00104",
      "target": "DB01100",
      "description": "Octreotide may increase the QTc-prolonging activities of Pimozide.",
      "name": "Pimozide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00960",
      "source": "DB00104",
      "target": "DB00960",
      "description": "Octreotide may increase the bradycardic activities of Pindolol.",
      "name": "Pindolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01132",
      "source": "DB00104",
      "target": "DB01132",
      "description": "Pioglitazone may increase the hypoglycemic activities of Octreotide.",
      "name": "Pioglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09244",
      "source": "DB00104",
      "target": "DB09244",
      "description": "Pirlindole may increase the hypoglycemic activities of Octreotide.",
      "name": "Pirlindole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09252",
      "source": "DB00104",
      "target": "DB09252",
      "description": "Pivhydrazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Pivhydrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09113",
      "source": "DB00104",
      "target": "DB09113",
      "description": "Octreotide may increase the bradycardic activities of Poractant alfa.",
      "name": "Poractant alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01278",
      "source": "DB00104",
      "target": "DB01278",
      "description": "Pramlintide may increase the hypoglycemic activities of Octreotide.",
      "name": "Pramlintide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01087",
      "source": "DB00104",
      "target": "DB01087",
      "description": "Octreotide may increase the QTc-prolonging activities of Primaquine.",
      "name": "Primaquine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01035",
      "source": "DB00104",
      "target": "DB01035",
      "description": "Octreotide may increase the QTc-prolonging activities of Procainamide.",
      "name": "Procainamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00420",
      "source": "DB00104",
      "target": "DB00420",
      "description": "Octreotide may increase the QTc-prolonging activities of Promazine.",
      "name": "Promazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01182",
      "source": "DB00104",
      "target": "DB01182",
      "description": "Octreotide may increase the QTc-prolonging activities of Propafenone.",
      "name": "Propafenone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00571",
      "source": "DB00104",
      "target": "DB00571",
      "description": "Octreotide may increase the bradycardic activities of Propranolol.",
      "name": "Propranolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01224",
      "source": "DB00104",
      "target": "DB01224",
      "description": "Octreotide may increase the QTc-prolonging activities of Quetiapine.",
      "name": "Quetiapine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00908",
      "source": "DB00104",
      "target": "DB00908",
      "description": "Octreotide may increase the QTc-prolonging activities of Quinidine.",
      "name": "Quinidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00468",
      "source": "DB00104",
      "target": "DB00468",
      "description": "Octreotide may increase the QTc-prolonging activities of Quinine.",
      "name": "Quinine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01367",
      "source": "DB00104",
      "target": "DB01367",
      "description": "Rasagiline may increase the hypoglycemic activities of Octreotide.",
      "name": "Rasagiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00912",
      "source": "DB00104",
      "target": "DB00912",
      "description": "Repaglinide may increase the hypoglycemic activities of Octreotide.",
      "name": "Repaglinide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00989",
      "source": "DB00104",
      "target": "DB00989",
      "description": "Octreotide may increase the bradycardic activities of Rivastigmine.",
      "name": "Rivastigmine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00412",
      "source": "DB00104",
      "target": "DB00412",
      "description": "Rosiglitazone may increase the hypoglycemic activities of Octreotide.",
      "name": "Rosiglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00817",
      "source": "DB00104",
      "target": "DB00817",
      "description": "Rosoxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Rosoxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08877",
      "source": "DB00104",
      "target": "DB08877",
      "description": "Ruxolitinib may increase the bradycardic activities of Octreotide.",
      "name": "Ruxolitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09253",
      "source": "DB00104",
      "target": "DB09253",
      "description": "Safrazine may increase the hypoglycemic activities of Octreotide.",
      "name": "Safrazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00936",
      "source": "DB00104",
      "target": "DB00936",
      "description": "Salicylic acid may increase the hypoglycemic activities of Octreotide.",
      "name": "Salicylic acid"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01232",
      "source": "DB00104",
      "target": "DB01232",
      "description": "Octreotide may increase the QTc-prolonging activities of Saquinavir.",
      "name": "Saquinavir"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06335",
      "source": "DB00104",
      "target": "DB06335",
      "description": "Saxagliptin may increase the hypoglycemic activities of Octreotide.",
      "name": "Saxagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01037",
      "source": "DB00104",
      "target": "DB01037",
      "description": "Selegiline may increase the hypoglycemic activities of Octreotide.",
      "name": "Selegiline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01104",
      "source": "DB00104",
      "target": "DB01104",
      "description": "Sertraline may increase the hypoglycemic activities of Octreotide.",
      "name": "Sertraline"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01261",
      "source": "DB00104",
      "target": "DB01261",
      "description": "Sitagliptin may increase the hypoglycemic activities of Octreotide.",
      "name": "Sitagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00489",
      "source": "DB00104",
      "target": "DB00489",
      "description": "Octreotide may increase the QTc-prolonging activities of Sotalol.",
      "name": "Sotalol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01208",
      "source": "DB00104",
      "target": "DB01208",
      "description": "Sparfloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Sparfloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06718",
      "source": "DB00104",
      "target": "DB06718",
      "description": "Stanozolol may increase the hypoglycemic activities of Octreotide.",
      "name": "Stanozolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00708",
      "source": "DB00104",
      "target": "DB00708",
      "description": "Octreotide may increase the bradycardic activities of Sufentanil.",
      "name": "Sufentanil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00359",
      "source": "DB00104",
      "target": "DB00359",
      "description": "Octreotide may increase the hypoglycemic activities of Sulfadiazine.",
      "name": "Sulfadiazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01015",
      "source": "DB00104",
      "target": "DB01015",
      "description": "Octreotide may increase the hypoglycemic activities of Sulfamethoxazole.",
      "name": "Sulfamethoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00263",
      "source": "DB00104",
      "target": "DB00263",
      "description": "Octreotide may increase the QTc-prolonging activities of Sulfisoxazole.",
      "name": "Sulfisoxazole"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06271",
      "source": "DB00104",
      "target": "DB06271",
      "description": "Sulodexide may increase the hypoglycemic activities of Octreotide.",
      "name": "Sulodexide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01268",
      "source": "DB00104",
      "target": "DB01268",
      "description": "Octreotide may increase the hypoglycemic activities of Sunitinib.",
      "name": "Sunitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB06402",
      "source": "DB00104",
      "target": "DB06402",
      "description": "Octreotide may increase the QTc-prolonging activities of Telavancin.",
      "name": "Telavancin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00976",
      "source": "DB00104",
      "target": "DB00976",
      "description": "Octreotide may increase the QTc-prolonging activities of Telithromycin.",
      "name": "Telithromycin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01405",
      "source": "DB00104",
      "target": "DB01405",
      "description": "Temafloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Temafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00624",
      "source": "DB00104",
      "target": "DB00624",
      "description": "Testosterone may increase the hypoglycemic activities of Octreotide.",
      "name": "Testosterone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04844",
      "source": "DB00104",
      "target": "DB04844",
      "description": "Octreotide may increase the QTc-prolonging activities of Tetrabenazine.",
      "name": "Tetrabenazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00679",
      "source": "DB00104",
      "target": "DB00679",
      "description": "Octreotide may increase the QTc-prolonging activities of Thioridazine.",
      "name": "Thioridazine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00373",
      "source": "DB00104",
      "target": "DB00373",
      "description": "Octreotide may increase the bradycardic activities of Timolol.",
      "name": "Timolol"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00697",
      "source": "DB00104",
      "target": "DB00697",
      "description": "Octreotide may increase the bradycardic activities of Tizanidine.",
      "name": "Tizanidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08895",
      "source": "DB00104",
      "target": "DB08895",
      "description": "Tofacitinib may increase the bradycardic activities of Octreotide.",
      "name": "Tofacitinib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00839",
      "source": "DB00104",
      "target": "DB00839",
      "description": "Tolazamide may increase the hypoglycemic activities of Octreotide.",
      "name": "Tolazamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01124",
      "source": "DB00104",
      "target": "DB01124",
      "description": "Tolbutamide may increase the hypoglycemic activities of Octreotide.",
      "name": "Tolbutamide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB09245",
      "source": "DB00104",
      "target": "DB09245",
      "description": "Toloxatone may increase the hypoglycemic activities of Octreotide.",
      "name": "Toloxatone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00539",
      "source": "DB00104",
      "target": "DB00539",
      "description": "Octreotide may increase the QTc-prolonging activities of Toremifene.",
      "name": "Toremifene"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB02665",
      "source": "DB00104",
      "target": "DB02665",
      "description": "Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Octreotide.",
      "name": "Trans-2-Phenylcyclopropylamine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00752",
      "source": "DB00104",
      "target": "DB00752",
      "description": "Tranylcypromine may increase the hypoglycemic activities of Octreotide.",
      "name": "Tranylcypromine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00072",
      "source": "DB00104",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Octreotide.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00197",
      "source": "DB00104",
      "target": "DB00197",
      "description": "Troglitazone may increase the hypoglycemic activities of Octreotide.",
      "name": "Troglitazone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00685",
      "source": "DB00104",
      "target": "DB00685",
      "description": "Trovafloxacin may increase the hypoglycemic activities of Octreotide.",
      "name": "Trovafloxacin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB05294",
      "source": "DB00104",
      "target": "DB05294",
      "description": "Octreotide may increase the QTc-prolonging activities of Vandetanib.",
      "name": "Vandetanib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB08881",
      "source": "DB00104",
      "target": "DB08881",
      "description": "Octreotide may increase the QTc-prolonging activities of Vemurafenib.",
      "name": "Vemurafenib"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00285",
      "source": "DB00104",
      "target": "DB00285",
      "description": "Venlafaxine may increase the hypoglycemic activities of Octreotide.",
      "name": "Venlafaxine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00661",
      "source": "DB00104",
      "target": "DB00661",
      "description": "Octreotide may increase the bradycardic activities of Verapamil.",
      "name": "Verapamil"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04876",
      "source": "DB00104",
      "target": "DB04876",
      "description": "Vildagliptin may increase the hypoglycemic activities of Octreotide.",
      "name": "Vildagliptin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04878",
      "source": "DB00104",
      "target": "DB04878",
      "description": "Voglibose may increase the hypoglycemic activities of Octreotide.",
      "name": "Voglibose"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB04832",
      "source": "DB00104",
      "target": "DB04832",
      "description": "Zimelidine may increase the hypoglycemic activities of Octreotide.",
      "name": "Zimelidine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00246",
      "source": "DB00104",
      "target": "DB00246",
      "description": "Octreotide may increase the QTc-prolonging activities of Ziprasidone.",
      "name": "Ziprasidone"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB01624",
      "source": "DB00104",
      "target": "DB01624",
      "description": "Octreotide may increase the QTc-prolonging activities of Zuclopenthixol.",
      "name": "Zuclopenthixol"
    }
  }
]